11830 Westline Industrial Drive St. Louis, Missouri 63146
SAUNDERS MANUAL OF SMALL ANIMAL PRACTICE, THIRD EDITION Copyright © 2006, 2000, 1994 by Saunders, an imprint of Elsevier Inc.
ISBN-13: 978-0-7216-0422-0 ISBN-10: 0-7216-0422-6
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Health Sciences Rights Department in Philadelphia, PA, USA: phone: (+1) 215 239 3804, fax: (+1) 215 239 3805, e-mail:
[email protected]. You may also complete your request on-line via the Elsevier homepage (http://www.elsevier.com), by selecting “Customer Support” and then “Obtaining Permissions.”
Notice Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on their own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Editors assumes any liability for any injury and/or damage to persons or property arising out or related to any use of the material contained in this book. ISBN-13: 978-0-7216-0422-0 ISBN-10: 0-7216-0422-6
Publishing Director: Linda Duncan Acquisitions Editor: Liz Fathman Senior Developmental Editor: Jolynn Gower Editorial Assistant: Stacy Beane Publishing Services Manager: Julie Eddy Senior Project Manager: Joy Moore Designer: Jyotika Schroff
Printed in the United States of America Last digit is the print number:
9 8 7 6 5 4 3 2 1
We dedicate this book to our families: To my wife, Susan Crisp; my children, Justin and Mary; my parents, Robert and Sandy; and my brother, Thomas. (SJB) To my wife, Sherrie, and my son, Cameron. (RGS)
W0422-PR.qxd
11/15/05
6:07 PM
Page vii
▼
Contributors
Nancy L. Anderson, DVM, PhD, ABUPC (Avian) Director of Wildlife Services, Lindsay Wildlife Museum, Walnut Creek, California Pet Rodents Basic Husbandry and Medicine of Pet Reptiles Francisco J. Alvarez, DVM Chief Resident, Clinical Oncology Service, Veterinary Medical Teaching Hospital, Department of Veterinary Clinical Services, The Ohio State University, Columbus, Ohio Respiratory Neoplasia Laura J. Armbrust, DVM, Diplomate ACVR Assistant Professor, Radiology, Clinical Sciences, Kansas State University College of Veterinary Medicine, Manhattan, Kansas Radiographic and Ultrasonographic Techniques Dennis N. Aron, DVM, Diplomate ACVS Professor, Small Animal Surgery, Department of Small Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, Georgia Luxation, Subluxation, and Shearing Injuries of the Tarsal Joint Shane W. Bateman, DVM, DVSc, Diplomate ACVECC Associate Professor-Clinical, Head of Emergency and Critical Care, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Emergency and Critical Care Techniques and Nutrition Fluid Therapy for Dogs and Cats
Jamie R. Bellah, DVM, Diplomate ACVS Staff Surgeon, Affiliated Veterinary Specialists, Orange Park, Florida Surgery of Intertriginous Dermatoses Larry Berkwitt, DVM, Diplomate ACVIM Chief of Staff, Internal Medicine, Veterinary Referral and Emergency Center, Norwalk, Connecticut Diagnostic Methods in Respiratory Disease Sonya V. Bettenay, BVSC (Hons), FACVSc (Dermatology), Diplomate ECVD Dermatopathology, Laboklin, Munich, Germany Skin Cytology and Biopsy David S. Biller, DVM, Diplomate ACVR Professor and Head of Radiology, Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas Radiographic and Ultrasonographic Techniques Stephen J. Birchard, DVM, MS, Diplomate ACVS Associate Professor, Small Animal Surgery, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Diseases of the Thyroid Gland Selected Skin Graft and Reconstructive Techniques Surgery of the Liver and Biliary Tract Diseases and Surgery of the Exocrine Pancreas Peritonitis Pleural Effusion Principles of Thoracic Surgery
Karin Muth Beale, DVM, Diplomate ACVD Staff Dermatologist, Gulf Coast Veterinary Specialists, Houston, Texas Dermatology Consultant, ANTECH Diagnostics, Irvine, California Dermatophytosis
Dale E. Bjorling, DVM, MS Diplomate ACVS Professor and Chair, Surgical Sciences, Affiliate Professor, Division of Urology, Department of Surgery, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin Surgery of the Kidney and Ureter Surgery of the Urethra Thoracic Trauma
Richard M. Bednarski, DVM, MS, Diplomate ACVA Associate Professor of Anesthesiology, Hospital Director, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Pain Management in the Surgical Patient
Mark W. Bohling, DVM Resident, Small Animal Surgery, Department of Clinical Sciences, Auburn University, Auburn, Alabama Management of the Traumatic Wound by Primary Closure vii
W0422-PR.qxd
viii
11/15/05
6:07 PM
Page viii
Contributors
John D. Bonagura, DVM, MS, Diplomate ACVIM (Internal Medicine, Cardiology) Professor, Cardiology and Internal Medicine, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Cardiovascular Radiography Cardiovascular Drugs Heart Failure in Dogs Syncope Valvular Heart Disease Cardiomyopathy Pericardial Diseases Vascular Diseases Congenital Heart Disease Respiratory Infections Jennifer Bonczynski, DVM, Diplomate ACVS Staff Surgeon, Department of Surgery, The Animal Medical Center, New York, New York Pancreatic Beta Cell Neoplasia Harry W. Boothe, DVM, MS Professor, Small Animal Surgery, Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama Surgery for Otitis Media and Otitis Interna Surgery of the Prostate Gland Surgery of the Testes and Scrotum Surgery of the Penis and Prepuce Randy J. Boudrieau, DVM, Diplomate ACVS Professor, Surgery, Clinical Sciences, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts Section Head, Small Animal Surgery, Henry & Lois Foster Hospital for Small Animals, North Grafton, Massachusetts Delayed Union, Nonunion, and Malunion Heather L. Bowles, DVM, Diplomate ABVP Fallston Veterinary Clinic, Fallston, Maryland Avian Reproductive Tract Disorders Ronald M. Bright, DVM, MS, Diplomate ACVS Affiliate Professor, Department of Clinical Sciences, College of Veterinary Medicine, Colorado State University Staff Surgeon, Surgical Referral Services, Fort Collins, Colorado Staff Surgeon, Veterinary Consultation Services, Inc., Knoxville, Tennessee Surgery of the Esophagus Diseases of the Stomach Surgery of the Stomach Surgery of the Intestines Anorectal Surgery
Marjory B. Brooks, DVM, Diplomate ACVIM Associate Director, Comparative Coagulation Laboratory, Animal Health Diagnostic Center, Population Medicine and Diagnostic Science, College of Veterinary Medicine, Cornell University Ithaca, New York Coagulation Diseases Steven C. Budsberg, DVM, MS, Diplomate ACVS Professor, Department of Small Animal Medicine and Surgery, University of Georgia, Athens, Georgia Orthopedic Disorders of the Distal Extremities C. Anthony Buffington, DVM, PhD, Diplomate ACVN Professor, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio Emergency and Critical Care Techniques and Nutrition Clay A. Calvert, DVM, Diplomate ACVIM Professor, Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia Heartworm Disease Marcia A. Carothers, DVM, Diplomate ACVIM (Internal Medicine) Staff Veterinarian, Akron Veterinary Referral and Emergency Center, Akron, Ohio Respiratory Neoplasia Sue Chen, DVM Gulf Coast Veterinary Specialists, Houston, Texas Avian Reproductive Tract Disorders Rabbits Dennis J. Chew, DVM, Diplomate ACVIM Professor, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio Fluid Therapy for Dogs and Cats Diseases of the Parathyroid Gland and Calcium Metabolism Diseases of the Urinary Bladder Lynette K. Cole, DVM, MS, Diplomate ACVD Assistant Professor, Dermatology, College of Veterinary Medicine, Veterinary Teaching Hospital, The Ohio State University, Columbus, Ohio Diseases of the Pinna Otitis Media and Otitis Interna Carmen M. H. Colitz, DVM, PhD, Diplomate ACVO Assistant Professor, Ophthalmology, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Diseases of the Lacrimal System
W0422-PR.qxd
11/15/05
6:07 PM
Page ix
Contributors
Sarah Colombini Osborn, DVM, MS, Diplomate ACVD Co-Owner, Dermatology, Gulf Coast Veterinary Dermatology & Allergy, Houston, Texas Consultant, Dermatopathology/Dermatology, Antech Diagnostics, Phoenix, Arizona Canine and Feline Demodicosis Paul A. Cuddon, DVM, Diplomate ACVIM (Neurology) Neurological Center for Animals, Lakewood, Colorado Disorders of the Spinal Cord Támara M. Costa-Gómez, DVM Arboretum View Animal Hospital, Downers Grove, Illinois Surgery of the Kidney and Ureter Surgery of the Urethra Kechia M. Davis, DVM Resident, Small Animal Surgery, Department of Clinical Sciences, Veterinary Teaching Hospital, North Carolina State University, Raleigh, North Carolina Mammary Gland Neoplasia
ix
William R. Fenner, DVM, Diplomate ACVIM (Neurology) Emeritus Faculty, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio Diagnostic Approach to Neurologic Disease Roger B. Fingland, DVM, MS, MBA, Diplomate ACVS Associate Dean, Clinical Programs, Professor and Director, Veterinary Medical Teaching Hospital, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas Surgery of the Urinary Bladder Surgery of the Ovaries and Uterus Surgery of the Vagina and Vulva Obstructive Upper Airway Disorders Richard B. Ford, DVM, MS, Diplomate ACVIM, Diplomate (Hon) ACVPM Professor, Medicine, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina Vaccination Guidelines for the Dog and Cat
Charles E. DeCamp, DVM, MS, Diplomate ACVS Professor, Michigan State University, East Lansing, Michigan Open Fractures
S. Dru Forrester, DVM, MS, Diplomate ACVIM (Small Animal Internal Medicine) Professor, College of Veterinary Medicine, Western University of Health Sciences, Pomona, California Diseases of the Kidney and Ureter
R. Tass Dueland, DVM, MS, Diplomate ACVS Professor, Orthopedic Surgery, Affiliate Professor, Division of Orthopedic Surgery, Medical School, University of Wisconsin-Madison, Madison, Wisconsin Orthopedic Disorders of the Stifle
Linda A. Frank, MS, DVM, Diplomate ACVD Professor, Dermatology, Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee Sex Hormone and Endocrine Look-alike Dermatoses
Joan Dziezyc, DVM, Diplomate ACVO Associate Professor, Department of Small Animal Medicine and Surgery, College of Veterinary Medicine Staff Ophthalmologist, Veterinary Medical Teaching Hospital, Texas A&M University, College Station, Texas Diseases of the Retina, Choroid, and Optic Nerve
Rance M. Gamblin, DVM, Diplomate ACVIM (Oncology) Staff Oncologist, Akron Veterinary Internal Medicine Oncology Practice, Metropolitan Veterinary Hospital, Akron, Ohio Principles of Oncology
Erick L. Egger, DVM, Diplomate ACVS Special Appointment, Small Animal Orthopedics, Veterinary Clinical Sciences, Colorado State University, Fort Collins, Colorado Fractures of the Tibia and Fibula Christine Ellis, DVM Exotic Animal Veterinary Service, Fort Collins, Colorado Ferrets
Jennifer Gieg, DVM Resident, Internal Medicine, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Diseases of the Urinary Bladder Stephen D. Gilson, DVM, Diplomate ACVS Sõnorã Veterinary Specialists, Scottsdale, Arizona Principles of Oncology
W0422-PR.qxd
x
11/15/05
6:07 PM
Page x
Contributors
Mary B. Glaze, DVM, MS, Diplomate ACVO Professor, Veterinary Ophthalmology, Louisiana State University, Veterinary Clinical Sciences Veterinary Ophthalmologist, Veterinary Teaching Hospital and Clinic, Louisiana State University, Baton Rouge, Louisiana Diseases of the Orbit Joanne C. Graham, DVM, MS, Diplomate ACVIM (Oncology) Assistant Professor and Staff Oncologist, Iowa State University, Ames, Iowa Soft Tissue Sarcomas and Mast Cell Tumors David Grant, DVM, MS, Diplomate ACVIM (Small Animal Internal Medicine) Clinical Instructor, Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, Virginia Diseases of the Kidney and Ureter Thomas K. Graves, DVM, PhD, Diplomate ACVIM Assistant Professor, Small Animal Medicine, Veterinary Clinical Medicine, University of Illinois, Urbana, Illinois Diseases of the Testes and Scrotum Diseases of the Penis and Prepuce Diseases of the Ovaries and Uterus Deborah S. Greco, DVM, PhD Staff Internist and Endocrinologist, Department of Medicine, The Animal Medical Center, New York, New York Diabetes Mellitus Henry W. Green, III, DVM, Diplomate ACVIM (Cardiology) Assistant Professor, Department of Veterinary Clinical Sciences, Purdue University School of Veterinary Medicine, West Lafayette, Indiana Congenital Heart Disease Tia B. Greenberg, DVM Westminster Veterinary Group, Westminster, California Avian Dermatology Craig E. Griffin, DVM, Diplomate ACVD Partner, Clinician, Animal Dermatology Clinic, San Diego and Garden Grove, California Flea Allergy Dermatitis Amy M. Grooters, DVM, Diplomate ACVIM Associate Professor and Chief, Companion Animal Medicine, Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana Deep Fungal Infections
Robert L. Hamlin, DVM, PhD, Diplomate ACVIM (Cardiology) Professor, Veterinary Biosciences and Biomedical Engineering, The Ohio State University, Columbus, Ohio Auscultation and Physical Diagnosis Don J. Harris, DVM Owner and Director, Avian and Exotic Animal Medical Center, Miami, Florida Avian Infectious Diseases Callum W. Hay, BVMS, Diplomate ACVS President, Veterinary Surgical Services, Inc., Tampa, Florida Osteomyelitis Osteoarthritis Immune-Mediated Arthritis Cheryl S. Hedlund, DVM, MS, Diplomate ACVS Professor, Surgery, Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana Surgery of the Nasal Cavity and Sinuses Karen Helton-Rhodes, DVM, Diplomate ACVD Veterinary Referral Centre, Little Falls, New Jersey Immune-Mediated Dermatoses Andrew Hillier, BVSc Associate Professor, Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Mycobacteriosis Scabies, Notoedric Mange, and Cheyletiellosis Atopic Dermatitis Feline Symmetrical Alopecia Cheryl Holloway, RVT Animal Health Technician, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio Emergency and Critical Care Techniques and Nutrition Robert V. Hitchinson, DVM Co-director, Animal Clinic Northview, Inc., North Ridgeville, Ohio Infertility and Breeding Disorders John A. E. Hubbell, DVM, MS, Diplomate ACVA Professor, Department of Veterinary Clinical Sciences, The College of Veterinary Medicine, The Ohio State University, Columbus, Ohio Practical Methods of Anesthesia Richard M. Jerram, BVSc, Diplomate ACVS Specialist, Small Animal Surgery, Veterinary Specialist Group, Auckland, New Zealand Fractures and Dislocations of the Mandible Fractures of the Maxilla
W0422-PR.qxd
11/15/05
6:07 PM
Page xi
Contributors
xi
Lynelle R. Johnson, DVM, PhD, Diplomate ACVIM (Small Animal Internal Medicine) Assistant Professor, VM: Medicine & Epidemiology, University of California, Davis, California Bronchopulmonary Disease
William C. Kisseberth, DVM, PhD, Diplomate ACVIM Assistant Professor, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Diseases of the Spleen
Susan E. Johnson, DVM, MS, Diplomate ACVIM (Internal Medicine) Associate Professor, Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Diseases of the Esophagus and Disorders of Swallowing Diseases of the Stomach Diseases of the Intestines Diseases of the Liver and Biliary Tract Diseases and Surgery of the Exocrine Pancreas
David W. Knapp, DVM, Diplomate ACVS Staff Surgeon, Angell Animal Medical Center, Boston, Boston, Massachusetts Management of the Open Wound
Matthew S. Johnston, VMD, DABVP (Avian) Assistant Professor, Zoological Medicine, Clinical Sciences, Colorado State University, Fort Collins, Colorado Avian Respiratory System Disorders Denise Jones, DVM, BS Partner and Staff Veterinarian, Findlay Animal Hospital, Findlay, Ohio History and Physical Examination Nancy D. Kay, DVM, Diplomate ACVIM Staff Internist, Animal Care Center of Sonoma County, Rohnert Park, California Diseases of the Prostate Gland Bruce W. Keene, DVM, MSc, Diplomate ACVIM (Cardiology) Professor, Cardiology, Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina Heart Failure in Dogs Thomas J. Kern, DVM, Diplomate ACVO Associate Professor, Ophthalmology, Department of Clinical Sciences, College of Veterinary Medicine Cornell University, Ithaca, New York Diseases of the Cornea and Sclera Peter P. Kintzer, DVM, Diplomate ACVIM Staff Internist, Boston Rood Animal Hospital, Springfield, Massachusetts Diseases of the Adrenal Gland Susan E. Kirschner, DVM, Diplomate ACVO Ophthalmologist, The Animal Eye Doctor, Beaverton, Oregon Diseases of the Eyelid
Shianne L. Koplitz, DVM, PhD Diplomate ACVIM (Cardiology) Cardiology Resident, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Syncope Michael P. Kowaleski, DVM, Diplomate ACVS Assistant Professor, Small Animal Orthopedic Surgery, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Fractures and Dislocations of the Carpus Osteochondrosis Gail A. Kunkle, DVM, Diplomate ACVD Professor, SACS-CVM, University of Florida, Gainesville, Florida Necrotizing Skin Diseases Kenneth W. Kwochka, DVM, Diplomate ACVD Vice President for Research and Development, DVM Pharmaceuticals, Miami, Florida Keratinization Defects Mary Anna Labato, DVM, Diplomate ACVIM (Small Animal) Clinical Associate Professor, Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University Staff Veterinarian, Small Animal Medicine, Foster Hospital for Small Animals, North Grafton, Massachusetts Disorders of Micturition Linda B. Lehmkuhl, DVM, MS, Diplomate ACVIM (Cardiology) Staff Cardiologist, Cardiology, Med Vet, Medical Center for Pets, Worthington, Ohio Cardiomyopathy Patricia J. Luttgen, DVM, MS, Diplomate ACVIM (Neurology) Staff Neurologist, Neurological Center for Animals, Denver, Colorado Disorders of the Spinal Cord
W0422-PR.qxd
xii
11/15/05
6:07 PM
Page xii
Contributors
Paul A. Manley, DVM, MSc, Diplomate ACVS Professor, Chief of Small Animal Services, Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin Osteoarthritis Immune-Mediated Arthritis Philip A. March, DVM, MS, Diplomate ACVIM (Neurology) Associate Professor, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Diagnostic Approach to Neurologic Disease Diseases of the Brain and Cranial Nerves Sandra Manfra Marretta, DVM, Diplomate ACVS, Charter Dipolomate AVDC Professor and Head, Small Animal Surgery and Dentistry, Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, Illinois Dentistry and Diseases of the Oropharnyx Hilary K. Matthews, DVM, PhD, Diplomate ACVIM Section Head, Internal Medicine, Capital Veterinary and Referral Center, Columbus, Ohio Diseases of the Urethra Margaret C. McEntee, DVM, Diplomate ACVIM (Medical Oncology), Diplomate ACVR (Radiation Oncology) Assistant Clinical Professor, University of California, Davis, School of Veterinary Medicine, Davis, California Diseases of the Spleen Mary A. McLoughlin, DVM, MS, Diplomate ACVS Assisstant Professor Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Diseases of the Urinary Bladder Diseases of the Vagina and Vulva Michael S. Miller MS, VMD, Diplomate, ABVP Co-owner and Cardiology Consultant, Veterinary Specialty Center of Delaware, Wilmington, Delaware, Director, Cardiology-Ultrasound Referral Service, Thornton, Pennsylvania Electrocardiography Disorders of the Cardiac Rhythm Nicholas J. Millichamp, BSC, BVM, PhD, DVOpthal, Diplomate ACVO, Diplomate MRCS Associate Professor, Small Animal Medicine and Surgery, College of Veterinary Medicine, Staff Opthalmologist, Veterinary Teaching Hospital, Texas A&M University, College Station, Texas Diseases of the Retina, Choroid, and Optic Nerve
Darryl L. Millis, DVM, MS, Diplomate ACVS Professor, Orthopedic Surgery, Small Animal Clinical Sciences, University of Tennessee, Knoxville, Tennessee Postoperative Physical Rehabilitation Milan Milovancev, DVM Resident, Small Animal Surgery, University of Wisconsin, Madison, Wisconsin Neoplasia of Thoracic and Pelvic Limbs Cecil P. Moore, DVM, MS, Diplomate ACVO Professor and Chairman, Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri Diseases of the Conjunctiva Daniel O. Morris, DVM, Diplomate, ACVD Assistant Professor and Chief, Dermatology and Allergy, Clinical Studies-Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania Malassezia Dermatitis Ralf S. Mueller, DMV, DMVH, Diplomate ACVD, FACVs Chief, Dermatology Service, Medizinische Tierklinik, Universität München, Munich, Germany Disorders of the Claw William W. Muir III, DVM, PhD, Diplomate ACVA, Diplomate ACVECC Professor, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University Columbus, Ohio Cardiopulmonary Cerebral Resuscitation Alan C. Mundell, DVM Animal Dermatology Service, Seattle, Washington Mycobacteriosis Rhett Nichols, DVM, ACVIM Endocrinology and Internal Medicine Consult, Antech Diagnostics, Lake Success, New York Diseases of the Hypothalamus and Pituitary James O. Noxon, DVM, Diplomate ACVIM (Internal Medicine) Professor, Department of Veterinary Clinical Sciences, Iowa State University, Ames, Iowa Adjunct Professor, Department of Companion Animals, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada Otitis Externa
W0422-PR.qxd
11/15/05
6:07 PM
Page xiii
Contributors
xiii
Barbara L. Oglesbee, DVM, Diplomate ABVP (Avian Practice) Adjunct Associate Professor, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio and Westminster Veterinary Group, Westminster, California Avian Techniques Avian Infectious Diseases Avian Digestive System Disorders
Anthony Pilny, DVM The Center for Avian and Exotic Medicine, New York, New York Avian Neurologic Disorders
Marvin L. Olmstead, DVM, MS, Diplomate ACVS Emeritus Professor, Small Animal Orthopedics, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Oregon Veterinary Associates, Springfield, Oregon Disorders of the Coxofemoral Joint
Michael Podell, DVM, MSc, Diplomate ACVIM (Neurology) Adjunct Professor, Veterinary Clinical Medicine, University of Illinois, Champaign-Urbana, Illinois Medical Director and Staff Neurologist, Animal Emergency and Critical Care Center, Northbrook, Illinois Adjunct Professor, Veterinary Biosciences, The Ohio State University, Columbus, Ohio Seizures
Rodney L. Page, DVM, MS, Diplomate ACVIM (Internal Medicine, Oncology) Professor, Oncology, North Carolina State University, Raleigh, North Carolina Principles of Oncology Matthew Palmisano, DVM, MS, Diplomate ACVS Veterinary Referral and Emergency Center, Norwalk, Connecticut Neoplasia of the Maxilla and Mandible Fractures and Dislocations of the Spine Orthopedic Disorders of the Stifle Surgery of the Skeletal Muscle and Tendon Neoplasia of Thoracic and Pelvic Limbs Pediatric Fractures
Lauren R. Pinchbeck, DVM Clinical Instructor, Veterinary Clinical Sciences, Department of Dermatology, The Ohio State University, Columbus, Ohio Scabies, Notoedric Mange, and Cheyletiellosis
James C. Prueter, DVM, Diplomate ACVIM Hospital Director, The Veterinary Referral Clinic, Cleveland, Ohio Diagnostic Methods in Respiratory Disease Katherine E. Quesenberry, DVM, Diplomate ABVP (Avian Practice) Avian and Exotic Pet Service, The Animal Medicine Center, New York, New York Avian Neurologic Disorders Rabbits
David L. Panciera, DVM, MS, Diplomate ACVIM (Small Animal Internal Medicine) Professor, Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Viginia Tech, Blacksburg, Virginia Diseases of the Thyroid Gland
John F. Randolph, DVM, Diplomate ACVIM Professor of Medicine, Cornell University Hospital for Animals, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York Diseases of the Hypothalamus and Pituitary
Robert B. Parker, DVM, Diplomate ACVS Chairman, Department of Surgery, Animal Medical Center, New York, New York Fractures of the Humerus
Rose E. Raskin, DVM, PhD, Diplomate ACVP Professor, Veterinary Clinical Pathology, Department of Veterinary Pathobiology, School of Veterinary Medicine, Purdue University, West Lafayette, Indiana Erythrocytes, Leukocytes, and Platelets
Janet L. Peterson, DVM, Diplomate ACVIM (Oncology) Staff Veterinarian, Mission MedVet, Mission, Kansas Tumors of the Skin and Subcutaneous Tissues Mark E. Peterson, DVM, Diplomate ACVIM Head, Division of Endocrinology, Department of Medicine, The Animal Medical Center, New York, New York Diseases of the Thyroid Gland Diseases of the Adrenal Gland Diseases of the Hypothalamus and Pituitary
Nyssa J. Reine, DVM Diplomate ACVIM Department of Medicine, The Animal Medical Center, New York, New York Pancreatic Beta Cell Neoplasia Laura G. Ridge, DVM, Diplomate ACVIM Internal Medicine Resident, Department of Small Animal Medicine and Surgery, University of Georgia, Athens, Georgia Heartworm Disease
W0422-PR.qxd
xiv
11/15/05
6:07 PM
Page xiv
Contributors
Mark C. Rochat, DVM, Diplomate ACVS Associate Professor and Chief, Small Animal Surgery, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma Fractures of the Pelvis Amputation of the Digit Wayne S. Rosenkrantz, DVM, Diplomate ACVD Partner, Animal Oncology Clinic, Tustin and San Diego, California Miliary Dermatitis and Eosinophilic Granuloma Complex Edmund J. Rosser, Jr., DVM, Diplomate ACVD Professor, Dermatology, Small Animal Clinical Sciences, Michigan State University, College of Veterinary Medicine, East Lansing, Michigan Pyoderma James K. Roush, DVM, MS, Diplomate ACVS Professor and Section Head, Small Animal Surgery, Veterinary Clinical Sciences, Kansas State University, Manhattan, Kansas Fractures of the Shoulder Miscellaneous Diseases of Bone John E. Rush, DVM, MS, Diplomate ACVIM (Cardiology), Diplomate ACVECC Professor and Associate Department Chair, Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts Valvular Heart Disease Valerie F. Samii, DVM, Diplomate ACVR Associate Professor, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Cardiovascular Radiolography Diagnostic Imaging in Respiratory Disease Randall H. Scagliotti, DVM Associate Clinical Professor, Department of Surgical and Radiological Sciences, University of California, Davis, California Neuro-opthalmology Vicki J. Scheidt, DVM, Diplomate ACVD Hanover Veterinary Clinic, Hanover, New Hampshire Feline Symmetrical Alopecia Patricia A. Schenck, DVM, PhD Assistant Professor, Diagnostic Center for Population and Animal Health, Endocrine Diagnostic Section, Michigan State University, Lansing, Michigan Diseases of the Parathyroid Gland and Calcium Metabolism
Eric R. Schertel, DVM, PhD, Diplomate ACVS COO, Surgery, MedVet, Worthington, Ohio Surgical Correction of Patent Ductus Arteriosus Shock Principles of Thoracic Surgery Karsten E. Schober, DVM, PhD, Diplomate ECVIM-CA Clinical Assistant Professor, Veterinary Teaching Hospital, The Ohio State University, Columbus, Ohio Cardiovascular Drugs Linda G. Shell, DVM, Diplomate ACVIM (Neurology) Editor and Consultant, Veterinary Information Network, Davis, California Neurology and Internal Medicine Consultant, Veterinary Neurology Education and Consulting, Pilot, Virginia Peripheral Nerve Disorders G. Diane Shelton, DVM, PhD, Diplomate ACVIM (Internal Medicine) Professor, Director, Comparative Neuromuscular Laboratory, Department of Pathology, University of California, San Diego, La Jolla, California Disorders of the Muscle and Neuromuscular Junction Robert G. Sherding, DVM, Diplomate ACVIM Professor, Small Animal Internal Medicine, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Feline Leukemia Virus Feline Immunodeficiency Virus Feline Infectious Peritonitis (Feline Coronavirus) Feline Infectious Respiratory Disease Canine Infectious Tracheobronchitis (Kennel Cough) Canine Distemper Intestinal Viruses Rabies and Pseudorabies Miscellaneous Viral Diseases Rickettsiosis, Ehrlichiosis, Anaplasmosis, and Neorickettsiosis Borreliosis (Lyme Disease) Systemic Bacterial Infectious Diseases Systemic Mycoses Toxoplasmosis and Other Systemic Protozoal Infections Diseases of the Esophagus and Disorders of Swallowing Diseases of the Stomach Diseases of the Intestines Diseases of the Liver and Biliary Tract Diseases and Surgery of the Exocrine Pancreas Constipation and Anorectal Diseases Respiratory Infections Pleural Effusion
W0422-PR.qxd
11/15/05
6:07 PM
Page xv
Contributors
Peter Shires, BVSc, MS, Diplomate ACVS Professor, Small Animal Surgery, Director, Veterinary Educational Technologies, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia Fractures of the Femur Gretchen K. Sicard, DVM Assistant Professor, Small Animal Surgery, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas Surgery of the Urinary Bladder Surgery of the Ovaries and Uterus Surgery of the Vagina and Vulva Daniel D. Smeak, DVM, Diplomate ACVS Professor, Small Animal General Surgery, Head, Small Animal Surgery, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Selected Skin Graft and Reconstructive Techniques Surgery of the External Ear Canal and Pinna Francis W. K. Smith Jr., DVM, Diplomate ACVIM (Cardiology, Small Animal Internal Medicine) Clinical Assistant Professor, Clinical Sciences, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts Vice-President, VetMed Consultants, Inc., Santa Fe, New Mexico Electrocardiography Disorders of the Cardiac Rhythm Mark M. Smith, VMD, Diplomate ACVS, Diplomate AVDC Center for Veterinary Dentistry and Oral Surgery, Gaithersburg, Maryland Fractures of the Skull Neoplasia of the Axial Skeleton
xv
Michael Stone, DVM, Diplomate ACVIM (Small Animal Internal Medicine) Assistant Clinical Professor, Department of Clinical Studies, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts Ultrasonographer, Veterinary Internal Medicine Mobile Specialists, North Woodstock, Connecticut Systemic Immune-Mediated Diseases Steven F. Swaim, DVM, MS Professor, Small Animal Surgery, College of Veterinary Medicine, Auburn University, Auburn, Alabama Management of the Traumatic Wound by Primary Closure Robert A. Taylor, BS, DVM, MS, Diplomate ACVS Clinical Affiliate, Veterinary Teaching Hospital, Colorado State University, Fort Collins, Colorado Chief Surgeon, Alameda East Veterinary Hospital, Denver, Colorado Scapulohumeral Luxation Larry P. Tilley, DVM, Diplomate ACVIM (Internal Medicine) VetMed Consultants, Inc., Santa Fe, New Mexico Electrocardiography Disorders of Cardiac Rhythm James Tomlinson, DVM, MVSc, Diplomate, ACVS Professor, Orthopedic Surgery, Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri Fractures and Growth Deformities of the Radius and Ulna, Luxation of the Elbow David M. Vail, DVM, Diplomate ACVIM (Oncology) Professor, Oncology, Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado Lymphoid Neoplasia
Rebecca L. Stepien, DVM, MS, Diplomate ACVIM Clinical Associate Professor, Cardiology, Clinical Cardiologist, Department of Medical Sciences, University of Wisconsin School of Veterinary Medicine, Madison, Wisconsin Vascular Diseases
Raymund F. Wack, DVM, Diplomate ACZM Assistant Clinical Professor, Medicine and Epidemiology, College of Veterinary Medicine, University of California, Davis, California Basic Husbandry and Medicine of Pet Reptiles
Elizabeth A. Stone, DVM, Diplomate ACVS Dean and Professor, Surgery, Ontario Veterinary College/University of Guelph, Guelph, Ontario, Canada Mammary Gland Neoplasia
Stephen D. White, DVM, Diplomate ACVD Professor, Medicine and Epidemiology, School of Veterinary Medicine, University of Califonia Davis, California Food Hypersensitivity David A. Wilkie, DVM, MS, Diplomate ACVO Associate Professor, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio Ophthalmic Equipment and Techniques Diseases of the Lens Diseases of the Uvea Glaucoma
W0422-PR.qxd
11/15/05
6:07 PM
Page xvii
▼
Preface
The world of small animal veterinary medicine continues to grow in scope and complexity. Practicing veterinarians and veterinary students are continuously bombarded with new information on the diagnosis and treatment of diseases affecting pet animals. Busy veterinarians have precious little time to keep up with current developments in the profession. We recognize that challenge, and thus we attempt to provide a comprehensive book that covers the commonly encountered disorders seen in small animal practice. Although difficult to include all the pertinent material in a one-volume text, the semi-outline format used in the Manual allows our authors to be concise, yet thorough. As in the first two editions, we continue to make information user friendly by including many key points, condensing information into tables and bulleted lists, and illustrating procedures and surgical techniques with many simple line drawings. However, it is impossible to provide an exhaustive discussion of all small animal diseases in one book. Pathophysiology of disease, rare conditions, and infrequently used diagnostic and treatment methods are not included. Readers are directed to many well-written veterinary textbooks or journals that cover various subjects in greater detail than what we have space for in the Manual. But the Manual seems to have found a niche. From what countless practitioners and students have told us, it is a text that is not kept on a bookshelf gathering dust, but is open on a counter, desk, or exam table where it is almost constantly being used to update or review important clinical information. This is exactly how we hoped the book would be used. Although we have stayed true to the book’s original style, we have added some new authors, section editors, and chapters. New chapters include Pain Management, Vaccination Guidelines, Disorders of the Claw, Postoperative Physical Rehabilitation, and Syncope. Examples of other new areas covered in the third edition are: new emerging infectious diseases; skin cytology for diag-
nosis of skin disorders; an overview of current imaging techniques such as digital radiography, computed axial tomography, and magnetic resonance imaging; technique for laser declaw; indications for laparoscopic and thorascopic surgery; and a brief discussion of arthroscopic procedures for certain joint disorders. Additionally, all chapters, even if rewritten by the same author, have been thoroughly and meticulously revised and updated, and several new illustrations have been added. The Appendix of Drug Dosage Guidelines has also been updated and many new drugs included. We are very grateful to all those who have contributed to the third edition of the Manual. The section editors and chapter authors have done an excellent job organizing and presenting information in their areas of expertise. They have correlated their own clinical experience with information available in the literature and have provided useful and practical information. We also wish to thank the faculty, residents, and students at The Ohio State University College of Veterinary Medicine for their support and advice on the preparation of this edition. The Manual is the result of a tremendous amount of organizing, copyediting, proofreading, and attending to details. We are indebted to the staff at Elsevier for all their hard work, particularly Ms. Jolynn Gower, Managing Editor. Thanks also to Ms. Joy Moore, Senior Project Manager. We also thank Ms. Sarah Self, Production Editor and the staff at Graphic World Publishing Services. Finally, we appreciate the work of our very talented medical illustrator, Ms. Felecia Paras. As we have indicated in both of the previous editions of the Manual, we are striving for continued improvement of our work. We welcome any comments or criticisms that will help make future editions an even more valuable part of the small animal clinicians’ library. Stephen J. Birchard, DVM, MS Robert G. Sherding, DVM
xvii
W0422-Ch001.qxd 11/10/05 4:39 PM Page 1
▼
Section
Chapter
▼
1 1
Patient Management Stephen J. Birchard
History and Physical Examination Denise Jones
Veterinarians are faced with many diagnostic challenges on a daily basis. By far the most important diagnostic tool that veterinarians possess is their ability to obtain a complete history and perform a thorough physical examination. This information, when accurately interpreted, lays the foundation for a logical diagnostic and therapeutic plan. A systematic and thorough history and physical examination prevents unnecessary diagnostic testing and needless cost to the owner.
GENERAL HISTORY Obtain both objective and subjective information when collecting the history.
•
• Objective data consist of the signalment, environ-
•
ment, diet, and medical history. For a patient’s first visit, determine the length of ownership and the place of origin. Subjective data include a description of the primary complaint and a historical overview of the patient’s general health. The owner often may not realize how a seemingly unimportant observation may be related to the primary problem. Tailor specific questions to the individual case.
Signalment • The signalment consists of the patient’s age, species, breed, and gender. Note whether the patient is intact
or neutered. The patient’s breed will sometimes become a key factor when formulating differential diagnoses. Congenital or hereditary disorders should be considered. For example, familial renal disease should be a primary differential for a young Shih Tzu presenting with polydipsia and polyuria. In other cases the disease process may not be congenital or hereditary, but it may be more prevalent in certain breeds than others. For example, a small-breed dog that presents with lameness that is localized to the hip is more likely to have avascular necrosis of the femoral head (Legg-Perthes disease) than hip dysplasia. Verify that previously recorded data are correct and up-to-date. For example, the patient may have been neutered since its last visit or the physical examination may indicate that the recorded age is questionable.
Environment • Gather environmental information as a routine part •
of the patient’s history. In many circumstances, where the pet is kept provides a vital clue in diagnosis. Determine whether the pet is free roaming or confined to a yard or house. If the patient is confined to a yard, ask the owner if the yard is fenced, if the pet is chained, and if an escape has been possible in the recent past. The free-roaming or recently escaped pet may have had access to toxins or have been 1
W0422-Ch001.qxd 11/10/05 4:39 PM Page 2
2
•
•
•
Section 1 / Patient Management
subject to trauma, which is less likely for an indoor pet. For example, in a dyspneic patient, diaphragmatic hernia ranks higher on the differential diagnosis list for a free-roaming pet than for a strictly indoor pet. Determine the geographic origin of the pet and any record of recent travels. This becomes paramount if the patient has been exposed to diseases endemic to certain regions but not prevalent in the current environment, such as systemic mycoses and vector-borne diseases. Determine the pet’s water source. This may be important if the pet has access to contaminated outdoor water, toilet-bowl water treated with deodorants or cleansers, or if the pet has limited access to water. Question the owner if there has been any potential exposure to toxins such as antifreeze, pesticides, or insecticides if the patient’s clinical presentation is indicative of intoxication. Exposure to houseplants or outdoor vegetation may also provide a clue. For a vomiting or anorexic patient, questions should include access to potential ingested foreign bodies.
Dietary History • Always include dietary information in the routine
•
database. Question the owner about the patient’s appetite and noticeable weight gain or loss. Also note whether the owner watches the pet eat. Determine the following pertinent facts in the dietary history: • Type of diet (e.g., dry, moist, semimoist, or table food) • Brand name of food • Type of snacks • Method of feeding (i.e., free-choice or individual meals) • Amount
Preventive Health Care Status • Evaluate the patient’s preventive health care status.
•
Prior Medical History: Previous Illnesses and Surgeries • Often the patient’s prior or ongoing health problems
• • •
•
dates of each. Avoid simply asking if the patient is current on vaccinations because many clients are unfamiliar with vaccination recommendations. Inform the client about what vaccinations are available as well as the indications and booster intervals for each (see Chapter 7). For a feline patient, discuss the subjects of feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV), including the dates and results of previous testing. Exposure to stray cats or cats known to be FeLV-positive or FIV-positive may also be relevant. History of previous cat fight wounds may warrant repeat testing for FIV. However, if the patient has been previously vaccinated for FIV, then further FIV
play a role in its presenting ailment; therefore, review the information previously recorded in the medical record and discuss previous problems managed by other veterinarians. Record the dates of the previous illness or surgery, followed by a brief description of the problem, how it was managed, and the response to treatment. Discern the relevance of prior illnesses before obtaining extensive details; otherwise, the history may become unnecessarily lengthy and confusing. Specifically question the owner as to any medications the patient is currently or has recently been given. Over-the-counter products as well as prescription medications should be noted.
Primary Complaint • Use the history to identify and localize the primary
• •
Review the patient’s prior medical record.
• Record all previous vaccinations received and the
testing will be invalid since the FIV test is an antibody test. For a canine patient, record heartworm test dates and results. If the patient is receiving heartworm preventive therapy, note the type, frequency, and dose (see Chapter 152).
•
problem. Much of this information is subjective, based mostly on the owner’s interpretation of the pet’s clinical signs and behavior. Be aware that some owners are extremely observant of their pet and others are not. Prompt owners to describe the pet’s behavior and clinical signs in their own words. An astute clinician collects all data and subjectively analyzes this information in context of an owner’s perceptivity. Encourage the owner to describe the patient’s problem from its onset so that a chronologic picture is obtained. Avoid leading questions that might result in a deceptive history. For example, ask if there has been any change in frequency of defecation. Do not ask if the patient is defecating more frequently than normal. Determine the last period of normalcy or the duration of the clinical signs. This will help determine how acute or chronic the problem may be and will guide the ranking of differential diagnoses. Some differentials are more likely for an acute problem; others are more likely for a chronic problem. For example, intestinal intussusception or an intestinal foreign body are likely differentials for a puppy presenting with an acute episode of persistent vomiting. A gastric foreign body or inflammatory bowel disease are more likely in a similar patient with chronic intermittent vomiting. The onset and severity of the illness influences how rapidly or aggressively the problem should be approached.
W0422-Ch001.qxd 11/10/05 4:39 PM Page 3
Chapter 1 / History and Physical Examination
• Determine the progression of the clinical signs. Once
•
•
•
again, this may help not only in formulating a list of differentials but also in developing a treatment plan. For example, a patient presenting with a history of seizures is managed more aggressively when the seizures are increasing in frequency and length than when they have been the same for months or years. Question the owner as to any intervening signs that might provide a clue to the most likely differential diagnosis. For example, a cat with chronic diarrhea and intermittent episodes of fever is considered a more likely candidate for infectious disease than for dietary intolerance. Attempt to further define and localize the problem. For example, characterize diarrhea as originating in the small or large bowel before proceeding to a diagnostic or therapeutic plan. Ask questions regarding frequency, appearance (color and consistency), and presence or absence of straining to help localize this problem. Specific questions oriented by body systems follow in the next section. Determine treatments and response. For example, a dog presenting with pruritus unresponsive to previous treatment with corticosteroids is a more likely candidate for food allergy dermatitis than for atopy. Record what medication was given, the dose, the duration of treatment, and the level of response observed.
HISTORY ORIENTED BY BODY SYSTEMS For a complete history, include a system-by-system review of the patient’s general health. This can be accomplished by the experienced clinician as the physical examination is performed. The novice may prefer to obtain the entire history before proceeding with the physical examination. Develop a consistent and systematic method. One method is to begin with questions concerning the patient’s head and proceed caudally, as demonstrated in the following text. It is left to the clinician’s discretion as to how in-depth the client is questioned about systems that do not appear to affect the primary complaint. Apply the general principles described in the previous section in the approach to all body systems (e.g., onset and duration).
Eyes • Ask if any ocular discharge has been noted. If so,
•
describe the discharge (serous, mucoid, or mucopurulent) and determine if it has been unilateral or bilateral. Determine if ocular pain or discomfort is present as indicated by blepharospasm, face rubbing or pawing, or photophobia. These signs may be seen with anterior uveitis, glaucoma, corneal ulcerations, or foreign bodies.
3
• Ask about ocular redness, swelling, and asymmetry. • Ask if the owner has noticed a color change in the pet’s
•
eye. This change can occur with anterior uveitis and iriditis, in which hyphema may be present or the iridial color may be altered. A localized pigment change in the iris may occur with an iris cyst or melanoma. Ask the owner if their pet seems to be experiencing any loss of vision. If there is an apparent problem, does it seem to be affected by daylight or darkness? Also ask if decreased vision appears to be a unilateral or bilateral problem. See also Section 10.
Head, Neck, Ears, Nose, and Oral Cavity • Record any history of swelling or asymmetry of the head and neck region.
• Inquire about head shaking, ear scratching, and otic
•
•
discharge or odor that may indicate the possibility of otitis or a foreign body in the ear. Determine if any loss of hearing has been evident. Ask if any nasal discharge has been present. Note the character of any nasal discharge (serous, mucoid, mucopurulent, or hemorrhagic) and whether it has been unilateral or bilateral. Note any history of sneezing, nose rubbing, nasal asymmetry, or stridor. Request information relating to the oral cavity, such as odor, difficulty eating or drinking, abnormal swellings involving the gingiva or tongue, and changes in gingival pigmentation. Ask if there has been any change in the patient’s ability to vocalize. The patient’s voice can be affected either by a mass in the laryngeal region or by laryngeal paralysis.
Cardiopulmonary System • Ask if cough, exercise intolerance, weakness, or fainting have been observed. These may indicate cardiopulmonary disease. ▼ Key Point Attempt to differentiate syncope from seizures based on the owner’s description of the event.
• Syncope is a transient loss of consciousness that may be precipitated by exercise in patients with underlying cardiac disease (see Chapter 148). During a syncopal episode the patient usually demonstrates very little motor movement. The episode typically lasts less than a minute, and usually the patient returns to normal within a short period of time. Seizures vary greatly in severity. They are often preceded by a preictal phase during which the patient may be anxious or disoriented. The actual seizure usually involves a loss of consciousness and active motor activity such as tonic-clonic limb movements and rapid jaw movements. The postictal phase may last from minutes to days. The patient may be either overly agitated or depressed during this time. Seizure disorders are discussed in Chapter 127.
W0422-Ch001.qxd 11/10/05 4:39 PM Page 4
4
Section 1 / Patient Management
• Characterize coughing as productive or nonproduc-
•
tive, moist or dry, and harsh or honking. Some owners may confuse a productive cough with vomiting; therefore, ask whether abdominal heaving occurs prior to the production of fluid or foam or whether coughing and gagging are more typical. Yellow or green fluid is indicative of vomitus. The circumstances surrounding the cough are often relevant. For example, cough associated with tracheal collapse is often elicited with excitement or pulling on the patient’s collar. Coughing secondary to congestive heart failure may be exacerbated with the pet in a sternal position. Is the pet routinely exposed to cigarette smoke? This can play a role in chronic bronchitis or feline asthma. Determine if dyspnea has been observed. It may be difficult for an owner to differentiate between heavy panting and true dyspnea. Ask if the pet is breathing the same during the exam as it was at home. Also inquire if the pet seems reluctant to exercise or lie down, as would be expected with most dyspneic animals. Open-mouth breathing for a cat is always considered abnormal except when it is excessively stressed. See also Chapter 142.
Digestive System Most problems related to the digestive system are clinically manifested as anorexia, regurgitation, vomiting, diarrhea, constipation, weight loss, or a combination of these. Determine which clinical sign is being exhibited, because the owner may incorrectly interpret what is observed. For example, owners often assume that their pet is constipated if it is observed straining to defecate, when diarrhea may be the actual cause. Ask specific questions to differentiate between vomiting and regurgitating. Regurgitation is characterized as a passive ejection of ingested material from the esophagus. It typically occurs soon after a meal is eaten. The regurgitated material is usually undigested and tubular in form. Vomiting frequently involves an abdominal heave movement or retching. Time of vomiting in relation to eating should be noted and is variable depending on the underlying disorder. Vomitus is not tubular in form and may consist of froth, fluid, yellow-green bile, food, or ingested foreign material. Include the following specific information in approaching a digestive system problem:
• Review dietary history, as previously described. Specifically ask about treats or access to garbage. environmental history, as previously described. • Has there been any exposure to toxins, drugs, or plants? • Are there any toys or other foreign objects that the pet may have ingested? Note vaccination status.
• Record
•
• Ask how the patient’s appetite has been and how it compares with its normal appetite.
• Has any vomiting been noted (onset, frequency,
•
progression)? • Has the owner actually observed the pet vomiting? In a multi-pet household, verify that it is the presenting patient that is actually vomiting. • Does the pet exhibit any retching or abdominal heaving when “vomiting”? • How frequently is the pet vomiting? • What is the relationship of vomiting to eating, if any? • What is produced when the pet vomits? Describe the vomitus—digested or undigested food, fluid, foam, and color. Green or yellow fluid is typical of bile. Has the owner witnessed the patient defecating, and are there any abnormalities? • How long since the last observed bowel movement? • Has any diarrhea been observed (onset, progression)? • Has the stool been persistently loose? • How frequently does the animal defecate? • What volume of stool is typically produced? Small amounts of stool produced frequently are indicative of large bowel disease, and larger amounts of stool produced less frequently are more typical of small bowel disease. • What is the color and consistency of the stool (formed but soft, cow patty–like, watery)? • What is the consistency of the last stool produced? • Is there any blood or mucus present? (These are indicative of large bowel disorders.) • Does the animal strain while defecating? Straining is typical of diseases localized to the colon, rectum, or anus. • Does the owner witness all eliminations (i.e., is the pet walked on a leash, does it have access to a fenced yard. or does it roam free)? Consider that owners may not be fully aware of what their pet is eliminating. See also Section 6.
Urinary System Often, the owner complaint may be that the pet is urinating excessively. The following questions help distinguish whether excessive urination is due to polyuria or pollakiuria:
• Has there been any change in the quantity of water that the pet consumes?
• Are there other pets in the household that have access to the same water source?
• Is the pet urinating inside the house (i.e., having “accidents”)?
W0422-Ch001.qxd 11/10/05 4:39 PM Page 5
Chapter 1 / History and Physical Examination
•
• •
•
• Are these urinations observed? (The owner should verify that this is the pet having the accidents versus another pet in the household.) • Does the owner know if the accidents occur while the animal is awake or asleep? If the owner has not observed the act, there may be other clues to pursue. Where has the owner found the accidents (where the pet sleeps, next to a door, etc.)? A patient that is experiencing urinary incontinence may be dribbling urine while resting in its sleeping area. Dogs that are well house-trained may urinate close to an outside door if they are unable to hold their urine until allowed access to the outside yard. Another clue to urinary incontinence is the presence of urine on the pet’s perineal region or rear legs. • Does the animal seem to be consciously aware of the act, or does the animal dribble urine without seeming to be aware? Has there been any change in frequency of urination? If the patient is urinating frequent small amounts (pollakiuria), then differentials should include lower urinary tract disorders such as cystitis, urolithiasis, and neoplasia. Does the animal appear to strain while urinating? (This is typical of lower urinary tract disease.) What quantity of urine is produced? Larger quantities of urine are indicative of polyuria, which occurs with a large number of underlying metabolic disorders (renal disease, liver disease, diabetes, mellitus, diabetes insipidus, hyperadrenocorticism, hypercalcemia, etc.). Has the owner noticed any blood in the urine? If so, is it before, during, or after urination? Bleeding only at the beginning of urination is more likely to be from the urethra. Hematuria present throughout the urination is most typical of bleeding of renal origin. Blood seen at the end of urination usually originates from the urinary bladder. Remember to consider the genital system as a potential source for the blood, as with prostatic disease or vaginal masses. See also Section 7.
Genital System Females
• Verify if the patient is intact or spayed. • Note any vulvar discharge and describe the amount, •
consistency, color, and odor. This type of discharge may be valid for spayed pets as well as intact ones. If the patient is intact, ask the following questions: • When did the owner last observe a heat cycle for the patient? Was it a normal cycle? How long did it last? • Have the heat cycles been at regular intervals? • Has the pet been intentionally bred or is there any possibility of an accidental breeding? Is there any
5
previous history of pregnancy? If so, were there any complications (e.g., dystocia, abortions, mastitis, metritis, etc.)? • If there is a history of successful pregnancy, how many puppies were whelped? • Has the patient been tested for brucellosis? When? Was the mate previously tested?
Males
• Verify if the patient is intact or neutered. • Has the patient exhibited any evidence of difficulty urinating or defecating?
• Has any preputial or penile discharge been noted? (Describe the amount, consistency, color, and odor.)
• The following questions apply to intact males: • Has the patient been used for breeding? If so, when was he last bred? Was there any difficulty in breeding? • Were any litters sired? If so, how many puppies were in each litter? • Has the patient been tested for brucellosis? When? Was the mate previously tested? See also Section 7.
Swelling or Masses Ask if any abnormal masses or swellings have been observed that have not been previously mentioned. Note the location, how long the mass or swelling has been present, and any change in appearance, character, or size. If the patient has not been examined in your practice before, ask if the mass has been previously sampled by either a fine needle aspirate or a surgical biopsy. Obtain a fine needle aspirate from masses that have not been previously investigated. ▼ Key Point Perform diagnostics on masses that are changing rapidly since there is a higher incidence of malignancy associated with these.
Skin An accurate and detailed history is essential for successful management of dermatologic problems. Remember that some systemic disease processes may manifest themselves in cutaneous changes, such as hyperadrenocorticism or systemic lupus erythematosus (SLE). Some clinicians prefer to have the owner fill out a standardized dermatologic history form prior to specific questioning. Include the following questions on such a form, or directly ask the owner:
• Has any hair loss been observed? Did hair loss involve the undercoat or the main coat?
• Is there evidence of pruritus (scratching, biting, or licking)?
• Where does the pet seem to be most pruritic? Many atopic and food-allergic patients may rub their faces
W0422-Ch001.qxd 11/10/05 4:39 PM Page 6
6
• • • • •
• • •
Section 1 / Patient Management
and lick their feet excessively. Flea-allergic patients predominantly chew the dorsal tail-base region. • If the pet is pruritic, how severe is it? Have the owner grade the degree of pruritus on a scale of 1 to 10, with 10 being the most severe. This helps subsequent evaluation of treatment response. • Is the skin problem continuous or seasonal? If seasonal, then determine when the pet is most severely affected. • Has the owner noticed fleas? What flea products have been used? Has the pet been on monthly preventive treatment? If so, which product? • What type of bedding does the pet use? • Is there any exposure to feathers? • What type of carpet is in the house (wool, synthetic, cotton)? • What is the diet? What treats are given? • Are there any indoor plants? • Is the pruritus worse indoors or outdoors? • Is there any exposure to tobacco smoke? • Has the pet ever had any drug reactions? (describe) Describe odors, pigment changes, or texture changes of the skin or hair coat. Does the pet have any dandruff? If so, what areas are involved? How often is the patient groomed (clipped, brushed, combed)? How often is the patient bathed? When was the pet last bathed, and what products were used? Are there other pets in the household? Has the pet been exposed to other animals outside of the household? Did any of these animals exhibit signs of skin disease? Do any members of the household have skin problems? Do any of the pet’s close relatives have a history of skin problems? Has there been any previous treatment? When was the pet last treated? What was the name of the drug, the dose, the route of administration, and the frequency of treatment? What level of response was noted? See also Section 5.
Musculoskeletal System • History relating to the musculoskeletal system generally focuses on lameness or discomfort.
• Remember to correlate the age and breed of the individual to the lameness observed. There are numerous examples in which the signalment may provide a clue to the underlying disorder. Many musculoskeletal disorders occur predominantly in young, large-breed dogs. These include but are not limited to osteochondritis dissecans, ununited anconeal process, panosteitis, and hypertrophic osteodystrophy. Middle-aged to older large-breed patients are more at risk for neoplasia such as osteosarcoma.
•
• •
•
• •
•
Small-breed individuals have a higher tendency toward medial patellar luxation and avascular necrosis of the femoral head. When lameness has been observed, discern if the patient has been bearing weight on the affected leg. Determine if lameness has been previously observed in this limb or other limbs. For example, panosteitis is often considered a shifting leg lameness. Ask if there are any other signs of illness in addition to the lameness. The lameness may be a manifestation of systemic disease such as SLE or Lyme disease. Has the owner noticed any swelling or masses associated with the affected limb? Is the lameness intermittent, progressive, or static? Is the lameness worse before or after exercise? Arthritic patients often “warm out” of their lameness. Question owner in regard to routine daily activity such as running, jumping, hunting, jumping on and off furniture, etc. Has the pet engaged in any activities out of the ordinary lately? These patients are more at risk for traumatic injuries such as a cranial cruciate ligament tear or a ruptured intervertebral disc. Ascertain any possibility of trauma that could have resulted in a fracture. In some cases, the owner may have witnessed the traumatic incident. In others, the patient may have been unsupervised during the time in question. Specifically ask if the patient was confined to the house or a fenced area. If the animal was free roaming and unobserved, determine how long it was unsupervised to help assess the possibility of a traumatic incident. Determine if the owner has observed loss of muscle mass, asymmetry of the limbs, or swollen joints. Ask if the patient has demonstrated any difficulty rising, climbing stairs, or descending stairs. These problems are frequently noted in patients with hip dysplasia, intervertebral disc disease, or neurologic diseases such as degenerative myelopathy. In regions endemic for Lyme disease, ask if any ticks have been observed on the pet. Check vaccination status regarding Lyme disease. In nonendemic areas, obtain a travel history. See also Section 8.
Nervous System Many questions related to the nervous system may have been previously asked while taking the history of the other body systems. Once again, consider the age and breed to help provide clues to the differential diagnoses. Small-breed dogs are more commonly seen with portosystemic shunts and may present with neurologic signs. Hypoglycemia and congenital diseases are prime differentials for seizuring puppies. Epilepsy typically has an onset in young adults. For seizures with an onset during middle age or geriatric years, consider metabolic disease or neoplasia. Diseases of the central nervous
W0422-Ch001.qxd 11/10/05 4:39 PM Page 7
Chapter 1 / History and Physical Examination
system (CNS) may be reflected by abnormalities in other systems (e.g., blindness, hearing loss, or urinary incontinence). With a presenting complaint of rear limb “weakness,” differentiate between disorders of the musculoskeletal system and those of the nervous system with the history and physical examination. Consider the following points in regard to the nervous system:
• Verify vaccination history for distemper and rabies. • Focus on obtaining a good environmental history,
• •
• •
•
such exposure to toxins or plants. Is there any possibility of a traumatic accident resulting in head trauma or spinal injury? Ask if any behavioral changes, such as aggression or dementia, have been observed. If these signs are present, are they intermittent or persistent? Is there any evidence of pain when the patient is touched or picked up? Does the pet cry or yelp when it moves? These signs can occur in a patient with intervertebral disc protrusion. Record any history of seizures, including their duration and the time interval between them. Obtain a description of the seizure. If behavioral changes or seizures have been observed, ask if there is any relationship between when the pet eats and when these signs occur. Neurologic signs may be exacerbated postprandially in patients with a portosystemic shunt. Ask if there has been any evidence of weakness in the patient. If present, is the weakness generalized or localized (i.e., to one side of the body, in the forelegs, or to the rear)? Determine if any abnormalities in posture or ambulation have been observed, such as the pet’s tendency to fall to one side, to circle to one side, to knuckle over, or to drag its toes. Be sure to note the acuteness of onset and the progression of the neurological signs.
•
cat. The most commonly used systems utilize either a 5- or 9-point scale. I prefer the 5-point scale, where score 1 correlates to an emaciated body condition and score 5 indicates a grossly obese state. Score 3 is considered an ideal weight for the patient. Those body conditions that fall between two scores are assigned a half score. For example, a patient that is just over its ideal weight would be scored as 3.5. Refer to Tables 1-1 and 1-2 for details of body condition scoring in dogs and cats, respectively. Record the patient’s body condition score (BCS) in the patient’s record each visit. If the collection of the history and the physical exam result in a vague, poorly defined illness, consider hospitalizing the patient for observation. Sometimes owners may find it difficult to accurately describe the pet’s behavior or clinical signs. Also, some patient’s may mask their depression or pain when they initially arrive in a new environment. A nervous patient should be reevaluated once it has adjusted to the hospital surroundings. Occasionally, animals become more agitated the longer they are away from their owner. Finally, many disease processes become more evident with time, so the physical should be repeated on any undiagnosed or hospitalized patient.
Table 1-1. BODY CONDITION SCORING FOR DOGS Score
Body Condition
Parameters Evaluated
1
Emaciated
2
Thin
3
Ideal
4
Overweight
5
Obese
Skeletal in appearance with no obvious body fat and minimal muscle mass. Boney prominences visible. Ribs slightly visible and easily palpable. Prominent waist and abdominal tuck from side and dorsal views. Ribs not visible but palpable with only a slight fat covering. Abdominal tuck present from side view, and waist present from dorsal view. Smooth contour over tail base. Difficult to palpate ribs because of moderate fat layer. Loss of abdominal tuck from side view, and wide waist from dorsal view. Thickening over tail base. Excessive fat cover over entire body. Ribs extremely difficult to palpate. No waist present from dorsal view. Fat skin folds droop from caudal abdomen on side view. Thick fat roll at tail base.
See also Section 9.
PHYSICAL EXAMINATION: GENERAL OBSERVATION • To begin the physical examination, watch the patient as it enters the room.
• Continue the visual evaluation of the patient while
•
the history is collected. Observe the general body condition and any abnormalities in behavior, attitude, posture, ambulation, and respiratory pattern. During this time, the patient may be placed on the examination table or allowed to roam the examination room. During the general observation of the patient, evaluate its body condition. Several body condition scoring systems have been developed to aid in assessing the amount of body fat present in the individual dog or
7
W0422-Ch001.qxd 11/10/05 4:39 PM Page 8
8
Section 1 / Patient Management
Table 1-2. BODY CONDITION SCORING FOR CATS Score
Body Condition
Parameters Evaluated
1
Emaciated
2
Thin
3
Ideal
Skeletal in appearance in the shorthaired cat. Boney protrusion of the wing of ilia and lumbar vertebra. Ribs easily palpable with only slight fat covering. Waist prominent caudal to ribs. Minimal abdominal fat present. Uniform distribution of body fat. Ribs palpable but not prominent. Slight waist present caudal to ribs. Minimal abdominal fat pad present ventrally. Ribs difficult to palpate. Loss of visible waist and some abdominal distention present. Moderate abdominal fat pad present ventrally. Ribs not palpable. Excessive fat deposits generalized but especially noted in abdominal region.
4
Overweight
5
Obese
PHYSICAL EXAMINATION: VITAL SIGNS Initially, record the vital signs and current body weight of every patient.
Body Temperature • Obtain the rectal temperature early in the course of
• •
the examination to help avoid an elevation of temperature that may result from anxiety or excitement. If you are unsure whether the elevated temperature is the result of environmental factors, then consider hospitalizing the patient to recheck the body temperature in a few hours. In emergency situations, attend to hypothermia or hyperthermia early in the course of the examination. Normal rectal temperature for dogs range from 99.5°F to 102.5°F. For cats the range is 100.5°F to 102.5°F. Note any blood or melena that is evident on the thermometer.
Pulse and Heart Rate • Record the pulse rate and evaluate the pulse quality. • Normal heart rate values (beats per minute) are as follows: • Large dogs—60 to 100 bpm • Medium-size dogs—80 to 120 bpm
•
• Small dogs—90 to 140 bpm • Domestic cats—140 to 250 bpm Determine if arrhythmias or pulse deficits are present.
Capillary Refill Time • Lift up the upper lip, press on the buccal mucous membranes, and determine how long it takes for the membranes to resume normal pink color (normal is <2 seconds).
Respiratory Rate • Evaluate the respiratory pattern as the rate is taken. • The normal respiratory rate for dogs is 10 to 30 •
breaths per minute. For domestic cats the normal rate is 20 to 30 breaths per minute. If moderate or severe dyspnea is present, observe caution in continuing with the remainder of the examination. The additional stress of restraint and examination may result in life-threatening respiratory compromise. Administer oxygen therapy followed by a rapid oral examination and thoracic auscultation to help determine the source of the dyspnea and the appropriate emergency therapy. After stabilizing respiratory function, continue with the remainder of the physical examination.
Hydration • Note if the eyes appear sunken or if the third eyelids • •
are protruding bilaterally. This can be seen in a markedly dehydrated patient. Note if the mucous membranes are dry or tacky, as is typical of a moderately dehydrated patient. Evaluate skin turgor by gently lifting the skin over the dorsal thorax. Geriatric or cachectic patients may appear to be dehydrated based on their skin turgor alone because of the loss of the skin’s natural elasticity.
PHYSICAL EXAMINATION: BODY SYSTEMS The physical examination should follow the same logical pattern as the history. A consistent approach is taken so that no part of the examination is overlooked. For example, analyze one body system at a time, starting with the patient’s head and proceeding caudally. Look at each body system as a piece of the puzzle. Attempt to link the results of the entire history and physical exam so that multisystemic disorders will not be overlooked. Additionally, your evaluation of one body system may affect what you recommend for an unrelated problem for another body system. Consider the whole patient when you formulate your diagnostic and therapeutic plans.
W0422-Ch001.qxd 11/10/05 4:39 PM Page 9
Chapter 1 / History and Physical Examination
Head • Examine the head carefully for evidence of asymme-
•
try or localized swellings. Palpation is necessary to assess the nature of any swelling or mass (firm or fluctuant, mobile or attached). Evaluate the posture of the head and neck. Ventriflexion may be observed in cats with hypokalemia, chronic organophosphate toxicity, thiamine deficiency, and polymyopathies. Reluctance to move the head may be noticed in a dog with cervical intervertebral disc protrusion.
• •
Eyes The ocular exam often provides information that relates to systemic disorders. Systemic infections may manifest themselves through retinal lesions (FeLV, toxoplasmosis, fungal infections, etc.) or as anterior uveitis (FeLV, feline infectious peritonitis, ehrlichiosis, etc.).
• Determine if abnormalities are present unilaterally or • •
•
• •
•
•
bilaterally. If only one eye is affected, examine the normal eye first. Note evidence of pain such as blepharospasm, photophobia, and pawing or rubbing at the eye(s). Observe the size and symmetry of the eyes. Congenital microphthalmia or acquired phthisis bulbi results in a smaller-than-normal eye, whereas chronic glaucoma results in a larger-than-normal eye. Examine the position of the eyes for evidence of enophthalmos, exophthalmos, or strabismus. Enophthalmos may be secondary to microphthalmia, loss of the orbital fat pad (e.g., cachexia), Horner syndrome, dehydration, or acute ocular pain (e.g., anterior uveitis). Exophthalmos may be due to space-occupying lesions of the orbit (neoplasia, abscess, or cellulitis), buphthalmos (glaucoma), myositis, or breed predisposition. Note ocular discharge and characterize it as serous, mucoid, or mucopurulent. Note any swelling or masses involving the eyelids. Evaluate the eyelids for entropion and ectropion. Carefully examine the palpebral margins under magnification for evidence of distichiasis. Magnification may be necessary to identify distichia. Evaluate the conjunctiva for hyperemia, chemosis, pallor, or jaundice of the underlying sclera. The superior conjunctiva is more reliable for evaluating hyperemia than the inferior conjunctiva, which may normally appear somewhat hyperemic over the surface of the third eyelid. Note any abnormal pigmentation or masses involving the sclera or conjunctiva. Protrusion of the third eyelid may be a reflection of enophthalmos or Haw syndrome in cats. Haw syn-
•
•
• •
•
•
9
drome is a bilateral protrusion of the third eyelids that may be seen in feline patients with gastrointestinal disease or parasites. Note any masses associated with the nictitans or prolapse of the gland of the nictitans. Apply gentle pressure to the superior globe to aid in exposing the nictitans. Apply topical anesthesia and grasp the third eyelid gently with forceps so that the posterior surface of the third eyelid can be examined for foreign bodies or follicular hyperplasia. Examine the cornea for cloudiness, pigmentation, vascularization, or obvious defects. Evaluate the anterior chamber for aqueous flare, hypopyon, hyphema, or abnormal masses. If a slit lamp is not available, use a magnifying lens and a penlight to produce a narrow beam of light so that subtle aqueous flare can be detected when the anterior chamber is viewed from the lateral aspect. Evaluate pupil size and symmetry and direct and consensual pupillary light reflexes. A darkened room aids in this examination. Persistent pupillary membranes may also be identified. Evaluate the iris for pigmentary changes, hyperemia, roughening, swelling, or synechia. Any of these changes can be seen with anterior uveitis. Tumors or cysts may occasionally occur on the iris. Melanoma of the iris may initially present as patchy pigmentation in the iris. Ask the owner when the color change was first noticed. Evaluate the lens via direct or indirect ophthalmoscopy for the presence of lenticular sclerosis, cataracts, or displacement of the lens. If a “red eye” is found during the exam, perform a Schirmer tear test, a fluorescein stain, and a measurement of intraocular pressure. Perform the Schirmer tear test prior to the other tests since eye drops used in the subsequent tests can affect results. A Tonopen is a valuable tool for easily measuring intraocular pressure. For a complete fundic examination, dilate the pupil with a short-acting topical mydriatic. Evaluate the fundus for vascularity, areas of hemorrhage, pigmentary changes, chorioretinal dysplasia or hypoplasia, and retinal detachment. Evaluate the optic disc for color, size, vascularity, fissures or colobomas, and abnormal masses. Practice and experience are the keys to retinal examinations. Evaluate vision by dropping a cotton ball in front of the patient or by rolling a cotton ball across the table or floor. Alternatively, create an obstacle course to discern if the patient has the visual ability to negotiate barriers. Compare the patient’s performance in full-light versus low-light settings. Evaluate the menace response. Young puppies and kittens (<6 weeks of age) normally do not respond appropriately to menace. See also Section 10.
W0422-Ch001.qxd 11/10/05 4:39 PM Page 10
10
Section 1 / Patient Management
Oral Cavity • Perform a thorough oral examination if the patient’s
•
• •
•
demeanor allows (Fig. 1-1). If this examination is indicated but the patient is uncooperative or aggressive, sedation (see Chapters 2 and 64) may be necessary. Sedation also allows the clinician to perform a more thorough oral exam in any patient presenting with clinical signs suggestive of oral cavity disease (i.e., ptyalism, halitosis, bleeding, or oral pain). Always carefully evaluate the mucous membranes for color, moisture, and capillary refill time to assess the hydration status. Hyperemia, congestion, cyanosis, jaundice, pallor, or petechiae can provide vital diagnostic clues to the underlying disorder. Note gingival masses, ulcerations, inflammation, or pigmentary changes. Examine the teeth for calculus or exudate at the gingival margin. Digital pressure applied to the gingiva may aid in expressing exudate when a tooth root abscess is suspected. Note any fractured teeth, and look for evidence of pulp exposure. Slab fractures of the upper fourth premolar may be difficult to identify. Be suspicious of a fracture if a significant amount of calculus has accumulated on the surface of this tooth compared to the surrounding teeth and the contralateral carnassial tooth. Examine the tongue for evidence of trauma or masses when unexplained oral hemorrhage has been observed.
▼ Key Point In the feline patient that presents for vomiting, examine the sublingual area for evidence of a linear foreign body.
• Use one of the following two methods:
• •
•
• Open the patient’s mouth and, with the middle finger of the hand depressing the mandible, apply pressure between the mandibular rami from the ventral aspect. In this manner, the tongue is elevated so that the sublingual surface can be seen (see Fig. 1-1, top). • Occasionally, a linear foreign body can be overlooked with the first method. The sublingual tissue can overlap a thin string that has been drawn taut so that it is not seen. In this case, the second method is to grasp the tongue with a gauze sponge and pull the tongue out and laterally so that the string can be seen more completely (see Fig. 1-1, bottom). Sedation may be required for this in some patients. Examine the hard palate in the neonate for clefts. Evaluate the soft palate (if possible) for defects or masses. Examine the pharyngeal region for asymmetry, masses, or foreign bodies or for evidence of inflammation or trauma. Examine the tonsils for enlargement or masses. Depress the caudal aspect of the tongue to see the caudal pharynx. Once again, sedation may be necessary for a thorough exam. In the cat, if pharyngeal polyps are a differential diagnosis based on the history, examine the soft palate for evidence of bulging. For a more complete exam, sedate the patient to look under the soft palate. See also Chapter 64.
Nose • Examine the nose for asymmetry or swelling. If a mass
•
•
Figure 1-1.
Oral examination of the feline mouth and tongue.
or swelling is present, palpate it carefully to determine whether it is firm or fluctuant. Evaluate brachycephalic breeds for stenotic nares. Note evidence of nasal discharge. Examine the nares closely to determine if the discharge is unilateral or bilateral. Characterize it as serous, mucoid, mucopurulent, or hemorrhagic. It may be beneficial to gently swab the external nares to detect a subtle discharge. If either nasal swelling or discharge is present, evaluate the patency of each nostril. Several techniques can be utilized to aid in this evaluation. Occluding one nostril at a time and listening for stertorous breathing may help identify a partially obstructed passageway. Another technique is wiping the examination table with an alcohol swab and positioning the patient’s nose close to the table to observe condensation of the patient’s breath on the surface. An alternative method is placing a wisp of cotton in
W0422-Ch001.qxd 11/10/05 4:39 PM Page 11
Chapter 1 / History and Physical Examination
front of each nostril and observing movement from air flow
• Examine both the horizontal and vertical canals for stenosis, masses, foreign bodies, discharges, and parasites (ear mites and ticks). Assess the tympanic membrane for rupture or evidence of otitis media (erythema or protrusion).
See also Chapter 160.
Ears • Inspect both the external and inner surfaces of the •
• • •
pinna for skin lesions, hair loss, erythema, or swelling. Examine the external ear canals for erythema, discharge, and odor before an otoscopic examination. Palpate the ear canal cartilages for calcification, masses, pain, or other abnormalities. An otoscopic exam is invaluable in assessing an earrelated problem. Otoscopic technique requires practice to be successful. Sedation of the pet may be required if the patient is painful or aggressive. Lift the pinna and gently place the otoscopic cone in the vertical canal from a dorsal approach and direct it ventrally (Fig. 1-2). As the otoscope is guided deeper into the vertical canal, pull the pinna and otoscope horizontally to bring the horizontal ear canal and tympanic membrane into view.
11
See also Chapters 58 to 60.
Neck • Palpate the paratracheal area from the larynx to the thoracic inlet. • In middle-aged to older cats, this palpation is especially important because of the high incidence of hyperthyroidism caused by thyroid adenomas. The normal thyroid is not palpable. • Stand behind the cat with it standing or sitting, extend the neck, and point the nose upward. Place your thumb and forefinger on each side of the trachea. Starting at the larynx, slide them down the length of the trachea using gentle pressure. The typical thyroid nodule will “pop” as your thumb and forefinger slip over the caudal pole (Fig. 1-3A). • Alternatively, palpate each side individually. Turn the patient’s head slightly to one side and place your forefinger between the trachea and the adjacent muscles on the opposite side (Fig. 1-3B). Once again, start at the larynx and slide your finger down to the thoracic inlet. Turn the patient’s head to the opposite side and repeat the procedure on the second side. Repeated palpation may be necessary to detect subtle nodules. • In dogs, palpation may detect a thyroid tumor.
B
A
Figure 1-2.
Otoscopic examination.
Figure 1-3. A, Paratracheal palpation of the thyroid. B, The alternative, palpation of each side of the thyroid gland individually.
W0422-Ch001.qxd 11/10/05 4:39 PM Page 12
12
Section 1 / Patient Management
• Palpate the trachea for collapse, soft cartilage, or
• The superficial cervical or prescapular lymph nodes
flattening. Attempt to elicit a cough by gently encircling the trachea with one hand and applying pressure on the tracheal muscle dorsally. If a cough is produced by this method, it suggests tracheal collapse or tracheobronchitis. Conduct this part of the examination after the thorax has been auscultated because it may induce paroxysms of coughing. Evaluate the jugular veins for distention. A jugular pulse extending more than one third of the way up the neck is indicative of right-sided heart disease. It may be necessary to moisten this area with alcohol or to clip the hair to aid in visualization of the jugular vein.
can usually be palpated just in front of the cranial border of the scapula. Grasp them by palpating beneath the scapular border. They may be more difficult to palpate in the obese or heavily muscled patient. The axillary lymph nodes are not always palpable because of their disc-like shape and the surrounding musculature. The superficial inguinal lymph nodes are located at the junction of the abdominal wall and the medial thigh and may be difficult to palpate in the obese patient. The popliteal lymph nodes are usually palpable caudal to the stifle joint. The surrounding subcutaneous fat may make these nodes seem larger than their actual size, especially in cats. Palpate the trunk and extremities for abnormal masses or swelling. When a mass is found, note the location, size, and consistency. Use calipers to accurately measure the size of the mass. Determine which tissues are involved (dermal, epidermal, subcutaneous, underlying tissue, etc.). Note whether the mass is freely movable or attached to the underlying muscle, fascia, or bone.
•
•
Lymph Nodes and Subcutaneous Masses • Palpate all external lymph nodes (Fig. 1-4). General-
•
ized lymphadenopathy usually indicates a systemic disease (systemic fungal infection, immune-mediated disease, or neoplasia), whereas local lymph node enlargement usually indicates a localized tumor or a regional infection. If enlarged lymph nodes are present, use calipers to measure and record the size of the affected node or nodes. This information is helpful in monitoring the patient’s response to treatment (antibiotics or chemotherapy). The mandibular lymph nodes are located at the angle of the mandible, slightly cranial and ventral to the parotid and submaxillary salivary glands. The nodes are generally smooth and ovoid in contrast to the irregular texture of the salivary glands. Practice distinguishing these lymph nodes from salivary glands.
• •
•
•
Thorax • As previously described, evaluate the respiratory rate, rhythm, and effort.
Palpation
• Palpate the thorax for evidence of fractured ribs, congenital malformations (pectus excavatum), subcutaneous emphysema, and masses. Palpate the areas
Parotid gland (salivary) Mandibular gland (salivary)
Inguinal Figure 1-4. nodes.
Submandibular lymph nodes Popliteal Prescapular Axillary
Commonly palpated lymph
W0422-Ch001.qxd 11/10/05 4:39 PM Page 13
Chapter 1 / History and Physical Examination
•
between the fourth and sixth intercostal spaces on either side of the thorax for the point of maximum intensity (PMI) of the heartbeat and for cardiac thrills. Attempt to compress the cranial thorax in cats to help identify the presence of a mediastinal mass. In a normal feline, the cranial thorax is easily compressible.
Auscultation
• Increased resonance (tympany) is indicative of pneumothorax, and decreased resonance (dull sounding) suggests pleural effusion, a diaphragmatic hernia, a large pulmonary mass, or an area of consolidation. See also Chapter 142.
Abdomen • Examine the external appearance of the abdomen
• Perform auscultation in a quiet room with a calm
•
•
• •
patient. Have the patient standing during the examination so that the heart is in its normal position. Evaluate the heart independently from the lungs. Disregard sounds that are artifacts. These sounds include rumbles secondary to shivering and crackles created by the stethoscope rubbing against the hair. Close the patient’s mouth for short periods of time to reduce upper respiratory noise. An additional technique is to apply moderate pressure on either side of the chest to help decrease motion caused by panting or shivering. Auscultate the heart initially over the PMI and identify the first and second heart sounds. Characterize the cardiac rhythm. Sinus arrhythmia is considered normal and is typified by increased cardiac rate during inspiration and decreased rate during expiration. Evaluate the femoral pulses for quality and deficits while auscultating the heart. Note split heart sounds, murmurs, and clicks. Auscultate all cardiac valve areas, because some murmurs are localized, such as the mitral, aortic, and pulmonic on the left hemithorax and the tricuspid on the right (see also Chapter 142). Note muffled heart sounds that may be due to obesity, pleural effusion, pericardial effusion, thoracic mass, or diaphragmatic hernia. Pulmonary auscultation requires practice and persistence. Normal bronchovesicular sounds may be increased, decreased, or normal. They may be intensified in the nervous or tachypneic patient. These sounds are heard equally on both sides of the chest. Abnormally quiet or dull areas are suggestive of pleural effusion, pneumothorax, thoracic mass, and pulmonary consolidation. Crackles are abnormal discontinuous sounds resulting from popping open of small airways or air moving through airway secretions. Wheezes are abnormal continuous, musical sounds resulting from passage of air through narrowed or partially obstructed airways.
Percussion
• Percussion is a technique for evaluating the resonance (pitch and tone) of sound produced by a series of quick taps of uniform force at various points on the chest wall using a finger or a percussion hammer.
13
•
for distention or asymmetry. If distention is apparent, perform percussion to help determine if it is a result of peritoneal effusion, air (gastric dilatation or volvulus), obesity, or a mass. Palpate the abdomen systematically proceeding in a cranial-to-caudal direction with the animal standing. Palpate the trunk superficially for evidence of skin masses or hernias. In puppies and kittens, check for evidence of umbilical or inguinal hernias. To palpate abdominal organs, apply firm but gentle pressure. In small animals, use a one-handed technique. With larger patients, two hands are needed, one on each side of the abdomen (Fig. 1-5). If the patient is nervous or tense, try to get the patient to relax by talking reassuringly and stroking its belly or sides just prior to palpation. Start again in a cranial-to-caudal direction just as you did with the superficial palpation. Use a systematic method to attempt to identify each organ.
Stomach
• Palpate the cranial abdomen for evidence of gastric distention (see also Chapter 67). The normal stomach is rarely palpable. Tympany indicates gastric dilatation or volvulus. Diagnosis and treatment should be pursued aggressively. Overeating may result in a doughy or fluid-filled stomach in the left side of the cranial abdomen.
Liver
• The liver may be difficult to palpate in the normal patient (see also Chapter 71). The caudal edges are barely palpable, smooth, and well defined. Hepatomegaly results in a liver that extends past the costal arch. The edges may be rounded rather than sharp. Palpation with the animal in lateral recumbency or standing on its hind legs may be helpful.
Spleen
• The spleen is located in the mid-abdomen and may not always be palpable (see also Chapter 25). If splenomegaly is present, it is usually palpable. Determine if the spleen is irregular or if a palpable mass is present. Use gentle palpation on mid-abdominal masses. It is possible to rupture a splenic or hepatic hematoma or hemangiosarcoma.
W0422-Ch001.qxd 11/10/05 4:39 PM Page 14
14
Section 1 / Patient Management
Figure 1-5. Perform abdominal palpation with two hands or with one hand (inset).
Intestines and Mesenteric Lymph Nodes
• Other organs in the mid-abdomen include the
•
•
mesenteric lymph nodes and intestines. The mesenteric lymph nodes are not usually palpable unless markedly enlarged, as with lymphoma. Occasionally, mesenteric lymph nodes are palpable in cats with inflammatory bowel disease. Palpate the thickness of the bowel wall and evaluate for the presence of gas, fluid, foreign bodies, or masses (see also Chapter 69). Plication and clumping of the intestines may sometimes be palpated in patients with a linear intestinal foreign body. Note if palpably abnormal sections of the bowel appear painful. Palpation of an intestinal foreign body frequently produces a painful response. Palpate the colon in the dorsal-caudal abdomen, and note the presence of feces. To determine whether the palpable structure is feces or a mass, apply gentle pressure to test for deformability of the stool. Evaluate quantity and consistency of the feces to aid in the diagnosis of constipation.
Kidneys
• The kidneys can be palpated in the feline patient in the dorsal region of the abdomen. The right kidney tends to be further cranial than the left and may be obscured by the caudal rib cage. Elevate the cat’s thorax with one hand while palpating with the other. This maneuver allows the kidneys to fall into a pal-
Figure 1-6.
Renal palpation in the cat.
pable position (Fig. 1-6). Palpate both kidneys and compare them for size, shape, firmness, and surface irregularities. The left kidney is especially movable. Do not mistake it for a mid-abdominal mass. The kidneys are not as readily palpable in the dog unless the patient is young or thin. The caudal and lateral aspects may be palpable in other patients. Kidney palpation will also be discussed in Chapter 77.
W0422-Ch001.qxd 11/10/05 4:39 PM Page 15
Chapter 1 / History and Physical Examination
Urinary Bladder
• In the male intact patient, palpate both testicles for symmetry, firmness, and irregularity. If both testicles are not present in the scrotum, examine the inguinal region for the presence of a retained testicle and palpate the abdomen for masses.
• If the urinary bladder is moderately or markedly distended, it can usually be palpated in the ventralcaudal abdomen (see also Chapter 79). The patient does not usually resist palpation of the normal bladder. Assess size, turgidity, and thickness of the bladder wall. The normal urinary bladder is thin walled. Careful palpation may reveal cystic calculi. A painful, firm distended urinary bladder indicates urethral obstruction.
Uterus
See also Section 7.
Rectal Examination • A rectal examination often provides valuable information during a physical examination.
• During a rectal examination, palpate the sublumbar
• The normal uterus usually cannot be palpated (see also Chapter 90). If it is markedly enlarged, because of pyometra or late pregnancy, the uterus is found in the mid- to-ventral abdomen, often extending from the diaphragm to the pelvic inlet. The uterus often is tubular in shape with pyometra or late pregnancy. In mid-gestation, the individual fetuses may be palpated. In the pregnant cat, these fetuses may feel similar to the urinary bladder but will usually be present in multiple numbers and feel slightly thicker walled than the bladder.
Prostate
•
• • •
• The prostate in intact male dogs can occasionally be palpated in the caudal abdomen ventral to the colon and caudal to the urinary bladder (see also Chapter 84). If found in this location, evaluate the prostate for size, shape, and surface irregularities.
•
External Genitalia • In the female patient, palpate the mammary glands
•
•
carefully for masses. If the history indicates a possibility of pregnancy or pseudopregnancy, gently express the nipples for signs of discharge or milk. In the nursing bitch or queen, examine the mammary glands for abnormal swelling, firmness, or heat, as seen with mastitis or abscessed glands. In the female patient, examine the vulva for conformational abnormalities, swelling, or discharge. Determine the color, consistency, and odor of the discharge. Examine the vulvar mucous membranes for evidence of jaundice, cyanosis, petechiae, or ulceration for clues of systemic disease. In dystocia or when a vaginal discharge is present, a vaginal examination is indicated. Vaginoscopy may be required to rule out the presence of vaginal masses. In the male canine, examine the prepuce and penis. Retract the preputial sheath caudal to the bulb so that the entire penis can be examined for any signs of trauma or masses. Inspect the penis for jaundice, cyanosis, petechiae, ulceration, or masses. Examine the tip of the feline penis for evidence of obstruction (discoloration or the presence of plug material) if indicated by the history.
15
•
lymph nodes in the dorsal aspect of the pelvic canal. Enlargement is usually suggestive of metastatic neoplasia. Note the symmetry of the pelvis and the presence of palpable fractures during the rectal examination. This is always indicated in a trauma victim. Evaluate abnormal masses in the pelvic canal for size, position, and consistency. During the rectal examination, evaluate the perineal and perianal regions for hernias or abnormal masses. Evaluate the anal sacs for evidence of infection, distention, or masses. Examine any fecal material obtained for amount, consistency, color, and presence of blood or mucus. Note the presence of foreign material such as bone fragments, gravel, cloth, or plastic. Perform a rectal examination in all mature male dogs to evaluate the prostate. The normal prostate is bilobed (characterized by the presence of the median raphe), symmetric, smooth, and nonpainful. If the prostate is enlarged, it may extend slightly over the brim of the pelvis or fall into the abdomen, as previously described for the palpation of the caudal abdomen. In female dogs, abnormal masses associated with the uterus or urethra may occasionally be detected on rectal palpation.
Skin • Inspect the general appearance of the haircoat for
•
luster, fullness, and areas of hair loss. Note symmetric alopecia as seen with endocrinopathies, such as hyperadrenocorticism, hypothyroidism, or sex hormone imbalances. Inspect areas of alopecia for broken hairs as seen with pruritic or psychogenic conditions. Check for erythema as will be seen in allergic or inflammatory conditions. When approaching a pet with a dermatologic problem, examine all areas of the body. Location of skin lesions often aids in the diagnosis. For example, localized demodicosis causes patches of alopecia involving the head and forelegs. Sarcoptic mange typically causes scaling and partial alopecia of the pinnae, elbows, and hocks. Do not overlook the interdigital areas and the foot pads. Examine mucocuta-
W0422-Ch001.qxd 11/10/05 4:39 PM Page 16
16
•
•
Section 1 / Patient Management
neous junctions (lips, anus, vulva, preputial orifice, etc.) for evidence of an immune-mediated disease. Identify all skin lesions and categorize them as primary or secondary. Primary lesions include papules, pustules, nodules, wheals, macules, and vesicles. Common secondary lesions are scales, crusts, ulcers, excoriations, lichenifications, hyperpigmentations, and hyperkeratoses. Note evidence of external parasites. Large flakes and scales in a pruritic patient may indicate Cheyletiella infestation. If fleas are not seen, search the patient for flea dirt, especially in the tail-head region. A flea comb is often helpful in discovering small amounts of flea dirt. Repetitive combing may be necessary to find small amounts of flea dirt in the flea allergy dermatitis patient. While combing the patient, you can educate the owner regarding flea control. See also Section 5.
Musculoskeletal System • Initially evaluate the musculoskeletal system by
• •
•
• • •
observing for lameness while the patient is in motion both at a walk and at a trot. Observe the patient’s posture with special attention to head carriage, head bobbing, arching of the back, or stilted gait. For forelimb lameness, an obvious downward bobbing of the head will be present as the sound leg makes contact with the ground. A complete musculoskeletal examination is not necessary unless evidence of lameness or pain is noted in the history or on initial observation of the patient. Gently manipulate the patient’s head dorsally, ventrally, and to either side to look for evidence of pain or resistance. Palpate the vertebral column for signs of a pain response. Pressure applied to either side of the dorsal spinal process of each vertebra may be necessary to elicit pain (see Chapters 100, 128). If lameness is present, examine the affected limb systematically to localize the area involved. First, examine the foot for evidence of traumatized or abnormal toenails or nail beds. Evaluate each interdigital area for erythema, swelling, or draining tracts, which may be indicative of a foreign body. Palpate each toe individually and note swelling or pain. Palpation proceeds proximally. Evaluate each long bone for pain, swelling, abnormal masses, or palpable fractures. Evaluate each joint for evidence of effusion, softtissue swelling, crepitation, or pain with flexion and extension. In examining the stifle, note the position of the patella in extension and flexion. If the patella is in its normal location, attempt to luxate it medially and laterally. Extension of the stifle usually aids in mobilizing the patella. Manipulate the stifle for evidence of a cranial drawer sign that indicates an anterior cruciate ligament tear (see Chapter 110).
• Evaluate each coxofemoral joint range of motion and
•
evidence of pain. Test for a positive Ortolani sign to evaluate for hip laxity if the patient’s breed is at risk for hip dysplasia (see Chapter 108 for more details). If difficulty arises in localizing the lameness, always compare the results of palpation and manipulation of the affected limb with those on the contralateral limb.
Nervous System As with the musculoskeletal system, a complete neurologic examination is not necessary unless specifically indicated by the history or the general physical examination. The details of the neurologic examination are discussed in Chapter 125. A brief overview of the basic procedures for the localization of lesions is provided here. • Observe mental status and behavior as previously described. • Evaluate the gait and posture while the patient is walking and standing. Pay particular attention to strength, symmetry, and coordination. • Always perform a complete cranial nerve examination when evaluating neurologic problems (see Chapters 125 and 126). This includes checking for a menace response, palpebral reflex, and pupillary light flexes. Note pupillary symmetry and ocular positioning. Facial sensation can be tested by lightly touching the nasal mucosa with a hemostat. The presence of a gag reflex should have been noted during the oral exam. • Evaluate and compare postural reactions in all limbs, including proprioception, “wheelbarrowing,” hopping, extensor postural thrust, and placing reactions. • Evaluate and compare spinal reflexes with the calm patient in lateral recumbency. Important segmental reflexes include the triceps, biceps, patellar, and cranial tibial reflexes, as well as the flexor (withdrawal) reflexes of the thoracic and pelvic limbs. Evaluate the panniculus reflex by needle stimulation of the thoracic or lumbar skin (see Chapter 125). • Evaluation of some parts of the neurologic examination is subjective. If you are unsure how the patient responded to a particular test, then repeat the test in question and compare the results. If the patient is hospitalized, the exam will need to be repeated at regular intervals to evaluate progression of the disease and response to treatment.
SUPPLEMENTAL READING Bistner SI, Ford R, Raffe M: Kirk and Bistner’s Handbook of Veterinary Procedures and Emergency Treatment, 7th ed. Philadelphia: WB Saunders, 2000, pp 284, 287. Bistner SI, Shaw D: Examination of the eye. Vet Clin North Am Small Anim Pract 11:595, 1981.
W0422-Ch001.qxd 11/10/05 4:39 PM Page 17
Chapter 1 / History and Physical Examination Crow SE, Walshaw SO: Restraint of dogs and cats. In Crow SE, Walshaw SO (eds): Manual of Clinical Procedures in the Dog and Cat. Philadelphia: JB Lippincott, 1987, pp 3–14. Laflamme DP, Kealy RD, Schmidt DA: Estimation of body fat by body condition score. J Vet Int Med 8:154, 1994. McCurnin DM, Poffenbarger EM: Small Animal Physical Diagnosis and Clinical Procedures. Philadelphia: WB Saunders, 1991.
17
Morgan, R: Handbook of Small Animal Practice, 3rd ed. Philadelphia: WB Saunders, 1997, p 1222. Schaer M: The medical history, physical examination, and physical restraint. In Sherding RG (ed): The Cat: Diseases and Clinical Management, 2nd ed. New York: Churchill Livingstone, 1994, pp 7–23.
Chapter
▼
W0422-Ch002.qxd 11/10/05 4:40 PM Page 18
2
Practical Methods of Anesthesia John A. E. Hubbell
Anesthesia is an integral part of the practice of companion animal medicine. In addition to surgical applications, some form of anesthesia may be required for a wide variety of procedures, such as radiography, endoscopy, cerebrospinal fluid collection, and bone marrow aspiration. ▼ Key Point The keys to successful anesthesia include (1) an understanding of what is “normal” in the various species; (2) a working knowledge of the pharmacology of anesthetic drugs; and (3) a systematic evaluation and reevaluation of the patient’s status (monitoring) during the period of anesthesia.
The understanding of what is “normal” comes with experience. Several excellent texts describe the pharmacology of anesthetic drugs (see “Supplemental Reading” at the end of this chapter). Monitoring is a matter of establishing a routine and maintaining the discipline to adhere to the routine. This chapter suggests some basic anesthetic techniques and protocols that can be used successfully in small animal practice.
GENERAL PRINCIPLES Preoperative Assessment (Table 2-1) • A history of vomiting or a recent meal is an indica-
•
18
tion for postponing surgery or using techniques that produce rapid induction, allowing rapid endotracheal intubation that minimizes the potential for aspiration of gastric contents. • On an elective basis, withhold food 6 to 8 hours before the administration of anesthetic drugs. • Do not withhold water. • Potential problems discovered from the history include exercise intolerance or cough, as an indicator of cardiorespiratory dysfunction; polyuria or polydipsia, as an indicator of endocrine or renal dysfunction; or any other recent change in the animal’s physical status. Perform a physical examination with emphasis on the cardiovascular and respiratory systems (Table 2-2 provides normal values).
• •
• Evaluate traumatized patients more extensively because of the potential for blood loss, cardiac arrhythmias (ventricular tachycardia), and thoracic trauma (pneumothorax). • Evaluate abnormalities discovered after auscultation, percussion, palpation, and examination of mucous membranes with ancillary tests, such as thoracic radiography and electrocardiography. • The pertinent abnormalities associated with various metabolic diseases are discussed in the appropriate chapters of this text. Weigh the animal. Estimate the lean body weight if the animal is obese to more accurately calculate correct anesthetic drug doses. Determine packed cell volume and total plasma protein to establish a baseline for reference if hemorrhage occurs. Check renal function with blood urea nitrogen (BUN) or creatinine concentrations in older (>7 years) animals. Increases in BUN or creatinine values may dictate a more careful perianesthetic fluid management to prevent further renal dysfunction (see Table 2-2).
Intravenous Catheterization Place an IV catheter before induction of anesthesia to provide a convenient pathway for the administration of drugs, to allow fluid or blood administration if required, and to ensure access to the vascular space if an emergency occurs.
Endotracheal Intubation A patent airway is essential to any anesthetic protocol.
• Place a cuffed endotracheal tube in the trachea soon after induction of anesthesia.
• Alternatively, use drugs that maintain the swallowing reflex (ketamine or tiletamine/zolazepam).
• Clean, thoroughly rinse, and dry endotracheal tubes
•
between uses. Sterilization of endotracheal tubes between uses is not necessary on a routine basis. Use chemical sterilization or discard the tube if a known pathogen is present. Glutaraldehyde is a safe disinfectant if the tubes are thoroughly rinsed following sterilization. See Table 2-3 for the suggested range of sizes of endotracheal tubes for dogs and cats.
W0422-Ch002.qxd 11/10/05 4:40 PM Page 19
Chapter 2 / Practical Methods of Anesthesia
Table 2-1. PREANESTHETIC CHECKLIST History and Physical Examination Age Body weight Temperature Auscultation Respiratory rate Pulse rate, rhythm, and strength Hydration, mucous membrane color, and capillary refill time Mentation Current medication history Cardiopulmonary, renal, and nervous system disease history Laboratory Data Packed cell volume Total plasma protein Blood urea nitrogen, creatinine, or serum dipstick analysis (Azostick) if less than 7 years Other tests optional, dependent on primary disease
19
PRODUCING A TRACTABLE ANIMAL Many procedures, such as radiography and cystocentesis, do not require complete anesthesia. In these instances, the combination of appropriate sedation and physical restraint can facilitate the completion of the procedure with minimal stress to the patient and minimal drug-induced cardiopulmonary depression. The choice of drugs is based on species, the patient’s temperament, physical status, the veterinarian’s familiarity with the drug, and the intended purpose. The agents that follow are employed as components of many anesthetic protocols. The doses of drugs alone and in combination are listed in Table 2-4 (dogs) and Table 2-5 (cats).
Tranquilizers
Drugs Appropriate anesthetic drugs Sufficient oxygen supply Emergency drugs Atropine or glycopyrrolate Lidocaine Epinephrine Sodium bicarbonate Intravenous fluids Dopamine Doxapram
Acepromazine
• A potent phenothiazine tranquilizer that produces sedation in the dog. It also has antiemetic and antiarrhythmic properties.
Equipment Syringes, needles, and catheters Leak-tested anesthetic machine Cuffed endotracheal tubes Optional monitoring equipment Electrocardiogram Blood pressure monitor (pulse detector) Stethoscope Pulse oximeter
Table 2-3. APPROXIMATE ENDOTRACHEAL TUBE SIZES Weight (kg)
Cuffed Tube Diameter (mm)
3–7 7–15 15–30 >30
3.0–5.0 5.0–7.5 7.5–9.5 9.5–12.0 2.5–4.0
Dogs
Cats
Table 2-2. NORMAL VALUES Dogs Awake Temperature (°F) Heart rate (bpm) Respiratory rate (breaths/minute) Capillary refill time (sec) Packed cell volume (%) Total plasma protein (g/100 ml) Total leukocytes (6,000–17,000/ml) Albumin (g/100 ml) Sodium (mEq/L) Potassium (mEq/L) Chloride (mEq/L) Calcium (mg/100 ml) Creatinine (mg/100 ml) Blood urea nitrogen (mg/100 ml) Arterial pH Arterial pCO2 (mm Hg) Arterial pO2 (mm Hg) Arterial HCO3 (mEq/L) Arterial base excess (mEq/L) CO2 combining power (mEq/L)
99.5–102.5 70–180 20–40 <1.5 35–54 5.7–7.3 6–18 2.1–3.6 140–155 3.8–5.3 105–121 8.8–11.3 0.3–1.3 8–25 7.30–7.43 30–49 91–97 18–22 -3 to +3 15–25
Anesthetized (If Different) 60–180 8–20
90–500 (>50% inspired O2)
Cats Awake 100.0–102.5 145–200 20–40 <1.5 27–46 6.3–8.3 6–20 2.3–3.6 149–162 3.6–5.4 105–135 8.3–11.3 0.8–1.8 15–35 7.27–7.40 35–49 91–97 18–25 -5 to +1.5 16–30
Anesthetized (If Different) 100–200 10–30
100–500 (>50% inspired O2)
W0422-Ch002.qxd 11/10/05 4:40 PM Page 20
20
Section 1 / Patient Management
Table 2-4. ANESTHETIC DRUGS AND DOSES IN DOGS Drug
Intravenous Dose (mg/kg)
Intramuscular or Subcutaneous Dose (mg/kg)
Anticholinergic Atropine Glycopyrrolate
0.02–0.04 0.005–0.010
0.02–0.04 0.005–0.010
Tranquilizer/Sedative Acepromazine Xylazine Medetomidine Diazepam Midazolam
0.05–0.20 0.3–0.8 0.007–0.020 0.10–0.25 0.05–0.20
0.1–0.3 0.5–1.5 0.01–0.04 0.10–0.25 0.1–0.2
Analgesic Morphine Oxymorphone Fentanyl Meperidine Butorphanol Nalbuphine Buprenorphine Hydromorphone
NR* 0.05–0.10 0.002–0.005 0.4–2.0 0.1–0.2 0.5–2.0 0.005 0.05–0.2
0.2–0.5 0.1–0.3 0.004–0.008 1.0–4.0 0.1–0.4 0.5–2.0 0.005 0.1–0.4
Anesthetic Tiletamine/zolazepam (Telazol) Thiopental Etomidate Propofol
0.5–4.0 6–10 1–4 2–6
4–10 NR NR NR
Combination Acepromazine/oxymorphone Acepromazine/butorphanol Ketamine/acepromazine Ketamine/xylazine Ketamine/diazepam (50 : 50)
0.05–0.10/0.01–0.02 0.05–0.10/0.1–0.2 2–5/0.05–0.10 1–5/0.1–0.8 1 ml/10 kg
0.1–0.2/0.1–0.2 0.1–0.2/0.1–0.2 5–10/0.1–0.2 5–10/0.3–1.5 NR
*NR, not recommended.
• Not an analgesic itself, but it may potentiate other
• Produces profound cardiopulmonary depression,
drugs that are analgesics. Produces hypotension through an a-adrenergic blockade, particularly in large doses. Potentiates hypothermia. Epinephrine reversal (i.e., hypotension after epinephrine administration) can occur. Calms excitable dogs. Aggressive dogs or cats may not become tractable. Combine with opioids or cycloheximides to produce the desired effect (see Tables 2-4 and 2-5). Avoid in animals with epilepsy, shock, bleeding disorders (inhibition of platelet function), or liver disease. Reduce the dose or choose another agent in stressed or older animals because effects may be exaggerated. Cats are calmed but usually still resist restraint.
including bradycardia, first- and second-degree atrioventricular blockade, catecholamine sensitization, and decreased respiratory rate. Combine with an anticholinergic (atropine or glycopyrrolate), particularly if large doses are administered. Do not use in patients with preexisting cardiac, liver, or kidney disease or with shock. Reverse effects with yohimbine, tolazoline, or atipamezole (see “Recovery and Reversal” for doses). Vomiting occurs in approximately 25% of dogs and 50% of cats. See Tables 2-4 and 2-5 for doses.
• • • •
• •
Xylazine
• An a -adrenergic agonist that produces sedation with
• • • • •
Medetomidine
• An a -adrenergic agonist that produces sedation with 2
•
2
muscle relaxation and analgesia.
• Produces an obtunded state from which the patient is difficult to arouse.
• Produces analgesia for minor procedures. Is not usually sufficient for surgery.
• •
muscle relaxation and analgesia (see Tables 2-4 and 2-5 for doses). Similar to but approximately 100 times more potent than xylazine with a longer duration of action. Produces analgesia for minor procedures. Combine with ketamine or opioids to enhance analgesia. Produces dose-dependent cardiopulmonary depression including bradycardia, decreased arterial blood pressure, and slowing of respiratory rate.
W0422-Ch002.qxd 11/10/05 4:40 PM Page 21
Chapter 2 / Practical Methods of Anesthesia
21
Table 2-5. ANESTHETIC DRUGS AND DOSES IN CATS Drug
Intravenous Dose (mg/kg)
Intramuscular or Subcutaneous Dose (mg/kg)
Anticholinergic Atropine Glycopyrrolate
0.02–0.04 0.005–0.010
0.02–0.04 0.005–0.010
Tranquilizer/Sedative Acepromazine Xylazine Medetomidine Diazepam Midazolam
0.05–0.20 0.4–1.0 0.01–0.03 0.10–0.25 0.05–0.20
0.1–0.3 0.8–1.8 0.03–0.08 0.10–0.25 0.1–0.2
Analgesic* Oxymorphone Butorphanol Nalbuphine Buprenorphine Hydromorphone
0.01–0.04 0.05–0.20 0.5–1.5 0.005 0.05–0.1
0.05–0.10 0.1–0.3 0.5–1.5 0.005 0.1–0.3
Anesthetics Ketamine Tiletamine/zolazepam (Telazol) Thiopental Etomidate Propofol
4–10 0.5–4.0 6–10 1.0–4.0 2–6
10–20 4–12 NR† NR NR
Combination Acepromazine/oxymorphone Acepromazine/butorphanol Ketamine/acepromazine Ketamine/xylazine Ketamine/diazepam (50 : 50)
0.05–0.07/0.01–0.04 0.05–0.07/0.07–0.15 4–8/0.05–0.10 4–8/0.1–0.8 1 ml/10 kg
0.1–0.2/0.05–0.20 0.1–0.2/0.1–0.2 7–15/0.1–0.2 7–15/0.3–1.5 NR
*Higher doses can be associated with nervousness and excitement. † NR, not recommended.
• Combine with an anticholinergic (atropine or • • •
glycopyrrolate), particularly if large doses are administered. Do not use in patients with preexisting cardiac or kidney disease or with shock. Reverse effects with yohimbine, tolazoline, or atipamezole (see “Recovery and Reversal” for doses). Vomiting, diuresis, and muscle jerking may occur.
Diazepam and Midazolam
• Benzodiazepine derivatives that produce mild seda-
• • • •
tion in dogs and cats. Neither is effective in calming an excited patient when used alone. Both are anticonvulsants. Use to enhance tractability in depressed patients or in combination with other agents (primarily opioids). Administer diazepam IM or slowly IV with caution. The drug is solubilized in a propylene glycol base that can produce bradycardia and hypotension. Administer water-soluble midazolam IV, SC, or IM. Use in patients with cardiorespiratory compromise or another metabolic disease. Both agents produce minimal cardiopulmonary side effects and provide muscle relaxation.
• Use both drugs as premedicants to parenteral or inhalation anesthesia.
• Occasionally, paradoxical responses occur, including disorientation and aggression.
• Diazepam can be given as an appetite stimulant in cats.
• See Tables 2-4 and 2-5 for doses and suggested combinations.
Analgesic Drugs (see also Chapter 6) Nonsteroidal Anti-inflammatory Drugs
• Use nonsteroidal anti-inflammatory drugs (NSAIDs)
• •
• •
for acute and chronic pain associated with inflammation. They reduce pain by inhibiting prostaglandin formation and through central effects. Potentiate the action of other analgesics. Use NSAIDs orally or by injection to provide analgesia, antipyresis, and as an anti-inflammatory in the perioperative period and for chronic pain. Analgesia produced is equivalent to opioids for some types of pain. NSAIDs can cause gastrointestinal injury and renal damage. See Table 2-6 for doses.
W0422-Ch002.qxd 11/10/05 4:40 PM Page 22
22
Section 1 / Patient Management
Table 2-6. NONSTEROIDAL ANTI-INFLAMMATORY DRUG USE IN DOGS Nonsteroidal Anti-inflammatory Drug Carprofen Deracoxib Etodolac Ketoprofen Meloxicam Phenylbutazone Tepoxalin
Dosage 2 mg/kg twice daily or 4 mg/kg once daily orally (injectable 4 mg/kg SC once daily) 3–4 mg/kg once daily orally for 7 days 10–15 mg/kg once daily orally 2.2 mg/kg IV, SC, or IM for dogs and cats, single dose 0.1 mg/kg (0.2 mg/kg loading dose) once daily, SC, PO (cats: if given SC, dose of 0.3 mg/kg is used one time only) 40 mg/kg daily in three divided doses for 2 days then reduce 10 mg/kg once daily orally
Opioids
Dissociative Anesthetics
•
Ketamine and Tiletamine/Zolazepam
• • •
• • • •
Use in dogs and cats to augment the effects of sedatives and tranquilizers and to provide analgesia. Minimal or no sedation is produced when administered alone, except for morphine and meperidine. Use in combination with tranquilizers or sedatives. Use lower doses in cats compared with dogs (see Tables 2-4 and 2-5), because higher doses have the potential to cause excitement and disorientation. Morphine, oxymorphone, fentanyl, hydromorphone, and meperidine are opioid agonist drugs frequently used in small animal practice. Regulations require rigorous recordkeeping and security. Vagal tone is increased (bradycardia), and respiration is depressed. Sensations of touch or vision are not diminished. Sensitivity to sound may be increased. May cause vomiting and defecation. Reverse agonists and agonist-antagonists with naloxone. Partial reversal of the respiratory and central nervous system (CNS) depressant effects of agonists can be accomplished with agonist-antagonists (e.g., butorphanol), which reverse the deleterious effects of the agonists and provide the animal with some analgesia.
Fentanyl
• Fentanyl can be administered transdermally using a
•
patch developed for human use. Time from patch application until full effect is 2 to 6 hours in cats and 12 to 24 hours in dogs. The skin must be clipped (or shaved) to facilitate absorption, but absorption varies considerably. Duration of action may be as long as 5 days. Prevent ingestion by the animal or humans.
Other Opioids
• Ketamine and tiletamine/zolazepam (Telazol, Ft.
• • • •
•
Dodge Animal Health, Ft. Dodge, Iowa) produce a unique form of sedation or anesthesia that has been called dissociative anesthesia. These maintain swallowing and ocular reflexes, increase muscle tone, and produce amnesia, superficial analgesia, and catatonia. They stimulate the cardiovascular system, resulting in increased heart rate and arterial blood pressure. They produce an apneustic (breath-holding) respiratory pattern. The intensity is dose related. Use low doses of ketamine (up to 6 mg/kg IM) in the cat to produce an obtunded state with malleable rigidity of the limbs, dilated pupils, and hypersalivation. Higher doses (14–20 mg/kg IM) have been used, but analgesia is not an appropriate level for visceral surgery. Using ketamine with other drugs (xylazine, medetomidine, diazepam, or midazolam) is a better approach in both dogs and cats. Do not give ketamine alone in the dog because of resultant muscle rigidity and seizure activity. See Tables 2-4 and 2-5 for doses. Use tiletamine/zolazepam (Telazol) to produce a state similar to that of ketamine with the addition of muscle relaxation. The drug is approved for IM use in both the dog and the cat. At low doses (2–4 mg/kg IM) it provides helpful restraint in both the dog and the cat. It is also used in small doses IV (0.5– 1.5 mg/kg) in a manner similar to ketamine/ diazepam for induction and short-duration restraint (see Tables 2-4 and 2-5 for doses).
INJECTABLE DRUGS FOR SHORT-TERM ANESTHESIA
• Butorphanol, nalbuphine, and buprenorphine are
•
opioid agonist-antagonist or partial agonist drugs. This classification means that these compounds produce analgesia but have less addictive potential. Degree of analgesia may be sufficient for mild to moderate pain but not for severe pain.
A variety of injectable drugs and drug combinations can be used for short-term anesthesia or restraint in dogs (Table 2-7) and cats (Table 2-8). Many of these combinations employ the drugs previously described. Prior administration or coadministration of sedatives or
W0422-Ch002.qxd 11/10/05 4:40 PM Page 23
Chapter 2 / Practical Methods of Anesthesia
23
Table 2-7. SUGGESTED ANESTHETIC PROTOCOLS FOR DOGS Patient (Agent)
Dose
Comments
Healthy (Elective Procedure) Acepromazine Thiopental Isoflurane* (or) Sevoflurane*
0.02 mg/kg SC or IM 6–10 mg/kg IV 0.5%–3.5%, inhaled 2.0%–4.5%, inhaled
Total dose not to exceed 4 mg Give 6 mg/kg initially, increase in 2 mg/kg increments Adjust to anesthetic depth Adjust to anesthetic depth
Aged Patient Intravenous fluids Ketamine/diazepam (50 : 50) (or) Propofol Isoflurane* (or) Sevoflurane*
1 ml/10 kg IV 2–4 mg/kg IV 0.5%–3.5%, inhaled 2.0%–4.5%, inhaled
Short duration of action
Patient in Pain Intravenous fluids Acepromazine Oxymorphone Thiopental Isoflurane* (or) Sevoflurane*
0.01–0.02 mg/kg IM 0.05–0.02 mg/kg IM 4–8 mg/kg IV 0.5%–3.5%, inhaled 2.0%–4.5%, inhaled
Can be mixed with oxymorphone Watch for bradycardia Dose is reduced after premedicant; start with 4 mg/kg
Critical Patient Intravenous fluids Diazepam and Propofol (or) Ketamine/diazepam (50:50) Isoflurane* (or) Sevoflurane*
0.02 mg/kg IV 2–4 mg/kg IV 1 ml/10 kg IV 0.5%–3.5%, inhaled 2.0%–4.5%, inhaled
Give slowly Give to effect
*Concentration required depends on fresh gas flow rate. The lower the flow rate, the higher the concentration required.
Table 2-8. SUGGESTED ANESTHETIC PROTOCOLS FOR CATS Patient (Agent)
Dose
Healthy (Elective Procedure) Acepromazine (with)
0.01–0.02 mg/kg SC or IM
Ketamine (and) Thiopental (or) Tiletamine/zolazepam (with) Thiopental Isoflurane* (or) Sevoflurane*
4–8 mg/kg IM 5–10 mg/kg IV 3–5 mg/kg IM 3–7 mg/kg IV 0.5%–3.5%, inhaled 2.0%–4.5%, inhaled
Aged or Renally Compromised Patient Intravenous fluids Midazolam with oxymorphone Ketamine (or) Thiopental (or) Propofol Isoflurane* (or) Sevoflurane*
0.05 mg/kg IM 0.1–0.2 mg/kg IM 1–2 mg/kg IV 3–7 mg/kg IV 2–4 mg/kg 0.5%–3.5%, inhaled 2.0%–4.5%, inhaled
Critical Patient Intravenous fluids Ketamine/diazepam (50:50) Isoflurane* (or) Sevoflurane*
0.5 ml/5 kg IV 0.5%–3.5%, inhaled 2.0%–4.5%, inhaled
*Use a non-rebreathing anesthetic system (Bain or Ayres T-piece).
Comments Mix acepromazine with ketamine; add opioid for analgesia Give to effect Tiletamine/zolazepam may be sufficient for intubation
Drugs can be mixed Give slowly to effect
Administer slowly
W0422-Ch002.qxd 11/10/05 4:40 PM Page 24
24
Section 1 / Patient Management
tranquilizers with drugs that produce anesthesia allows a reduction in the dose of the anesthetic drug. Anesthetic drugs tend to produce more depression of cardiopulmonary function than do sedatives or tranquilizers; thus the patient benefits from the decreased dose. Thiobarbiturates are the primary addition to the list of drugs already discussed. Other drugs, such as etomidate and propofol, offer potential advantages, such as fewer cardiopulmonary effects and lack of cumulative effects, but are expensive. Although endotracheal intubation is not required for the delivery of injectable anesthetic drugs, patients can benefit from intubation for protection of the airway and for oxygen supplementation.
Thiobarbiturates (Thiopental) • Sedative or hypnotic agents that produce short-term IV anesthesia.
• Barbiturates produce CNS depression that ranges
Propofol • A phenolic compound that produces hypnosis similar to thiopental.
• Depresses hemodynamics comparable to thiobarbi• • • • •
from drowsiness to coma.
• Not good analgesics at subhypnotic doses. When • • •
•
doses are increased to produce unconsciousness, anesthesia is produced. Cause respiratory depression and some arterial blood pressure depression. Sensitize the heart to catecholamine-induced arrhythmias. Ventricular bigeminy is often noted but resolves without treatment. Duration of effect is primarily determined by redistribution away from the brain into muscle and lean body tissues. Level and duration of anesthesia produced by a given dose depends on what other drugs have been administered, the rate of administration, and the level of awareness of the animal at the time of administration. Use with caution in patients with preexisting cardiovascular disease, hypotension, or shock.
turates, but does not sensitize the myocardium to epinephrine-induced arrhythmias. Depresses respiration. Administer slowly IV over a 30- to 60-second period to minimize the potential for apnea. Use with analgesics for painful procedures. Anesthesia can be maintained using propofol as a continuous IV infusion (0.4–0.8 mg/kg/min). Noncumulative, so recovery following multiple doses or an infusion occurs within the same time frame as that following a single dose. Relatively insoluble. Supports microbial growth if contaminated. Discard unused drug. Useful for induction of anesthesia in sighthounds and patients requiring cesarean section. Useful in compromised patients because of the lack of residual effects.
Ketamine Mixtures Use ketamine in combination with sedatives and tranquilizers to provide short-term injectable anesthesia.
Ketamine/Diazepam
• Administer ketamine with diazepam in a 50:50
•
▼ Key Point Do not use thiobarbiturates in greyhounds or other sighthounds because of prolonged elimination.
(volume-to-volume) mixture at a dose of 1 ml/10 kg IV. Give for brief periods (5–10 minutes) of restraint. Provides enough analgesia for minor surgical procedures. Readminister as needed to effect. Works well in depressed or geriatric patients. May not be effective in young, excited, or aggressive animals. Produces moderate muscle relaxation, cardiopulmonary support, and increased salivation. Ocular and swallowing reflexes are maintained, but orotracheal intubation can be accomplished.
Ketamine/Acepromazine
• •
•
•
Administer to effect, beginning with doses in the range of 4 to 6 mg/kg, increasing in 2 mg/kg increments. Onset of action is within 30 seconds. Can be mixed 50:50 (volume to volume) with propofol to allow a reduction in the dose of both drugs as a way to reduce cost. Can cause sloughing of tissues if administered perivascularly. Use for induction to inhalation anesthesia. Compatible with all agents previously described. Reduce the dose by approximately half if sedatives or tranquilizers are given prior to administration. Duration of action is prolonged by hypoproteinemia and acidosis. Administer IV fluids to shorten duration by promoting diuresis, and administer NaHCO3 (2 mEq/kg) to shorten duration by alkalinizing the urine.
• Use ketamine with acepromazine to produce a quieter recovery than that with ketamine/diazepam but less muscle relaxation. Usually produces enough anesthesia for minor peripheral surgery, but visceral analgesia is not sufficient for abdominal surgery.
Ketamine/Xylazine and Ketamine/Medetomidine
• These combinations produce muscle relaxation, •
sedation, and analgesia that are improved over other combinations. Bradycardia and depression of cardiac contractility and respiration occur. Coadminister an anticholinergic. Use in young animals with good cardiopulmonary reserve. Avoid in animals with preexisting
W0422-Ch002.qxd 11/10/05 4:40 PM Page 25
Chapter 2 / Practical Methods of Anesthesia
25
cardiovascular disease, particularly those with cardiac conduction abnormalities. The combination of medetomidine (60–80 mg/kg), butorphanol (0.2 mg/kg), and ketamine (5 mg/kg) administered IM is a useful preanesthetic in cats that is sufficient for some surgery and is easily augmented with inhalants.
and endotracheal intubation. The injectable drugs and drug combinations previously described, with the possible exception of ketamine/xylazine combinations, can be used to induce anesthesia. Ketamine/xylazine combinations produce significant cardiopulmonary depression that can be extreme when inhalant anesthetic drugs are added.
Tiletamine/Zolazepam • Use IV or IM to produce anesthesia. • Produces muscle relaxation and support of hemody-
Inhalant Anesthetics • Inhalant anesthetics have several advantages, includ-
•
• •
namics, but also produces respiratory depression. Maintains oropharyngeal reflexes. Recovery is prolonged with increasing doses. Recovery is usually uneventful in the cat but may be stormy in the dog. Administer low doses of acepromazine to quiet a difficult recovery.
Etomidate • A nonbarbiturate hypnotic that can be used for shortterm IV anesthesia.
• Produces a hypnotic state with little cardiovascular • •
effect. Etomidate is expensive. Limit to patients with significant cardiovascular and respiratory disease. Recovery can be stormy, with vomiting and muscle tremors. Premedicate the animal with sedatives or tranquilizers to minimize these effects.
Anticholinergics • Used to reduce salivation, block vagal inhibition of
ing the coadministration of oxygen, the ease with which anesthesia depth is changed, and the fact that recovery does not depend on metabolism. The agents are primarily eliminated by exhalation. Administer via breathing circuits, with circle anesthetic systems being the most common.
Equipment Circle Anesthetic Systems
• A carbon dioxide absorber removes carbon dioxide from the exhaled gas.
• Exhaled gas is rebreathed, making the system an economic one.
• Use 4 to 7 ml/kg/min as the minimum fresh gas flow rate for oxygen. This rate matches the animal’s metabolic need for oxygen. Increase the fresh gas flow rate for oxygen to 10 to 20 ml/kg/min if nitrous oxide is given. Add the nitrous oxide flow to the oxygen flow rate. The pop-off valve in the circle system needs to be open to vent the excess gas at this flow rate.
the heart, and quiet the digestive tract if indicated.
• Not innocuous. Respiratory dead space is increased • • • •
(bronchodilation). Ventricular arrhythmias are more likely to occur. Use if bradycardia occurs or is likely to occur. Not routinely indicated in anesthesia. Myocardial oxygen consumption is increased owing to tachycardia. Secretions become more viscous. Glycopyrrolate is more potent and has a longer duration of action than atropine. It does not cross the placental or blood-brain barrier. Give IM, SC, or IV when expediency is important. Atropine dose is 0.02 to 0.04 mg/kg. Glycopyrrolate dose is 0.01 mg/kg.
Non-rebreathing Anesthetic Systems
• Bain and Modified Jackson Rees (Hudson RCI; Temecula, California) (SurgiVet; Waukesha, Wisconsin).
• Use for patients less than 2 to 4 kg, because less resistance to respiration is produced.
• Use a fresh gas flow of 1.5 times the minute ventilation (approximately 150 ml/kg/min). Fresh gas flow rates are higher because the fresh gas removes carbon dioxide from the system.
Scavenging Equipment ▼ Key Point Use of inhalation anesthetics mandates
ANESTHESIA FOR MAJOR PROCEDURES Anesthesia for major procedures, requiring optimal hypnosis, analgesia, and muscle relaxation for relatively long periods, usually incorporates the inhalant anesthetics (see Tables 2-7 and 2-8). Although inhalant drugs can be given as the sole source of anesthesia, injectable drugs are usually given to facilitate induction
the removal of expired and waste gases from the operating room environment.
• Exhaust waste gases using suction systems or vent them to the outside via a hole in an exterior wall.
• Directing gases to the floor is insufficient. • Use activated charcoal canisters as alternatives to absorb halogenated compounds. This is not effective for nitrous oxide.
W0422-Ch002.qxd 11/10/05 4:40 PM Page 26
26
Section 1 / Patient Management
Isoflurane
• The combination of morphine, lidocaine, and ketamine can be used to supplement analgesia and reduce the requirement for inhalant anesthetics. Add 15 ml of 2% lidocaine (300 mg), 0.6 ml ketamine (60 mg), and 1.6 ml morphine (24 mg) to 1 L balanced electrolyte solution. Administer the combination at the standard rate (10 ml/kg/hour IV).
• Halogenated ether that produces anesthesia when inhaled in concentrations of 1.0% to 3.0%.
• Produces very rapid induction and recovery; relatively insoluble in blood.
• Maximal attainable concentration at room temperature is 30%.
• Use in precision out-of-the-circle vaporizers. • Produces dose-dependent cardiopulmonary depres• •
sion. Adequate ventilation is usually maintained. Ventricular arrhythmias are not enhanced. Use in patients with metabolic disease, in geriatric patients, and in patients prone to cardiac arrhythmias. Is minimally metabolized (<1%).
Sevoflurane
LOCAL ANESTHESIA AND ANALGESIA • Local anesthetics (lidocaine, mepivacaine, bupiva• •
• Newest inhalant anesthetic approved for use in animals.
• Cardiopulmonary effects similar to isoflurane. • Very insoluble in blood, and similar to nitrous oxide in speed of induction and recovery.
• Inoffensive odor is useful for masking. • Administer at concentrations of 5% of induction
• •
followed by maintenance at 2.5% to 3.5%.
caine, ropivacaine, etc.) produce complete analgesia with few cardiopulmonary effects. Local anesthesia can be used alone for some minor surgery, such as skin mass removal. Use local anesthetics in combination with other techniques prior to surgery to prevent pain “wind-up,” allowing for better postoperative pain relief. Block the digital nerves at the level of the carpus prior to performing surgery of the paw, such as declawing cats. Epidural injection of local anesthetics or opioids (morphine) is used to produce analgesia for surgery of the rear limbs and caudal abdomen.
• Use in a precision out-of-the-circle vaporizer. • Is minimally metabolized (3%). Do not used with desiccated carbon dioxide absorbent because of fire hazard.
Nitrous Oxide
• A nonirritant gas that produces some analgesia when inhaled in concentrations of 50% to 70%.
• Cannot produce anesthesia when administered
• • •
alone. Can reduce the required concentration of the other, more potent, gases (e.g., isoflurane) by approximately one third when coadministered. Recovery can be complicated by diffusion hypoxia. Oxygen should be supplemented for 3 to 5 minutes after cessation of nitrous oxide administration. Total fresh gas flow rate must be increased if nitrous oxide is given. Not employed widely in veterinary practice because of its limited potency and potential problems with hypoxia.
MONITORING THE ANESTHETIZED PATIENT Monitoring is the cornerstone of safe anesthetic practice. Because irreversible CNS changes can occur within 4 or 5 minutes of cardiac arrest, a convenient monitoring interval of 5 minutes is appropriate. The skills needed in basic monitoring of anesthetized patients parallel those needed for performing a physical examination.
Anesthetic Record • Prompts the anesthetist to evaluate the patient at regular intervals. Serves as a legal document.
• Contains the following information, at minimum: • Summary of preoperative physical examination • Purpose of anesthesia • Drugs administered, including dose, route, and time • Regular recording of heart or pulse rate and respiratory rate
▼ Key Point Do not use nitrous oxide in patients with pneumothorax, gastric torsion, or intestinal obstruction because it will diffuse into closed gas spaces and enlarge them.
Adjuncts to Inhalant Anesthesia
• Inhalant anesthetics may be too depressant for some patients.
• Intravenous opioids such as fentanyl (0.002–0.006 mg/kg IV) can be administered to augment analgesia with little cardiopulmonary effect.
Heart Rate • Measured by auscultation using an esophageal stetho•
scope (Mallinckrodt), precordial stethoscope, or Doppler flow probe. Palpate a peripheral pulse to determine heart rate and provide additional subjective information concerning the strength of cardiac contraction. Feel the pulse on the ventral side of the tongue (lingual
W0422-Ch002.qxd 11/10/05 4:40 PM Page 27
Chapter 2 / Practical Methods of Anesthesia
• • •
pulse). Alternatively, use the femoral pulse if the animal’s head is covered. Administer anticholinergics (atropine or glycopyrrolate) if the heart rate falls to less than 60 bpm in dogs and 90 bpm in cats. Evaluate the patient for hypotension or anesthetic plane that is too light if the heart rate is greater than 150 bpm in dogs or greater than 180 bpm in cats. Evaluate patients with irregular heartbeats or heartbeats of variable intensity with an electrocardiogram for abnormal cardiac rhythms.
Electrocardiogram
• Use an electrocardiogram (ECG) to measure heart •
Capillary Refill Time and Mucous Membrane Color • Gives further information on homeostasis. • Capillary refill time should be less than 1.5 to 2
• Use Doppler flow probes (Parks Electronics; Aloha,
•
•
seconds.
• May be altered by the anesthetic agent chosen. Other Monitoring Parameters • Assess jaw tone to determine the degree of muscle
•
relaxation present. This is an index of anesthetic depth. • Gently push the jaws apart and note the resistance to movement. • Dissociative agents do not produce muscle relaxation. Pinch a toe and look for a withdrawal response to check the depth of anesthesia prior to incision.
Monitoring Equipment A wide variety of instruments are available to aid in monitoring patients.
Stethoscope
• Use esophageal stethoscopes (Mallinckrodt) to hear heart and respiratory sounds. Amplified stethoscopes are also available.
rate and to determine if cardiac arrhythmias are present. The ECG does not always ensure that the heart is beating or producing effective cardiac output.
Pulse and Blood Pressure Monitors
Respiratory Rate • Measure respiratory rate by watching the movements of the thoracic wall or the rebreathing bag of the anesthetic machine. • Most anesthetics are respiratory depressants. • Increases in rate or depth of respirations or panting usually indicate a plane of anesthesia that is too light. • Check the anesthetic depth in patients with irregular respirations; this can be a sign of excessive medullary depression. An apneustic pattern is expected after ketamine or tiletamine administration.
27
Oregon) to detect peripheral pulses. Place the probe over a peripheral artery. An audible signal is created as pulses of blood pass under the probe and the sound waves emitted by the Doppler probe are altered. Place an occlusive cuff proximal to the Doppler probe to obtain an estimate of systolic arterial blood pressure. This monitor is reliable as a pulse detector but unreliable as an estimator of blood pressure. It can be used to follow trends. Use cuff widths approximately 30% of the circumferences of the extremity. Oscillometric units (Dinamap, Critikon; Tampa Bay, Florida) can record heart rate and estimate systolic, mean, and diastolic blood pressures. The units inflate an occlusive cuff and slowly release pressure. Characteristic pressure fluctuations during deflation are used to estimate blood pressure. These monitors are expensive and tend to lose accuracy as blood pressure falls. Use cuff widths approximately 30% of the circumference of the extremity. Dorsal pedal artery can be catheterized with an overthe-needle catheter to directly measure arterial blood pressures. Connect an aneroid manometer to the catheter as a simple way to determine the mean arterial blood pressure. Use a pressure transducer to make more definitive measurements.
Pulse Oximetry
• Detects pulses and uses reflectance or absorbance of light to estimate hemoglobin saturation.
• Pulse oximeters do not assure adequacy of ventila• • • •
tion, only adequacy of oxygenation. Most units also display pulse rate. Values should be in excess of 90%. Probes are usually placed on the tongue. Reposition the probe periodically as needed to maintain signal.
Blood Gas Analysis
• More definitive monitoring of respiratory and metabolic integrity is accomplished by measuring arterial pH and blood gas values. See Chapter 5 for the characterization and treatment of acid-base disorders.
W0422-Ch002.qxd 11/10/05 4:40 PM Page 28
28
Section 1 / Patient Management
Table 2-9. ANTAGONISTS USED TO REVERSE ANESTHESIA
•
Benzodiazepine (Diazepam, Midazolam, Lorazepam) Antagonists Flumazenil 0.01–0.02 mg/kg IV
•
a2-Adrenergic (Xylazine, Medetomidine) Antagonists Yohimbine 0.1–0.4 mg/kg IV Tolazoline 0.5–2.0 mg/kg IV Atipamezole 0.2–0.4 mg/kg IV
•
Narcotic Analgesic (Opioid) Antagonist Naloxone
0.003–0.010 mg/kg IV or IM
• • •
RECOVERY AND REVERSAL
•
Watch the patient after anesthesia until it can remain in sternal recumbency without being assisted.
• If reversible drugs have been given, the administra•
•
tion of antagonists speeds recovery (Table 2-9). Do not administer an antagonist indiscriminately. Doxapram (1–5 mg/kg) is a nonspecific stimulant of respiration and the CNS. Doxapram can be given to cause arousal in an emergency, but it can also produce undesirable excitement. Animals recovering from anesthesia may go through a period of emergence delirium. This period apparently results from a rapid return to consciousness with disorientation. The animal may or may not be in pain. Many animals respond to a reassuring voice and
•
petting. Provide analgesia, sedation, or both for animals that do not respond to these actions. Check the animal’s temperature. Most animals lose body heat during anesthesia. Some animals do not return to consciousness until body temperature is restored to 95°F to 97°F (35°C to 36.1°C). Warm animals by placing them on recirculating, warm-water heating pad; by providing radiant heat from a lamp; or by using a forced-air blanket. Take care to not burn the patient, particularly when heating lamps are used. Oxygen use increases dramatically with shivering. Monitor the patient, and provide oxygen if necessary. Leave the endotracheal tube in place until the animal regains the oropharyngeal reflexes (i.e., begins to swallow). Give oxygen if necessary. Remove IV catheters, if no longer necessary, after the patient is rewarmed and conscious. Postoperative hypotension can occur, particularly if the patient does not rapidly return to consciousness. Monitor the patient periodically until it can stand unassisted.
SUPPLEMENTAL READING Gaynor JS, Muir WW: Handbook of Veterinary Pain Management. St. Louis: CV Mosby, 2002. Muir WW, Hubbell JAE, Skarda R: Handbook of Veterinary Anesthesia, 3rd ed. St. Louis: CV Mosby, 2000. Thurmon JC, Tranquilli WJ, Benson GJ: Essentials of Small Animal Anesthesia and Analgesia. Philadelphia: Lippincott Williams & Wilkins, 1999.
Chapter
▼
W0422-Ch003.qxd 11/10/05 4:41 PM Page 29
3
Emergency and Critical Care Techniques and Nutrition Shane W. Bateman / C. Anthony Buffington / Cheryl Holloway
This chapter describes commonly used techniques in emergency and critical care medicine. See appropriate chapters for information about diseases that require critical care.
• Needle holders, tissue forceps • Monofilament skin suture appropriate to patient • Skin staples (optional) Technique
INTRAVENOUS CATHETERIZATION BY CUTDOWN Indications ▼ Key Point Venous access is required in every emergency situation.
Perform venous cutdown when percutaneous venous catheterization has been unsuccessful after one or two attempts (depending on the urgency with which access is required). Nonurgent venous cutdown can also be performed when numerous percutaneous catheterization attempts have resulted in severe peripheral hematoma formation or thrombophlebitis.
Contraindications Relative contraindications include severe hemostatic dysfunction. However, occasionally such patients require IV catheterization, necessitating an easily compressible location as the best choice for a cutdown procedure.
Objective Obtain vascular access for administration of fluid and drugs.
Equipment • Local anesthetic • Scalpel handle and #10 or #15 blade • Iris scissors (very small sharp/sharp) • Thumb forceps • Curved mosquito hemostat • Suitable size IV catheter (e.g., Surflo catheter, Terumo Medical Corp.)
1. When the patient is semicomatose or moribund, local anesthesia is not required. Otherwise, infiltrate small amounts of local anesthetic into the aseptically prepared skin site. 2. In general, the lateral saphenous (canine) or medial saphenous (feline) are easier to approach than the cephalic veins. Jugular cutdown can also be performed with the same technique, but the vein is deeper and may be more troublesome for inexperienced surgeons to find. 3. After aseptic skin preparation and use of aseptic technique, identify the vessel. In many situations the vessel may not be visible even when occluded, so the anatomy of the vessel is important to understand. 4. Place the scalpel blade gently on the skin over the vessel and, without cutting the skin but maintaining skin contact with the blade, pull the skin laterally to the vessel (Fig. 3-1). 5. Incise approximately 1 to 1.5 inches parallel to the vessel. 6. Allow the skin to retract back into place over the vessel. 7. The bluish hue of the vessel should be obvious if the incision was made in a correct location. Move the skin to attempt to identify the vessel if it is not immediately obvious. To differentiate the vessel from underlying muscle bellies, the vessel should blanch with minimal digital pressure; muscle bellies will not. 8. Hold the iris scissors with the thumb and index finger in the finger rings with the tips of the scissors pointing across the palm of your hand, not extending out from the fingers. This allows the shaft of the scissors to be perpendicular to the patient and the vessel. 9. Place the tips of the scissors as close to the vessel wall as possible, apply gentle pressure to the tissue, 29
W0422-Ch003.qxd 11/10/05 4:41 PM Page 30
30
Section 1 / Patient Management
Figure 3-1.
Position of scalpel and skin for skin incision. Figure 3-2. A, Blunt dissection of the vessel using sharp/sharp scissors. B, Catheterization of vessel using stay sutrue.
10.
11. 12.
13. 14.
and extend the blades maximally, bluntly dissecting the fascia from the vessel wall (Fig. 3-2A). Repeat this procedure on both sides of the vessel wall until the vessel is freed from its fascial attachments and the mosquito hemostat can be placed under the vessel. Take care not to place the tips of the blades on the vessel itself. In addition, if small side branches of the vessel are present, choose a more proximal or distal location. Pull a loop of suture ventrally underneath the vessel to exteriorize and serve as a manipulator to allow positioning of the vessel for catheterization. Examine the vessel for remnants of fascia. It is easy to catheterize one of these fascial planes by mistake and think that you are in the vessel lumen. Strip the vessel of any remaining fascia by gently using one arm of the Adson thumb forceps. Catheterize the vessel using the suture as a handle to manipulate the vessel into an appropriate position (Fig. 3-2B). It is easy to puncture both sides of the vessel wall, so prior to advancing the catheter, verify that the metal of the stylet cannot be seen underneath or beside the vessel wall by gently moving the catheter.
15. Flush the IV catheter to confirm successful catheterization. 16. Remove the loop of suture, connect IV fluids to the catheter, suture or staple the skin with the catheter exiting from the suture line, and secure the catheter to the skin with the normal taping method.
INTRAOSSEOUS ACCESS FOR FLUID ADMINISTRATION Indications Intraosseous access is typically utilized only in neonatal or pediatric patients because of the small size of their peripheral vessels.
Contraindications ▼ Key Point Do not use intraosseous access where severe tissue trauma exists or in areas of potentially infectious dermatitis.
W0422-Ch003.qxd 11/10/05 4:41 PM Page 31
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
Equipment • Local anesthetic • 22- to 20-gauge, 1- to 1.5-inch spinal needle (with stylet)
• Commercial intraosseous catheter (optional) Technique 1. Aseptically prepare the skin over the appropriate site. In general, the intertrochanteric fossa or the tibial crest is the easiest site to gain access (Fig. 3-3). 2. Infuse a small quantity of local anesthetic into the periosteum and the skin surrounding the site. Be cautious that the volume administered is not in the toxic range for the size of the animal. Lidocaine can be diluted to 1% to prevent toxicity if necessary. 3. Using aseptic technique, identify the site of needle insertion into the appropriate long bone (femur or tibia) and palpate firmly to identify the appropriate direction and angle of needle advancement. Direct the needle as straight as possible down the marrow cavity of the shaft of the long bone. 4. Advance the needle using gentle but steady forward pressure as you slowly twirl the shaft of the needle back and forth.
31
5. Once the needle is firmly seated into the bone, remove the stylet and attempt to aspirate through the needle. Ability to aspirate bloody fluid (bone marrow) generally indicates successful placement. If awake, animals will often object to aspiration as they would for bone marrow aspiration. 6. Gently flush the needle with isotonic fluid and gently palpate around the long bone for accumulation of fluid. If fluid accumulates outside the bone, then the needle has penetrated the cortex and must be repositioned into the marrow cavity. 7. If successfully placed, attach the IV line to the needle (a luer lock tip assists in prevention of accidental disconnection). Carefully bandage the limb and exposed needle to minimize movement.
Complications Poor needle placement can result in inappropriate needle tip placement into the cortex or outside the cortex. Repositioning of the needle usually results in success. Patients that are moving vigorously or traumatizing the needle may shift the tip to an inappropriate location, allowing fluid accumulation in the subcutaneous tissue. Regular monitoring of the limb and needle are warranted to detect this complication.
ARTERIAL SAMPLING FOR BLOOD GAS ANALYSIS Indications intertrochanteric fossa
Collection of an arterial blood sample is often helpful in assessing respiratory function and effective gas exchange. Analysis of a blood gas for acid-base status is more meaningful when venous blood is utilized.
Contraindications Presence of a severe coagulopathy is a relative contraindication. In general, with firm direct pressure for prolonged periods, significant blood loss is not a concern. The sample is most easily obtained when the patient is in lateral recumbency; thus observe patients with respiratory compromise carefully for worsening of respiratory distress during the procedure and give supplemental oxygen as required. tibial crest
Objectives • Obtain arterial blood for blood gas analysis • Prevent hemorrhage Equipment Use either of the following: Figure 3-3.
Anatomic locations for intraosseous access.
• Dry heparin blood gas syringe • A heparinized regular syringe
W0422-Ch003.qxd 11/10/05 4:41 PM Page 32
32
Section 1 / Patient Management
Technique 1. If no commercially available dry heparin blood gas syringes are available, heparinize a regular syringe by withdrawing liquid heparin into the syringe so that the insides of the syringe barrel are in contact with the heparin. Depress the syringe plunger to extrude the liquid heparin out of the needle. A small quantity of liquid heparin should remain in the syringe hub. Place a new needle onto the syringe prior to puncturing the skin. 2. The two most commonly utilized sites for arterial sampling are the femoral artery medial to the femur in the inguinal region (Fig. 3-4A) and the dorsal metatarsal artery medial to midline and distal to the tarsus joint (Fig. 3-4B). 3. Hold the tips of the index and middle fingers of the nondominant hand perpendicular to the artery but parallel to the long axis of the patient and gently palpate the region until the pulsation of the artery can be felt underneath both finger tips. Excessive pressure will often occlude the artery and prevent successful palpation of the pulsation. 4. Gently stabilize the artery and skin between the fingers of the nondominant hand. A
5. Hold the sampling syringe with the dominant hand. Place the needle between the fingers over the artery and advance slowly at an acute angle (45 degrees or greater for the dorsal metatarsal artery, slightly less than 90 degrees for the femoral artery). 6. Observe the hub of the needle carefully for a blood flashback to “jump” into the hub. Frequently, pulsations can be observed if the patient’s blood pressure is high enough. Self-filling blood gas syringes should fill rapidly if the pressure is normal. Withdraw the sample volume if a conventional syringe is being utilized. Slow flashbacks, lack of observable pulsations, color of the blood sample, slow filling of self-filling syringes, and the blood gas results may all indicate that the sample is venous or mixed rather than a pure arterial sample. 7. Place gentle but firm pressure over the sampling site for 3 to 5 minutes, then observe for an additional 30 to 60 seconds to ensure that the puncture site has sealed to prevent hematoma formation.
Complications Hematoma formation is infrequent and can be prevented by applying pressure for an appropriate duration. Avoid accidental puncture of the nerve that courses parallel to the artery; puncture can cause a painful reaction.
NASAL CATHETER PLACEMENT Indications Patients require supplemental oxygen or enteral feeding.
Contraindications • Patients with severe deforming facial trauma • Brachycephalic breeds with respiratory distress • Severe thrombocytopenia or other coagulopathy • Severe or protracted vomiting (if placing a feeding
Femoral a.
tube) B Dorsal metatarsal a.
Objectives • Provide oxygen therapy using a nasal catheter • Provide nutritional supplementation using a nasogastric tube
Equipment • Nasal oxygen cannula or nasoesophageal or nasogas-
Figure 3-4. A, Femoral artery puncture. B, Dorsal metatarsal artery puncture.
• • • • •
tric feeding tubes Topical ophthalmic local anesthetic Tape Needle holders and tissue forceps Monofilament skin suture appropriate to the patient Skin staples
W0422-Ch003.qxd 11/10/05 4:41 PM Page 33
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
Technique 1. Install several drops of local anesthetic into the nostril with the patient’s head tipped up slightly; allow several minutes to reach peak effect. 2. Premeasure the catheter to (a) the last rib for nasogastric tube, (b) the base of the heart for nasoesophageal tube, or (c) the junction of the zygomatic arch and the cranial edge of the ramus of the mandible for nasal oxygen. 3. Restrain the patient with the head tipped slightly up and place the tip of the catheter gently into the nostril. 4. Use the thumb of the nondominant hand to push gently up on the nasal philtrum. With the index finger of the same hand, gently squeeze against the thumb from the top of the nasal planum (Fig. 3-5). 5. Advance the catheter quickly and gently, forcing the tube in a ventral and medial direction into the ventral meatus. The patient will often retract away from you, so release your advancing fingers immediately after you have advanced the tube. This is a similar motion to holding and throwing a dart. 6. Advance the catheter with repetitive motions until the premeasured catheter length has been inserted. If placing a nasal oxygen cannula, advance the tube past the nasopharynx if possible to confirm placement into the ventral meatus, then pull back to the premeasured length. Tubes that will not advance past the nasopharynx may be in the dorsal meatus and should be repositioned. 7. Place a small length of tape to the dry tube where it exits the nostril.
Figure 3-5.
Positioning for placement of nasal catheter.
33
8. Place a simple interrupted suture at the ventromedial corner of the nostril. Place a finger trap suture pattern over the tape on the tube to secure the tube to the nostril (Fig. 3-6A–D). Tie multiple knots to complete the finger trap. 9. Place a second simple interrupted suture to the ventrolateral corner of the nostril at the mucocutaneous junction using the remaining ends of the suture to further secure the tube from accidental removal (Fig. 3-6C). 10. Use skin staples to attach the end of the tube to the patient’s face, generally either on the side of the face or up the center of the face between the eyes and to the top of the head (Fig. 3-6D). 11. Verify feeding tube placement with radiographs or capnographic confirmation.
Complications Occasionally the tube will not advance past the nasopharynx (even through the ventral meatus) because of anatomical conformation in individual animals. In such patients, pass the tube through the opposite nasal passage. In addition, feeding tubes may be inadvertently passed into the trachea and airway, especially in sedated, anesthetized, or obtunded patients. Confirm placement using radiography or capnography. Feeding tubes can also be vomited back up the esophagus and chewed off by the patient, so closely observe patients with nasal feeding tubes.
Figure 3-6.
Finger trap suture pattern.
W0422-Ch003.qxd 11/10/05 4:41 PM Page 34
34
Section 1 / Patient Management
EMERGENCY TEMPORARY TRACHEOSTOMY Indications Patient has life-threatening upper airway obstruction (proximal to the cervical trachea) and cannot be intubated with an endotracheal tube.
Contraindications Airway obstruction distal to the site of tracheostomy. Severe coagulopathy is a relative contraindication, but this can be treated with transfusion component support and direct pressure.
Objectives • Establish a patent airway • Maintain the patent airway by frequently cleaning or
10. Depending on the experience and skill of the surgeon, two approaches to incising the trachea are possible: a. If the surgeon feels comfortable and excellent surgical precision is possible, incise the trachea transversely “between” two rings in the mid cervical trachea (Fig. 3-7). Extend the incision over the ventral two thirds of the circumference of the trachea. Do not incise into the dorsal tracheal membrane. b. Alternatively, if the surgeon is less comfortable and a lesser degree of surgical precision is likely, incise longitudinally “through” several rings (Fig. 3-8). Holding the scalpel upside down and gripping the blade carefully to allow only 10 to 15 mm of blade to be exposed, incise approximately four tracheal rings beginning with ring 3 and continuing through ring 6 distal to the larynx. 11. Direct oxygen toward the incision.
replacing the tracheostomy tube
Equipment • Scalpel handle and #10 or #15 blade • Mayo scissors • Large, curved Kelly or Carmalt hemostat • Tracheostomy tube • Monofilament suture material appropriate to patient Technique 1. Position the patient in dorsal recumbency with the head extended slightly off and over the edge of the table or with the neck over a rolled towel or sandbag. 2. Make one attempt to insert a large over-the-needle peripheral IV catheter into the trachea at the base of the neck close to the thoracic inlet to provide oxygen to the patient while final preparations are made. 3. Rapidly clip and aseptically prepared the skin. 4. The patient will need rapid IV anesthesia for the procedure unless it is moribund. 5. Incise the skin from the larynx to the thoracic inlet. 6. Bluntly force the closed tips of Mayo scissors into the first tissue plane, open and insert one tip into the tissue plane created, then incise the tissue plane to each end of the incision. Attempt to use the sharp edges of the scissors to cut by advancing with the blades open rather than “scissoring” through the tissue. 7. Incise the sternohyoideus muscles (strap muscles) in a similar way, exposing the trachea. 8. Identify the neurovascular bundle on each side and bluntly insert a hemostat through the fascia dorsal to the trachea, allowing it to be elevated into the surgical incision. 9. Do not damage the vessels overlying the trachea.
Figure 3-7. placement.
Between-the-rings tracheostomy with stay suture
Figure 3-8. placement.
Through-the-rings tracheostomy with stay suture
W0422-Ch003.qxd 11/10/05 4:41 PM Page 35
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
12. Place stay sutures (3-0 or 4-0 silk) in the edges of the tracheal incision. If a transverse incision was made, place stay sutures in the ventral-most aspect of the trachea and around the first proximal and first distal ring. If a longitudinal incision was made, place stay sutures around two adjacent rings, approximately 3 to 5 mm from the tracheal incision and encompassing 2 tracheal rings on both sides of the incision. Leave the suture ends long. 13. Insert the tracheostomy tube into the trachea. Several types of specialized tracheostomy tubes are commercially available. Each has advantages and disadvantages. A simple tracheostomy tube can also be easily constructed from an endotracheal tube (Fig. 3-9). 14. The most critical aspect of tube placement is the size and fit of the tube. If the tube exerts circumferential pressure on the tracheal mucosal, then significant pressure necrosis, scarring, or fibrotic web formation are more likely to occur as a complications. Choose a tube that fits loosely in the trachea with no major points of mucosal pressure. Do not inflate the cuff unless positive pressure ventilation is required. 15. Suture the skin edges to allow easy access to the tracheal incision when the tube needs to be changed.
Postoperative Care and Complications • Clean or replace the tube as necessary to maintain patency.
• Clean the “dirty tube” and allow it to soak in an
• • •
appropriate and safe antimicrobial solution, then rinse carefully with sterile saline prior to the next tube exchange. Do not apply suction to the tube. Keep the animal well hydrated. Protect the skin around the tube with petrolatum (Vaseline).
If possible, use tracheostomy heat and moisture exchange devices (HME) to maintain airway humidification and thus decrease viscosity of secretions. These
Figure 3-9. tube.
Tracheostomy tube construction from endotracheal
35
devices add a small amount of increased resistance that contributes to the work of breathing. In patients with marginal muscle strength, this may be significant and lead to a vicious cycle of hyperthermia and increased work of breathing. Monitor the patient’s temperature regularly. Routine administration of saline into the tracheostomy site is not recommended. A poorly fitting tube and inappropriate inflation of the cuff are the most common cause of fibrosis and web formation as a long-term complication.
ABDOMINOCENTESIS Indications Physical examination or radiographic evaluation indicates moderate quantities of peritoneal effusion, and cytological or chemical analysis of the fluid will assist in the diagnostic process.
Contraindications Severe coagulopathy is a relative contraindication depending on the value or benefit of obtaining a fluid sample. Relative contraindications to use of a blind technique include a large abdominal mass; significant organomegaly, particularly of a vascular organ such as the spleen, liver, or kidney; or distension of a hollow viscus such as bowel or uterus. Consider ultrasonographic guidance if available.
Objectives • Aseptically obtain fluid from the abdominal cavity for analysis and culture
• Avoid trauma to abdominal organs Equipment • 22- to 20-gauge, 1- to 1.5-inch needle and syringe appropriate to patient size (e.g., 3- to 12-ml syringe)
Technique 1. If possible, allow the patient to stand or be positioned in sternal recumbency to allow access to the most dependent site on the abdomen. Alternatively, place the patient in left lateral or dorsal recumbency. 2. The goal of the patient position and of the location and direction of the abdominocentesis attempt is to avoid the spleen, thus preventing hemorrhage that will contaminate the sample. 3. Clip and aseptically prepare the skin. Local anesthetic can be infiltrated if desired. 4. Advance the needle and syringe through the skin and withdraw the plunger of the syringe to create a small amount of negative pressure in the syringe prior to advancing the needle into the peritoneal cavity and away from the presumed location of the spleen.
W0422-Ch003.qxd 11/10/05 4:41 PM Page 36
36
Section 1 / Patient Management
5. In sternally recumbent or standing patients, frequently productive sites are caudal to the spleen, on or slightly to the right side of midline, with the needle directed toward the cranial aspect of the bladder. In left laterally recumbent patients, frequently productive sites are slightly caudal to the umbilicus, on or slightly to the right of midline, with the needle directed toward the cranial aspect of the bladder and slightly toward the dependent or left side of the patient. If these areas are unproductive, attempt a second site just cranial to the umbilicus, on or slightly to the right of midline, with the needle directed perpendicular to the long axis of the patient or at a 20° to 30° angle (needle tip toward the cranial aspect of the patient). In dorsal recumbency, frequently productive sites are caudal to the umbilicus, on or slightly to the right of midline, with the needle directed toward the cranial aspect of the bladder. If this attempt is unproductive, attempt a second site just cranial to the umbilicus, to the right of midline, with the needle directed perpendicular to the spine. 6. In general, extremely gentle aspiration of the syringe may yield a larger sample size and prevent clogging of the needle with omentum.
Complications Complications are minimal. Inadvertent splenic aspiration may occur, but unless the patient has a bleeding tendency, this is unlikely to create a problem except for contamination of the sample with blood or potential contribution to an erroneous diagnosis of hemoabdomen.
TENCKHOFF PERITONEAL DIALYSIS CATHETER PLACEMENT Indications Tenckhoff peritoneal dialysis catheter placement is ideal for short-term (24 to 48 hours) access to the peritoneal cavity. This may be useful for treating patients with acute intoxication with drugs or chemicals that can be effectively removed by peritoneal dialysis; for core warming or cooling of patients with severe hypothermia or hyperthermia, respectively; for short-term management of uremia in unstable uroabdomen patients; or for performing diagnostic peritoneal lavage (DPL).
Contraindications Relative contraindications to use of the blind technique for placement include large abdominal masses; significant organomegaly, particularly of a vascular organ such as the spleen, liver, or kidney; or distension of a hollow viscus such as bowel or uterus.
Objectives • Obtain abdominal fluid or perform DPL • Perform peritoneal dialysis • Avoid organ damage • Avoid subcutaneous leakage of fluid Equipment • Local anesthetic • Scalpel blade (#11 or #15) • Needle holders and thumb tissue forceps • Monofilament skin suture appropriate to the size of the patient
• Tenckhoff peritoneal catheter (numerous commercially available kits, e.g., Sherwood Davis & Geck)
• Connecting adapters and fluid lines to maintain a closed ingress-egress system
Technique 1. Place the patient in left lateral recumbency and aseptically prepare a wide area around the abdominal entry site. Infiltrate the site with local anesthetic. Drape the area appropriately and perform the procedure aseptically. 2. The site of entry is just cranial to the umbilicus and slightly to the right of midline. 3. Make a small stab incision through the skin and the external fascial plane of the external rectus abdominus muscle large enough to just accommodate the diameter of the catheter. 4. Several types of catheter kits are available for purchase with differing methods and equipment for actual placement of the catheter through the abdominal wall. Follow the instructions with the kit or modify them to allow placement of the catheter into the peritoneal cavity. Kits using the peel-away introducer or Seldinger (over the wire) technique generally have a lower risk of injury to internal organs. 5. Position the catheter tip near the pelvic canal. Secure the catheter to the patient using the finger trap suture method (see Fig. 3-8). ▼ Key Point Use aseptic technique and ensure that the system remains closed.
Complications Minor hemorrhage may be expected for a short time after placement. Ongoing evidence of hemorrhage into the draining fluid indicates more significant hemorrhage. Frequently, the omentum may occlude the openings of the catheter and prevent appropriate drainage. In patients with a thin or compliant body wall or poor body condition, gently palpate the catheter inside the peritoneal cavity and gently strip the omentum from the catheter tip if necessary. Introduction of infection into the peritoneal cavity may have devastating conse-
W0422-Ch003.qxd 11/10/05 4:41 PM Page 37
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
quences and requires vigilant attention to the care and maintenance of the drainage system.
THORACOCENTESIS Indications Perform diagnostic thoracocentesis on all patients that present with symptoms of pleural space disease (rapid shallow breathing, respiratory distress, symmetrical or asymmetrical dullness, or absence of lung sounds on auscultation) as described in Chapter 142. Patients with significant respiratory distress that are unsuitable candidates for radiographic evaluation may also benefit from diagnostic thoracocentesis.
Contraindications Patients with long-standing chronic effusions (particularly cats with chylous effusion) may be at a higher risk for development of fibrosing (restrictive) pleuritis. Inadvertent needle contact with, and subsequent laceration of, the diseased pleura in this syndrome can produce significant and life-threatening pneumothorax. Exercise extreme caution in using sharp instruments to drain thoracic fluid in such patients.
Objectives • Evacuate fluid or air from the pleural space • Avoid iatrogenic pneumothorax or trauma to the lungs, heart, and intercostal blood vessels
Equipment • 19- or 22-gauge butterfly catheter, 18- to 22-gauge
• • •
over-the-needle intravenous catheter, 18- to 22-gauge, 1- to 1.5-inch needle, or metal stylet from 18- to 22-gauge over-the-needle catheter with catheter removed IV extension set Three-way stopcock Syringe
Technique 1. Clip hair from the site and aseptically prepare the skin. Many patients will tolerate the procedure without instillation of local anesthetic and often resent the injection of local anesthetic more than the procedure. 2. The site of thoracocentesis will depend on whether air or fluid is suspected to be causing respiratory distress. If fluid is suspected, select a ventral location in intercostal spaces 3 to 7 approximately one third of the distance between the costochondral junction and the sternum. If air is suspected, select a dorsal location in intercostal spaces 5 to 9 at the junction of the dorsal one third and ventral two thirds of the chest wall.
37
3. Choose a needle or catheter of sufficient size and length appropriate to the situation and patient. Ensure that the three-way stopcock is closed to the atmosphere. 4. Advance the sharp point of the needle or stylet through the skin, then place a small amount of negative pressure on the syringe. Advance the needle tip cautiously until a slight “pop” through the parietal pleura is felt, which ideally is accompanied by productive aspiration of air or fluid from the pleural space. 5. Use one of the following methods: a. If using a rigid metal device, attempt to reposition the needle or stylet tip into the intercostal space (parallel to the ribs with the bevel facing into the chest) so that as the pleural cavity is drained and the lung expands closer to the chest wall, there is less likelihood that the lung will be lacerated by the needle tip (Fig. 3-10A). b. Alternatively, advance the needle under the cranial rib and flatten the needle against the caudal rib (perpendicular to the ribs with the bevel facing into the chest). This method should cause the cranial rib to be pushed gently from the chest, again protecting the tip of the needle and preventing laceration of the lung parenchyma (Fig. 3-10B). c. In a third method, grasp the rigid shaft of the needle or stylet between the index finger and the thumb such that only the tip of the needle or stylet is within the pleural cavity. Guard the needle or stylet firmly to prevent inadvertent advancement into the thoracic cavity. As soon as a “scratching” or “scraping” sensation is detected on the needle, immediately withdraw it to prevent inadvertent laceration of the lung (Fig. 3-10C). 6. Gently reposition the needle or stylet or withdraw it if there is lack of continuing production of fluid or air from further attempts at aspiration. 7. Drain as much as possible from the pleural cavity using the three-way stopcock, syringe, and collection basin (a second thoracocentesis may be required on the contralateral chest wall in some cases).
Complications Patients with chronic fluid accumulations, especially with significant quantities of fibrin, may have significant compartmentalization of fluid that is difficult to remove with routine thoracocentesis. Ultrasound-guided attempts may be more successful in collecting fluid from such patients; alternatively, consider a chest drain (see the next section). Inadvertent laceration of lung parenchyma resulting in pneumothorax is rare (except in fibrosing pleuritis patients) and can be managed with chest drain placement and intermittent or continuous suction. Laceration of a coronary artery is an extremely rare complication and likely only if the position of
W0422-Ch003.qxd 11/10/05 4:41 PM Page 38
38
Section 1 / Patient Management
Objectives • Aseptically place an indwelling thoracic drain tube without causing iatrogenic trauma to thoracic viscera
• Minimize iatrogenic pneumothorax • Place the tube so that it effectively drains pleural air or fluid A
Equipment • Scalpel handle with #10 or #15 blade • Adson Thumb forceps • Mayo scissors • Needle holders • Curved Kelly or Carmalt hemostat appropriate to the size of the patient and tube
• Chest catheter or tube of appropriate size (two thirds B
•
of the intercostal space) (Argyle trocar catheter or red rubber feeding tube) Monofilament skin suture material appropriate to patient (i.e., 3-0 to 0)
Technique
C Figure 3-10. A, Needle position for parallel intercostal approach to thoracocentesis. B, Needle position for perpendicular intercostal approach to thoracocentesis. C, Needle position for subpleural approach to thoracocentesis.
the heart is significantly deviated within the thoracic cavity.
THORACIC CATHETER OR TUBE PLACEMENT Indications Consider placing a thoracic catheter or tube in patients with large volumes of air or fluid production that are not reasonably and effectively drained with intermittent thoracocentesis.
Contraindications Significant coagulopathy is a relative contraindication for this procedure. Severe trauma or instability of the chest wall at the proposed site is a contraindication to nonsurgical placement of the catheter or tube.
1. Use either general anesthesia or heavy sedation with local anesthesia and intercostal nerve blocks. 2. Pull the patient’s lateral chest wall skin cranially as far as comfortably possible. 3. Clip the hair and aseptically prepare the skin from the 5th to the 12th intercostal space. Use local anesthetic to infiltrate into the 7th or 8th intercostal space at the junction of the dorsal one third and ventral two thirds of the lateral body wall. 4. Incise the skin at the 10th intercostal space. Make the incision approximately 5 mm longer than the diameter of the tube being placed. 5. Using thumb forceps and sharply incise the subcutaneous and latissimus dorsi muscle tissue. Do not use excessive blunt dissection so that you have a tight seal around the tube. 6. Clamp the thoracostomy tube tip 3 to 5 mm behind the tips of the Kelly or Carmalt hemostat (Fig. 311A). Ensure that the open end of the tube is clamped or plugged with a collection device. Alternatively, use an Argyle trocar catheter. 7. Premeasure the tube from the intercostal entry site (seventh or eighth intercostal space) to the point where the elbow naturally overlies the sternum. 8. Place the clamped tube into the deepest part of the incision, ensuring that the hemostat is curved toward the elbow and the tips are in the intercostal space and not over a rib. 9. Stand at the patient’s back and grasp the shaft of the tube or hemostat with the nondominant hand, allowing one finger’s width between the patient and the bottom of the nondominant hand. Form a fist over the finger rings of the hemostat (or trocar catheter) with the dominant hand (Fig. 3-11B).
W0422-Ch003.qxd 11/10/05 4:41 PM Page 39
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
stab incision in 7-8 intercostal space dorsal 1/3 ventral 2/3
tips toward elbow
B Figure 3-11.
A, Position of thoracic tube in Kelly or Carmalt forceps. B, Technique for placement of thoracic tube.
39
W0422-Ch003.qxd 11/10/05 4:41 PM Page 40
40
Section 1 / Patient Management
10. Place the tube into the chest cavity at the seventh or eighth intercostal space with a sharp, quick, and forceful motion. 11. Open the hemostat and slide the tube gently into the chest cavity while the hemostat is removed. 12. After inserting the tube to the premeasured length, release the skin to slide caudally, forming a “tunnel” over the tube as it exits the chest wall. 13. Place a purse-string suture in the skin around the tube. Leave both suture ends of approximately equal length. 14. Place a finger trap suture pattern to secure the tube to the skin (see Fig. 3-6). Also, if desired to prevent leakage around the subcutaneous portion of the tube, place a simple interrupted suture around the tube between its entry site in the skin and where it enters the thorax. 15. Cover the skin-tube interface with copious amounts of antibiotic ointment and bandage it into place.
Postoperative Care and Complications • Use an Elizabethan collar if necessary to prevent tube damage.
of a percutaneous endoscopically placed gastrostomy tube (PEG tube).
Contraindications Contraindications for esophagostomy tube placement include megaesophagus or localized infection at the desired tube insertion site. Coagulopathy is a relative contraindication. Consider severity of the hemostatic dysfunction and the urgency of nutritional support.
Objectives
• Provide nutritional supplementation using an esophageal catheter
• Avoid excessive trauma to the esophagus Equipment
• Scalpel handle with #15 or #11 blade • Large curved Kelly or Carmalt hemostat • Appropriate red rubber feeding tube (size 14 Fr or larger)
• Monofilament skin suture appropriate to the patient
• Change the chest bandage every other day or more • •
• • • •
often if necessary. Check tube position during bandage changes. Frequently check tube connection devices for leaks. A small amount of subcutaneous air or fluid ventral to the tube entry site may occur. However, consider replacing the tube in a new site if large amounts of fluid or air drain to the subcutaneous space. Obtain thoracic radiographs if necessary to check tube position. Reposition the tube if necessary. Pull the chest tube when minimal fluid or air is drained. The chest tube can create 1 to 2 ml/kg/24 hours of pleural fluid. Remove sutures and pull the tube quickly and smoothly from the chest. Submit the tube tip for culture if indicated. Apply antibiotic ointment and bandage the incision.
FEEDING TUBE PLACEMENT Nasal Feeding Tubes (Nasoesophageal, Nasogastric) See “Nasal Catheter Placement” in this chapter.
Esophagostomy Tube Placement Indications Enteral tube feeding is required for long-term home feeding in patients with good gastric motility and when longer anesthetic periods or expense precludes the use
Technique 1. Commercially available customized esophagostomy kits are available. If using a kit, follow the instructions for placement that accompany the kit. 2. Anesthetize the patient and place in right lateral recumbency with an endotracheal tube in place. 3. Premeasure the tube to ensure that the tip of the tube is in the distal esophagus (from the entry site to the eighth rib). 4. Clip and aseptically prepare the skin over the left neck caudal to the ramus of the mandible. 5. Insert a curved hemostat into the mouth with the curve pointed laterally. Use a mouth gag to facilitate hemostat placement if necessary. Advance the hemostat into the esophagus and palpate the tips of the hemostat on the left lateral neck. 6. Place the tips of the hemostats to the level of the second to third cervical vertebral body and as far dorsal from the jugular vein (furrow) as possible. Push outward or upward to “tent” the skin of the neck. 7. Have an assistant’s index finger and thumb grasp the tips of the hemostat and gently push down to stretch the skin over the tips of the hemostat to hold it firmly in place and prevent it from moving (Fig. 3-12). 8. Have the assistant make a stab incision directly over the tips of the forceps, making contact with the metal tips with the scalpel blade. Do not remove the blade until the tips of the hemostat penetrate the incision. The goal is to gently use the scalpel to enlarge the incision only until it permits exit
W0422-Ch003.qxd 11/10/05 4:41 PM Page 41
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
Figure 3-12. Technique for esophagostomy tube placement.
41
Forceps
Angle of mandible Jugular vein
Figure 3-13. Positioning of tube after placement of esophagostomy tube.
of the hemostat. A large or ragged incision is not desirable. 9. Push the hemostat tips outward through the stab incision. If resistance is felt, the blade of the scalpel can be “wiggled” slightly to allow the hemostat to penetrate. 10. Open the jaws of the hemostat, place the distal tip of the feeding tube parallel to the tips, and clamp it into place. 11. Pull the tube through the mouth to the appropriate length and remove the clamp.
12. Direct the end of the tube down the esophagus and advance the tube as far as possible (Fig. 3-13). 13. Gently pull out the tube exiting the neck, and twist while attempting to advance the tube in place into the patient’s pharynx. The tube should straighten and “unkink.” If correct and unkinked placement has been achieved, the tube can be advanced and withdrawn smoothly from the esophageal incision with little resistance. 14. Suture the tube to the skin using the finger trap suture pattern (see Fig. 3-6).
W0422-Ch003.qxd 11/10/05 4:41 PM Page 42
42
Section 1 / Patient Management
15. Verify correct tube placement using a portable capnograph (no visible waveform and end-tidal carbon dioxide measured at 0 mmHg) or with lateral and ventrodorsal radiographic views of the thorax before feeding.
Postoperative Care and Complications
• Keep the incision clean and covered with a light bandage or stockinette.
• See the nutrition section of this chapter for supplementation guidelines.
• If the tips of the hemostats remain slightly open
•
•
during creation of the stab incision, a strip of esophageal mucosa may get trapped between the jaws of the hemostats. When the tube is being pulled into the esophagus from the skin, the strip of tissue will make it difficult to pull the tube back into the esophagus until the tissue breaks or the tube dislodges from the hemostats. • Ensure that the hemostat tips are not opened until they are completely free from the skin-esophageal incision. If the tube will not straighten or unkink during insertion of the tube down the esophagus, do the following: • Ensure that the tube tip is in the esophagus and not the trachea. • Gently withdraw the tube from the neck incision and continue twisting. • Realize that the tube is not large enough, so it has insufficient tensile strength or memory to straighten or unkink (ensure that the tube is at least 14 Fr). If the jugular vein is lacerated, take the following steps: • Apply direct pressure to the wound for several minutes to prevent blood loss. • Extend the incision and isolate the jugular vein, then ligate it above and below the laceration, sacrificing the vessel.
Percutaneous Endoscopically Placed Gastrostomy Tube Indications
• Consider a PEG tube for any patient for which long-
•
term (weeks to months) nutritional support is warranted. It is generally the feeding tube of choice for long-term nutritional support when an endoscope is available to assist in placement. Use a PEG tube to bypass the oral cavity and esophagus.
Contraindications Infection at the site of insertion is a contraindication. Coagulopathy is a relative contraindication. Consider the severity of the hemostatic dysfunction and the
urgency of nutritional support in the decision. Placement of the tube described later in this section is also a relative contraindication in large-breed (especially deepchested) dogs because of the increased risk of inadvertent tube removal from the stomach, resulting from excessive tension between the paracostal placement site and the stomach wall. Consider placement of a customized tube with a large, nonremovable inner flange for these patients. Removal of such tubes must also occur using an endoscope and cannot be accomplished percutaneously. The presence of neoplasia or severe disease of the stomach wall increases the risk of leakage and peritonitis and is a relative contraindication.
Objectives
• Allow nutritional supplementation bypassing the oral cavity and esophagus
• Provide a leakage-free, chronic, indwelling gastric tube
Equipment
• Gastrointestinal (GI) endoscope • Endoscopic grasping forceps • Bard urologic catheter (18- to 24-Fr Pezzer mushroom-tip model)
• Sovereign over-the-needle IV catheter (14 gauge) • Three-way stopcock and adapters • Vetafil suture, size 2-0 (3–5 feet depending on patient • • • • •
size) #11 blade 20-gauge, 1-inch needle Scissors Hemostats Stockinette (cut to fit for “sweater”)
Technique 1. Prepare the Pezzer catheter by removing the flared end and cutting the flared end into two pieces of approximately equal length. Make a long axis stab incision in the center of each piece large enough to accommodate the diameter of the Pezzer catheter. Advance the hemostats through the stab incision of one piece and pull the catheter through. Advance this “inner flange” piece down to the mushroom tip. Some clinicians prefer to snip off the nipple-shaped tip of the Pezzer catheter to reduce occlusion of the tube with food particles. Cut the shaft of the opposite end of the catheter at an approximately 60 degree angle to leave a tapered tip. 2. Place the anesthetized animal in right lateral recumbency, and clip and aseptically prepare a 10- to 14-cm2 area of the skin just caudal to the costal arch. 3. Insert an endoscope and distend the stomach with air. Gently palpate the distended stomach from the abdominal wall just caudal to the last rib using an extended finger. Observe using the endoscope to
W0422-Ch003.qxd 11/10/05 4:41 PM Page 43
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
ensure that the proposed exit site is positioned in the body of the stomach away from the pylorus. 4. Quickly and forcefully insert the Sovereign IV catheter percutaneously into the distended stomach and observe using the endoscope. Withdraw the needle, leaving the catheter in place (Fig. 3-14A). 5. Thread Vetafil suture material through the catheter into the stomach. 6. Using endoscopic grasping forceps, grasp the Vetafil suture and withdraw the entire endoscope, along with the luminal end of the suture, out through the mouth. Ensure the end of the suture
43
exiting the body wall does not enter the stomach accidentally (Fig. 3-14B). 7. Withdraw the Sovereign IV catheter from the body wall. Place a hemostat on the body wall end of the suture to prevent inadvertent pull-through into the stomach (Fig. 3-14C). 8. Insert the luminal end of the suture through the narrow end of the Sovereign IV catheter and advance the catheter toward the patient’s mouth (Fig. 3-14D). 9. Secure the pointed tip of the Pezzer catheter to the luminal suture end using a horizontal mattress suture.
E
A
C
D B
F
G
Figure 3-14. Placement of percutaneous endoscopic gastrostomy (PEG) tube. A, Over-the-needle catheter is placed through the skin and into the air-distended stomach; B, suture threaded through the catheter is grasped by endoscopic forceps and pulled out through the mouth (C); D, over-the-needle catheter is threaded onto the suture, which is tied to the gastrostomy tube. (E) and subsequently pulled into the stomach and out the gastric and body wall. The flange at the end of the gastrostomy tube should press snugly against the gastric mucosa. See text for F and G.
W0422-Ch003.qxd 11/10/05 4:41 PM Page 44
44
Section 1 / Patient Management
10. Slide the Sovereign IV catheter back down the suture toward the Pezzer catheter and firmly seat the pointed tip and suture knot (if possible) into the large flared end of the catheter (Fig. 3-14E). 11. Lubricate the IV catheter and the gastrostomy tube. 12. Pull the percutaneous end of the suture until the IV catheter tip is through the skin surface. Frequently, the skin will need to be incised a few millimeters (cautiously using a #11 blade). Place firm downward pressure around the exit site and pull the gastrostomy tube out through the body wall until the mushroom tip and inner flange are positioned against the gastric mucosa and the stomach is pulled up against the body wall. Pull the tube out gently and observe the position of the mushroom tip using the endoscope to ensure correct placement (Fig. 3-14F). 13. Slide the “outer flange” over the external end of the Pezzer catheter to ensure a snug fit to the patient’s body wall. Secure the tube into place (Fig. 3-14G). 14. Wrap a small piece of tape circumferentially around the tube at the junction of the tube and the outer edge of the outer flange to identify ideal positioning and serve as a method for detecting inadvertent flange movement or slippage. 15. Remove the pointed tip of the catheter and the suture material with scissors and place the three-way stopcock into the tube tip. Alternatively, place a small, graduated Christmas tree adapter in the tube tip. Place a cap on all openings of the stopcock or Christmas tree adapter. 16. Cut a 4 ¥ 4 gauze sponge on the folded edge and tuck around the feeding tube-skin interface. 17. Cut a sufficient length of stockinette and pull one end through so that both cut ends are together. Cut holes near the folded end of the stockinette for the patient’s front legs and place the stockinette to protect the tube site. Tuck the free end of the tube under the stockinette to prevent inadvertent removal. 18. Small amounts of water can generally be administered through the tube immediately, but delay feeding 12 to 24 hours to allow an appropriate fibrin seal to form around the insertion site.
Postoperative Care and Tube Removal
• Cleanse the skin-tube interface using saline- or water-
•
•
there is concern regarding obstruction because of the tip, retrieve it endoscopically. Alternatively, remove the tube percutaneously by grasping and pulling the mushroom tip through the body wall while applying firm downward pressure to stabilize the body wall. A blunt stylet (e.g., cotton-tip applicator) can be placed inside the tube against the nipple tip to stretch the mushroom tip, making it easier to remove. The inner flange slides off the mushroom tip and passes out the GI tract. Once a strong seal has developed between the stomach and the body wall (at least 2–3 weeks), the Pezzer mushroom catheter can be replaced by any of a variety of low-profile or “button” gastrostomy tubes. These are placed percutaneously into the stoma immediately following extraction of the original Pezzer tube.
Complications
• The opening in the inner or outer flange may be too
•
•
small and may cause severe constriction of the tube and obstruction to feeding. Observe the tension on the catheter walls when the inner and outer flanges are placed to prevent this complication. Inadvertent tube removal from the stomach wall can result in leakage and peritonitis. Stomach wall integrity because of disease and excessive tension on the stomach wall in large-breed dogs because of deepchested conformation may contribute to this complication. Use caution when placing a tube in a gastric site suspected to have infiltrative disease. Consider alternative tubes for large-breed deep-chested dogs. Inadvertent removal of the tube from the body wall by the patient or by snagging on another object is not a concern if the tube has been in place 10 to 14 days or more to allow fibrous seal or stoma formation. Tube replacement can occur through the same stoma if it is still patent, or a low profile tube (button tube) can be considered. Tube obstruction with food can also be a complication. In general, mechanical removal or an attempt to advance the obstruction forward with a narrow diameter stylet is preferable to the use of chemical dissolution methods.
NUTRITIONAL MANAGEMENT OF THE CRITICAL CARE PATIENT
moistened gauzes once daily.
• Prevent damage to the tube by covering it with a light •
bandage or stockinette. When the tube is no longer required, it can be removed in one of two ways: • Cut the tube close to the patient’s body wall and push the mushroom tip gently into the stomach using the wooden end of a cotton-tip applicator. Let the mushroom tip pass through the GI tract; if
The goal of nutritional support of critical care patients is to get them from the intensive care unit to the ward and then out of the ward to eating their own food at home as efficiently as possible. Until this goal can be achieved, the next best thing is for the patient to eat its own food in the hospital. Encourage feeding of usual and favorite foods whenever possible. Animals, particularly cats, offered novel foods may not eat them and may
W0422-Ch003.qxd 11/10/05 4:41 PM Page 45
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
develop learned aversions if the food is associated with illness-related nausea or other negative sensations. Encourage owners of hospitalized patients to provide whatever food is typically offered at home and to feed the pet during hospitalization (many pets eat more willingly for their owners than for strangers) when possible. In some cases, however, patients cannot eat by themselves and need more invasive approaches to nutrition support.
• Use a muscle condition score (MCS) (Fig. 3-16) to •
• Nutritional Assessment • If malnutrition is not present initially, reevaluate the
•
patient periodically during hospitalization to ensure that malnutrition does not develop secondary to an ongoing disease process, administered drugs or treatments, persistent inability to eat, or inadvertent food deprivation. Nutritional support is part of the primary therapy for malnourished patients and when voluntary food intake is impossible for prolonged periods.
Oral Feeding
• Oral feeding is the safest, least expensive, most ben• •
• The steps of nutritional assessment include a history
•
• •
(including a complete diet history), a physical examination, and an evaluation of any supporting laboratory data. Increased risk for malnutrition is suggested by a recent history of one or more of the following clinical situations: • Greater than 10% weight loss • Decreased food intake • Increased nutrient needs because of trauma or surgery • Increased nutrient losses resulting from vomiting, diarrhea, or burns • Acute exacerbation of a chronic disease problem Obtain a diet history to determine the quality and appropriateness of the diet fed and the total daily intake of food. Ask if corticosteroids, cancer chemotherapeutic agents, antibiotics, diuretics, or other drugs that may adversely affect nutritional homeostasis have been administered recently. Perform a thorough physical examination, including assigning a body condition score (BCS) (Fig. 3-15). Underweight animals lose subcutaneous fat and experience muscle wasting. Patients in a moderate or overweight body condition also may be tissue depleted but may not appear so because of an “overcoat” of fat. This situation occurs when muscle tissue is broken down more quickly than is adipose tissue. Affected patients usually can be recognized by a poor haircoat; easily pluckable hair; thin, dry skin; and abnormal prominence of the bones of the head.
quantify the assessment. Structural impediments to eating also may be identified during the examination. Hypoalbuminemia, lymphopenia, and anemia are nonspecific laboratory findings that can be associated with severe malnutrition. Decreased resistance to the passage of a needle for blood collection because of loss of skin collagen also is a reasonably sensitive indicator of peripheral protein depletion. Assess a serum biochemical profile to provide important information regarding visceral organ function, which may influence the composition of the diet or the route of administration. For example, evidence of significant abnormalities of liver or kidney function could indicate the need for protein restriction, and severe pancreatitis could necessitate parenteral administration of nutrients.
Routes of Nutrient Delivery
▼ Key Point Do not begin nutritional support until the initial goals of fluid therapy—rehydration, electrolyte replacement, and normalization of acidbase status—have been achieved.
45
•
•
•
•
eficial physiologically, and most convenient method of feeding; thus, use oral feeding whenever possible. Try nursing techniques to improve food intake (often referred to as “coax-feeding”) before proceeding to more invasive methods. Attempt hand-feeding, petting or stroking, vocally reassuring the animal, offering food when the animal is outside of the cage (during a walk outside or in a quiet area of the hospital), warming the food to body temperature to enhance aroma, or offering a favorite food. When new diets must be introduced to hospitalized patients, offer 15 to 30 g of the food initially. If resistance is observed, remove all food and attempt again in 1 to 2 hours. If no intake is observed within another 1 to 2 hours, or if the food hardens, remove it immediately and offer a different food. If the diet is intended for long-term patient management, offering it after the patient is home and feels better improves the probability of long-term acceptance and success. If attempts to restore food consumption fail, try forcefeeding using a syringe for 1 to 2 days. Force-feeding provides some nutrition, but the inconvenience and the stress imposed on the patient during feeding limit its usefulness. A feeding tube also may be passed through the mouth into the stomach for each feeding. Passing an orogastric tube is relatively simple; limited restraint and the opening of the animal’s mouth just enough to introduce the tube minimize the patient’s opposition to this procedure.
Enteral Routes
• If the patient is too debilitated to tolerate repeated tube feedings, or if nutritional support is required for
W0422-Ch003.qxd 11/10/05 4:41 PM Page 46
46
Section 1 / Patient Management
BCS 1
Emaciated
What you see Obvious ribs, pelvic bones, and spine (backbone), no body fat or muscle mass What you feel Bones with little covering muscle
BCS 2
Thin
What you see Ribs and pelvic bones, but less prominent; tips of spine; an “hourglass” waist (looking from above) and a tucked-up abdomen (looking from the side) What you feel Ribs (and other bones) with no palpable fat, but muscle present BCS 3
Moderate
What you see Less prominent hourglass and abdominal tuck What you feel Ribs, without excess fat covering
BCS 4
Stout
What you see General fleshy appearance; hourglass and abdominal tuck hard to see What you feel Ribs, with difficulty
BCS 5
Obese
What you see Sagging abdomen, large deposits of fat over chest, abdomen, and pelvis What you feel Nothing (except general flesh)
Figure 3-15.
•
Body condition scoring. (Buffington CAT, et al: Manual of Veterinary Dietetics. St. Louis: WB Saunders, 2004.)
more than 2 days, place either a nasogastric or a nasoesophageal tube (see the technique described in “Nasal Catheter Placement”). Tube placement is simple, does not require anesthesia or sedation, and allows provision of fluid and nutrients for days to weeks. If a nasal tube cannot be placed, or if a prolonged course of feeding is anticipated, place an esophagostomy tube in patients that have a functional GI tract and no history of vomiting or regurgitation (see “Esophagostomy Tube Placement”).
• When access proximal to the stomach is not available
•
in patients with normal GI function, place a gastrostomy feeding tube. Surgical gastrostomies are the safest but the most expensive and difficult to place. Alternatively, a feeding tube can be placed using an endoscope or a blind placement device (see “Percutaneous Endoscopically Placed Gastrostomy Tube”). Gastrostomy tubes can be maintained in patients for months with good nursing care. Rarely, a needle catheter jejunostomy or gastrojejunostomy may be necessary when gastric atony, gas-
W0422-Ch003.qxd 11/10/05 4:41 PM Page 47
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
3 Normal muscle mass Muscle easily palpated over the temporal bones, ribs, lumbar vertebrae, and pelvic bones
47
Skin
Fat
No visible bony prominences when viewed from a distance
Muscle Bone
2 Moderate muscle wasting Thin layer of muscle covering the temporal bones, ribs, lumbar vertebrae, and pelvic bones on palpation Bony prominences slightly visible from a distance
1 Marked or severe muscle wasting No muscle covering the temporal bones, ribs, lumbar vertebrae, and pelvic bones on palpation Bony prominences highly visible from a distance “Overcoat syndrome” Clinically, body condition score (BCS) and muscle condition score (MCS) are not directly related, because of the “overcoat syndrome” (OS), which occurs when an animal has less muscle and more fat, making an MCS of 1 or 2 look relatively normal. We suspect OS when the history and physical do not match. Palpation is required for a diagnosis of OS. Although some areas of the body may feel relatively normal (as shown at right), marked wasting is felt over bony prominences. Figure 3-16.
•
Muscle condition scoring. (Buffington CAT, et al: Manual of Veterinary Dietetics. St. Louis: WB Saunders, 2004.)
troduodenal obstruction, neoplasia, regurgitation, or vomiting prevent feeding using more proximal sites. Jejunostomy tubes are typically placed at surgery. Patients requiring extensive surgical procedures of the stomach, duodenum, pancreas, or hepatobiliary system also can be fed in the immediate postoperative period through these tubes. Small feeding tubes also can be threaded into the jejunum through a surgically placed gastrostomy tube at the time of surgery if the patient is not expected to eat orally for a prolonged period. Patients can be
fed immediately postoperatively using the jejunal tube, which can be removed from the gastrostomy tube to permit gastrostomy feeding once motility returns to the stomach.
Nutrient Needs Calories Provide hospitalized patients with their basal energy needs. Graphs of the basal energy needs of dogs and cats over a range of body weights are presented in
W0422-Ch003.qxd 11/10/05 4:41 PM Page 48
48
Section 1 / Patient Management
Figure 3-17. These graphs were constructed using the following equation: 97 kcal ¥ kg of body weight0.655 per day. Use the exponential equation for patients weighing less than 2 kg or more than 50 kg. For animals weighing between 2 and 50 kg, a linear equation such as (30 ¥ kg body weight) + 70 = kcal/day can be used. These estimates are conservative and may be lower than the energy needs of some patients during the course of their disease. They are only initial guidelines, also intended to avoid adverse consequences of overfeeding. Provide slightly less food than needed to avoid the potential for overfeeding. The estimated energy needs of a patient can be converted to food needs by assuming that many canned foods contain approximately 1 kcal/g and that many dry foods contain approximately 350 kcal/8 oz. If more accurate values are needed, consult the pet food’s manufacturer.
• In patients with no disease-related limitations on
•
• Choose an appropriate diet for the disease-related nutrient modifications required.
• Secondary factors include both size and location of the feeding tube.
• Liquid diets specifically formulated for veterinary use (e.g., CliniCare; Abbott Laboratories) are available and may be fed through a tube of any size. To maximize success and minimize the risk of clogged tubes, feed only liquid diets through tubes smaller than 12 Fr. Feed veterinary or commercial canned pet foods that have been processed in a blender (with water added as needed) through tubes larger than 12 Fr. Tables of veterinary foods are available in the Manual of Veterinary Dietetics (see “Supplemental Reading”) and at www.nssvet.org.
Feeding
Protein
•
Diet Selection
protein intake, 7 to 10 g of protein per 100 kcal of energy is usually adequate. Patients with advanced liver and kidney disease require careful use of limited amounts of high-quality protein, probably in the range of 2 g (in dogs) to 3 g (in cats) of a high-quality protein per kilogram of body weight per day. Monitor animals consuming these amounts or less for signs of protein depletion.
Minerals and Vitamins In addition to energy and protein, provide vitamin and mineral intake near the National Research Council requirements for growth in the absence of a specific contraindication.
• Provide food or water soon after the patient recovers from anesthesia.
• Estimate and deliver fluids and nutrients in four to six feedings over a 24-hour period.
• Give small volumes distributed over several meals
•
during the first 24 to 48 hours of feeding to avoid overdistention of the stomach, vomiting, or regurgitation. In severely ill patients, use slow, constant administration rates to help minimize incidents of diarrhea and cramping and to maximize absorption of the nutrients. Hang small volumes of liquid diet (approximately a 12-hour supply) in fluid therapy bags or burettes for gravity-assisted constant-rate infusion to minimize the possibility of “overdosing” patients with the feeding solution during continuous feeding.
Approximate Resting Energy Needs of Dogs and Cats 2000 1800
1400 1200 Kilocalories per Day
1000 800 600 400
600
Figure 3-17. Basal energy requirements of dogs and cats.
500 400 300 200 100 0 0
200
5
10 15 20 25 Body Weight - Pounds
30
12 0 13 0 14 0 15 0 16 0 17 0 18 0 19 0 20 0
90 10 0 11 0
70 80
50 60
30 40
0
0 10 20
Kilocalories per Day
1600
Body weight - Pounds
W0422-Ch003.qxd 11/10/05 4:41 PM Page 49
Chapter 3 / Emergency and Critical Care Techniques and Nutrition
• Flush tubes with water before and after each feeding •
to avoid occlusion with food or mucus. Diarrhea (usually small amounts of soft, pasty feces) can occur in enterally fed patients. It is generally more of a nuisance than a threat to the patient and usually results from rapid gastric emptying caused by overly rapid administration of a bolus meal. Reduce the feeding rate and feed diets that contain fiber or higher concentrations of fat (>50% of total kcal) to delay gastric emptying.
Parenteral Nutrition
trolled with insulin therapy as needed (see “Glucose Monitoring”).
Calorie and Protein Content Estimate energy needs of PN patients as previously described. Attempt administration of nutrients at rates exceeding resting energy needs only after the initial goal has proved tolerable for the animal. Provide 2.5 g of protein per kilogram of body weight. Restrict protein intake to approximately 2 g/kg/day in animals with severely compromised liver or kidney function.
Minerals and Vitamin Content
• Parenteral nutrition (PN), or intravenous feeding,
•
allows the provision of short-term metabolic and immune system support to animals with severe GI disease or pancreatitis. Because PN therapy is relatively expensive and is associated with more complications than feeding through the GI tract, use enteral feeding whenever the GI tract can tolerate it. PN is also not indicated when the patient’s prognosis is hopeless. The high osmolality of PN solutions requires the use of a central venous catheter inserted in the external jugular vein or placed in a peripheral catheter and advanced into a central vein. Proper insertion and maintenance of the PN catheter is one of the keys to successful PN therapy. Use aseptic technique when placing the intravenous catheter. If well cared for, central vein catheters may be used for prolonged periods. Do not remove the catheter unless a specific indication for removal exists.
▼ Key Point Once a catheter is placed and designated for PN therapy, do not use it for other purposes, such as drawing blood samples, administering medications, or measuring central venous pressure.
Adverse drug-nutrient reactions and clogged catheters are serious potential complications of these practices.
Glucose Content
• Formulate glucose-based PN solutions based on the
•
patient’s estimated nutrient needs. The most commonly used PN solution for patients at Ohio State University contains 17.5% glucose. Glucose-based PN solutions are filterable, bacteriostatic because of the high osmolality, relatively easy to prepare, and relatively inexpensive. On the other hand, their hyperosmolality necessitates central venous access, and thrombophlebitis may result if solutions are infused at high rates into small veins. Hyperglycemia, usually less than 600 mg/dl, is also more common with glucose-based solutions than with lipid-based solutions. This has minimal pathophysiologic significance but needs to be monitored and con-
49
The macromineral portion of the solution is provided by an amino acid-electrolyte solution. Zinc, copper, manganese, and chromium, as well as water-soluble vitamins, are routinely added to PN solutions. The essential fatty acids, fat-soluble vitamins, and minerals necessary for prolonged PN therapy do not appear to be necessary for the short-term PN more typically provided to veterinary patients.
Apparatus and Delivery
• The apparatus required for PN administration
•
includes the solution, the solution container, an administration set, a 0.22-mm filter, a dedicated central venous catheter, and, preferably, an infusion pump. Provide PN at a rate intended to meet resting energy needs by the end of the first 24 hours, then advance to slightly higher rates of intake, if necessary, over the next 24 to 48 hours as patient tolerance allows.
Glucose Monitoring
• During the initiation phase, measure blood glucose every 4 to 6 hours until stable. Once goals are reached, monitor the patient as described subsequently. At the end of therapy, wean the patient from the solution over 4 to 24 hours as tolerance permits by progressively halving of the infusion rate to avoid hypoglycemia, particularly if insulin has been infused. If the patient is able to eat, offer food and record the food intake. As soon as signs of appetite are observed, decrease the PN administration rate to approximately half the previous rate to encourage the animal to begin eating on its own. ▼ Key Point The most important monitoring parameter for patients receiving glucose-based PN is blood glucose, which is monitored closely during initiation of therapy.
• Treat patients when blood glucose concentrations exceed 250 mg/dl with intramuscular administration of 0.25 U of regular insulin per kilogram of body weight every 4 to 6 hours as necessary. Insulin therapy
W0422-Ch003.qxd 11/10/05 4:41 PM Page 50
50
Section 1 / Patient Management
is not commonly required for dogs, although consider it for cats during the first 36 hours to control hyperglycemia. Diabetic animals placed on PN often require continuous infusions of higherthan-expected quantities of insulin to control their blood glucose concentration effectively. When insulin is used, caution must be exercised with regard to the central venous catheter, which is presumed to be in place continually. If insulin is given and then vascular access is lost, give a 5% glucose infusion through a peripheral vein immediately to prevent severe rebound hypoglycemia.
Complications of PN The most common PN-related complications are mechanical, technical, and related to glucose abnormalities. Use a strict protocol for prevention, diagnosis,
and treatment of sepsis. PN-related infections occur only rarely.
Returning to Normal Food Intake
• In general, discontinue assisted feeding when patients begin eating a quantity of food that contains at least half of their calculated daily energy needs. Ideally, the weaning process should take place gradually over at least a day or two before the feeding tube is removed or PN administration stopped.
SUPPLEMENTAL READING Buffington CAT, Holloway C, Abood SK: Manual of Veterinary Dietetics. St. Louis: WB Saunders, 2004.
Chapter
▼
W0422-Ch004.qxd 11/10/05 4:43 PM Page 51
4
Radiographic and Ultrasonographic Techniques David S. Biller / Laura J. Armbrust
The purpose of the radiograph is to provide a lasting record of maximum information. The sequence of the major operations involved in transforming the altered morphology and tissue density within a diseased animal into a two-dimensional, black-and-white radiograph and then reaching a diagnosis is complex and includes the following steps: (1) making a properly exposed and positioned radiograph; (2) recording the x-ray picture with the assistance of accessory equipment; (3) reviewing radiographs in proper conditions and in a systematic and detailed manner; (4) recognizing lesions—therefore [requiring] a knowledge of normal radiographic anatomy and its variation by age, species, and breed and the ability to recognize and understand artifacts; and (5) evaluating radiographic abnormalities with respect to clinical and laboratory findings.
•
Recommendations • The 300-mA machine may have adjustable mA stations
Dr. Peter Suter
• X-RAY MACHINE
•
Milliampere-Second and Kilovolt Peak • mA (milliampere) ¥ seconds (time) = mAs (milliampere-
•
second), which affects the degree of blackness (density) of the radiograph with no effect on contrast. A direct relationship exists between mA and radiographic density. Time and mA both influence the number of x-rays produced but have no effect on the penetrating ability of the beam. To quickly check the adequacy of the mAs on a film, hold the film up to room light and place a white sheet of paper about 1 inch behind the film. Place a finger between the film and the paper. If the finger can be readily seen through the film in the black area (the most exposed), increase the mAs. kVp (kilovolt peak) is the only machine factor that influences radiographic contrast and has some control over the amount of radiographic density (blackness). The contrast can be expressed as being low, which means that there are many shades of gray (long scale) between the extremes of black and white. The term high contrast means that there are few shades of gray
(short scale). Lowering the kVp increases the contrast, and raising the kVp reduces the contrast. To adjust the technique to alter film contrast while maintaining the same radiographic density, consider the following: • The mAs and the kVp have to be in balance. • As the mAs increases, the kVp must decrease. • As the kVp increases, the mAs must decrease. • Doubling radiographic density requires doubling the mAs or increasing the kVp by 10% in the 40- to 100-kVp range or 15% in the 100-kVp or greater range.
• •
• •
•
of 25, 50, 100, 200, and 300 and two (1 and 2 mm or smaller) focal spots. An ideal kVp range is 40 to 120 and is adjustable in 1 or 2 kVp per step. A timing device is necessary to control the duration of an x-ray exposure. Modern x-ray machines have electronic timers with ranges that can control motion in the patient and prevent blurring. With a timed exposure of 1/120 second, all significant motion is stopped. The line voltage compensator is automatic or manual. The tube stand moves along the full length of the table and has an adjustable height from 0 to 60 inches (152 cm). The tube is able to rotate 90 degrees around the vertical axis and 180 degrees around the horizontal axis. The table is 5 to 6 feet in length with a top that has floating motion in four directions. The collimator decreases scatter radiation and human and patient exposure as it increases film quality. Always leave a clear margin of collimation on every film. The collimator is lighted and has a centering mark. A high-quality, dial-adjustable, multileaf lead shutter collimator is highly recommended. Filters have the primary function of reducing patient radiation dose by removing scatter radiation and increasing (mean beam energy) quality. Most x-ray equipment has inherent filtration equal to 1.5- to 51
W0422-Ch004.qxd 11/10/05 4:43 PM Page 52
52
•
• •
Section 1 / Patient Management
2.0-mm aluminum. Increased film quality can be obtained by adding an additional 2.0-mm aluminum filtration. Total filtration must be at least 2.5-mm aluminum. Grids consist of a flat plate with a series of lead foil strips separated by transparent spacers. They are made in various sizes and improve the diagnostic quality of radiographs by absorbing the greater part of the scatter radiation. Position grids between the patient and the cassette, usually under the table. Use only for body parts thicker than 10 cm. The reciprocating grid (Potter-Bucky diaphragm) includes a mechanism that moves the grid during exposure to eliminate grid lines from the radiograph. This grid is optional equipment but recommended for the bestquality radiographs. • Grids can be classified in three ways: the lead content (g/cm2), the number of lines per inch, and the ratio of lead strip height to the space between the lead strips. In general, high-ratio grids absorb scatter better but are more expensive. More lines per inch give better quality, because the lead strips are narrower and therefore lines become less prominent; however, they cost more. The most common grid is an 8:1 with 103 lines per inch. • The higher the grid ratio, the more critical the x-ray tube alignment. Always stay within the focal zone of the grid. This is usually written on the grid and is 36 to 42 inches (90–105 cm) in most instances. Exposure switches include the two-position exposure switch on the console and the two-position exposure foot switch, with a cord of sufficient length. High-frequency x-ray machines have a few advantages over single-phase x-ray machines. A 150-mA highfrequency generator can produce a quantity of x-rays equal to that of a 300-mA, single-phase x-ray
•
machine. Many of the units use 110 volts. They are reliable, with less downtime than single-phase machines. Their cost, at present, is greater than that of single-phase machines but most likely will decrease in the future. For a list of x-ray machine manufacturers, see Table 4-1.
ACCESSORY RADIOGRAPHIC EQUIPMENT Intensifying Screens The screen is a suspension of phosphor crystals in a binder. The phosphor in the screen converts x-ray photons into visible light, to which the film is more sensitive. A latent image is created by exposure of the film to this light. This technique reduces x-ray exposure to the patient by at least 10 times and the time of x-ray exposure, thus decreasing the chance of blurring.
• Screen speed depends on the thickness of the phos-
•
•
phor layer, the size of phosphor crystals, and the efficiency of phosphor crystals at absorbing x-rays and converting them to light. Screen classification varies because each company has a slightly different system for labeling screen speed. Resolution ability of the screen is inversely related to speed. Increased speed gives decreased resolution. Have a technique chart available for each screen speed. Par speed is the starting point for comparison of screens. High speed has a speed 2 times that of par speed. Ultraspeed is 4 times par speed. High detail speed is half that of par speed. Types of Screens • Calcium tungstate screens reduce the amount of radiation necessary to expose film by 10 times com-
Table 4-1. X-RAY MACHINE MANUFACTURERS Company Bennett X-Ray Technologies Continental X-ray Control-X Medical Fischer Imaging Corp. MinXray Summit Industries Universal (Del Medical Systems)
Address 445 Oak St. Copiague, NY 11726-2719 2000 S. 25th Ave. Broadview, IL 60153 West Pointe Business Park 2289 W. Brooke Dr. Columbus, OH 43228 12300 North Grant St. Denver, CO 80241-3120 3611 Commercial Ave. Northbrook, IL 60062-1822 2901 W. Lawrence Ave. Chicago, IL 60625 11550 W. King St. Franklin Park, IL 60131
Phone Number
Website
800-922-9399 708-345-3050 800-777-9729
www.cxmed.com
800-825-8257
www.fischerimaging.com
847-564-0323
www.minxray.com
800-729-9729
www.summitindustries.net
800-800-6006
www.delmedical.com
W0422-Ch004.qxd 11/10/05 4:43 PM Page 53
Chapter 4 / Radiographic and Ultrasonographic Techniques
•
•
pared with film exposed without a screen. They are also less expensive than rare-earth screens. Calcium tungstate emits a broad spectrum of light in the ultraviolet and blue range. • Rare-earth screens are more expensive than calcium tungstate screens. The light emitted is in the ultraviolet, green, or blue range. The major advantage of rare-earth over calcium tungstate screens is that rare-earth screens are fast, because of a more efficient production of light. Therefore, they decrease the production of scatter, the exposure time, the radiation dose, the chance of motion and subsequent blurring, and the wear and tear on the x-ray tube. System speed is the speed of film and screen in combination. It is not an additive system. A very low system speed results when screens and films with different color spectrum sensitivities are put together. Ask the film dealer what system speed you have with your particular screens and film. The higher the system speed number, the more sensitive the system and the less radiation necessary to make an exposure. System speeds can vary from 50 to 3200 and higher. The higher the system speed number, the less radiation to the patient and to personnel within the room; however, the lower the system speed number, the better the resolution qualities. When you know the system speed, changing the technique chart is simpler. If the system speed doubles, change the mAs on the technique chart by half. If the system speed decreases by 50%, double the mAs on the technique chart. Exposure time
▼ Key Point Always use the shortest exposure times possible to eliminate blurring.
•
• For thoracic radiographs, exposure times of 1/60 second or shorter stop the effects of respiratory and heart motion. • For abdominal radiographs, employ exposure times of 1/40 second or shorter to eliminate gastrointestinal motion. • For extremity radiographs, exposure times of 1/20 second or shorter eliminate the effects of patient motion. Rare-earth screens have a system speed that allows the shortest exposure times possible to eliminate motion problems and to lower radiation exposure to patient and personnel. In general, when using a 300-mA machine and a 400 to 800 speed system, with an 8:1 grid, good-quality radiographs are attainable even for large-breed dogs. In a feline practice, a slower system, such as a 100 to 250 speed system, provides excellent quality. As the crystal size gets larger, the system gets faster but resolution is reduced.
53
• Clean screens with the product recommended by the manufacturer on a regular schedule (monthly) and whenever debris is noted on the radiographs.
Film Radiographic film provides a permanent record containing the maximum amount of diagnostic information.
• Film is made of a light-sensitive emulsion, composed
•
•
•
•
•
•
of gelatin and silver halide with other ingredients attached to a plastic (polyester) base. The silver halides are sensitive to light and change when exposed to light to produce a latent image. The process of developing changes silver ions into black silver, thus producing the radiographic image. Fixer removes all unexposed silver from the film. The emulsion may be attached to one or both sides of the base. X-ray film may be most sensitive to direct x-ray exposure (nonscreen film) or to blue, green, or ultraviolet light. Films vary in their contrast. Some films appear more black and white after exposure and development. Use the film that is recommended by your screen manufacturer to match the spectrum of light produced by your screens. Choose a film that results in the contrast range most pleasing to you. Use a film that gives you a system speed that results in quality radiographs. Make sure to match film, screens, and processing chemicals. Film must be sensitive to the type of light emitted by the screens in use. Film speed determines the amount of light required to produce an image on the radiograph. Fast film has large crystals (silver halide), requires less exposure, and produces a grainy image. Slow film has small crystals, requires greater exposure, and produces a sharper image. Screen film is manufactured with crystals that are sensitive to fluorescent light. Nonscreen film is a direct exposure–type film and is manufactured to be sensitive to x-rays. Nonscreen film requires 10 to 25 times more radiation than screen film. Film is available in both metric and nonmetric measurements. The most common sizes used in small animal practice are 8 ¥ 10 inches, 10 ¥ 12 inches, and 14 ¥ 17 inches. X-ray film is sensitive not only to light and x-ray photons but also to humidity, chemicals, and physical stress. Film is stored on end to reduce pressure on the face of the film. High humidity causes film fogging, and low humidity causes film static; therefore, between 30% and 40% humidity is appropriate for film storage. Storage temperature should not exceed 50°F to 70°F (10°C to 21.1°C). Store the film away from developing chemicals and ionizing radiation. Do not put pressure on the film when loading or unloading film. Film and screen companies are provided in Table 4-2.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 54
54
Section 1 / Patient Management
Table 4-2. FILM AND SCREEN COMPANIES Company AGFA Eastman Kodak Co. Fuji Medical Systems Konica Minolta Medical Imaging Picker International 3M Medical Imaging System
Address
Phone Number
100 Challenger Rd. Ridgefield Park, NJ 07660 Health Sciences Division Rochester, NY 14650 90 Viaduct Rd. Stamford, CT 06907 411 Newark Pompton Turnpike Wayne, NJ 07470 595 Miner Rd. Highland Heights, OH 44143 3M Center St. Paul, MN 55144-1000
Cassettes Cassettes are used primarily to contain and protect film. Two basic types are available: rigid cassettes that contain both the film and the screen and cardboard cassettes that hold nonscreen film.
• • •
• Rigid cassettes protect both screens and film from
• •
physical damage and film from exposure to light. The cassette provides snug contact between the film and the screens. The front of the cassette is usually a rigid plastic, aluminum, or other substance that absorbs relatively few x-ray photons. Usually, a small rectangle in the corner of the cassette shields the film from x-rays to allow an unexposed area for film identification. The back of the cassette is lined with lead to absorb backscatter radiation. The back of the cassette is also equipped with latches to provide a lightproof seal. Cassettes for a nonscreen film only protect the film from light exposure. They are usually made from cardboard. Cassettes are numbered. When defects are noted on a radiograph, they can be traced to the correct cassette. Dropping a cassette causes warping and results in poor film-screen contact and a distorted radiographic image.
Miscellaneous Accessories • Use the screen cleaner that is recommended by your screen manufacturer.
• Use safety devices (lead aprons, lead gloves, glasses, •
• •
and lead thyroid shield) when personnel are required in the x-ray room for patient positioning. Film markers consist of right and left lead film markers, Mitchell markers (for horizontal radiographs), and time markers (for upper gastrointestinal and intravenous urography radiographs). A device capable of measuring body-part thickness and determining the kVp for exposure is needed. Positioning devices include sponge wedges, sandbags, Plexiglas or foam trough, rope, tape, and agents for
•
Website
877-777-2432
www.agfa.com
800-926-1519
www.kodak.com
800-431-1850
www.fujimed.com
800-934-1034
www.medical.konicaminolta.us
800-635-972 888-364-3577
www.3m.com
chemical restraint to avoid human exposure associated with hand-holding whenever possible. Film filing envelopes are needed. Contrast media are required (see “Contrast Studies” and Table 4-6). Monitoring devices (film badges) for employees and room monitoring, a film viewer (at least one double bank), and a hot light (high-intensity light) are needed. Radiographic accessory companies are listed in Table 4-3.
CHECKING X-RAY MACHINE ACCURACY Milliampere Station Check • Use an aluminum step wedge to check mA station (setting) accuracy. Use the step wedge to determine if your mA stations are linear. It cannot determine if all your mA stations are off by the same amount. A step wedge (see Table 4-3 for sources) gives a general idea about the mA stations. A step wedge is inexpensive ($100) and easy to use. Place the step wedge on a loaded cassette; make many separate exposures of the step wedge, changing the mA but always having the same mAs and kVp. If you cannot keep the same mAs throughout all mA stations, do as many as possible at one mAs setting then go back and check the rest at another mAs. Example 25 mA 50 mA 100 mA 300 mA 100 mA 200 mA
1
/10 second /20 second 1 /40 second 1 /120 second 1 /60 second 1 /120 second 1
2.5 2.5 2.5 2.5 1.7 1.7
mAs mAs mAs mAs mAs mAs
70 70 70 70 70 70
kVp kVp kVp kVp kVp kVp
Compare the densities of all exposures. They should be the same for all mA stations taken at the same mAs. An exposure that varies from the average shows that there is a problem with that mA station. This test
W0422-Ch004.qxd 11/10/05 4:43 PM Page 55
Chapter 4 / Radiographic and Ultrasonographic Techniques
55
Table 4-3. RADIOGRAPHIC ACCESSORY COMPANIES Company
Address
Bar-ray Products
P.O. Box 36 Monarch St. Littlestown, PA 17340 5201 8th Ave. South St. Petersburg, FL 33707 5201 Naimen Parkway Solon, OH 44139 P.O. Box 570 2630 Kaneville Ct. Geneva, IL 60134 3954 SE 44th St. Grand Rapids, MI 49512 595 Miner Rd. Highland Heights, OH 44143 4131 S.W. 47th Ave., Ste. 1404 Davie, FL 33314 10625 Telge Rd. Houston, TX 77095 182 NW Earl St. Madras, OR 97741-0069 3M Center St. Paul, MN 55144-1000 420 Hempstead Turnpike West Hempstead, NY 11552
Burkhart Cone Instruments Fischer Industries Medical I.D. Systems Picker International Pulse Medical (Radiation Concepts) S&S Technology Shielding International 3M Animal Care Products Wolf X-ray Corp.
does not tell you if all mA stations are accurate, but it does tell you if a particular station has a problem.
• A digital, electronic mA-checking device is the most accurate way to compare your mA stations.
▼ Key Point The only accurate way to check the kVp is the Wisconsin test cassette ($1300; see Table 4-3 for sources).
• The Wisconsin test cassette has many kVp settings listed on the front of the cassette. Under each of these settings is a certain amount of material to attenuate the beam. After exposure and processing, this film provides information to determine if the kVp settings are accurate. Another less accurate way to obtain a general check of kVp accuracy is to vary mAs and kVp. Go through all kVp settings, employing density-changing factors to keep the densities the same throughout all these exposures.
Example 100 mAs at 50 kVp 50 mAs at 55 kVp 25 mAs at 61 kVp 12.5 mAs at 67 kVp 6.2 mAs at 74 kVp
Website
888-422-7729
www.bar-ray.com
800-872-9729
www.usaxray.com
800-321-6964
www.coneinstruments.com
800-356-5911
www.fischerind.com
800-262-2399
www.medid.com
800-635-9729 800-342-5973
www.rci-pulsemed.com
800-231-1747
www.ssxray.com
800-292-2247
www.shieldingintl.com
888-364-3577
www.3m.com
800-356-9729
www.wolfxray.com
If your mA stations and kVp settings are working correctly, each exposure has the same density but a different contrast range. Remember to employ densitychanging factors when necessary.
Exposure Timer Check (Single-Phase Machine)
Kilovolt Peak Check
•
Phone Number
3.1 1.5 0.8 0.4 0.2
mAs mAs mAs mAs mAs
at at at at at
81 90 99 108 124
kVp kVp kVp kVp kVp
Use a spinning-top test tool. It can be purchased from the same company as the machine (see Table 4-1) or from an accessory company (see Table 4-3). This tool is inexpensive ($50) and easy to use. It is a flat metal spinning top with a hole in one side. The top is set on a loaded cassette and spun. Take an exposure at 1 /120 second. Move the top to another corner of the film, spin again, and expose at 1/60 second. This maneuver is repeated at 1/40 and 1/30 second. At 1/120 second, only one dot should be seen; at 1/60, two dots; at 1/40, three dots; and at 1/30, four dots. If more or less dots are on the film than expected, the timer is not accurate.
Line Voltage Line voltage is the amount of current coming into the machine. The amount of current may vary, depending on electrical wiring, consistency of voltage in the area, and usage of current on the same circuit in the particular practice. Almost all machines used for small animals have a line voltage-check device. Some have a meter and a dial to adjust line voltage and do not permit exposure until the voltage is manually adjusted. Other machines have an automatic line voltage adjustment.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 56
56
Section 1 / Patient Management
Almost all equipment in small animal practice uses 120 volts (i.e., right out of the socket).
FILM PROCESSING Manual Processing Film developing is a chemical process and therefore depends on both time and temperature.
Advantages and Disadvantages
• Advantages
•
• Less expensive setup costs than those of an automatic processor. • No special electrical or structural changes are necessary for the darkroom. Disadvantages • Valuable technician time to develop films and maintain chemical baths (i.e., increased labor costs). • Quality is not consistent, due to human error, compared with automatic processors. • Longer time to prepare diagnostic films compared with automatic processors.
Accessories
• • • • • • • •
Developing tanks Two stirring paddles Two thermometers Film developing hangers of different sizes Chemicals Adjustable mixing valve for measuring temperature Timer Dust-free drying cabinet or area
water
Darkroom Safelight Darkroom safelights must produce enough illumination in the darkroom so that a person can see to process radiographic film (load and unload cassettes) without unwanted density (fog) to the film. Safelights utilize a wavelength of light different from that to which the film is sensitive. A Wratten 6B filter is adequate for bluesensitive film. A GBX-2 filter is employed with greensensitive or both green- and blue-sensitive films. Usually, 15-watt bulbs are used with safelights. The safelight is about 4 feet from the film-handling area. No system is 100% safe; therefore, expose the film no longer than necessary.
Radiograph Labeling
• A radiograph is a legal document and must therefore have permanent labeling. On the label, include the hospital or veterinarian’s name, the date the radiograph was taken, and the owner’s name or the
animal’s file number. Label the radiograph with right or left, dorsoventral or ventrodorsal (DV/VD), a time marker on contrast studies, and a Mitchell marker when a horizontal beam is used. Basic types of permanent marking systems are available: • Lead letters and numbers in a holder with the hospital or veterinarian’s name, placed on the cassette during exposure. • Radiopaque marking tape (lead-impregnated tape). Information may be written on the tape, and the tape is placed on the cassette before exposure. • A darkroom printer transfers data from a card to the corner of the x-ray film that was shielded from radiation during exposure. This system requires cassettes with special windows. The film is removed from the cassette, and the corner of the film where it was blocked from light exposure is imprinted by exposing the patient information on a 5 ¥ 7-inch card onto the film.
Silver Recovery Recover silver from fixer solutions by either manual or automatic systems. Fixer solutions may be sold to companies for silver recovery. Alternatively, you may purchase a system (metallic replacement process, electrolytic recovery, or chemical precipitation) for silver recovery in your practice. Exposed developed and undeveloped film may also be sold for silver recovery. Usually, the supplier of the x-ray films or processing solutions can be consulted to determine if silver recovery is feasible and who to contact.
Procedure for Manual Film Processing
• Check temperatures, turn off room lights, use safelights, and agitate (mix) solutions well.
• Place the film on development hangers, making sure all four corners are attached.
• Set and start time depending on the temperature in the developing tank.
• Place the hanger with the film into the developing tank. Rap hard against the tank wall to dislodge air bubbles. Agitate by pulling film out of the developer, and let the developer drain to one lower corner. Return film to the developer. Repeat agitation every minute. Manufacturers recommend a specific temperature for the developed solution that they produce, usually 68°F (20°C). Adjust for change in temperature (increased temperature, decreased time, and vice versa). The chemical manufacturer can provide a time-temperature development chart. Example 60∞F 65∞F 68∞F 70∞F 75∞F
(15.5∞C) (18.3∞C) (20.0∞C) (21.1∞C) (23.8∞C)
8.5 6.0 5.0 4.5 3.5
minutes minutes minutes minutes minutes
W0422-Ch004.qxd 11/10/05 4:43 PM Page 57
Chapter 4 / Radiographic and Ultrasonographic Techniques
• At the end of the developing time, remove the hanger • • • • • • • • • •
from the developer and drain over the rinse tank. Agitate film in rinse water for 30 seconds. Place the hanger with film in fixer at the end of the developing time. Set the timer. Fixer time equals twice the development time. Agitate film every 2 to 3 minutes while in the fixer. At the end of fixation time, remove film from fixer and drain. Place the hanger in wash water at the end of fixer time. Agitate after 2 to 3 minutes. Wash for 15 to 30 minutes, depending on water flow and temperature in wash tank. Provide no less than four water changes per hour in the wash tank. At the end of the wash, remove from water and drain. Place film in a drier cabinet or hang up to dry.
Automatic Processing • Processors are a good investment for most veterinary practices. New, small, tabletop models are priced from $3500. Most of these processors develop an excellent quality film in 90 to 210 seconds. They can use cold water for processing; therefore, no special needs exist for plumbing. They are also easy to maintain.
•
• •
•
•
•
▼ Key Point If your small animal practice is processing 7 to 10 films a day, consider an automatic processor.
• Advantages • Highly repeatable results • Short waiting time for diagnostic films • Ability to process large quantity of films quickly and accurately
• •
57
• Good quality control • Smaller darkroom necessary Disadvantages • Machine is expensive. • Darkroom structural changes are expensive. • Needs daily and weekly maintenance. • Repairs can be expensive. Equipment includes processor, safelight, water for processing, chemicals, sponges to clean rollers of processor, and processor cleaning solution. Tabletop film processors are easy to install (no special plumbing or wiring). Different models process films as fast as 90 seconds or as long as 31/2 minutes. Most are made for easy care and cleaning. They are relatively inexpensive (from $3000 to $7000). Large, hard-wired, 90-second film processors need special plumbing and electrical wiring, but they are able to process many films. They need special cleaning and repairs and are expensive ($15,000– $25,000). The more a processor is used, the fewer problems it will have. It is made to be used on a 24-hour basis. Chemical buildup on rollers can cause film artifacts. Rollers age and crack if oxidized chemicals are left on them. Clean processors often. • All processors need cleaning daily when not in use. Take out the rollers and wash them down with a sponge and water. Dry and replace the rollers. Clean the chemical tanks. Once a month, clean with processor cleaning solution. Cleaning a processor takes about 15 minutes a day but saves in wasted film and time. Consider purchasing a processor with a standby mechanism. This function helps conserve water, energy, and chemicals. Automatic processor companies are listed in Table 4-4.
Table 4-4. AUTOMATIC PROCESSOR COMPANIES Company AFP Imaging Corp. AGFA All Pro Imaging Corp. Eastman Kodak Co. Fischer Industries Konica Minolta Medical Imaging Picker International
Address 250 Clearbrook Rd. Elmsford, NY 10523 100 Challenger Rd. Ridgefield Park, NJ 07660 70 Cantiague Rock Rd. P.O. Box 870 Hicksville, NY 11801-1127 Health Sciences Division Rochester, NY 14650 P.O. Box 570 2630 Kaneville Ct. Geneva, IL 60134 411 Newark Pompton Turnpike Wayne, NJ 07470 595 Miner Rd. Highland Heights, OH 44143
Phone Number
Website
914-592-6100
www.afpimaging.com
877-777-2432
www.agfa.com
800-247-8324
www.allproimaging.com
800-926-1519
www.kodak.com
800-356-5911
www.fischerind.com
800-934-1034
www.medical.konicaminolta.us
800-635-9729
W0422-Ch004.qxd 11/10/05 4:43 PM Page 58
58
Section 1 / Patient Management
Darkroom
Technique Chart (with Grid) (Fig. 4-3)
Recommendations
Thorax with Grid
• Darkroom location: Locate the darkroom close to
1. Use a dog of average size and body condition for all measurements. 2 Take a lateral measurement across the chest at the widest point. 3. Find that measurement on your technique chart. 4. Underneath this lateral measurement, set your kVp at 95—a value in the middle of the ideal kVp parameters for a thorax. 5. Fill out your chart according to the kVp per centimeter increments. 6. Once the kVp values have been assigned, take three chest films at different mAs values. You may begin with 0.8, 1.6, and 3.2 mAs for a rare-earth system and 5, 10, and 20 mAs for calcium tungstate, for example. Select the mAs value at 95 kVp that provides you with the best technique.
•
water and drains for plumbing purposes, and close to radiographic area to reduce unnecessary walking and to increase efficiency. Darkroom layout (Figs. 4-1 and 4-2): Darkrooms do not have to take up much room but are at least 6 ¥ 8 feet. Many darkrooms are located where a bathroom might have been. This eliminates the process of bringing in new plumbing and electrical outlets. Try to include a sink for cleanup and processor maintenance. Keep wet and dry areas separate to eliminate contamination of screens and unexposed film by chemicals. Always have good ventilation to keep heat, humidity, and chemical fumes from destroying film and to reduce exposure of personnel to chemical fumes. Paint all walls white to reflect light from the safelights and for a brighter working environment. Use an adequate number and type of safelights. Make sure all safelights are 40 inches from the working area to prevent film fogging.
TECHNIQUE CHARTS • Have a working knowledge of equipment (tube rating
•
charts and anode cooling curves). A constant focal film distance is recommended. The same film, screens, and darkroom technique are used, as described previously. The technique chart is set up to take radiographs of normal animals. Different animals may have the same lateral thoracic measurement but different body types (obese, emaciated, etc.). The emaciated animal may be overexposed with the technique from the chart; therefore, you will need to decrease the exposure (kVp). The obese animal may be underexposed following the chart technique; therefore, you will have to increase the exposure (kVp). • The technique may need to be increased (2– 30%) for numerous reasons (e.g., obesity, pregnancy, ascites, pleural effusion, or disease processes that increase lung opacity, such as pneumonia and atelectasis) and for positive-contrast studies. • The technique may need to be decreased (2– 30%) for numerous reasons, including emaciation, pneumothorax, emphysema, gastric dilatation, and volvulus.
Abdomen with Grid 1. Follow the first three steps under “Thorax with Grid.” 2. Set your kVp at 85. 3. Fill out the chart according to the kVp per cm increments. 4. Double the mAs value used in the thorax technique.
Spine with Grid 1. Follow the first three steps under “Thorax with Grid.” 2. Set your kVp at 65. 3. Fill out the chart according to the kVp per cm increments. 4. Set the mAs value 4 times that used for the abdomen. This setting also works for femur, humerus, shoulder, and pelvis.
Technique Chart (Tabletop without Grid) (Fig. 4-4) Thorax, Abdomen, and Spine 1. On the grid chart for thorax, abdomen, and spine, find the last kVp setting for 11 cm. 2. Decrease the kVp as the thickness decreases. For example, if 74 kVp is at 11 cm, use 72 kVp at 10 cm, 70 kVp at 9 cm, and so forth. 3. Adjust the mAs by reducing to half (possibly more depending on the type of grid) the mAs value for the base techniques for the thorax, abdomen, and spine. If films are still overexposed, reduce the mAs by half again.
Extremity ▼ Key Point Always select the shortest possible exposure times. This entails choosing the highest mA value to achieve the shortest exposure times.
1. Measure a normal dog carpus. The average is 4 to 5 cm. 2. Underneath that measurement, set your kVp at 60 (a value in the middle of your ideal kVp parameters for extremities).
W0422-Ch004.qxd 11/10/05 4:43 PM Page 59
Chapter 4 / Radiographic and Ultrasonographic Techniques
Figure 4-1. processing.
Floor plan for a darkroom using manual (wet tank)
59
W0422-Ch004.qxd 11/10/05 4:43 PM Page 60
60
Section 1 / Patient Management
Figure 4-2. processing.
Floor plan for a darkroom using automatic
W0422-Ch004.qxd 11/10/05 4:43 PM Page 61
Chapter 4 / Radiographic and Ultrasonographic Techniques
Figure 4-3. with a grid.
Technique chart to use
Figure 4-4. Technique chart. For tabletop exposures, take the Buckey grid technique and reduce the mAs by 50% to 75%. Continue kVp down from Buckey chart.
61
W0422-Ch004.qxd 11/10/05 4:43 PM Page 62
62
Section 1 / Patient Management
3. Fill out the chart, according to the kVp per cm increments. 4. Take films at three different mAs values (0.8, 1.6, and 3.2 with rare earth; 5, 10, and 20 with calcium tungstate). Continue selecting the mAs values until an appropriate exposure has been made. Your tabletop extremity chart is now complete. Employ this chart for all extremities distal to and including the elbow and stifle.
Nonscreen Film Technique Chart • For the nonscreen film technique chart, the mAs in
• Need to have computers and a software package to integrate with medical records
DIGITAL RADIOGRAPHY Direct digital radiography (DR) uses specialized x-ray equipment that has a digital imaging sensor. Once the image is transferred to the computer system, image analysis and storage are similar to those previously listed for CR.
your technique chart may vary up or down from the example shown in Figure 4-5.
Advantages • A digital image is generated (these can easily be sent
COMPUTED RADIOGRAPHY
• Excellent image quality. • Film, processor, and darkroom can be eliminated.
to specialists if needed).
Computed radiography (CR) is an indirect digital imaging technology in which a plate (which looks similar to a cassette but is filmless) is used to record the image. A reader is required to extract the data, which is converted to a digital image and viewed on a computer screen. CR utilizes standard x-ray machines. Components of CR include both the hardware described previously and the software (for display, storage, and archiving). New technique charts must be developed when switching from a traditional film-screen system to CR. CR software allows image manipulation that can adjust for exposure and contrast. Images can also be drawn, and measurements can be taken. ▼ Key Point The ability of the viewer to appreciate the image quality provided by CR depends on the quality of the computer monitor.
Disadvantages • Currently more expensive than CR systems (cannot be used with existing x-ray equipment).
• Few current systems allow horizontal beam radiography.
• Need to have computers and a software package to integrate with medical records.
POSITIONING AND TECHNIQUE Measuring for Radiographic Studies • Measure all animals standing. • Measurements for the thorax, abdomen, and thora-
Advantages • A digital image is generated (these can easily be sent • • • •
to specialists if needed). Existing radiography equipment can be used. Excellent image quality. Initially less expensive than digital radiography. Film, processor, and darkroom can be eliminated.
Disadvantages • Still have to use an imaging plate • Need to purchase new plates and a reader
•
• •
columbar spine are all taken at the same location on the animal. Observe the animal from above, taking the lateral measurement from the widest point across the ribs. The DV/VD measurement is made at the same point. The widest point is usually at the thoracolumbar junction. Measure the pelvis across the wings of the ilium. This is a very accessible area to measure, giving highly repeatable results. The same measurement is used for both the lateral and the VD. Measure extremities at the widest point. Make sure all personnel measure all areas at the same point; otherwise, the technique will vary from one study to the next.
Figure 4-5. Technique chart to use with nonscreen film. Use a lateral measurement across the skull to set technique. Always use 50 kVp for the best contrast.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 63
Chapter 4 / Radiographic and Ultrasonographic Techniques
63
• For a lateral (right or left) radiograph, pull the legs
Thorax Obtain thoracic films at full inspiration. Include from the thoracic inlet to behind the diaphragm. In a large dog, this may take two radiographs for both lateral and DV/VD views. Short exposure times of 1/60 second or less decrease motion artifact from cardiac and respiratory motion. A high-kVp, low-mAs technique increases latitude (increased shades of gray). • For the lateral (right or left) measurement, elevate the sternum to the same plane as the spine. Pull the animal’s legs cranially to reduce soft tissue over the cranial thorax. Include the sternum, and take the radiograph during peak inspiration (Fig. 4-6). • For the DV/VD view, the sternum is superimposed over the spine. Center the beam at the caudal border of the scapula; center the beam on the spine. Take the radiograph during peak inspiration. VD radiographs are preferable to DV for evaluation of the accessory lung lobe and the caudal mediastinum. DV radiographs are preferred if evaluation of the caudal pulmonary vessels is important. The dog’s disposition, clinical status (e.g., heart failure, pulmonary edema, or pleural effusion), or position of previous radiographs help choose between VD and DV thoracic radiographs (Fig. 4-7). A Plexiglas or foam trough is useful for positioning for the VD view (add 10% kVp to your technique when using a trough). • Take both right and left lateral views of the thorax with a DV/VD view to evaluate for pulmonary metastases or focal disease.
•
•
•
caudally but not enough to stretch the abdominal musculature taut. Place the edge of the cassette 1 to 2 inches cranial to the xiphoid and at the coxofemoral joint (palpate for the greater trochanter). Take the radiograph at peak expiration (Fig. 4-8). The DV/VD is the same as that for the lateral abdomen (Fig. 4-9). A Plexiglas or foam trough is useful for positioning for the VD view (add 10% kVp to your technique when using a trough). A horizontal beam radiograph can be used to check for free abdominal air. Place the animal in left lateral recumbency for 10 minutes before radiography. Air is demonstrated around the right liver lobes. The technique is similar to the vertical beam technique in that distance remains at 40 inches. Remember to reduce the mAs if a grid is not used. In compression radiography, a wooden spoon can be used to compress the abdomen for separation of
Abdomen Withhold food for at least 12 hours for optimal abdominal radiographs. Encourage the animal to defecate and urinate before being radiographed. Radiographs include the diaphragm to the coxofemoral joints. For large-breed dogs, this may require two 14 ¥ 17-inch films for both the lateral and DV/VD views. Use a 1/40-second or less exposure time to reduce motion; use a kVp in the 70 to 90 range for maximum latitude.
Figure 4-7. radiograph.
Positioning for dorsoventral or ventrodorsal thoracic
Center beam over caudal scapula
Sternum
Figure 4-6.
Positioning for lateral thoracic radiograph.
Figure 4-8.
Positioning for lateral abdominal radiograph.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 64
64
Section 1 / Patient Management
Mediolateral (ML) The animal is in lateral recumbency, with the down side to be radiographed. Extend the leg about 45 degrees from the vertebral column. Flex the opposite leg and place it over the thorax. Pull the head and neck back so that the cervical spine and trachea are not overlapping the joint space.
Humerus Caudocranial The animal is in dorsal recumbency, with the legs extended. Rotate the sternum away from the side being radiographed. Center the x-ray beam at the midhumerus. The radiograph includes both the shoulder and the elbow joints.
Mediolateral Figure 4-9.
Positioning for ventrodorsal abdominal radiograph.
structures. The spoon can separate the colon from the urinary bladder to demonstrate the uterus, for example. Remember to reduce the kVp, because you are decreasing the thickness of the tissue being radiographed.
Extremities For radiography of the extremities, the animal needs a clean, dry haircoat. Remove splints and bandages if possible. Place the limb to be radiographed closest to the film. Employ a high-mAs, low-kVp (50–70) technique to produce high-contrast radiographs. Collimate closely. Use tabletop (nongrid) techniques on parts less than 10 cm thick. Administer anesthesia or tranquilizers whenever needed. Use positioning devices. Measure the part to be radiographed over the thickest area. If the part thickness varies greatly, two exposures (e.g., lateral pelvis and femur) may be necessary. In the case of moderate variation, choose the greater measurement to set the exposure and “hot light” the slightly overexposed areas when reading the film. When long bones are being radiographed, include the joints proximal and distal. ▼ Key Point Radiograph the opposite limb for comparison to determine normal from abnormal.
Scapula and Shoulder Joint
Place the animal in a position similar to that for the ML view of the scapula and the shoulder joint. Center the x-ray beam at the mid-humerus. The radiograph includes both the shoulder and the elbow joints.
Elbow Joint Craniocaudal The animal is in sternal recumbency, with the elbow joint in full extension. If the elbow cannot be completely extended, angle the x-ray beam 10 degrees to 20 degrees, craniodistal to caudoproximal.
Mediolateral The animal is in lateral recumbency, with the elbow slightly flexed. Pull the opposite leg caudally. Center the beam on the palpable medial epicondyle. The elbow is in extreme flexion if identification of the anconeal process is of importance.
Craniolateral-Caudomedial Oblique This aids in imaging of the lateral aspect of the medial coronoid.
Antebrachium Craniocaudal Place the animal in sternal recumbency. Extend the leg and position the elbow for a true craniocaudal projection. The film includes both elbow and carpus.
Caudocranial
Mediolateral
The animal is in dorsal recumbency, with the sternum rotated away from the side being radiographed. The leg is fully extended. Center the x-ray beam at the midscapula. For the shoulder joint, center the beam at the point of flexion for the joint.
The animal is in lateral recumbency, with the leg in the neutral position. Move the opposite limb caudally; center the beam on the midshaft radius. It may be easier to obtain the radiograph if the elbow is slightly flexed. Include the elbow and carpal joint on the film.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 65
Chapter 4 / Radiographic and Ultrasonographic Techniques
65
Carpus or Metacarpus
Lateral
Dorsopalmar
The animal is in lateral recumbency, with the dependent leg pulled cranially. Elevate the nondependent leg with a foam block parallel to the tabletop.
By convention, positional terms change from cranial and caudal to dorsal and palmar distal to the radius. Place the animal in sternal recumbency, with the extremity extended. Allow the elbow to abduct slightly so that the carpus is in true dorsopalmar (DP) view. Center the x-ray beam on the carpus or metacarpus.
Mediolateral Place the animal in lateral recumbency, with the affected leg down. Slightly flex the carpus; center the xray beam on the carpus. A lateral view of the metacarpus is often unrewarding.
Lateral Oblique Place the animal in lateral recumbency. Place a foam wedge to elevate the pelvis approximately 20 degrees. Push the upper leg proximally to rotate.
Ventrodorsal Flexed Hip (Frog-Leg Position) Place the animal in dorsal recumbency, and flex and abduct the femurs so that the stifles are lateral to the abdomen. Place the femurs at an angle of 45 degrees to the spine.
Oblique Views
Femur
Place the animal in sternal recumbency, with the carpus/metacarpus in DP. Rotate the extremity 45 degrees in both directions for the two oblique views (dorsolateral to palmar medial oblique and dorsomedial to palmar lateral oblique).
Craniocaudal
Digits
Mediolateral
Dorsopalmar
Place the animal in lateral recumbency with the leg to be examined on the cassette. Abduct the opposite leg and rotate out of the x-ray beam’s path. Center the x-ray beam at mid-femur. Include the hip and stifle on the film.
Place the paw flat against the cassette.
Mediolateral Place the animal in lateral recumbency. Pull the specific digit to be examined dorsally with tape.
Place the animal in dorsal recumbency or in the erect sitting position, with the leg extended. Center the x-ray beam at mid-femur. Include the hip and stifle on the radiograph. Measure at the proximal femur.
Stifle
Oblique Views
Caudocranial
Place the animal in sternal recumbency, with the carpus/metacarpus in DP. Rotate the extremity 45 degrees in both directions for the two oblique views (dorsolateral to palmar medial oblique and dorsomedial to palmar lateral oblique). Cotton can be placed between the digits to help with separation.
Place the animal in ventral recumbency with the leg to be examined pulled caudally into maximum extension. In large dogs, angle the x-ray beam 15 degrees caudodistal to cranioproximal. Center the x-ray beam at the joint space.
Pelvis
Position the animal as for the mediolateral femur view, with the x-ray beam centered on the joint space. Usually, the tarsus is away from the cassette, so you need to place a foam wedge under the hip and femur.
Tranquilization may be necessary for routine VD and lateral radiographs. General anesthesia is recommended for Orthopedic Foundation for Animals (OFA) or Penn-Hip radiographs.
Mediolateral
Tibia and Fibula
Ventrodorsal Extended Hip
Caudocranial
The animal is in dorsal recumbency, with the legs extended. The pelvis is straight; the femurs are parallel and as close to the cassette as possible. Patellae are superimposed over the distal femurs. Center the x-ray beam on the hip joints. Include the stifles on the radiographs. Legs are the same distance apart as the acetabula.
Position the animal as for the caudocranial stifle view. The x-ray beam remains vertical and centered at the mid-tibia. Include stifle and tarsus on the film.
Mediolateral Place the animal in lateral recumbency with the tibia and fibula included on the film.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 66
66
Section 1 / Patient Management
• In the average-size dog, five vertebral segments can be
Tarsus Dorsoplantar Place the animal in dorsal recumbency. Extend the leg, and center the x-ray beam at the proximal intertarsal joint.
Mediolateral Place the patient in lateral recumbency. Slightly flex the tarsocrural joint. Center the x-ray beam at the proximal intertarsal joint.
adequately evaluated per film. Because of the divergence of the x-ray beam, all areas of interest have to be centered to evaluate intervertebral disc spaces. ▼ Key Point Poor patient positioning and poor radiographic quality commonly occur when animals are not anesthetized or heavily sedated for spinal films. Many radiographic lesions can be obscured by poor technique. Conversely, a normal structure can be falsely identified as a lesion.
• Ideal spinal survey studies are listed in Table 4-5.
Oblique Views Dorsolateral to palmar medial oblique and dorsomedial to palmar lateral oblique. Position the animal in dorsal recumbency, then rotate 45 degrees in each direction (lateral and medial) for the two oblique views.
Cervical Spine
Metatarsus and Digits
For radiography, the spine must be parallel to the cassette. In many cases, support the center of the neck with radiolucent positioning blocks (sponges). Place the head in a normal position (neither flexed nor extended) relative to the neck. The head must be lateral because it controls the position of the proximal neck. Pull the front legs back over the thorax to allow thinning of the tissues over the caudal neck. The thorax must be in the accurate lateral position because it controls the position of the caudal neck. Extending the entire neck may help open up the caudal cervical disc spaces. Include both occipital and cervicothoracic areas on the radiograph.
Position the animal as for the metacarpus and digits of the forelimbs.
Spinal Positioning and Technique: General Principles • Materials needed include sandbags, foam wedges, •
• •
markers (right and left), and a Plexiglas trough to aid in positioning the animal without anyone in the room. Use general anesthesia or heavy sedation in all but the most subdued animals. Exceptions are suspected fracture, congenital malformation with instability, and other diseases in which the animal’s condition or protective mechanisms that have maintained stability will be compromised. Short-scale, high-contrast (high-mAs, low-kVp) technique provides good detail. Use a grid and collimate to include only the spine. At least two radiographic views of the area of interest are needed: lateral and VD.
Measure at the caudal cervical spine for all views.
Lateral View
Ventrodorsal View The spine is not parallel to the cassette because of the anatomic variation between the head and the thorax. The spine inclines away from the cassette at the thorax. Place the head in normal position (hard palate and dorsal nose at a 60 degree angle to the cassette). If the head is in a true VD position, an undesirable arch is pro-
Table 4-5. SPINAL SURVEY STUDIES Study
Centering—Lateral
Cervical spine (C1-5) Cervical spine (C6-T2)
C3-4 C6-7
Occipitoatlantoaxial
C1 C1 flexion, C1 oblique T6-7 T12-13 L3-4 LS LS flexion LS extension Center on area of suspected lesion
Thoracic spine (cranial) Thoracolumbar spine (T12-13) Lumbar spine Lumbosacral spine Post-trauma
Centering—Ventrodorsal C3-4 C6–T1 (x-ray beam angled 15 degrees ventrocaudal to dorsocranial) C1 (rostrocaudal open mouth to visualize the dens) T6-7 T12-13 L3-4 LS Cross-table (horizontal beam); center on area of suspected lesion
W0422-Ch004.qxd 11/11/05 4:09 PM Page 67
Chapter 4 / Radiographic and Ultrasonographic Techniques
67
duced in the cervical spine. The midplane of the head and thorax must be perpendicular to the cassette. Tilting the x-ray tube ventrocaudal to dorsocranial approximately 10 to 20 degrees permits imaging of the intervertebral disc spaces.
Thoracolumbar Spine Lateral View The midplane of the entire body must be parallel to the cassette. Most animals must have the sternum elevated for good lateral views of the spine. Pull the front legs cranially and the rear legs caudally to straighten the spine. Extending the entire neck may help open up the cranial thoracic disc spaces.
Ventrodorsal View
Nonscreen packet
Figure 4-10. Positioning for dorsoventral occlusal (intraoral) radiograph of the skull.
The midplane of the entire spine must be perpendicular to the cassette. When the dorsal spines are prominent, as in thin animals, radiolucent positioning blocks may be beneficial. The body may be held by placing tension on the legs.
Skull Radiography • General anesthesia or deep tranquilization of the patient is essential, if not specifically contraindicated by the patient’s physical condition, to obtain radiographs of good diagnostic quality. ▼ Key Point The lack of proper patient restraint is the most common cause of skull radiographs of nondiagnostic quality.
• The highest-resolution (detail) radiographic image
•
of the skull is produced with a nonscreen film or an ultradetail film-screen combination. Nonscreen film necessitates a 10- to 20-fold increase in the mAs compared with film in par speed screen cassettes. The positioning of the patient and the number of projections needed for a complete study depend upon the area of the skull being evaluated. A minimum of two views is necessary.
Figure 4-11. Positioning for the ventrodorsal (20∞ to 30∞ tube angle), open-mouth view of the skull.
Routine Skull Lateral and DV views are used.
Nasal Cavity and Paranasal Sinuses Lateral and DV occlusal (Fig. 4-10), VD open mouth (extraoral film) (Fig. 4-11), frontal (primary beam parallel to the hard palate) (Fig. 4-12), and lateral oblique (right and left) (Fig. 4-13) are used to evaluate small frontal sinuses.
Figure 4-12. skull.
Positioning for the rostrocaudal (frontal) view of the
W0422-Ch004.qxd 11/11/05 10:39 AM Page 68
68
Section 1 / Patient Management
Figure 4-13. Positioning for the open-mouth lateral oblique (20∞ to 30∞) view of the frontal sinuses.
Figure 4-15. Positioning for the open-mouth lateral oblique (20∞ to 30∞) view of the mandible.
Figure 4-16. Positioning for the ventrodorsal occlusal (intraoral) view of the mandible. Figure 4-14. Positioning for the open-mouth lateral oblique (20∞ to 30∞) view of the maxilla.
Central beam
Dental Arches
• Maxillary: Right and left lateral obliques (20–30 •
degrees) (Fig. 4-14), VD open mouth (extraoral film), and DV occlusal. Mandibular: Right and left lateral obliques (20–30 degrees), open mouth (Fig. 4-15), and VD occlusal (Fig. 4-16).
Long axis of tooth 90 Bisecting angle Film Bisecting angle technique for radiographing the
Bisecting Angle Technique
Figure 4-17. teeth.
Project the central beam perpendicular to an imaginary plane that bisects the angle formed by the long axis of the tooth (or teeth) and the plane of the film (Fig. 4-17).
Foramen Magnum
Tympanic Bullae (Middle Ears) DV, open mouth frontal. The primary beam bisects the angle of the opened temporomandibular joint (TMJ) (Fig. 4-18); right and left lateral obliques (30 ¥ 30 degrees) (Fig. 4-19). Palpate the jugular processes; when these processes are oblique, the bullae will also be properly oblique.
Rostrodorsal-caudoventral oblique (fronto-occipital). The central beam passes between the eyes and exits through the foramen magnum (Fig. 4-20).
Temporomandibular Joint DV, open mouth frontal (see Fig. 4-18). The primary beam bisects the angle of the opened temporomandibular joint; right and left lateral obliques (20–30 degrees) (see Fig. 4-13).
W0422-Ch004.qxd 11/10/05 4:43 PM Page 69
Chapter 4 / Radiographic and Ultrasonographic Techniques
69
Mandible DV, lateral, and lateral oblique (right and left).
Maxilla DV occlusal, VD open mouth, lateral, and lateral oblique (right and left).
Zygomatic Bone and Orbit DV, lateral, and lateral oblique (right and left); frontal; and VD open mouth. Figure 4-18. Positioning for the open-mouth rostrocaudal (basilar) view of tympanic bullae.
CONTRAST STUDIES Contrast Medium • Positive-contrast medium: iodine (ionic, nonionic), barium (liquid, paste) (Table 4-6)
• Negative-contrast medium: room air, carbon dioxide, nitrous oxide
Excretory Urogram (Intravenous Pyelogram, Intravenous Urogram) • A well-prepared animal is important for this contrast study (excretory urogram[EU], intravenous pyelogram, and intravenous urogram are synonymous terms). Withhold food for 12 to 24 hours. Give enemas the night before and at least 2 hours before the study. Determine renal function (blood urea nitrogen and serum creatinine) before initiating the study. ▼ Key Point Always take scout films before performing contrast studies of the urinary tract.
Figure 4-19. Positioning for the lateral oblique (30∞ nose elevated, then 30∞ oblique) view of tympanic bullae.
• The primary contraindication in animals is dehydra-
•
• Figure 4-20. Positioning for (fronto-occipital) view of the skull.
the
rostrodorsal-caudoventral
tion. Contrast medium is hypertonic and will compromise an already unstable patient. Make sure the patient is properly hydrated before EU. Other contraindications in people include diabetes mellitus, multiple myeloma, heart failure, and known hypersensitivity to the contrast medium. Use a water-soluble, iodinated ionic contrast media (Renografin, Conray, Hypaque, Renovist, etc.). Dose is 2 ml/kg intravenously (approximately 300–400 mg/ml of iodine), not to exceed 90 ml or 35 g of iodine. For animals with impaired renal function, the dose may need to be doubled (4 ml/kg). Place an indwelling catheter to help avoid perivascular injections and to allow intravenous access if complications occur. Give the bolus as fast as possible. Increase radiographic technique (mAs) 5% to 10% over scout films. Keep the kVp approximately 70 to produce better differentiation between the kidney and the contrast medium.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 70
70
Section 1 / Patient Management
Table 4-6. RADIOGRAPHIC CONTRAST AGENTS Type of Contrast Agent Barium products
Iodinated gastrointestinal contrast agent Iodinated contrast agent Myelographic contrast agent
Brand Names
Manufacturers
Intropaste (barium paste) Barosperse (barium suspension) Novopaque (barium suspension) E-Z-ML- 196 (barium suspension) Gastrografin Omnipaque (iohexol) Renografin 60 or 76 Hypaque-76 Conray 30 or 400 Omnipaque (iohexol) Isovue (iopamidol)
Lafayette Pharmacal (Lafayette, IN) Mallinckrodt (St. Louis, MO) Lafayette Pharmacal (Lafayette, IN) E-Z-EM (Westbury, NY) Bracco Diagnostics (New Brunswick, NJ) Amersham Health (Piscataway, NJ) Bracco Diagnostics (New Brunswick, NJ) Amersham Health (Piscataway, NJ) Mallinckrodt (St. Louis, MO) Amersham Health (Piscataway, NJ) Bracco Diagnostics (New Brunswick, NJ)
Technique 1. Immediate postinjection VD film demonstrates nephrographic phase. 2. VD and lateral films at 5 minutes. 3. In some cases, if there is poor filling of the renal pelvis, between 10 and 20 minutes following contrast administration place an abdominal wrap between the bladder and the kidney to compress the ureters, causing the pelvis and diverticula of the kidney to completely distend for better evaluation. This is contraindicated in cases of severely diseased bladder walls or mass lesions, in which it may cause rupture. 4. VD and lateral films at 15 minutes for evaluation of the pyelographic stage. 5. VD and lateral films at 30 minutes. 6. Remove the compression wrap and take lateral and VD radiographs. 7. Modify this technique as needed for the suspected disease entity. For example, to evaluate for ectopic ureters, take oblique films off lateral at the bladder trigone between 15 and 20 minutes. A pneumocystogram may also be helpful for identifying the distal ureters and vesicoureteral junctions. • Complications include perivascular injection, which can be treated by instilling saline into tissues to dilute; nausea or vomiting; adverse systemic (anaphylactoid) reaction; and contrast-induced renal failure. The study may be nondiagnostic when the kidneys become bright (contrast enhanced) and remain that way, but there is no opacification of the collecting system, ureters, or bladder. Be careful in VD positioning to avoid aspiration.
Cystography • Contrast medium: For negative contrast, use nitrous
• •
oxide, room air, or carbon dioxide; for positive contrast, use a water-soluble iodinated ionic contrast medium (not barium). Catheters: Foley, tom cat, male dog, or metal female catheters Sterile lubricant gel
• Three-way stopcock • Contrast studies • Negative-contrast cystogram (pneumocystogram) • Positive-contrast cystogram (technique of choice for identifying urinary bladder location and tears) • Double-contrast cystogram (superior for demonstrating lesions involving the urinary bladder wall and intraluminal filling defects)
Technique (Double Contrast) 1. Withhold food for 12 to 24 hours. 2. Administer warm-water cleansing enemas the night before and 3 to 4 hours before the procedure if needed. 3. Sedation or tranquilization may be necessary for catheterization, especially in cats and female dogs. 4. A small amount of 2% lidocaine (2–5 ml) infused into the urinary bladder before the contrast agent may reduce urinary bladder spasm. 5. Place the catheter tip within the bladder neck. 6. Empty the urinary bladder. 7. Infuse the positive-contrast medium (1–3 ml in cats and dogs <25 pounds; 4 to 6 ml in dogs >25 pounds), rotate the patient, and massage the bladder to distribute the contrast medium and coat the entire mucosal surface. 8. Slowly infuse negative-contrast material (approximately 10 ml/kg, but range is extremely variable). Complete distention is desirable and can be judged by palpation, back pressure felt on syringe plunger, or reflux of gas around catheter. 9. Take a lateral, two lateral obliques, and a VD radiograph to examine the bladder full on doublecontrast cystograms. 10. Evacuate contrast material from the bladder after the study.
Technique (Positive Contrast)
• Increase exposure technique by 10% for a positivecontrast study.
• Only lateral and VD views are necessary for positivecontrast cystograms.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 71
Chapter 4 / Radiographic and Ultrasonographic Techniques
• Use the technique described previously for catheter •
71
taken if needed. Follow-up radiographs may be helpful if a bolus of contrast material is retained within the esophagus.
placement. Administer 3 to 5 ml/kg of positive-contrast medium.
Complications
Complications
• Fatal air embolism (rare cases). An increased risk
• Aspiration. • Leakage of barium into mediastinum. Low osmolal-
•
exists with ulcerative or erosive cystitis. Carbon dioxide is more soluble than room air in blood and thus less likely to cause this problem. Air embolism occurs immediately after the administration of negative-contrast medium. Place the animal in left lateral recumbency, and lower the head to maintain normal blood circulation through the heart. The air is trapped in the right ventricle. Iatrogenic trauma (hematuria or rupture) and infection (bacterial contamination or cystitis).
Urethrography • Retrograde positive-contrast study of the urethra using iodine.
• Equipment includes catheter (Foley, metal, male dog), sterile gel, lidocaine, and water-soluble iodinated contrast medium.
Technique 1. Evacuate the colon with an enema, if needed, before the study; take scout films before the study to evaluate technique and preparation. 2. Pass a urinary catheter into the distal urethra. Inflate the balloon if a Foley catheter is used (in distal urethra for female dogs or cats and proximal to the os penis in male dogs when possible). 3. Administer 2 to 5 ml of 2% lidocaine before injecting contrast material to reduce urethral spasm. 4. Position male dogs with their legs drawn cranially. 5. Administer 10 to 20 ml of contrast medium for male dogs and 5 to 10 ml for female dogs and cats. Inject as a bolus and take radiographs during the last few milliliters of injection. 6. A lateral radiograph may be sufficient, but subsequent lateral and VD oblique views may be helpful.
Complications
• Iatrogenic trauma and bacterial contamination Esophagography Technique 1. Take survey cervical and thoracic radiographs. 2. Position the animal in lateral recumbency. 3. Administer contrast medium (see Table 4-6) (barium sulfate suspension, Esophotrast, barium burger) slowly into the buccal pouch. 4. Dose is variable (5–20 ml); use enough to induce swallowing and coat esophagus. 5. Obtain radiographs following swallows. The lateral view is most informative; additional views can be
ity, nonionic iodinated contrast medium (iohexol) may be indicated if perforation is suspected.
Gastrography ▼ Key Point Before contrast studies of the gastrointestinal tract, discontinue all drugs that may influence motility.
Technique 1. Fast patient 12 to 24 hours before the study. 2. Give cleansing enema the night before and 3 to 4 hours before the study, especially if complete upper gastrointestinal study is to be done. 3. Take plain films before the study. Then pass a stomach tube for administration of contrast medium. 4. Obtain negative-contrast gastrogram (pneumogastrogram) by administering 6 to 16 ml of room air per kilogram of body weight using a stomach tube. Immediately take four views (right and left lateral, VD, and DV). This is often valuable in the diagnosis of radiolucent foreign bodies. 5. Obtain positive-contrast gastrogram using barium (suspension, 30% weight-to-volume) at a dose of 6 to 12 ml/kg (see Table 4-6). Administer through a stomach tube, and take films immediately (right and left lateral, VD, and DV). Use this procedure to document gastric displacement, certain gastric foreign bodies, and gastric perforation. Barium begins leaving the stomach within 5 to 15 minutes. The stomach is emptied by 30 to 60 minutes in cats and 1 to 2 hours in dogs. 6. A double-contrast gastrogram can be done as a separate study or during an upper gastrointestinal study. Give barium, 60% weight-to-volume at a dose of 1.5 to 3 ml/kg, and insufflate with room air at 10 ml/kg. Immediately take DV, VD, and right and left lateral films. This study is indicated in cases of suspected gastric wall and mucosal lesions.
Upper Gastrointestinal Study • Preparation requires a 12- to 24-hour fast and an • •
enema the night before and 3 to 4 hours before the study. Use barium suspension, 30% to 60% weight-tovolume, for routine studies (see Table 4-6). Dose is 8 to 16 ml/kg. Use iodinated contrast (ionic and nonionic) agents (see Table 4-6) with suspected perforation for quick determination of small intestine patency and location
W0422-Ch004.qxd 11/10/05 4:43 PM Page 72
72
•
Section 1 / Patient Management
and when endoscopy is planned immediately following the contrast study. For restraint in canines use acepromazine, and in felines use ketamine/acepromazine preparations. See Chapter 2 for doses. These sedatives have less effect on motility than do many others.
Technique 1. Take survey radiographs (right lateral and VD). 2. Immediately after administration of barium, take right and left lateral and DV and VD views. Obtain right lateral and VD radiographs at 15, 30, and 60 minutes. Be consistent unless a lesion is identified that is better evaluated by repositioning the animal. Then, proceed at hourly intervals until the contrast material reaches the colon. 3. Modify this protocol for each individual depending on the suspected disease entity or the lesions visualized during the procedure. 4. Expected transit time to the colon is 3 to 4 hours for dogs and 1 hour for cats.
Complications
• Aspiration of barium with or without gastric contents. • Leakage of barium indicates a gastrointestinal (GI) perforation, which is a surgical emergency. Barium itself induces a chemical peritonitis that may make treatment of GI perforation more difficult. ▼ Key Point Whenever GI perforation is suspected, use nonionic iodinated contrast medium (e.g., iohexol) instead of barium.
Myelography • Myelography is the radiographic evaluation of the •
•
•
spinal cord by injection of a positive-contrast agent into the subarachnoid space. Indications • To evaluate transverse myelopathy • To determine nature, location, and extent of a lesion prior to surgery • To identify multiple lesions when one lesion might be masked by another and therefore not detected clinically Contraindications • Diffuse myelopathy that is not amenable to surgery • Meningitis, which may be aggravated by contrast medium • Not indicated when survey radiographs and clinical signs are adequate for diagnosis Contrast medium (see Table 4-6) • Dose for cisternal tap: Cervical study (0.2– 0.3 ml/kg); thoracolumbar study (0.45 ml/kg) • Dose for lumbar tap: Cervical study (0.45 ml/kg); thoracolumbar study (0.3 ml/kg)
▼ Key Point Always obtain survey spinal radiographs before myelography.
Basic Technique 1. Animals must be under general anesthesia. 2. Perform sterile preparation of the puncture site. 3. Collect and analyze cerebrospinal fluid (CSF) if deemed necessary.
Cisternal Tap Procedure 1. Position the animal in lateral recumbency. 2. Place the nose parallel to the tabletop and perpendicular to the spine. 3. Use a 20- or 22-gauge, 1.5- to 2.5-inch spinal needle with the bevel directed caudally. 4. Insert the needle on the dorsal midline between the occipital protuberance and the wings of the atlas. 5. Direct the needle toward the mandible. 6. If the needle hits bone, move the needle cranially or caudally until it falls into the atlanto-occipital (AO) space. 7. Remove the stylet and check for CSF flow often while advancing the needle. 8. Inject contrast material slowly after seeing CSF in the needle. Prior to injection, collect a specimen if CSF for later analysis is indicated. 9. Elevate the head for 5 minutes before taking radiographs. 10. Take lateral and VD radiographs (also VD oblique if necessary). Remove the endotracheal tube, if necessary, for the VD radiograph.
Lumbar Tap Procedure 1. Position the animal in lateral or sternal recumbency, and flex the rear legs to help open the interarcuate spaces. 2. Use a 20- or 22-gauge, 1.5- to 3.5-inch spinal needle. 3. Insert the needle through the L5-6 interarcuate space for small dogs and cats and L4-5 for large dogs. Place the needle on the dorsal midline just lateral to the dorsal spinous processes of L6 at a 50 to 60 degree angle in a cranioventral direction toward the interarcuate space at L5-6. In cats, insert the needle off the cranial edge of the L6 dorsal spinous process perpendicular to the long axis of the spine. Direct the needle ventrally through the interarcuate space. 4. Inject in either the dorsal or the ventral subarachnoid space. Always check for CSF flow before injection; however, it is not always obtained. Increase the likelihood of obtaining CSF by elevating the head and shoulders before placing the needle. 5. Perform a small test injection (0.25–0.50 ml) followed by a radiograph to check needle placement. 6. Slowly inject total dose. Take radiograph views based on localization determined by neurologic examination.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 73
Chapter 4 / Radiographic and Ultrasonographic Techniques
Complications
• Seizures (incidence is reduced with new contrast • • • • •
agents, e.g., iohexol) Exacerbation of clinical signs Hyperesthesia Apnea during injection Epidural injection will not negatively affect the health of the animal but negatively affects the quality of the myelogram. Central canal filling occurs when the needle is placed through the center of the cord. It usually appears thin on radiograph and sharply defined in the normal animal.
Interpretation Lesions are divided into three categories (Fig. 4-21): 1. Extradural, characterized by a. Displacement of the spinal cord b. Narrowing or compression of the subarachnoid space c. Deviation of the subarachnoid space d. Spinal cord may appear wide on opposite view 2. Intradural extramedullary, characterized by a. Filling defect within the subarachnoid space (“golf tee” sign) b. Possibly associated extradural or intramedullary component 3. Intramedullary, characterized by a. Spinal cord widening in all views
Extradural
Intradural Extramedullary
Intramedullary
Lateral
Ventrodorsal
RADIATION SAFETY Basic Radiation Safety The objectives of radiation safety are to obtain the maximum amount of diagnostic information while keeping the radiation exposure to personnel and animals to a minimum. ▼ Key Point The responsibility for radiation safety lies solely with the owners of the practice.
Radiation protection in veterinary medicine is the subject of the National Council on Radiation Protection and Measurements (NCRP) Report No. 36, titled Radiation Protection in Veterinary Medicine. This report specifically outlines when radiation protection surveys are made. The report makes recommendations concerning tube housing, aluminum filtration, collimation types, and centering devices. A special section discusses radiography with portable and mobile diagnostic equipment. All practices need a copy of this report. Other NCRP reports that may be pertinent are No. 116, which discusses protection devices and provides recommendations for the maximum permissible dose (MPD); No. 107, which explains the concept of ALARA (as low as reasonably achievable) for medical and dental personnel; and No. 35, which discusses dental applications of diagnostic radiology. The MPD was established to keep the radiation exposure of workers below a level at which adverse effects might be observed during a lifetime and to minimize the incidence of genetic effects in the entire population. The MPD does not apply to animal patients, to radiation emitted from natural background sources, or to radiation therapy. The actual risk to an individual exposed to MPD is small, but the risk is directly proportional to the received dose. Therefore, radiation exposure must be kept as low as possible. Radiation can cause both tissue and genetic damage. The effects of radiation can be demonstrated in a short time, or they can be cumulative and not observed for a long time. Federal regulations regarding use of x-ray equipment and radiation protection are published in the Code of Federal Regulations, available at university and public libraries. Individual states publish radiation control regulations that are reprinted from the state codes. These regulations include information concerning the licensing of x-ray machines, the licensing fee, and the procedure to be followed in obtaining licensing. The goal in diagnostic radiology is to obtain radiographs with minimum exposure to both patient and personnel.
Maximum Permissible Dose Figure 4-21.
Radiographic patterns of myelographic lesions.
73
The MPD is currently 5 rem per year.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 74
74
Section 1 / Patient Management
▼ Key Point Be familiar with federal, state, and local regulations regarding use of x-ray equipment and radiation safety.
Reducing Exposure Three methods reduce radiation exposure: (1) increased distance between the individual and the radiation source, (2) decreased duration of exposure, and (3) protective barriers between the individual and the radiation source.
• •
• Limiting radiation exposure • Limit the number of individuals within the room where the procedure is taking place. Use positioning devices, such as sandbags, sponges, tape, and Plexiglas or foam trough. Use chemical restraint whenever possible. ▼ Key Point When you must be present within the radiographic room during film taking, always wear protective clothing.
• Protective lead apparel includes apron, gloves, thyroid shield, and protective goggles. Lead apparel is usually 0.5-mm lead equivalent. Hang aprons up to prevent the lead from cracking. Store gloves so that liners can dry. Check all protective clothing at least twice a year for cracks and tears. Place the items on a film cassette and radiograph them at an exposure of approximately 85 kVp. ▼ Key Point Never permit any portion of the body to be within the primary beam, even if covered with protective clothing.
• •
• Never hand-hold any x-ray tube. All x-ray tubes leak radiation from the housing. • Use a shielding device whenever possible to protect all or part of your body. Lead glass may be part of this shield so that you may continue to see the patient. When using a horizontal x-ray beam, never position any part of your body behind the cassette. Use collimation. An unexposed border on the radiograph demonstrates that the primary beam did not
•
•
exceed the size of the cassette (film). This practice helps reduce scatter radiation by decreasing the interaction between the primary beam and the tissue, therefore increasing radiographic quality. Check the collimator light for accuracy; replace the bulb as needed. Use fast film, fast rare-earth screens, and high-kVp techniques to lower the exposure factors and the amount of radiation produced. Use a 2.0-mm aluminum filter installed at the tube housing port to remove the softer (less energetic) radiation portion of the x-ray beam. This aids in the reduction of scatter radiation and exposure to the patient. Individuals within the room should always stand as far from the radiation source as possible. If you double the distance from the source of radiation, you decrease your exposure level by a factor of 4 (inverse square law). All personnel working with radiation are required to wear a film badge or some other method of monitoring the amount of exposure if they have the potential to receive greater than 1/4 MPD. Remember that wearing the device does not protect the individual, but it serves as a reminder of working in a potentially hazardous environment. For a monitoring device to be most helpful in determining exposure to radiation, wear it consistently in the same location on the body outside the apron at the neck. Film badges register when exposed to heat, light, water, or pressure. They can be purchased through companies listed in Table 4-7.
▼ Key Point Never permit anyone under the age of 18 or a pregnant woman in the room during a diagnostic procedure.
• Rotate personnel, thus reducing the amount of exposure to each person.
• Do not direct the x-ray beam into adjacent rooms that may be occupied.
• Use a gonadal shield for the patient. • Always plan radiographic procedures (e.g., proper position and technique), thus reducing the number of films needed, which ultimately reduces the exposure to patient and personnel.
Table 4-7. SOURCES OF FILM BADGES Company Landauer Teledyne Brown Engineering
Address
Phone Number
Website
2 Science Rd. Glenwood, IL 60425 50 Van Buren Ave. Westwood, NJ 07675
800-323-8830
www.landauerinc.com
201-664-7070
www.tbe.com
W0422-Ch004.qxd 11/10/05 4:43 PM Page 75
Chapter 4 / Radiographic and Ultrasonographic Techniques
Clinic Construction • Check with your state’s health department (radiation • •
•
protection division) for the latest laws on radiation safety and clinic construction. Register your x-ray machine with the state. Many states are now conducting “surprise spot checks” of x-ray machines and radiographic records. Maintain film and technique logs for complete records (Figs. 4-22 and 4-23). If constructing a new clinic, a drawing of the layout must be sent to the state radiation protection department. This drawing indicates the location of the x-ray machine and demonstrates how the space in the room where the x-ray machine is located will be used. The use of the adjoining rooms and an estimate of the degree of traffic in these areas are determined. The radiation safety department then sends a computerized layout of wall, ceiling, and floor materials to be used in certain areas of your clinic.
From the differential list, additional tests can be done to help formulate a definitive diagnosis.
• Successful interpretation of radiographs depends on many factors. ▼ Key Point The most important factor in the successful interpretation of radiographs is the quality of the radiographs being examined.
• At least two views at right angles to each other are
• • • •
RADIOGRAPHIC INTERPRETATION Radiology is a valuable adjunctive diagnostic tool. Do not interpret radiographs without considering the history, clinical signs, physical examination findings, and laboratory data. Radiographic signs are rarely pathognomonic; therefore, a specific diagnosis is seldom possible. History + Physical exam + Lab findings + Radiographs = Differential list
Figure 4-22. inventory log.
Film usage and
75
• • • • • •
needed. The use of right or left lateral radiographs is based on the preference of the individual reading the radiographs. The same holds true for VD and DV views, but be consistent. Maximize viewing conditions. Dark, quiet room. At least two view boxes to evaluate two views simultaneously. Always place the film on the view boxes such that the anatomic structures are in the same position and direction: DV/VD radiograph with the animal’s right to your left; lateral radiograph with the head to your left. Have a shielded, high-intensity (hot) lamp available. Read films slowly and thoroughly. Always have radiology and anatomy texts nearby. Evaluate the radiographs using a systematic approach. Evaluate the entire film before concentrating on obvious lesions. Use an area method, evaluating the radiograph either peripheral to center or center to peripheral. Use an organ system method. Evaluate all parts of a system before examining the next system.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 76
76
Section 1 / Patient Management
Figure 4-23. nique log.
• However you choose to evaluate films, be consistent •
from case to case. Knowledge of normal radiographic anatomy is essential.
Radiographic Signs • Radiopacity: Various radiographic opacities are caused
• •
by the differential absorption of x-rays. The opacity of surrounding material also influences the observed opacity of a structure. The five radiopacities in decreasing order (white to black) are those of metal, bone, soft tissue (fluid), fat, and gas. Metal is the only one that is not a biologic opacity. Geometry: Size, shape, position, margination, and number. Function: Excretion (intravenous urography), motility (upper gastrointestinal), patency, and integrity. Evaluation of function often requires contrast medium and multiple films.
COMPUTED TOMOGRAPHY Computed tomography (CT) is a cross-sectional imaging technique that allows identification of structures without the superimposition present with radiographs. Like radiographs, CT uses x-rays to produce an image. There are many different types of CT
Radiology tech-
machines, but all produce a thin fan of x-rays that are directed through the patient and strike a row of radiation detectors. The amount of radiation going through a specific part of the patient, and therefore reaching the detector, is related to the density of the body part. Based on numerous views of each part and the image density of different areas, a computer is used with various algorithms to form a cross-sectional, gray-scale image. Similar to radiographs, when looking at a CT: bone = white, air = black, fat = dark gray, and soft tissues/fluid = various shades of gray. Once the image has been acquired, post-processing parameters can be adjusted to optimize viewing of certain areas (i.e., bone, soft tissue, lung, and brain). Thus, the term soft-tissue or bone window is commonly used when evaluating CT images. Often, the same study is viewed in multiple windows for a complete evaluation. For example, a CT of the thorax would need to be viewed in a soft-tissue window (for the mediastinum), a lung window (for the pulmonary parenchyma), and a bone window (for the ribs and spine). The adjustment in a bone versus a soft-tissue window is made by changing the window width and window level. The window width defines how many shades of gray are seen over a given density of tissue (providing a long or short scale of contrast). The window level is the midpoint of the window width. CT studies are normally performed with slices in the transverse (axial) plane through the area of interest. This information can then be used to reformat the area
W0422-Ch004.qxd 11/10/05 4:43 PM Page 77
Chapter 4 / Radiographic and Ultrasonographic Techniques
of interest into a different plane (sagittal, coronal, or oblique), therefore maximizing interpretation. Common areas to use CT in veterinary medicine are the nasal cavity, middle ears, skull (bone changes or trauma), skeletal (elbows and spine), thorax, abdomen, and areas of neoplasia (for surgical or radiation planning). Magnetic resonance imaging (MRI) is considered best for soft-tissue structures, particularly the brain and spinal cord.
Advantages • The cross-sectional image is provided without
•
superimposition of structures, allowing more accurate detection and assessment of the extent of disease. CT is considered better than MRI for evaluation of bone abnormalities (MRI is best for soft tissue).
Disadvantages • Higher cost compared with radiographs (less expen-
77
termed the Tesla. Low-field magnets are less than 0.5 Tesla, mid-field magnets are 0.5 to 1 Tesla, and highfield magnets are more than 1 Tesla. Although all types of magnets are utilized, the cost of the machine and the time needed to acquire the image depend on field strength. In general, high-field magnets are more expensive, but images are acquired more quickly than from low-field units. Images are acquired using different pulse sequences (imaging acquisition parameters). These different sequences are used because the signal intensity (appearance of the image) will vary depending on primarily the water, fat, and mineral content of the area being imaged. Typical sequences are termed T1-weighted, T2weighted, and proton density. There are a variety of fat saturation techniques and variations in the sequences that are also utilized. Contrast material is generally given to patients and the T1-weighted sequences are repeated. The contrast material is a ferromagnetic substance that enhances signal intensity on T1-weighted sequences.
sive than MRI).
• The animal must not move during the CT study, so the patient must undergo general anesthesia in most cases.
MAGNETIC RESONANCE IMAGING MRI is a cross-sectional imaging technique that is considered excellent for imaging soft tissues. CT is still considered the best cross-sectional imaging modality when assessment of bone is required. MRI utilizes a magnetic field, radiofrequency (RF) waves, and the hydrogen protons in the patient for creation of the images. The equipment consists of a magnet, receiving coils, and hardware and software of the control station. MRI technology utilizes a magnet to polarize hydrogen atoms in the tissues and monitor the summation of the spinning energies within living cells. When a patient is put in a strong magnet, some of the atoms become aligned with the magnetic field. If an RF pulse is sent into the patient, the vector direction of the hydrogen protons can be changed. As the atoms realign themselves with the magnetic field, they give off an RF pulse that can be detected by the receiver coil. The amount of RF signal given off and the time at which it is released are characteristic for certain tissues. This information is again processed by a computer to provide a cross-sectional image with various shades of gray. The shade of gray of a certain tissue depends on the acquisition parameters. In other words, fluid may be dark gray in one acquisition and bright white in a different acquisition. Cortical bone and air will always be black with MRI. The images can be acquired in any plane without reformatting. There are different types of magnets, ranging from low- to mid- to high-field units. The unit strength is
Advantage • MRI is useful for areas that cannot be evaluated by more conventional methods (radiographs or ultrasound) such as the central nervous system, particularly the brain.
Disadvantage • Limited access • High cost ULTRASOUND Ultrasound is rapidly becoming an accepted imaging modality in small animal practice. New and used equipment is available at reasonable prices, and usefulness has increased to include ophthalmic, cardiac, abdominal, and reproductive disease diagnosis. It is a safe, noninvasive diagnostic technique that provides information about the internal architecture of organs within the abdomen and thorax. Functional information can also be obtained with echocardiography. Ultrasound is not meant to replace diagnostic radiography but to complement it. Ultrasound is operator dependent. The quality of the image and the information gained are directly related to the ability of the person doing the study.
Equipment The major components of the diagnostic ultrasound imaging system are pulser, transducer, receiver, memory, and display. Electrical pulses are produced by the pulser, and these drive the transducer. The transducer produces ultrasound pulses for each electrical
W0422-Ch004.qxd 11/10/05 4:43 PM Page 78
78
Section 1 / Patient Management
pulse it receives. The transducer also produces electrical pulses for each ultrasound pulse (reflection) it receives from tissues. The electrical pulses go to the receiver, where they are converted to information that the memory can utilize. Information from the memory drives the display, which produces an image. Suppliers of ultrasound equipment are listed in Table 4-8.
• Mechanical: In a mechanical (sector) scanner, the
•
Machines
• Questions to consider before purchasing or leasing ultrasound equipment:
• What kind of scanning will I be doing (e.g., heart,
•
abdomen, real-time, B-mode, or M-mode)? • How large or small are my patients? • Is someone in the practice willing to accept primary responsibility for learning and doing the procedures? • How much money can I invest? There are multiple types of transducers • A linear array scanner produces a rectangular image and can be used to evaluate broad areas, where no bony or gas-filled structures interfere. These scanners are usually less expensive. The major drawback is the transducer contact zone, which makes intercostal and subcostal (heart, liver, biliary tract, and right kidney) imaging difficult. • A sector scanner produces a pie-shaped image. A smaller contact zone is used, which makes intercostal and subcostal imaging less difficult.
•
sound wave is focused a certain distance from the transducer (focal point). The sound wave is within focus for some distance on both sides of the focal point (focal zone). Resolution is best within this fixed focal zone. The scanner contains moving parts. Electronic: These are linear or sector scanners with no moving parts; therefore, they are more durable than mechanical scanners. The beam is formed by adding together many small beams from an array of small crystals. The scanner has variable (dynamic) focusing. The focal zone therefore can be placed anywhere in the image depth. Image display • M-mode (motion-mode): Documents motion, especially that of the heart (echocardiography). A thin ultrasound beam is directed into the heart, is reflected back, and then is shown on the screen as numerous moving lines. Motion is indicated along the side, and time is shown along the bottom of the screen. • B-mode (brightness-mode): Echoes are displayed as dots. The brightness of the dot changes with the amplitude of reflection. The larger the reflection, the brighter the dot—no reflection, black dot. The location of the dot corresponds to the location of the reflector in the body. • Real time: The image is continually updated during the entire examination. This permits direct observation of moving structures (e.g., heart or bowel peristalsis).
Table 4-8. ULTRASOUND COMPANIES Company Aloka Alliance Medical U.S.A. Classic Medical Supply Hitachi Medical Corp. Jorgensen Laboratories Medelex Products Group International Sound Technologies SoundVision Ultrasource Universal Medical Systems
Address 10 Fairfield Blvd. Wallingford, CT 06492-7502 112 N. Bridge St. Smithville, MO 64089 19900 Mona Road, Ste. 105 Tequesta, FL 33469 1959 Summit Commerce Park Twinsburg, OH 44087 1450 N. Van Buren Ave. Loveland, CO 80538 732 N. Pastoria Ave. Sunnydale, CA 94086 447 Main St. P.O. Box 1807 Lyons, CO 80504 5939 Darwin Ct, Ste. 101 Carlsbad, CA 92008 417 Tory Dale Ct. Roseville, CA 95747 5241 Plainfield Ave. NE, Ste. Q Grand Rapids, MI 49525 299 Adams St. Bedford Hills, NY 10507
Phone Number 800-442-5652
Website www.aloka.com
888-689-3070 800-722-6838
www.classicmedical.com
800-800-3106
www.hitachimed.com
800-525-5614
www.jorvet.com
800-644-0692
www.medelex.com
800-336-5299
www.productsgroup.com/vet_index.html
800-268-5354
www.soundvet.com
800-957-5565
www.soundvisionweb.com
888-680-6989
www.ultrasource.net
800-842-0607
www.u-m-s.com
W0422-Ch004.qxd 11/10/05 4:43 PM Page 79
Chapter 4 / Radiographic and Ultrasonographic Techniques
• New versus used equipment • New equipment purchase is ideal because some companies offer training (in-house or continuing education course) and a year-long warranty with service and parts (in-house service or another unit is made available while your unit is serviced by the company). Manufacturer-reconditioned units may provide a year-long or shorter warranty. The major disadvantage of new equipment obviously is the higher cost. • A great deal of used equipment is available with the advent of newer technology. Older, used, outdated equipment is being replaced with new equipment based on new technology. The price of old equipment is very attractive, sometimes as low as $1000. Although initial cost is low, some significant expense may be required, including service, maintenance, transducers, and accessories. If the appropriate frequency transducers do not come with the unit (often only 2- and 3-MHz transducers come with units that were used on human patients), the cost can increase 3 to 4 times to purchase 5- and 7.5-MHz transducers.
Transducers
• Transducers are available in a variety of frequencies
• •
(2–15 MHz). Low-frequency transducers provide greater depth of penetration, but because of large wavelength, resolution is poorer. High-frequency transducers provide excellent resolution, but the beam is rapidly attenuated in tissue. They are therefore used to evaluate superficial tissues. Use as high a frequency transducer as possible to maximize resolution but still allow penetration to the depth needed. For transducer uses, see Table 4-9.
• • • •
There are various methods of preserving the image for inclusion in the animal’s medical record: • Polaroid camera—Heat-sensitive, thermal-paper recorder • Multiformat camera—Can record multiple images on x-ray film • Videotape—Images are recorded, allowing evaluation by others at a later time • Digital images or digital video
Ultrasound Technique • Patient preparation
This may include a guided biopsy attachment for the transducer, calipers, a screen-labeling device, and an Mmode/B-mode split screen. Portability of the machine must also be considered.
Ultrasonographic Accessories
•
• Positioners • V-trough is easily constructed from wood or Plexiglas. Table 4-9. TRANSDUCER SELECTION Transducer Type 7.5 MHz 5.0 MHz 3.5 MHz
Use Eye, feline heart and abdomen, small canine abdomen (<25 lb), testicles Medium-size canine (<55 lb) heart and abdomen Very large-breed canine heart and abdomen
• Surgical table can be formed into a V-trough. • Cardiac table (wood or Plexiglas) with holes so that the transducers may be brought up under the recumbent patient. Lateral recumbency causes the heart to lie against the chest wall, providing an ultrasonographic window to the heart. Standoff pad to place between the transducer and the skin for imaging superficial tissues. Coupling gel is necessary to transmit sound from the transducer through the skin. Numerous brands are commercially available. Water-soluble, hypoallergenic gel is available.
Image Storing
•
Ancillary Equipment
79
•
• Tranquilization is usually not required, but the patient must always be adequately restrained. • The most common problem in obtaining goodquality images is poor transducer skin contact. Clip the hair over the area to be imaged with a #40 blade. Hair tends to trap air, acting as a barrier to the ultrasound. Clean the exposed skin to remove dirt, oil, and debris before applying the coupling gel to help achieve the best image. Patient positioning • Most abdominal imaging is done from the ventral surface. Alternate scanning planes from lateral and lateral intercostal can be chosen to avoid gas. When gas is a problem, gentle abdominal pressure from the transducer usually displaces it. • The heart is imaged through the intercostal spaces, usually while the animal is in lateral recumbency. Ultrasound image • It is a two-dimensional representation of a threedimensional object. • Ultrasound reflects the anatomy tomographically (cross-sectionally). • Ultrasound permits identification of internal organ architecture. Image viewing • Abdomen (Figs. 4-24 and 4-25) • Cardiac • Longitudinal scan: Cardiac base to the right • Transverse scan: Pulmonary valve (outflow tract) on the right of the screen
W0422-Ch004.qxd 11/10/05 4:43 PM Page 80
80
Section 1 / Patient Management
• Ultrasonographic windows: Soft-tissue organs adjacent
•
to the body wall used to help avoid gas or bone and to facilitate deeper imaging. Examples include imaging through the spleen on the left lateral abdominal wall to identify the left kidney and imaging through the urinary bladder to identify the area where sublumbar lymph nodes are found. Acoustic enhancement (through transmission): Sound passes through an anechoic structure with little attenuation and emerges with more intensity than expected in surrounding echogenic areas. This occurrence is expected deep to fluid-filled structures (e.g., gallbladder and hepatic cyst).
Organ Echogenicity Figure 4-24.
Viewing a longitudinal (sagittal) ultrasound image.
• Rank of abdominal parenchymal organs from least to most echogenic: • Renal medulla • Renal cortex • Liver • Spleen • Prostate • Renal sinus
Ultrasound Use See respective chapters for ultrasound use in specific diseases. See Table 4-10 for an overview of ultrasound in various organs.
Interventional Ultrasound
• Uses
Figure 4-25.
Viewing a transverse (axial) ultrasound image.
Principles of Interpretation Ultrasound Terminology
• Anechoic: Area void of echoes (seen as black). • Hypoechoic: Lower level of echogenicity (darker) than
•
adjacent structures.
• Hyperechoic: Higher level of echogenicity (brighter) than adjacent structures.
• Isoechoic: Level of echogenicity similar to adjacent structures.
• Complexly echogenic: Area of multiple echogenicities. • Ultrasonographic barriers: Highly reflective or absorptive interfaces within the body that cause an almost complete attenuation of the sound beam. Examples include bone, mineral, and air. This barrier results in an absence of echoes deep to the interface (acoustic shadow).
•
• Ultrasound-guided needle biopsy for histopathology and culture • Ultrasound-guided fine needle aspiration (FNA) for cytology and culture • Cystocentesis to obtain urine (small bladder, difficult animals) • Gallbladder aspiration for culture and cholangiography • Abscess diagnosis and drainage • Cyst diagnosis and drainage • Renal pyelocentesis Equipment • Real-time B-mode scanner • Transducer biopsy guide (or can be done freehand) • Needles, syringe, slides, culture medium, formalin containers • Sterile glove or transducer cover • Sterile ultrasound gel or alcohol • Sedatives, lidocaine Patient preparation • Complete an abdominal ultrasound examination. • Choose the site for FNA biopsy. • FNA: Rarely need sedation; sterile preparation of skin and transducer sterile glove cover.
W0422-Ch004.qxd 11/10/05 4:43 PM Page 81
Chapter 4 / Radiographic and Ultrasonographic Techniques
Table 4-10. ULTRASOUND USES Location Heart
Pleural space Thorax (extracardiac) Peritoneal cavity
Liver
Kidney
Urinary bladder Adrenal gland Gastrointestinal
Pancreas Reproductive tract
Prostate Eye
Pathology
Usefulness
Wall thickness Wall motion Valve morphology Valve motion Mass lesion Pericardial disease Pleural effusion Pleural mass Pulmonary mass* Diaphragmatic hernia Mediastinal disease Carcinomatosis Lymphadenopathy Diffuse disease Neoplasia Abscess Biliary disease Portacaval shunt Nodular hyperplasia Diffuse disease† Hydronephrosis Pyelonephritis Parenchymal disease‡ Calculi Perirenal disease Neoplasia Calculi Cystitis Neoplasia Hyperplasia Neoplasia Enteritis Obstruction Intussusception Foreign body Neoplasia Pancreatitis Pseudocyst Ovary Testicular neoplasia Peritesticular lesion Pregnancy Pyometra Prostatitis Paraprostatic cyst Neoplasia Detached retina
+++ +++ +++ +++ +++ +++ +++ +++ +++ ++ ++ + +++ +/++ ++/+++ ++/+++ ++/+++ +/++ +/++ +/++ +++ +/++ +/++ ++/+++ +++ +++ +++ +/++ +++ +/++ +++ + ++/+++ +++ ++/+++ ++/+++ +/++ ++ + +++ +++ +++ +++ ++ +++ ++ +++
*If mass contacts thoracic wall. † Lipidosis, steroid hepatopathy, suppurative hepatitis (dependent on severity of disease). ‡ Glomerulonephritis, amyloidosis, ethylene glycol toxicity, renal dysplasia (dependent on severity of disease). +++, good; ++, fair; +, poor.
• Tissue biopsy: Sedation and/or local anesthesia; general anesthesia is sometimes necessary. Surgical preparation of skin and transducer.
•
•
81
• Sterile glove cover. • Determine packed cell volume (PCV); total plasma protein, activated clotting time, and platelet count. • Check prothrombin time and partial thromboplastin time. • Monitor patient closely for signs of internal hemorrhage for 3 to 4 hours following biopsy. Methods • Guided: Transducer has an attachable biopsy guide. Ultrasound machine has biopsy capabilities (software). Biopsy guide maintains needle in the scanning plane so that the entire procedure can be seen. • Directed: Image the organ or lesion of interest. Determine the location, entrance angle, and depth. Obtain biopsy or aspirate blindly without ultrasound observation. More dependent on sonographer’s experience. Biopsy guide and biopsycapable machine are not necessary. • Freehand: Localize biopsy site with transducer perpendicular to the skin. Place the needle with the other hand into the scanning plane to the desired depth. Biopsy procedure can be observed in real time and depends more on sonographer’s experience. Biopsy guide and biopsy-capable machine are not necessary. Complications: Very low incidence with all procedures • Peritonitis • Hemorrhage • Tumor spread to local tissues
SUPPLEMENTAL READING Barber DL, Lewis RE: Guidelines for Radiology Service in Veterinary Medicine. Schaumberg, IL: American Veterinary Medical Association, 1982. Hathcock JT, Stickle RL: Principles and concepts of computed tomography. Vet Clin North Amer 23(2):399–415, 1993. Kleine LJ, Warren RG: Mosby’s Fundamentals of Animal Health Technology: Small Animal Radiology. St. Louis: CV Mosby, 1983. Morgan JP, Silverman S: Techniques of Veterinary Radiography, 3rd ed. Davis, Calif: Veterinary Radiology Associates, 1984. National Council on Radiation Protection and Measurements: Radiation Protection in Veterinary Medicine: Recommendations of the National Council on Radiation Protection and Measurements (NCRP Report No. 36). NCRP Publications, PO Box 30175, Washington, DC 20014. Shores A: Magnetic resonance imaging. Vet Clin North Amer 23(2):437–459, 1993. Stickle RL, Hathcock JT: Interpretation of computed tomographic images. Vet Clin North Amer 23(2):417–435, 1993. Thomson CE, Kornegay JN, Bern RA, et al: Magnetic resonance imaging: A general overview of principles and examples in veterinary neurodiagnosis. Vet Rad & Ultrasound 34(1):2–17, 1993. Ticer JW: Radiographic Technique in Veterinary Practice, 2nd ed. Philadelphia: WB Saunders, 1984.
Chapter
▼
W0422-Ch005.qxd 11/10/05 4:44 PM Page 82
5
Fluid Therapy for Dogs and Cats Shane W. Bateman / Dennis J. Chew
Fluid therapy can be the single most important therapeutic measure used in seriously ill animals. Effective administration of fluids requires an understanding of fluid and electrolyte dynamics in both healthy and sick animals. An overview of a general approach to fluid therapy decision making can be found in Figure 5-1.
DECISION-MAKING CHECKLIST Answer these questions to decide when fluid therapy is needed:
• Does the patient have a form of shock that requires fluid resuscitation?
• Does a serious deficit (or excess) of fluid or water exist?
• Is there an anticipated loss of substantial fluid volume?
• Are there serious electrolyte disturbances (excesses or deficits)?
• Is there a serious disturbance in the acid-base balance?
• Is there a serious disturbance in oncotic pressure or excessive protein loss?
• Is there an immediate need for full nutritional support with calories and protein?
• Does the patient have an anemia that may be affecting oxygen delivery?
• Does the patient have a coagulopathy? Answer these questions in order to provide appropriate fluid therapy:
• • • • • • •
What type(s) of fluids will be given? What volume of fluids will be given? How fast will fluids be given? Through what route will fluids be given? What, if any, supplements will be added to commercially available fluids? If more than one fluid type is being given, can they be administered together? If medications are to be administered with fluids, are they compatible?
▼ Key Point If no laboratory testing is immediately available, start correction of dehydration with isotonic-balanced electrolyte solutions. 82
Figure 5-1. General decision tree for fluid therapy. (From Finco DR: A scheme for fluid therapy in the dog and cat. J Am Anim Hosp Assoc 8:178–180, 1972.)
INDICATIONS FOR FLUID THERAPY • Most commonly for resuscitation from shock syn•
dromes and the correction of dehydration, hypokalemia, and metabolic acidosis Less commonly for specific correction of other electrolyte disturbances (sodium, potassium, chloride, calcium, or magnesium), acid-base disturbances (metabolic alkalosis or mixed acid-base disorders), and disorders of oncotic pressure
W0422-Ch005.qxd 11/10/05 4:44 PM Page 83
Chapter 5 / Fluid Therapy for Dogs and Cats
• For parenteral nutrition (see Chapter 3) • For treatment of anemia and coagulopathies (see Chapters 22 and 23)
83
Electrolytes • Sodium and chloride exist in high concentration in ECF and low concentration in ICF.
• Potassium, magnesium, and phosphorus exist in high concentration in ICF and low concentration in ECF.
DISTRIBUTION OF BODY WATER AND ELECTROLYTES Water • Total body water (TBW) represents 50% to 70% of
• •
•
body weight in adults. Usually 60% is arbitrarily chosen as an average figure, although cats possess slightly less water. Young animals and especially neonates possess more water (70%). Two-thirds of TBW is within cells, so intracellular water (ICF) represents on average about 40% of body weight. One-third of TBW is outside of cells, so extracellular water (ECF) represents on average about 20% of body weight. The ECF comprises both the interstitial fluid and the fluid in the intravascular space. The distribution of ECF between the interstitial and the intravascular spaces is about 75% to 25%, respectively. Thus the interstitial fluid comprises about 12% to 14% of the body weight, and the intravascular fluid comprises about 6% to 8% of body weight.
Figure 5-2. Maintenance fluid and electrolyte requirements for caged normal dogs and cats. (Finco after Harrison JB: J Am Anim Hosp Assoc 8:179, 1972.)
MAINTENANCE REQUIREMENTS Maintenance is defined as the volume of fluid (ml) and the amount of electrolyte (mEq or mg) that must be taken in on a daily basis to keep the volume of TBW and the electrolyte content normal. Obligatory losses of water and electrolytes occur daily as a consequence of normal metabolism. Water taken into the body in all of its forms is equal to the loss of water in the normal animal. See Figure 5-2 for specific maintenance requirements of electrolytes and water in caged dogs and cats that have normal food intake.
• Water can be taken in by drinking, combined • •
mechanically with food, or derived from metabolism of food or tissue breakdown. Water is lost from the body through evaporation during breathing, from feces, and from urine. Obligatory loss of electrolytes occurs in fecal water and in urine, but the overall loss of electrolytes is proportionally less than the loss of water.
W0422-Ch005.qxd 11/10/05 4:44 PM Page 84
84
Section 1 / Patient Management
Table 5-1. DAILY FLUID REQUIREMENTS FOR HOSPITALIZED NON-ANORECTIC DOGS* Body Weight (kg) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
Total Daily Fluids (ml/day)
Total Daily Fluid per Body Weight (ml/kg/day)
Hourly Rate of Total Daily Fluid (ml/hr)
132 214 285 348 407 463 515 566 615 662 707 752 795 837 879 919 959 998 1037 1075 1256 1427 1590 1746 1896 2041 2182 2319 2453 2583 2710 2836 2960 3080 3200 3316
132 107 95 87 81 77 74 71 68 66 64 63 61 60 59 57 56 55 55 54 50 48 45 44 42 41 40 39 38 37 36 35 35 34 34 33
6 9 12 15 17 19 21 24 26 28 29 31 33 35 37 38 40 42 43 45 52 59 66 73 79 85 91 97 102 108 113 118 123 128 133 138
Table 5-2. DAILY FLUID REQUIREMENTS FOR HOSPITALIZED NON-ANORECTIC CATS* Body Weight (kg) 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0
•
•
excrete excess amounts of potassium, resulting in urine that typically has a much lower concentration of sodium and a higher concentration of potassium compared to plasma. The volume of fluid required daily varies with the size of the animal. Large patients (with low mass-to-body surface area ratios) require less fluid per kilogram on an individual basis than small animals (with high mass-to-body surface area ratios), as shown in Table 5-1 for dogs and Table 5-2 for cats. Maintenance volume is comprised of two subcomponents: • Insensible losses (not readily measured losses from respiratory evaporation and the passage of normal feces) are estimated at 20 ml/kg/day in normal animals but can increase during
Total Daily Fluid per Body Weight (ml/kg/day)
Hourly Rate of Total Daily Fluid (ml/hr)
80 108 135 159 182 205 226 247 268 287 307 326 344 363 380 398 416 433 450
80 72 67 64 61 58 57 55 53 52 51 50 49 48 48 47 46 46 45
3 5 6 7 8 9 9 10 11 12 13 14 14 15 16 17 17 18 19
*Based on 80 ¥ BW (kg)0.75.
•
•
*Based on 104–132 ¥ BW (kg)0.75.
• In most situations, the kidneys conserve sodium and
Total Daily Fluids (ml/day)
•
febrile states, panting, and high environmental temperatures. • Sensible losses (readily measured as urine production) are estimated to be 20 to 40 ml/kg/day in normal animals that are consuming food. Urine output can dramatically decrease during: • Acute intrinsic renal failure—Oliguria or anuria • Urinary obstruction—Anuria • Severe dehydration—Oliguria Urine output can dramatically increase during: • Polyuric renal failure • Post-obstructive diuresis Consider maintenance fluid therapy for hospitalized patients who are not eating and drinking on their own but are not dehydrated. Maintenance fluids should be low in sodium, chloride, and osmolality and high in potassium compared to normal plasma.
▼ Key Point Lactated Ringer’s and 0.9% sodium chloride solutions are not ideal maintenance solutions because they contain too much sodium and chloride, are too high in osmolality, and do not contain enough potassium.
▼ Key Point A 0.45% sodium chloride solution (in water or in 2.5% dextrose) is more suitable as a maintenance solution due to its sodium and chloride content and its osmolality. It does not contain adequate potassium; therefore, potassium must be added.
W0422-Ch005.qxd 11/10/05 4:44 PM Page 85
Chapter 5 / Fluid Therapy for Dogs and Cats
DEHYDRATION (REPLACEMENT NEEDS) Dehydration exists when TBW decreases to less than normal.
•
• Technically, dehydration refers to loss of pure water, • • •
but clinical fluid loss is usually accompanied by some loss of electrolytes. Acute fluid and electrolyte loss in any disease process is initially lost from intravascular fluid. Compensatory shifts of water and electrolytes from intracellular and interstitial compartments subsequently occur. The magnitude of these shifts depends on the tonicity and hydrostatic pressure of the remaining extracellular fluid. Consequently, dehydration can occur to different degrees in the various compartments.
Causes of Dehydration Decreased Water Intake (Hypodipsia, Adipsia)
• Lack of food intake also decreases available water • •
(water from oxidation and that physically present within the food). Appetite and thirst centers may be depressed in systemically ill animals. Accidental or deliberate deprivation of adequate water and food decrease available water.
Increased Water Loss
• • • • •
Urinary (polyuria): Common Gastrointestinal (vomiting, diarrhea): Common Respiratory (fever, panting) Skin (burns, large wounds) Excessive salivation
•
85
ence of dehydration. It occurs because of loss of water and electrolytes in proportion to that found in normal serum (isotonic loss). Hypertonic dehydration is the next most common type. It is defined by finding an elevated serum sodium concentration (158 mEq/L or greater) in the presence of dehydration. It occurs as a consequence of predominantly water loss or water lost in excess of solute found in normal serum (hypotonic loss). Hypotonic dehydration is the least common type. It is defined by finding a low serum sodium concentration (143 mEq/L or less) in the presence of dehydration. It theoretically occurs as solute is lost in excess of the concentration found in normal serum (hypertonic loss), but this is probably not the most significant mechanism. More likely, it is the loss of isotonic fluid and concurrent intake and absorption of hypotonic fluids (such as drinking of water) with the net dilutional effect on the remaining extracellular sodium concentration below normal.
Detection of Dehydration Clinical tools to detect dehydration are limited in both sensitivity and specificity. There is no single test or procedure to accurately assess the magnitude of dehydration. Integration of historical findings, abnormalities on physical examination, and laboratory measurements will be necessary to quantify dehydration. Dehydration is not detectable by clinical means until approximately 5% of body weight in water has been lost. An acute loss of greater than 12% body weight in water is considered life threatening (Table 5-3).
History History often leads the clinician to suspect dehydration and to assess its magnitude more accurately. Question
▼ Key Point Fluid losses from the urinary and gastrointestinal tracts are the most frequent causes of dehydration.
Characterization of Dehydration (Type) Disease processes can display a spectrum of fluid and electrolyte loss combinations, from mostly water loss (hypotonic loss) to water loss with significant quantities of accompanying electrolytes (isotonic or hypertonic). Evaluation of the tonicity and sodium concentration of the extracellular fluid in a dehydrated patient will give clues to the nature of the fluid that was lost and helps determine the type of fluid that will be given as replacement during treatment. The type of dehydration is defined based on the serum sodium concentration at the time of dehydration.
• Isotonic dehydration is the type that occurs most commonly. It is defined by finding a normal serum sodium concentration (145–157 mEq/L) in the pres-
Table 5-3. PERCENTAGES OF DETECTABLE DEHYDRATION Dehydration <5% 5% 6–8% 8–10% 10–12%
>12%
Signs Not detectable on physical exam; history is suggestive of losses; acute body weight changes Subtle loss of skin elasticity Mild delay of skin tent, slight prolongation of CRT, dry mucous membranes Obvious delay of skin tent, slight prolongation of CRT, dry mucous membranes, eyes slightly sunken in orbits Severe prolongation of skin tent, eyes sunken in orbits, dry mucous membranes, signs of shock likely present (prolonged CRT, tachycardia, weak pulses etc.) Moribund
*CRT, capillary refill time.
W0422-Ch005.qxd 11/10/05 4:44 PM Page 86
86
Section 1 / Patient Management
the owner about volume of intake (adipsia, hypodipsia, polydipsia, or normal intake of water). Because volume of water intake may, in part, be a function stimulated by food intake, note also the presence or absence of anorexia. Abnormal losses of body fluid may be determined from owner responses to questions about vomiting, diarrhea, polyuria, panting, excessive salivation, or other bodily discharge. The duration of these historical signs and the magnitude of losses affect the magnitude of clinically detectable dehydration.
Physical Examination Physical examination provides general guidelines for detecting dehydration but is subjective (see Table 5-3). Signs of listlessness and depression may occur from dehydration but may be partially attributable to the underlying disease or to concomitant electrolyte and acid-base abnormalities. As dehydration becomes more severe, decreased skin turgor, sunken eyes, dryness of mucous membranes, tachycardia, diminished capillary refill, and signs of shock may occur. An accurate and recent body weight, when available, can be used for comparison to evaluate change in body weight as an indicator of body water change.
Skin Turgor Artifacts Many artifacts confuse interpretation of skin turgor.
• Skin turgor of obese animals may appear normal •
• • •
despite dehydration, owing to the large amounts of subcutaneous fat. The skin of an emaciated animal with normal hydration may fail to return to its normal position owing to a lack of subcutaneous fat and elastic tissue. Consequently, underestimating dehydration in obese animals and overestimating dehydration in emaciated animals can occur. Avoid testing cervical skin because redundant skin in the neck area confuses the result. Skin turgor changes in longhaired animals are more difficult to detect than those in shorthaired animals. Differences in turgor assessment can occur in the same animal in the standing versus recumbent positions.
▼ Key Point Dehydration may be as much as 5% of body weight loss in lean dogs and 10% or more in obese dogs before loss of skin turgor is detected.
Other Physical Examination Artifacts ▼ Key Point An acute increase or decrease in an animal’s body weight often reflects acute gain or loss of body water. This is the most sensitive clinical tool for assessment of dehydration and rehydration. An acute loss or gain of 1 kg is the equivalent of losing or gaining 1 L of fluid.
• Dry mucous membranes may occur in animals that pant continually and in those given anticholinergics.
• Sunken eyes may be seen with catabolic diseases that decrease the soft tissue behind the globe or with atrophy of the muscles of mastication. ▼ Key Point Assessment of fluid, electrolyte, and acid-
Skin Turgor Skin turgor assessment during physical examination is important for estimating the percentage of body weight loss due to dehydration. Skin turgor is evaluated by determining the time required for skin gently lifted from the body to return to its original position (referred to as the skin pinch or skin tent). Normal skin pliability (skin turgor) depends on hydration of the tissues in the area tested. Skin turgor is largely determined by hydration status of the interstitial tissues, although both vascular and intracellular hydration also contribute. Elastin and adipose within skin and subcutaneous tissues will also influence the apparent skin turgor. Choose skin from the trunk as a test area. Avoid dependent areas and skin from the neck. Normal skin returns immediately to its initial position when lifted a short distance and released. Dehydrated skin shows varying degrees of slow return to the original position. As dehydration progresses, the time required for the return of the skin pinch to its initial position becomes greater. The clinician assigns increasing percentages of dehydration to abnormal skin turgor of increasing severity (see Table 5-3).
base status will frequently be in error if only the history and physical examination are available for interpretation. The more seriously ill an animal is, the more important evaluation of laboratory data becomes.
Laboratory Assessment of Dehydration Packed Cell Volume and Total Plasma Protein Simple laboratory testing is helpful in evaluation of intravascular hydration. Packed cell volume (PCV) recorded in percentages (SI unit: L/L) and total plasma protein (TPP) recorded in gm/dl (SI unit: g/L) can be rapidly and inexpensively determined using microhematocrit tubes and a refractometer. These two tests require only a few drops of blood and can be taken by capillary action from a 25-gauge venipuncture. TPP concentration may be more helpful in the detection of dehydration than PCV. Increased TPP and PCV provide documentation for intravascular dehydration. Simultaneous evaluation of PCV and TPP is recommended in order to minimize interpretation errors due to preexisting anemia or hypoproteinemia. (Table 5-4) Additional value is obtained when PCV and TPP are followed
W0422-Ch005.qxd 11/10/05 4:44 PM Page 87
Chapter 5 / Fluid Therapy for Dogs and Cats
Table 5-4. INTERPRETATION OF CHANGES IN PACKED CELL VOLUME (PCV) AND TOTAL PLASMA PROTEIN (TP) PCV
Total Protein
≠ ≠
≠ N or Ø
N
≠
Ø
≠
Ø N
N N
Ø
Ø
Possible Interpretation Dehydration Splenic contraction Erythrocytosis Hypoproteinemia with dehydration Hyperproteinemia Anemia with dehydration Hypertonic dehydration (RBC shrinkage) Anemia with dehydration Anemia with pre-existing hyperproteinemia Non-blood-loss anemia, normal hydration Normal hydration Dehydration, after secondary compartment shift Dehydration with pre-existing anemia + hypoproteinemia Acute hemorrhage Blood loss anemia Overhydration
serially as increasing values identify progressive dehydration.
Urinalysis Urinalysis (UA) is important in all cases of suspected dehydration. An elevated specific gravity (SG) represents the healthy kidneys’ response to decreased perfusion. The finding of dilute urine (<1.030 SG) from a dehydrated animal immediately incriminates the kidneys as a major cause of, or contributor to, the dehydration.
Serum Biochemistry Evaluation of serum electrolytes may help characterize the nature of the fluid that was lost.
Blood Gases Abnormalities in blood-gas values may appear in dehydrated animals owing to net loss or gain of acid or buffer. The most common acid-base disturbance in dehydrated patients is metabolic acidosis that typically develops because of a decrease in urine production and an impaired ability of the kidneys to excrete the daily acid burden. In addition, moderate to severe forms of dehydration are accompanied by decreased perfusion to major tissue beds, resulting in a switch to anaerobic metabolism and the production of lactic acid. ▼ Key Point Animals may be severely dehydrated yet exhibit little or no change in their serum biochemical test results. Likewise, their PCV or TPP can be normal in the face of dehydration.
87
Anticipation of Dehydration with Specific Diseases Dehydration should be anticipated in sick animals with certain disease syndromes known to predispose a patient to dehydration regardless of physical exam or laboratory findings. For example, a collapsed diabetic is very likely to be dehydrated, as is an animal with advanced chronic renal failure or a patient with upper intestinal obstruction.
Correction (Replacement) of Dehydration The volume of fluid to be replaced is calculated as follows based on the assessed percentage of dehydration and the patient’s present body weight:
• % dehydration ¥ weight (kg) = L of fluid to be replaced.
• % dehydration ¥ weight (lbs) ¥ 500 = ml of fluid to be replaced.
• Alternatively, if a known recent body weight is avail•
able for comparison, replace 1 L of fluid for every kilogram (500 ml/lb) of acute body weight loss. The type of fluid that is chosen to accomplish this rehydration is based primarily on the patient’s ability to tolerate a sodium challenge, the serum electrolyte (sodium, chloride, and potassium) concentrations, and the presence of any acid-base disturbances.
▼ Key Point Initial replacement with adequate fluid volume is usually more important than correcting minor electrolyte or acid-base disorders.
• Administer to the patient both the volume and the type of fluid that has been lost or continues to be lost from the body. Base the volume calculation on volumetric measurement of the losses or, more practically, from estimates. Base the type of the fluid on actual measurements from the patient or, more commonly, on the predicted biologic composition of fluid losses associated with a specific disease. ▼ Key Point Choose a fluid type or add supplements to stock fluids so that electrolytes deficient in the plasma or body are administered and those that are excessive in the plasma are avoided.
Contemporary (Ongoing) Losses Although initiation of fluid therapy is aimed at replacing fluid lost from the patient, persistence of uncontrolled signs or untreated diseases will permit the dehydrating process to continue. Consider replacement of contemporary or ongoing losses that begin after fluid therapy has begun. Estimate gastrointestinal fluid loss (e.g., from vomiting or diarrhea). When ongoing loss is from the urinary tract, temporary urethral catheter collection may increase the accuracy of estimating the magnitude of the loss. Less invasive but feasible methods of estimation include collecting urine in a container (free
W0422-Ch005.qxd 11/10/05 4:44 PM Page 88
88
Section 1 / Patient Management
catch from dogs or litter box from cats) and measuring the volume or weight change of the container.
Table 5-5. ALTERNATIVE METHOD TO CALCULATE MAINTENANCE + DEHYDRATION NEEDS*†
Volume To Be Administered The initial volume of fluids to be administered over the first 24 hours can be calculated (Figure 5-3). The multiples of maintenance volumes method is less accurate but is acceptable for routine use in uncomplicated cases of simple dehydration (Table 5-5).
FLUID THERAPY FOR SHOCK See Chapter 156 for a discussion of shock treatment.
TYPES OF FLUIDS AND THEIR SELECTION Crystalloid Solutions Crystalloid fluids contain no large macromolecules, allowing them to redistribute quickly from the vascular
Maintenance +% Dehydration M M M M M M
+ + + + + +
5% 6% 7% 8% 9% 10%
Multiplication Factor
ml/kg/day
ml/lb/day
1.80 2.00 2.17 2.33 2.50 2.70
110 120 130 140 150 160
55 60 65 70 75 80
*Maintenance (M) is defined in this table as 60 ml/kg/day or 30 ml/ lb/day. † Contemporary fluid losses are not considered in these calculations.
space to the interstitial and intracellular fluid spaces. Thus they exert their greatest effect in rehydration or replacement of prior fluid loss. Expansion of the vascular fluid space initially occurs, but with time, redistribution minimizes this effect.
Method 1 _________ml
=
Deficit
= estimated % dehydration ¥ weight (kg), or = estimated % dehydration ¥ weight (lb) ¥ 500
=
Maintenance
= use Table 5-1 (dogs), or Table 5-2 (cats) = 40–60 ml/kg/day depending on patient size
+ _________ml
_________ml
Total 24-Hour Needs
∏ 24 _________ml/hr
Hourly Needs
+ _________ml/hr
Hourly Contemporary Losses = accrued volume of loss observed over time ∏ hours in observation interval
_________ml/hr
Hourly Fluid Rate (administered for same number of hours as observation interval above and then recalculated)
Method 2 _________ml
=
Deficit
= estimated % dehydration ¥ weight (kg), or = estimated % dehydration ¥ weight (lb) ¥ 500
=
Insensible
= 20 ml/kg/day (10 ml/lb/day)
+ _________ml _________ml
Total 24-Hour Needs
∏ 24 _________ml/hr
Hourly Needs
+ _________ml/hr
Hourly Sensible Losses (measured)
_________ml/hr
Hourly Fluid Rate (administered until sensible losses are measured again)
Figure 5-3. needs.
Two methods of calculating fluid
W0422-Ch005.qxd 11/10/05 4:44 PM Page 89
Chapter 5 / Fluid Therapy for Dogs and Cats
89
Table 5-6. COMPOSITION OF COMMON COMMERCIAL FLUID TYPES Sodium (Na)
Potassium (K)
Chloride (Cl)
Calcium (Ca)
Magnesium (Mg)
Osmoles (OSM)
Bicarbonate Precursors
D5W (5% Dextrose in Water) 0.45% NaCl 0.45% NaCl + 2.5% Dextrose 0.9% NaCl LRS P-148, Norm-R
0 77 77 154 130 140
0 0 0 0 4 5
0 77 77 154 109 98
0 0 0 0 3 0
0 0 0 0 0 3
278 154 290 308 278 308
3% NaCl 5% NaCl
513 856
0 0
513 856
0 0
0 0
1026 1712
0 0 0 0 23 lactate 23 acetate/ 23 gluconate 0 0
Fluid
Osmolality Crystalloid fluids can be classified according to osmolality by comparison to the animal’s normal serum osmolality of approximately 300 mOsm/kg. Table 5-6 lists the composition of a variety of commercially available crystalloid fluids. Osmolality of commercial fluids is largely determined by sodium and glucose concentrations. Fluids with osmolality of less than 300 mOsm/ kg are hypotonic (e.g., 0.45% saline in water), those with osmolality of greater than 300 mOsm/kg are hypertonic (e.g., 5.0% dextrose added to 0.9% sodium chloride), while those with osmolality near 300 mOsm/ kg are isotonic (e.g., lactated Ringer’s solution, Plasma-Lyte 148, and Normosol-R). Physiologic saline (0.9% sodium chloride) at 308 mOsm/kg is also within the isotonic range. Lactated Ringer’s solution is often referred to as an isotonic solution in some species, but at 272 mOsm/kg it is mildly hypotonic for small animals.
Replacement Fluids Crystalloid fluids can also be classified by their intended function for maintenance or replacement. Replacement fluids must be formulated for specific electrolyte or alkali deficits. Additives such as potassium chloride, magnesium, calcium, or sodium bicarbonate will often be added to commercially available solutions, but this will vary greatly with the disease process and the patient’s laboratory measurements. Replacement fluids are usually ideally suited to replenish fluid losses and resulting dehydration.
Maintenance Fluids Maintenance fluids are polyelectrolyte solutions that differ greatly from serum as they are lower in sodium, contain additional potassium, and contain glucose. Although at administration they are isotonic, after the glucose is metabolized their effect is hypotonic. This class of fluids is intended for use in patients who have been rehydrated and are simply being maintained on IV fluids during hospitalization.
The amount of energy derived from dextrose in these fluids is insufficient to meet patient needs. Use parenteral nutrition solutions if nutritional support is necessary. The importance of introducing enteral nutrition in ill patients early in the course of hospitalization (when appropriate) also minimizes the need to switch to maintenance-type solutions after rehydration of the patient has been accomplished. Maintenance fluid and electrolyte needs can often be met with nutritional support rather than through maintenance crystalloid administration. Patients with an intact renin-angiotensin-aldosterone axis should be able to excrete the higher sodium load present in replacement crystalloids if these fluids are utilized for a short-term basis after rehydration is accomplished. Maintenance crystalloid solutions with their lower sodium content are ideally suited for the treatment of patients with congestive heart failure or advanced liver or kidney disease, who cannot tolerate the sodium load present in replacement solutions, or of patients with true water losses and hypernatremia.
Colloid Solutions Colloid solutions differ from crystalloids because they contain large macromolecules (natural or synthetic). These molecules, because of their size, do not readily pass through the normal endothelium, thus giving them oncotic pressure effects. This allows them to affect water movement from the interstitial fluid space. In addition, the large net negative charge carried by these molecules attracts sodium and thus water from the interstitial spaces, which contributes to their volume expanding effect. Depending on the clinical situation, colloid molecules exert most of their effect in the intravascular space, making them ideal for volume expansion of the intravascular space but less suitable for replacement of extravascular fluid losses.
Natural Colloids Natural colloids are produced by the body, harvested from volunteer donors, and stored for later use. In small
W0422-Ch005.qxd 11/10/05 4:44 PM Page 90
90
Section 1 / Patient Management
Table 5-7. CHARACTERISTICS OF COLLOID SOLUTIONS Fluid 5% Albumin 25% Albumin 6% Dextran-70 6% Hetastarch 10% Pentastarch Oxypolygelatin Oxyglobin
Molecular Weight (MW) (KDa)
Range (KDa)
Solvent
Colloid Osmotic Pressure (COP)
Molar Subst’n
69 69 70 480 260–280 30–35 200
— — 10–80 10–3400 10–1000 5.6–100 65–500
— — 0.9% NaCl or D5W 0.9% NaCl 0.9% NaCl Electrolyte Solution Modified LRS
20 100 40 30 40 45–47 42
— — 0.5 0.7 0.4–0.5
animal medicine, this group of fluids includes the blood transfusion components that possess albumin and other plasma proteins (whole blood and plasma). Indications for use of blood component therapy are covered elsewhere (see Chapter 22).
higher size ranges and molar substitution ratios are more difficult to metabolize; thus these solutions tend to have a longer biological effect.
• Synthetic colloids should rarely be utilized by them-
Concentrated Human Albumin In human medicine, 5% and 25% concentrated albumin products are also manufactured. Unconcentrated natural colloids do not expand the vascular space except by the volume administered. Concentrated natural colloids will expand the vascular space by up to 5 times (25% albumin) their volume owing to their impressive oncotic pressure. Concentrated human albumin products have been used with success in small animals, but their use carries risk of adverse reaction. Most commonly, concentrated human albumin solutions are used when severe decreases (<12 mmHg) in colloid osmotic pressure (COP) are measured or the patient’s albumin concentration is severely decreased (<1.5 g/L or <15 g/dl).
•
Synthetic Colloids The commercially available synthetic colloids, which are currently finding more frequent use in small animal medicine, are all complex polysaccharide molecules. The reported average molecular weight, COP, and molar substitution ratio of these molecules are listed in Table 5-7. The complex behavior and pharmacokinetics of these molecules do not allow accurate prediction of actual biological behavior. As a result, the dose and duration of administration of these solutions vary with individual preference and the patient characteristics and requirements. In addition, availability of these products in some countries depends on national health and safety licensing. In general, the smaller the average molecular weight, the more potent the effect on intravascular expansion. This is due generally to the higher COP of these solutions. Breakdown of synthetic molecules depends on their size (molecular size range) and the complexity of branching (molar substitution ratio). Molecules with
—
selves but are useful adjuncts to standard crystalloid fluid therapy in several well-defined situations. Patients with hypoproteinemia and lowered oncotic pressure are likely to benefit from continuous infusions of hydroxyethyl starch (hetastarch or pentastarch) at doses of 20 ml/kg every 24 hours (cats—10–15 ml/kg every 24 hours) or more if needed. The measurement of COP is a useful monitoring tool to determine infusion rate and end point. In addition, synthetic colloid solutions may play a valuable role in shock resuscitation (see the previous section). Patients with diffuse vascular injury to the pulmonary vasculature and who are at risk for non-cardiogenic pulmonary edema formation may be very sensitive to sudden elevations in intravascular volume. Thus if increased oncotic pressure is desirable, continuous infusion rather than bolus administration of colloids is recommended.
▼ Key Point Use synthetic colloids with caution, and at very reduced doses, in patients with congestive heart failure and those with renal origin oliguria or anuria as rapid volume expansion could be detrimental.
• Of the three synthetic colloids mentioned in Table
•
5-7, dextran 70 has the most potential to interfere with hemostasis. While clotting times become elevated with use of the hydroxyethyl starches, clinically apparent hemostatic abnormalities are typically not encountered if the recommended dosages are utilized. Dextran 70 also carries a small risk of anaphylactic reaction, whereas reactions to administration of hydroxyethyl starches have not been reported. Consequently, and also as a result of the decreasing cost differential between dextrans and hydroxyethyl starch, dextrans are being used infrequently.
W0422-Ch005.qxd 11/10/05 4:44 PM Page 91
Chapter 5 / Fluid Therapy for Dogs and Cats
Fluids To Be Kept on Hand
Table 5-8. MODIFIED SLIDING SCALE OF SCOTT
▼ Key Point Clinical correction of most fluid problems can be accomplished by maintaining only a few stock solutions, usually lactated Ringer’s solution, Plasma-Lyte 148, or Normosol-R; 0.9% sodium chloride; and 5% dextrose in water.
• It is convenient, although not essential, to have 2.5%
•
•
•
•
dextrose with or without 0.45% sodium chloride available for use in patients who cannot tolerate high sodium loads. Mixing equal portions of 0.9% sodium chloride with 5% dextrose in water provides the same solution. An alkalinizing basic electrolyte solution (lactated Ringer’s solution, Plasma-Lyte 148, Normosol-R) is most often chosen as a “physiologic” solution that is similar in composition to normal animal plasma with the exception of protein. It is usually the fluid of choice in the absence of laboratory data until more information about electrolyte, osmolality, and acidbase status is available from the laboratory. A 0.9% sodium chloride solution is chosen when “extra” sodium or chloride is needed to maintain volume expansion or for the correction of metabolic alkalosis. Low-sodium fluids (0.45% saline in 2.5% dextrose, Plasma-Lyte 56, Normosol-M, or 5% dextrose in water) are chosen when treating sodiumintolerant patients or patients with a water deficit (hypernatremia). It is useful to have one synthetic colloid solution available. Synthetic colloids should be administered in conjunction with crystalloids when there is lowered oncotic pressure or when rapid (and low volume) intravascular expansion is desired.
Serum K+ (mEq/L) <2.0 2.1–2.5 2.6–3.0 3.1–3.5 >3.5 < 5.0
Potassium Supplementation Potassium supplementation is usually provided as potassium chloride, although potassium phosphate is used in special situations. It is most common to use commercially available sterile vials with 2 mEq/ml of potassium for addition to fluids. Potassium supplementation to fluids is indicated if the serum potassium concentration is less than 3.5 mEq/L.
• The modified Sliding Scale of Scott (Table 5-8) recommends adding potassium chloride to maintenance
mEq KCl Added to 250 ml
mEq KCl Added to 1000 ml
Maximal Infusion Rate (0.5 mEq/kg/hr)
20 15 10 7 5
80 60 40 28 20
6 ml/kg/hr 8 ml/kg/hr 12 ml/kg/hr 18 ml/kg/hr 25 ml/kg/hr
K+, potassium; KCl, potassium chloride; mEq/L, milliequivalents per liter.
•
•
SUPPLEMENTATION OF PARENTERAL FLUIDS After sodium, potassium considerations are most important. Hypokalemia is commonly encountered in hospitalized animals, particularly with prolonged anorexia and while receiving potassium-deficient fluids. Other supplements can include alkali, magnesium, dextrose, phosphate, calcium, and vitamins.
91
•
fluid volumes proportional to the degree of hypokalemia; the lower the potassium concentration, the greater the amount of potassium added to the fluids. An exact number of milliequivalents for supplementation is not calculated using this method. Potassium supplementation using this scale can be started during correction of dehydration if fluids will be distributed evenly throughout the day. Alternatively, a fixed concentration of potassium from 20 to 30 mEq/L can be given in maintenance fluids and is particularly helpful when frequent monitoring of serum potassium is not possible. This concentration corresponds to the lower end of the Scott scale. Potassium up to 35 mEq/L can be given in subcutaneous fluids without irritation to local tissues. Potassium supplementation may still be indicated when its concentration is from 3.5 to 4.5 mEq/L and especially if ventricular arrhythmias are present. This can prevent the development of hypokalemia during fluid treatment and also can help replenish total body potassium deficits that are not yet reflected by the serum potassium concentration. High normal levels of potassium (>4.5 mEq/L) are helpful when managing arrhythmias because they reduce membrane hyperpolarization caused by low serum potassium levels. Maintenance needs for potassium in healthy dogs and cats is shown in Table 5-8 in mEq/day, but enhanced losses through the urine during fluid administration can be expected.
▼ Key Point Add approximately 20 to 30 mEq/L of potassium for maintenance fluids when serum potassium concentration is from 3.5 to 4.5 mEq/L.
• Caution should be used whenever potassiumenriched fluids are infused. The rate of potassium infusion is usually more important than the total number of milliequivalents. Do not exceed a rate of 0.5 mEq/kg/hr to lessen the risk for development of hyperkalemia or cardiotoxicity. Infusion of greater than 0.5 mEq/kg/hr should only occur in crisis situ-
W0422-Ch005.qxd 11/10/05 4:44 PM Page 92
92
•
•
•
•
Section 1 / Patient Management
ations and continue for no longer than 3 to 4 hours before the serum potassium is rechecked. Animals with alkalosis and translocation of potassium may not require vigorous potassium supplementation if the alkalosis can be corrected rapidly. Potassium can rapidly return from the cells to the ECF. Animals with severe emaciation have reduced lean body mass available for potassium uptake and should be less vigorously supplemented with potassium in their fluids. Reduced renal function and azotemia can lead to potassium retention and hyperkalemia during infusion of potassium-supplemented fluids, particularly if oliguria is present. Less vigorous potassium supplementation and careful monitoring is indicated in this situation. Potassium chloride supplementation increases the osmolality of fluids, particularly when high concentrations are provided. For example, potassium supplementation at 40 mEq/L increases the osmolality of the fluid by 80 mOsm/kg, 40 Osm each from potassium and chloride. If the infused potassium enters cells or is excreted, this lessens the effects of the osmolality.
•
▼ Key Point Patients with inadequate respiratory compensation for a metabolic acidosis or a mixed acidosis are at risk for worsened acidosis by administration of bicarbonate. Focus on fluid resuscitation, if they are in shock, or investigate the cause of respiratory dysfunction. Re-evaluate acidbase status using blood gas analysis prior to administration of bicarbonate.
▼ Key Point Do not add sodium bicarbonate to fluids that contain calcium (lactated Ringer’s solution), as calcium precipitates may occur.
• Calculate alkali replacement from either the bicarbonate value reported on a blood gas analysis or the total CO2 value on a serum biochemical profile. Total CO2 (mEq/L) can be substituted for bicarbonate in these calculations since the difference is usually only 1 to 2 mEq/L.
▼ Key Point Although potassium supplementation is often beneficial, excessive supplementation can result in death of the patient due to hyperkalemia. Do not use potassium supplementation at higher concentrations unless serum potassium concentration can be measured on an urgent basis. Electrocardiographic monitoring may be needed during supplementation of fluids with potassium in animals that are at risk for development of hyperkalemia.
Methods for Calculating Bicarbonate Dose
• Assume that normal HCO is 24 mEq/L. • Subtract measured patient HCO from 24, which is 3
3
equal to the HCO3 deficit in mEq/L.
Method A
• HCO deficit ¥ 0.6 ¥ body weight (kg) = “missing” 3
• Alkali Supplementation Addition of alkali to fluids is sometimes needed for partial correction of metabolic acidosis. It is not usually necessary or desirable to entirely correct metabolic acidosis to normal by supplementation alone.
• Add sodium bicarbonate to fluids when alkali replacement is needed quickly.
• Do not rely on bicarbonate precursors (lactate, glu• •
•
conate, or acetate) in commercially available solutions to correct severe metabolic acidosis. Bicarbonate precursors require metabolic conversion to bicarbonate before they can contribute to correction of acidosis. Supplementation of bicarbonate is most safely accomplished when blood gas analysis is present to determine the contribution of the respiratory system to the acid-base disturbance. Bicarbonate buffers acid by combining with a proton to form carbonic acid, which is subsequently broken down by carbonic anhydrase into water
and carbon dioxide (HCO3- + H+ Æ H2CO3 ∫ H2O + CO2). Patients that do not have adequate ability to exhale CO2 formed in this reaction are at risk for worsened acidosis by administration of bicarbonate.
mEq bicarbonate from TBW at the time of sampling Administer total calculated replacement mEq over 8 to 12 hours or longer; it may take as long as 18 hours for administered bicarbonate to equilibrate inside cells.
Method B
• HCO deficit ¥ 0.3 ¥ body weight (kg) = “missing” 3
•
mEq bicarbonate from ECF at the time of sampling Use this formula when multiple injections of bicarbonate are anticipated, ongoing production of acid or loss of alkali is anticipated, and access to multiple HCO3 measurements is possible. Without access to blood gas analysis or total CO2, it is difficult to know with any certainty the magnitude of need.
Empirical Method If the clinical diagnosis and suspicion for metabolic acidosis is high, bicarbonate may be administered empirically.
• Estimate of mild acidosis: Give 3 mEq/kg bicarbonate over 24 hours
W0422-Ch005.qxd 11/10/05 4:44 PM Page 93
Chapter 5 / Fluid Therapy for Dogs and Cats
• Estimate of moderate acidosis: Give 6 mEq/kg bicar• •
bonate over 24 hours Estimate of severe acidosis: Give 9 mEq/kg bicarbonate over 24 hours In crisis situations requiring bicarbonate, administer 0.5 to 1.0 mEq/kg of sodium bicarbonate over 5 to 10 minutes and reevaluate. Electrocardiographic monitoring is recommended during the injection if it is available.
• •
Precautions for Bicarbonate
• Remember that along with bicarbonate, sodium is
•
administered, which can result in hypernatremia, hyperosmolality, hypertension, overhydration, and volume overload if the administered sodium is not excreted. Overtreatment with alkali can result in alkalosis, paradoxical cerebrospinal fluid acidosis, shifts of ionized calcium, a shift of the oxyhemoglobin dissociation curve (decreasing oxygen unloading), and seizures.
• As magnesium is primarily an intracellular ion, serum measurements are often not reflective of total body stores. It is generally thought that low total serum magnesium is reflective of low total body magnesium status, but this is often a late finding. Ion-specific electrodes are more sensitive for detecting hypomagnesemia but are not in common use. ▼ Key Point In patients with documented hypokalemia, and especially hypokalemia that seems to be resistant to supplementation efforts, magnesium supplementation is indicated. In addition, patients with diabetic ketoacidosis, congestive heart failure, and ventricular arrhythmias (and concurrent hypokalemia) are likely to benefit from magnesium supplementation.
• Magnesium sulfate and magnesium chloride are the commonly available sources of magnesium. Magnesium sulfate is preferred to prevent excessive chloride administration. The dosage of magnesium sulfate supplementation is 2.5 to 5 mg/kg/hour and can
be added to most commercially available fluid types. A loading dose of 30 mg/kg of magnesium sulfate can also be administered over 20 minutes to 1 hour prior to beginning the lower rate of hourly supplementation. Magnesium supplementation can be extremely helpful in achieving and maintaining high normal levels of potassium when treating cardiac arrhythmias. Do not use magnesium supplementation in oliguric patients as this is the primary route of excretion of excessive amounts.
Dextrose Supplementation If supplementation with dextrose is necessary, use varying amounts of 50% dextrose to achieve the desired concentration or the percentage of dextrose in the final solution.
• To increase the dextrose concentration by 2.5%,
Magnesium Supplementation Magnesium has recently emerged as an important but seldom considered ion. It is a metabolic cofactor in hundreds of metabolic functions, most importantly as a cofactor in the sodium-potassium pump (NaK-ATPase). Deficiencies in magnesium can thus lead to potassium loss from the body. Hypokalemia and hypomagnesemia are often found concurrently in many ill or dehydrated patients. Magnesium is lost alongside other cations when urinary and gastrointestinal losses result in dehydration. Inadequate intake in anorexic patients will exacerbate hypomagnesemia.
93
•
add 25 g of dextrose or 50 ml of 50% dextrose to 1000 ml of stock solution (e.g., lactated Ringers solution). Long-term supplementation of dextrose through a peripheral vein should not exceed concentrations over 5%, as the hypertonicity can induce significant phlebitis. Indications include hypoglycemia due to sepsis, insulin overdosing, insulinoma, and liver disease. Dextrose supplementation at greater than 10% to 15% is necessary to provide sufficient calories for anorectic animals.
Vitamin Supplementation The benefits of supplemental vitamins during parenteral fluid therapy in cats or dogs are plausible but not proven. Water-soluble vitamins can be conservatively added to parenteral fluids without known harm and may replenish rapidly depleted stores.
• Dogs or cats in polyuric renal failure may benefit •
from additional water-soluble vitamins in parenteral fluids because of urinary losses of these vitamins. Thiamine deficiency can be of clinical concern in cats and can develop during anorexia while on fluids, as the storage period of thiamine is short. • Initial signs of thiamine deficiency include anorexia, vomiting, and ataxia that can progress to dilated pupils and tonic ventriflexion of the neck, which may be confused with seizures. True seizures can also occur. Death usually occurs within 24 hours of onset of convulsions if the deficiency is not treated. • It is common practice to add 0.5 to 1.0 ml of watersoluble multi-vitamins to each liter of fluids to provide needed vitamins and to prevent thiamin deficiency. • B-complex vitamins are light sensitive, so the IV fluid bag should be covered to prevent degeneration. Fluids with B-complex vitamins added should
W0422-Ch005.qxd 11/10/05 4:44 PM Page 94
94
Section 1 / Patient Management
also be replaced every 24 to 48 hours to maximize the potential benefits of vitamin supplementation.
Calcium Supplementation • Calcium gluconate and calcium chloride can be sup-
•
plemented in replacement and maintenance fluids for the correction of symptomatic hypocalcemia. Many small animals with low serum albumin will have low total serum calcium concentrations. Most of these will not require calcium supplementation as the ionized calcium is not usually as depressed as the total calcium. When ionized calcium is substantially decreased, supplementation with calcium salts may be required. The percentage of calcium contained varies widely by the specific calcium salt. There is no difference in effectiveness of IV calcium salts to correct hypocalcemia when the dose is based on elemental calcium content. Calcium gluconate is often chosen as the calcium salt of choice because it is non-irritating if the solution is injected outside of a vessel. In contrast, calcium chloride is extremely irritating to tissues but provides more elemental calcium in each milliliter of solution.
Acute Infusion for Hypocalcemic Tetany
• Tetany or seizures due to hypocalcemia require treat-
•
ment with IV calcium salts. Calcium is administered to effect at 5 to 15 mg/kg of elemental calcium (0.5– 1.5 ml/kg of 10% calcium gluconate) over a 10- to 20-minute period. Monitor heart rate and electrocardiogram during acute infusion of calcium salts. Bradycardia may signal the onset of cardiotoxicity from an excessively rapid infusion rate of calcium.
• •
Subcutaneous Injection Never give calcium salts subcutaneously as severe skin necrosis and calcification have been observed in some patients, even when the calcium salts have been diluted prior to subcutaneous administration.
Phosphorus Supplementation Hypophosphatemia is present when the serum concentration is less than 0.8 mmol/L (2.5 mg/dl). Mild hypophosphatemia (0.65–0.80 mmol/L or 2.0– 2.5 mg/dl) is common and often transient. Hypophosphatemia often resolves quickly during therapy directed at the underlying cause. Severe hypophosphatemia (<0.48 mmol/L or <1.5 mg/dl) is uncommon but can be life threatening, particularly when less than 0.32 mmol/L (1.0 mg/dl). Use supplementation with phosphate salts when the serum phosphorus concentration is very low (<0.48 mmol/L or <1.5 mg/dl). ▼ Key Point Clinically significant hypophosphatemia that requires phosphate replacement therapy is most likely to be encountered in patients with diabetic ketoacidosis 12 to 48 hours after initiation of insulin therapy or in patients in whom enteral nutrition is initiated after prolonged periods of anorexia.
▼ Key Point Treat severe symptoms of ionized hypocalcemia (tetany and seizures) by administering 0.5 to 1.5 ml/kg of 10% calcium gluconate intravenously over 10 to 20 minutes while observing a continuous electrocardiogram.
at a maintenance volume of 60 ml/kg/day (2.5 ml/ kg/hour). Approximately 1, 2, or 3 mg/kg/hour of elemental calcium are provided by adding 10, 20, or 30 ml of 10% calcium gluconate, respectively, to each 250-ml bag of fluids. Do not add calcium salts to fluid therapy preparations that contain lactate, acetate, bicarbonate, or phosphates, since calcium salt precipitates can occur. Alkalinizing fluid therapy containing sodium bicarbonate decreases ionized calcium and may expose clinical signs of hypocalcemia in patients with borderline hypocalcemia; consequently, it should not be used.
Continuous Intravenous Infusion
When necessary, sodium phosphate or potassium phosphate can be supplemented to replacement and maintenance fluids for the correction of symptomatic or severe hypophosphatemia.
• Continuous IV infusion of calcium is recommended
• Do not add phosphate salts to fluids that contain
•
from 60 to 90 mg/kg/day of elemental calcium (2.5– 3.75 mg/kg/hour) until oral medications provide control of serum calcium. Give initial doses in the higher range to patients with more severe hypocalcemia and decrease the dose according to calcium level achieved. Reduce the dose of IV calcium as oral calcium salts and vitamin D metabolites become more effective. Ten milliliters of 10% calcium gluconate provides 93 mg of elemental calcium. A convenient method to infuse calcium is available when IV fluids are given
calcium.
• Treat only if hypophosphatemia is severe and a concurrent likely cause is present.
• The dosage for phosphate supplementation is 0.01 to 0.03 mmol/kg/hour, intravenously, for 3 to 6 hours.
• Severe cases may require prolonged supplementation •
or higher dosages of phosphate (0.06–0.12 mmol/ kg/hour intravenously). Continue supplementation only until the serum phosphorus concentration is greater than 0.65 mmol/L (2.0 mg/dl).
W0422-Ch005.qxd 11/10/05 4:44 PM Page 95
Chapter 5 / Fluid Therapy for Dogs and Cats
• Avoid oversupplementation that can cause hyperphosphatemia, hypocalcemia, tetany or seizures, soft-tissue mineralization, hyperkalemia (if using potassium phosphate), and hypernatremia (if using sodium phosphate).
GENERAL GUIDELINES FOR FLUID SELECTION Serum Sodium Level as a Guide Normal Sodium If the serum sodium concentration is normal, the animal has isotonic dehydration and needs replacement fluids that are nearly normal in serum sodium concentration and osmolality. Lactated Ringer’s solution, Plasma-Lyte 148, Normosol-R, or 0.9% sodium chloride would be appropriate selections.
Hypernatremia If the serum sodium concentration is elevated, the animal has hypertonic dehydration and needs more water than salt for replacement (hypotonic fluid). Choose fluids that are effectively hypotonic (5% dextrose in water, 0.45% NaCl in 2.5% dextrose). Dextrose solutions in 2.5% to 5% concentration are considered effectively hypotonic because of rapid dextrose metabolism removing its contribution to osmolality. The magnitude of the elevation in serum sodium and the patient’s clinical status will determine whether dextrose in water or dextrose in some concentration of saline should be administered. Lowering of severe hyperosmolality and hypernatremia excessively rapidly can be detrimental, particularly to the brain. A general guideline is to allow sodium concentration to fall no faster than 0.5 mEq/L/hour or no more than 12 mEq/L in 24 hours. Pure water without some electrolyte or glucose to add osmolality is not given as this can cause severe problems with hemolysis and rapidly decreased serum osmolality.
Hyponatremia If the serum sodium concentration is low, the animal has hypotonic dehydration and needs additional sodium relative to water. Hypertonic fluid infusion is theoretically indicated, but clinically is not chosen unless the hyponatremia and hyposmolality are very severe and the patient is symptomatic. Isotonic fluids are usually chosen for replacement since the kidneys should excrete unnecessary water and reclaim needed sodium.
Other Laboratory Abnormalities Further selection of fluid type requires laboratory measurement of albumin, total protein, potassium, chloride, magnesium, calcium, phosphorus, and blood
95
gases. When serum concentration of an electrolyte is elevated, choose a fluid for infusion that is devoid or low in that electrolyte concentration. When serum concentration of an electrolyte is low, choose a fluid for infusion that contains high concentration of that electrolyte or provide supplementation of that electrolyte to the fluid. In some instances, supplemental electrolyte can be given to prevent deficits (as previously mentioned for potassium). Evaluate final osmolality of fluids for infusion following supplementation of base solutions to ensure that they are appropriate, as supplementation of base solutions often results in unappreciated hyperosmolality. Selection of fluid type can be confusing when clinical problems dictate that disparate fluid types should be chosen; for example, use an acidifying solution (0.9% sodium chloride) in a patient that is severely acidemic, because high sodium content of this fluid is desirable. Thus in these situations, identify the most severe problem and choose the initial fluid to address this issue. Subsequently, as resolution of the most urgent problem is accomplished, correct secondary abnormalities. Fluid therapy is often dynamic, and changes of fluid type and additives are frequently needed over the course of therapy.
Preservatives ▼ Key Point Never use fluids containing preservatives of any kind for administration to cats, puppies, or small dogs because of the likelihood of severe toxic reactions.
• Benzoic acid derivatives are commonly used in fluids
•
for their antibacterial and antifungal effects. Cats are extremely susceptible to toxic effects from these compounds even at low doses. Benzyl alcohol at 0.9% is commonly added to multiple dose vials of sodium chloride for injection. Clinical signs of toxicity are mostly neurological, and early signs include changes in behavior, apprehension, aggression, hyperexcitability (light and sound), salivation, marked ataxia, fasciculations of the muscles of the head and ears, widely dilated nonresponsive pupils, convulsions, coma, and death.
ROUTES OF ADMINISTRATION FOR PARENTERAL FLUIDS The route of fluid therapy depends on the nature of the clinical disorder, its severity, its onset (acute versus chronic), the nature and magnitude of ongoing losses, and the composition of fluids to be given. The availability of personnel and equipment required for monitoring during IV therapy also influences decisions about the appropriate route of administration.
W0422-Ch005.qxd 11/10/05 4:44 PM Page 96
96
Section 1 / Patient Management
other irritating drugs because of greater dilutional effects from greater blood flow, and the ease of obtaining serial blood samples from the IV line (use care to avoid clotting within the line). • The prime disadvantage of peripheral veins is that limb position often changes the rate of fluid infusion owing to partial or complete occlusion of the indwelling catheter when gravity flow is used. When fluid pumps are used, this effect is minimized.
Subcutaneous Route • Subcutaneous administration of fluids is common in •
dogs and cats; choose isotonic or mildly hypotonic fluids to enhance absorption. Subcutaneous infusions may be given under gravitational forces through IV administration tubing or by direct injection from a large-volume hypodermic syringe.
▼ Key Point Do not give 5% dextrose in water as an isotonic solution subcutaneously in cases of severe dehydration. Delayed absorption, with consequent equilibration of ECF electrolytes into the pocket of pooled, unabsorbed subcutaneous fluid, may occur.
Catheter Selection
• In cats and small dogs use 20- to 22-gauge catheters; in medium and large dogs use 14- to 20-gauge catheters. Use short, larger-bore catheters, or catheterize two veins in emergency situations requiring rapid fluid administration. Clinician preference determines the type of catheter used.
• Absorption of subcutaneous fluid is unreliable in con-
•
•
ditions characterized by peripheral vasoconstriction (e.g., shock, severe dehydration, or hypothermia). Never rely on this route for the emergency replacement of fluid in critically ill or severely dehydrated patients. This route may correct minimal dehydration or prevent dehydration in the anorexic animal. The volume of fluid that can be administered subcutaneously is limited by the patient’s skin elasticity. Animals differ in their abilities to tolerate the infused volume comfortably. Choose the site of the subcutaneous infusions somewhere on the trunk so that the fluid does not gravitate into the limbs. Avoid areas with surgical wounds because fluid may drain from the incision or dissect through the healing tissues.
Intravenous Route Give hypotonic, isotonic, and hypertonic fluids by the IV route as the need arises. Large volumes of fluid are more readily administered to a patient using the IV route. Rapid administration of fluid should always be administered intravenously. ▼ Key Point Use IV fluid administration whenever accurate delivery of fluid volume and potent pharmacotherapeutic agents are required.
Vein Selection
• The jugular vein and cephalic vein are most com• •
monly chosen for indwelling IV catheterization. The lateral saphenous and femoral veins also may be used. Use the jugular vein in cats and small dogs to prevent occlusion of fluid flow when the animal’s limb is bent. Use the jugular vein in serious diseases regardless of patient size. It is also easier to maintain aseptically if the patient has diarrhea. • Advantages of using the jugular vein include the ability to measure central venous pressure (CVP), the ability to administer hypertonic solutions and
Intravenous Catheter Care
• Always perform aseptic catheter placement using
• •
wide clipping of hair over the vein and a standard surgical scrub. After securing the catheter in the vein, place a gauze sponge with an antimicrobial cream over the puncture site. Catheter complications include thrombophlebitis, thromboembolism, bacteremia, bacterial endocarditis, and catheter-fragment foreign body. To minimize problems: • Place the catheter aseptically and keep the catheter site clean. • Check the catheter site once to twice daily. If no redness, swelling, pain, or patient discomfort when injecting are present, the catheter may be left in place. Routine catheter changes at 72 hours are no longer recommended. • Monitor the patient for fever, leukocytosis, and heart murmurs. • Ensure that all injections made into the IV catheter or lines are done aseptically. • Ensure that the IV line remains a closed and aseptic system. Do not disconnect the IV line unless absolutely necessary, and ensure aseptic technique is followed when changing IV fluid bags. • When the catheter is not in use, flush regularly to prevent clotting.
Intraperitoneal Route • Severely anemic puppies and kittens may be transfused by this route (see Chapter 22 for details of blood transfusion). • This route may be considered for rewarming very hypothermic animals. • Use isotonic to mildly hypotonic fluids for rehydration (an IV route is preferred when possible).
W0422-Ch005.qxd 11/10/05 4:44 PM Page 97
Chapter 5 / Fluid Therapy for Dogs and Cats
Intraosseous Route • Provides rapid access to circulation when venous catheterization is not successful or possible.
• Consider using in puppies and kittens and in emergency situations where immediate IV access is difficult.
• Blood and crystalloid solutions can be infused safely. • Catheterize the bone marrow of the femur, tibia, or
•
humerus with a bone marrow or spinal needle and secure it in place (see Chapter 3 for technique).
RATE OF FLUID INFUSION The rate of fluid administration depends on the extent and rapidity of the fluid loss, as well as on the composition of the fluid to be infused. Rapid or extensive fluid losses demand rapid replacement. In chronic disorders, it is not always necessary to replace the dehydration deficit rapidly. Patients displaying symptoms of shock require a fluid resuscitation phase prior to correction of any dehydration that is present. For simple dehydration with no signs of shock, there are many acceptable methods to rehydrate the patient. Some clinicians prefer to calculate the dehydration deficit, add it to the daily maintenance requirements, and distribute this fluid load over 24 hours. Others prefer to replace part of the dehydration deficit over the first few hours (referred to as “front-end loading”). Deficit replacement of 75% to 80% on the first day and the remaining 25% deficit on the second day is recommended by some clinicians.
ence will most likely be lost in the urine. In this situation, increased urine production is a misleading indicator of hydration status of the patient, so other physical examination and laboratory parameters as well as serial monitoring of the patient’s weight must be considered. If fluid infusion can be observed for only part of the day, give the 24-hour needs over the number of hours that personnel can watch the drip, then flush the catheter with heparinized saline to maintain patency until infusion resumes. If severe dehydration has been corrected, give additional fluids subcutaneously until the IV drip can be restarted the next day.
Drip Rate • The rate of infusion for the total 24-hour volume of
•
• •
• Measure urine output during rapid fluid infusion as a guide to organ perfusion. With persistent oliguria, be careful about maximal fluid infusion and monitor CVP response to fluid challenge to avoid overhydration.
24-Hour Infusion Rate • In less critical conditions, distribute fluids evenly
•
throughout the day. Physiologically, this may be advantageous because it allows more time for adequate equilibration of water and electrolytes between the body compartments. Ideally, a constant or continuous infusion of IV fluids over a 24-hour period would accomplish this. This ideal situation may not be possible if very small volumes of fluid are being infused or if 24-hour monitoring of the IV lines is unavailable. Front-end loading of fluids to correct dehydration can be given over a 4- to 8-hour period when an animal’s clinical condition dictates more rapid correction of dehydration. Maintenance and contemporary losses can then be infused evenly over the remaining hours of the day. If the intrinsic ability of the patient’s tissues to absorb fluid is less than the volume of the fluid being administered, the differ-
•
•
97
•
fluid should be specified as to the required number of milliliters per hour and the number of drops per minute to ensure accurate delivery of prescribed fluids. IV administration sets are available in standard “macrodrip” volumes of 10, 15, or 20 drops/ml. Pediatric administration sets also are available in the “microdrip” volume of 60 drops/ml. Patient size and volume of fluid to be infused determine the choice between the microdrip and the macrodrip systems. The microdrip administration set is most suitable for cats and small dogs because it allows easier quantitation of small volumes of fluid for infusion. For small dogs and cats, consider the use of a Buretrol (Baxter Healthcare) or a similar device to accurately premeasure the volume of fluid to be administered. Fluids from the reservoir bag are then periodically used to reload the Buretrol device. The use of such a device minimizes the chances of overhydration because it allows controlled and accurate delivery of small volumes. Commercially available devices (Control-A-Flow; Baxter Healthcare) can also be used to limit gravitational flow to relatively accurate flow rates. Once the drip set has been adjusted to the desired rate, mark the IV bottle or bag with adhesive tape to monitor the hourly volume of fluids received. Disruptions of flow can be detected in this way to ensure that the desired volume of fluid is being administered over the desired timeframe. The rate of IV fluid infusion is important when considering fluids that have been supplemented with any additive or medication. Accuracy is enhanced by using infusion pumps or syringe pumps (see below).
“Ins and Outs” • In hydrated animals with either severe oliguria or polyuria, measurement of urine output may be helpful for accurately matching the needs of the animal to the fluid therapy (“ins and outs”). Without
W0422-Ch005.qxd 11/10/05 4:44 PM Page 98
98
Section 1 / Patient Management
this technique, there is a tendency to overestimate the actual fluid needs in an oliguric animal (resulting in overhydration) and to underestimate the fluid needs in an animal undergoing extensive diuresis (resulting in failure to correct dehydration). • Choose an observation interval (every 1–8 hours) and begin quantifying urine production. At the end of the first interval, a new fluid rate is calculated that will include the insensible losses for the upcoming interval (22 ml/kg divided by the observation interval) and the measured sensible (urine) losses from the previous observation interval. For example, a 10-kg dog will be placed on ins and outs every 6 hours. In the previous 6-hour period, 120 ml of urine was produced. The fluid amount to be given over the next 6 hours will be 120 cc plus insensible loss ({10 ¥ 22 = 37/6} ml) to equal 157 ml of fluid. • This type of close attention to fluid volume administration is of benefit in the initial management of critically ill animals, particularly when CVP and renal status are uncertain. • Remember that with this technique the volume of fluid administered (ins) will exceed the volume of fluid (urine) that is measured (outs) by the daily insensible needs. If the patient is rehydrated, your calculations are accurate, and no other source of fluid loss exists, then the patient’s weight should remain static.
Infusion Pumps Infusion pumps provide an extremely accurate means of administering IV fluids.
• Enter ml/hr or drops/min depending on the type of • •
machine. Most are equipped with an alarm system that indicates if fluid flow is interrupted. New pumps are expensive (refurbished, used machines may be surprisingly affordable).
• These pumps are especially useful for small dogs, cats, and animals receiving fluids supplemented with potassium or other agents.
Syringe Pumps Syringe pumps provide an extremely accurate method of administering small volumes of medication or fluid into a patient’s IV drip or directly into the IV catheter.
• Sophisticated machines exist that allow complex dosages (such as mg/kg/min) to be easily programmed.
• Drug administration errors because of mathematical
• •
error can thus be eliminated, and rapid changes to new dosing rates are easily and accurately accomplished. Most machines allow extremely accurate dosing of very small volumes (0.1–0.01 ml). Refurbished machines are becoming more widely available, making them cost effective for many practices.
MONITORING EFFICACY OF FLUID THERAPY Perform a physical examination several times daily during the initial fluid management to document rehydration, prevent overhydration, and detect contemporary fluid loss. The indicators of successful fluid therapy are normalization of skin turgor, moistening of mucous membranes, strengthening of pulses, increased perfusion (decreased refill time), and increased alertness. Table 5-9 provides guidelines to assess the success of fluid therapy, and Table 5-10 lists possible reasons dehydration has not been adequately corrected.
Body Weight • Increased body weight should occur during successful rehydration. An acute gain or loss of 1 kg suggests an increase or decrease of 1000 ml of body water (1 lb = 500 ml).
Table 5-9. DATA BASES TO EVALUATE EFFICACY OF FLUID THERAPY
Body Weight PCV/TPP Urine Specific Gravity Electrolytes (Na, K, Cl) Bicarbonate (Total CO2) Electrocardiogram Blood Gas (ven ± art) Lactate Central Venous Pressure (CVP) Ionized Calcium (Ca)/Magnesium (Mg) Na, Sodium; K, potassium; Cl, Chloride.
Minimum (Mildly Ill/Dehydrated)
Extended (Severe Dehydration/Collapse)
Advanced (Shock/Oliguria/ Heart Failure)
✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
W0422-Ch005.qxd 11/10/05 4:44 PM Page 99
Chapter 5 / Fluid Therapy for Dogs and Cats
to detect the possible consequences of volume expansion and changes in the underlying disease process.
Table 5-10. REASONS FOR FAILURE TO CORRECT DEHYDRATION ADEQUATELY 1. 2. 3. 4.
Calculation and mathematical error Error in assessment of initial degree of dehydration Larger contemporary losses than expected Too-rapid infusion resulting in diuresis and loss of fluid from body 5. Mechanical catheter problems, calculated volume not infused 6. Increased sensible loss not appreciated (fever, panting) 7. Increased sensible loss not appreciated (polyuria)
99
▼ Key Point Successful fluid therapy ultimately depends on the clinician’s ability to detect and correct the underlying cause for the loss of fluid and loss or retention of electrolytes. Identifying and stopping ongoing fluid losses is particularly important.
OVERHYDRATION • An anorexic animal, however, loses 0.1 to 0.3 kg of its body weight per day per 1000 calories of daily caloric requirement owing to tissue catabolism. Measure and record body weight accurately at least once daily.
Packed Cell Volume and Plasma Protein • Follow PCV and TPP serially during fluid therapy.
Overhydration rarely occurs as a spontaneous disorder; it usually is iatrogenic following fluid therapy. Inability to excrete free water, which can occur in a variety of renal and liver diseases and in congestive heart failure, predisposes a patient to overhydration.
Decreases in both PCV and TPP suggest successful intravascular rehydration (see Table 5-4).
Clinical Signs • Body weight increases above and beyond that ex-
Central Venous Pressure • In difficult cases (particularly those with renal or
• CVP is persistently elevated or increases suddenly. • Increased volume and/or frequency of urinations
• •
•
•
heart failure), monitor CVP to minimize chances of overloading the heart and causing pulmonary edema when administering fluids rapidly. Monitor CVP with a jugular catheter, the tip of which is in the cranial vena cava or near the right atrium. Normal CVP is 0 to 5 cm H2O. A sudden increase in CVP during fluid therapy indicates the inability of the cardiovascular system to accommodate the rate of fluid administration. Reduce the rate of administration accordingly. A persistent increase in CVP following administration of a fluid challenge indicates adequate volume expansion of the patient. Patients with mild or moderate degrees of hypovolemia will have a rapid return to baseline CVP following fluid challenge. Signs of overhydration, unfortunately, can still occur even without a change in CVP.
Electrolyte and Acid-Base Status • Closely monitor all animals receiving fluid therapy.
•
Determine serial serum electrolyte values and acidbase status in severely dehydrated animals receiving fluid therapy at least every 12 to 24 hours. Ideally, animals that had serum electrolyte deficiency or excess or severe acid-base disturbances will show improvement toward normal values after appropriate therapy. Follow electrolyte determinations and acid-base status in those cases that had initially normal values
pected to accomplish rehydration.
• • • •
may be noticed as the patient attempts to rid the body of excess water, but the volume excreted may not be sufficient to prevent overhydration. A gelatinous feel to the subcutaneous tissues may precede the development of obvious peripheral edema. Pulmonary edema, manifested as lung crackles and tachypnea, may be detected. Vomiting, diarrhea, serous discharge from the nose and eyes, and chemosis can develop. Venous overdistension may also be noted.
Laboratory and Radiographic Findings • Progressive decreases in PCV and total protein may be measured (see Table 5-4).
• Radiographs may reveal increased lung density compatible with pulmonary edema; cardiac enlargement or pulmonary venous distension may be noted if congestive heart failure is imminent.
Treatment • Immediate correction may be difficult when renal or cardiac function is impaired.
• Discontinue all IV infusions, and give furosemide
•
from 2 to 4 mg/kg IV. Give another dose of furosemide (4–8 mg/kg IV) if no diuresis is seen within 15 minutes. Morphine may be considered as a treatment to increase compliance of pulmonary vessels.
Chapter
▼
W0422-Ch006.qxd 11/10/05 4:46 PM Page 100
6
Pain Management in the Surgical Patient Richard M. Bednarski
Like anesthesia, the perioperative assessment of pain and the provision of analgesia have become an integral part of companion animal medicine. Regardless of the type of medical or surgical procedure performed, pain management must be considered a part of the perianesthetic drug plan. ▼ Key Point The keys to developing a successful perianesthetic analgesia plan include (1) understanding basic concepts of pain transmission and modulation; (2) recognizing and differentiating the signs of pain; (3) gaining a working knowledge of the pharmacology of analgesic drugs and techniques associated with their use; and (4) knowing how to integrate these drugs and techniques into a perianesthetic plan.
A multimodal approach to analgesia is generally more effective than reliance on a single drug or technique. One or multiple sites in the anatomic pain pathway are targeted. A multimodal approach involves choosing more than one drug or technique from the available categories of analgesic drugs. These are opioid analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), local anesthetics, alpha-2 agonists, and dissociative N-methyl-D-aspartate (NMDA) receptor antagonists. Several texts describe in detail the pharmacology and techniques associated with these drugs (see “Supplemental Reading”). This chapter suggests some perioperative analgesic protocols and techniques that can be used commonly in small animal practice.
DEFINITIONS • Pain: Pain is defined as an unpleasant sensory and
•
emotional experience associated with actual or potential tissue damage. The inability to communicate in no way negates the possibility that an individual is experiencing pain and is in need of appropriate pain relieving treatment. Nociceptor: Specialized sensory nerve endings that respond to the mediators of tissue damage. These mediators are mechanical, thermal, and chemical.
100
• Nociception: The sensing and ascending neural trans•
•
• •
•
mission of a noxious stimulus. Nociception that is centrally processed can be interpreted as pain. Somatic pain: Pain caused by activation of nociceptors within the skin and musculoskeletal tissue. This is usually described in people as sharp and localized when associated with superficial tissue and dull or aching when associated with deeper tissues. Visceral pain: Pain that is poorly localized and described by people as a pressure-like or squeezing sensation. It is associated with activation of nociceptors within a body cavity. Neuropathic pain: Pain related to nervous system damage. This is usually described in people as a burning sensation. Acute versus chronic pain: Acute pain is the normal response to an inciting stimulus, such as the pain resulting from surgical stimulation, trauma, or thermal injury. Perioperative analgesic plans are formulated to minimize this type of pain. Chronic pain persists longer than that associated with healing of an acute condition or that associated with a malingering condition. Perianesthetic analgesia can temporarily alleviate this type of pain. Preemptive analgesia: The concept of administering analgesic drugs to prevent central sensitization of pain pathways (see below). Often erroneously referred to as simply administering analgesics preoperatively.
PAIN PATHWAYS • Transduction: Tissue injury releases chemical mediators (prostaglandins, histamine, and cytokines) that can activate nociceptors. Continued nociceptive stimulation sensitizes the nociceptors (peripheral nociceptive sensitivity), resulting in hyperalgesia (increased response to a painful stimulus) and allodynia (pain from a normally non-painful stimulus) localized to the area of insult. ▼ Key Point NSAIDs and local anesthetics can block or modify transduction. Preventing or reducing
W0422-Ch006.qxd 11/10/05 4:46 PM Page 101
Chapter 6 / Pain Management in the Surgical Patient
nociception prior to applying the inciting stimulus can reduce pain perception. This is the concept behind preemptive analgesia.
• Transmission: Nociceptive signals are transmitted to
•
•
the spinal cord by primary afferent A-delta or C fibers. The thinly myelinated A-delta fibers conduct rapidly and are responsible for rapid reflex responses such as limb withdrawal from the inciting stimulus. The non-myelinated C fibers conduct more slowly. Cell bodies of these fibers are located in the spinal cord dorsal horn. Axons from these neurons synapse in the superficial layers of the spinal cord dorsal horn. Activated dorsal horn neurons send their impulses toward the brain via ascending spinal tracts. Interneurons located within the dorsal horn can modify the nociceptive signals via the release of endogenous opioids. Continued C-fiber dorsal horn stimulation increases sensitivity of these neurons to nociceptive stimulation (central sensitization), resulting in allodynia in anatomic areas adjoining the area of initial insult. This central sensitization is referred to as “wind-up.” Perception: Ascending nociceptive transmission results in perception or awareness of pain in some part of the body. Cortical and limbic systems of the brain are involved. This evokes the autonomic and affective behavioral aspect of pain. Modulation: Descending inhibitory signals from the brain act in the dorsal horn to modify nociceptive signals via opioids, norepinephrine, serotonin, and gaminobutyric acid (GABA).
▼ Key Point Opioid analgesics, alpha-2 agonists, GABA-mimetic drugs, and NMDA-receptor antagonists can modify nociception within the spinal cord dorsal horn.
Table 6-1. SIGNS OF PAIN Behavioral Signs Vocalization Withdrawal, avoidance, fear, and fear biting Unwillingness to move Refusal to lie down, sleep, or groom Refusal to bear weight Guarding Trembling Licking or mutilation of site Withdrawal to the back of the cage or enclosure Refusal to eat Physiologic Signs Tachycardia Tachypnea Bradypnea Mydriasis Ptyalism
•
• Pain is an individual experience and can be difficult •
•
•
to quantitate given the diversity of species, breeds, and individual temperament. Pain-related behaviors such as vocalizing, guarding, lameness, and trembling are easily recognized. However some animals, particularly cats, will not develop these “obvious” signs (Table 6-1). Furthermore, vocalization can be a manifestation of emergence from anesthesia, breed or individual temperament, or opioid induced dysphoria. As yet, no one blood chemical value specifically relates to pain. Plasma glucose, cortisol, catecholamine, and endorphin concentrations are not specific for pain. Changes in physiologic variables such as heart rate, blood pressure, and respiratory rate are nonspecific
for pain and can change in response to anesthetic recovery. In addition to recognizing the commonly perceived signs of pain, anticipating pain related to a type of procedure facilitates preemptive treatment (Table 6-2). In general, the greater the degree of tissue trauma related to a surgical procedure, the greater the pain. The degree of tissue trauma also relates to the surgeon’s experience and skill as well as the duration of the procedure.
PAIN SCORING SYSTEM • Use a pain scoring system when assessing pain. A
• PAIN ASSESSMENT
101
standardized scoring system minimizes person-toperson inconsistency in evaluation. A pain scoring system minimizes observer bias based on breed characteristics. Scoring systems range from extensive to simple and take into account combinations of physiologic, behavioral, and neurochemical responses. A simplified scoring system that relies on observation of behavior can be performed quickly (Table 6-3).
Table 6-2. PROCEDURES ASSOCIATED WITH SIGNIFICANT PAIN Amputation, particularly of proximal limb Fracture repair, particularly of proximal limb Extensive soft tissue resections* Total ear canal ablation Thoracotomy, particularly median sternotomy Onychectomy Sectioning and extraction of large teeth Extensive open abdomen procedures *Generally significant tissue mass resection and severing of major nerve trunks result in relatively greater pain response.
W0422-Ch006.qxd 11/10/05 4:46 PM Page 102
102
Section 1 / Patient Management
Opioid Agonists
Table 6-3. SIMPLIFIED PAIN SCORING SYSTEM Reaction to Gently Probing of Wound While Animal Is Awake No response Looks at wounded area, may slightly withdraw affected area Turns toward wounded area, withdrawal of affected area, some vocalization Dramatic response such as violent withdrawal, loud vocalization Comfort Asleep, calm and resting quietly Refusal to lie down or assume normal posture but willing to approach when coaxed Severe vocalizing, thrashing, extreme guarding of affected area, withdrawn and motionless, unresponsive to coaxing Physiologic Responses Normally expected postoperative changes in heart rate and respiratory rate Tachycardia, tachypnea not explainable by other physiologic causes (dehydration, stress, hypoxemia, etc.), dilated pupils Respiratory Pattern Normal Guarded, mild abdominal Marked abdominal Observation and scoring must be influenced by observation of behavior prior to induction of painful stimulus Minimum score (no pain) Maximum score (maximum pain) Any score other than zero warrants consideration of analgesic therapy, with higher scores suggesting more potent and multimodal therapy
0 1 2 3
Opioid agonists (e.g., morphine, hydromorphone, fentanyl, oxymorphone, and meperidine) are generally considered the most potent analgesics for treating acute pain. Opioids are controlled substances and are subject to state and federal regulations.
Duration of Action
• Morphine, hydromorphone, and oxymorphone pro0 1
vide 4 to 6 hours of analgesia.
• Meperidine is relatively short acting (less than 1
2
• 0 2
0 1 2
=0 =9
• Regardless of the pain score, use common sense. If a given procedure would cause you pain, then administer perioperative analgesic therapy. If you think the animal is experiencing pain, administer analgesia.
Administration
• Opioids combine well with acepromazine, alpha-2 •
•
• Bradycardia is the most common cardiovascular side
ANALGESIC DRUGS AND TECHNIQUES General Principles • Consider preemptive analgesia as a part of every anesthetic plan.
• Consider multimodal analgesic therapy with some
•
• •
combination of opioid, NSAID, local anesthetic, NMDA-receptor antagonist, and alpha-2 agonist for more painful procedures (see Table 6-2) or for animals with higher pain scores. Analgesic drugs and techniques are compatible with general anesthesia. As with anesthetic drugs, their selection should be influenced by preoperative patient status (see Chapter 2). Assess postoperative pain using a pain scoring system (see Table 6-3) and treat for pain whenever indicated. Do not rely on drugs used to induce and maintain anesthesia (propofol, thiopental, isoflurane, or sevoflurane) to provide preemptive analgesia or postoperative control of pain.
agonists, and benzodiazepines for preoperative sedation and preemptive analgesia. They are most often administered parenterally as discrete boluses or they can be administered by infusion. Preservative free morphine is useful for epidural analgesia. Cats are more sensitive to opioid-induced dysphoria; give relatively low doses.
Side Effects
• (Tables 6-4 to 6-8)
hour), so it must be re-dosed more frequently than the other opioid agonists. Fentanyl is very potent but short acting (15–20 minutes). It is most suitably administered by continuous intravenous (IV) administration or a transdermal patch.
•
effect. Respiratory depression can occur during general anesthesia but is not generally an issue in awake animals. Prolonged opioid administration (days) can result in urinary retention and the need to periodically express the bladder or insert a urinary catheter. Opioids can induce dysphoric behavior (vocalizing and pacing) that can be confused with pain behavior. Opioid-induced dysphoria can be treated using small incremental boluses of naloxone (1–2 mg/kg), an opioid antagonist.
Opioid Agonist-Antagonist (Butorphanol) and Partial Agonist (Buprenorphine) These two drugs are generally considered less potent analgesics than the opioid agonists. They are controlled substances and are subject to state and federal regulations.
Duration of Action
• Butorphanol lasts up to 2 hours in a cat but less than 1 hour in a dog.
• Buprenorphine is effective up to 8 hours. Onset of action is relatively slow (30 minutes), so it is not useful for immediate pain relief.
W0422-Ch006.qxd 11/10/05 4:46 PM Page 103
Chapter 6 / Pain Management in the Surgical Patient
103
Table 6-4. OPIOID DRUGS FOR TREATING PAIN IN DOGS AND CATS Drug
Dog Dose (mg/kg) (IV, IM, SC)
Morphine
0.2–1.0
0.1–0.2
2–4 in dogs 4–5 in cats
Hydromorphone
0.1–0.2
0.1–0.2
2–4 in dogs 4–5 in cats 2–4 <20 min 3–4 days
Oxymorphone Fentanyl Fentanyl Transdermal patch
Meperidine Butorphanol Buprenorphine Pentazocine
0.05–0.1 0.004–0.008 25 mg/kg/hr in small dogs; 50 mg/kg/hr in medium dogs; 75 mg/kg/hr in large dogs; 100 mg/kg/hr in giant breeds 2–5 0.1–0.4 0.005–0.02 2–3
Cat Dose (mg/kg) (IV IM, SC)
0.05–0.1 0.002–0.004 25 mg/kg/hr size
2–5 0.1–0.4 0.005–0.02 1–2
Duration of Action (hr)
0.5–1.0 <1 in dogs; £2 in cats 6–8 £2
Comments
Histamine release possible with large IV bolus dose; CRI*: 0.1–0.3 mg/kg/hr; Epidurally†: 0.1 mg/kg preservative free product
DEA Schedule II
II CRI*: 2–6 mg/kg/hr At least 6–12 hr (cat) and 18 hr (dog) to reach therapeutic concentrations
Do not administer IV due to histamine release
II II
II IV
Useful orally in cats bid–tid; Epidurally†: 5 mg/kg Higher doses provide £2 hr
V IV
*CRI, constant rate infusion; usually preceded by a bolus dose to rapidly achieve therapeutic plasma concentration. Use lower end of infusion rate in cats. †Duration of action after epidural use is up to 24 hours for morphine and buprenorphine.
Table 6-5. OTHER SEDATIVE AND ANESTHETIC DRUGS FOR TREATING PAIN IN DOGS AND CATS Drug
Dog Dose
Cat Dose
Duration of Action
Ketamine
CRI*: 2–10 mg/kg/min
CRI*: 2–10 mg/kg/min
Duration of infusion
Xylazine
0.1–0.2 mg/kg IV, IM
0.1–0.2 mg/kg IV, IM
<1 hr
Medetomidine
2–10 mg/kg IV, IM
10–20 mg/kg IV, IM
1–2 hr
Morphine/lidocaine/ketamine†
CRI*: 0.2/3.0/0.6 mg/ kg/hr
0.2/3.0/0.6 mg/kg/hr
Duration of infusion and several hours beyond
Comments
DEA Schedule
Subanesthetic dose, useful as analgesic adjunct when given with other analgesics Epidurally: 2 mg/kg diluted in sterile 0.9% NaCl; 1 ml/4.5 kg body weight Sedation accompanies analgesia, not recommended if cardiovascular compromise present Sedation accompanies analgesia, not recommended if cardiovascular compromise present Useful as an adjunct to inhalation anesthesia in dogs, compatible with other perioperative analgesics and anesthetics
III
—
—
Morphine: II Ketamine: III
*CRI, constant rate infusion. †To 500 ml of crystalloid, add 10 mg of morphine SO4, 150 mg of 2% lidocaine HCl, and 30 mg of ketamine HCl. Administer at 10 ml/kg/hr intra-operatively. Concentration can be adjusted (increased) to be compatible with postoperative maintenance fluid rates.
W0422-Ch006.qxd 11/10/05 4:46 PM Page 104
104
Section 1 / Patient Management
Table 6-6. NONSTEROIDAL ANTIINFLAMMATORY DRUGS FOR TREATING PAIN IN DOGS AND CATS Drug Aspirin Carprofen Deracoxib Etodolac Ketoprofen Meloxicam Naproxen Tepoxalin Firocoxib
Dog Dose (mg/kg)
Cat Dose (mg/kg)
10–22 PO bid 2 PO, SC, bid or 4 PO, SC, sid 3–4 PO sid for £7 days 10–15 mg PO sid 2 PO, SC, initially followed by 1 PO daily
10 PO q 48 hr 4 one time only Not recommended Not recommended 2 PO, SC, initially followed by 0.5–1.0 PO, SC 0.3 SC, one time only Not recommended Not recommended
0.2 PO, SC, initially followed by 0.1 daily for 2–3 days 1.2–2.2 PO q 1–2 days 10–20 PO first day followed by 10 PO sid subsequent days’ 5 PO, sid
Administration
• Buprenorphine is effective and well accepted orally in cats. It is useful for “at home” administration.
• Buprenorphine can be used epidurally (see Table 6-4).
Side Effects
• Side effects are similar to those listed for opioid agonists.
Alpha-2 Agonists (Xylazine, Medetomidine) Medetomidine and xylazine produce dose related analgesia for mild to severe pain. Analgesia is accompanied by a dose dependent sedation; it can be difficult to separate analgesia from sedation.
Not recommended
Table 6-7. LOCAL ANESTHETIC DRUGS Drug Lidocaine Bupivacaine Ropivacaine
Duration of Action (hr)
Constant Rate Infusion (mg/kg/min)*
Nerve Block or Local Infiltration (mg/kg)†
Epidural (mg/kg)
1 2–6 2–6
20–60 — —
1–2 1–2 1–2
4 1–2 1–2
*Not recommended for use in cats because of cardiovascular depression. †Includes maxillary and mandibular nerve blocks; nerve blocks for onychectomy; splash blocks; intercostal nerve blocks; and incisional line blocks.
Table 6-8. SAMPLE PAIN TREATMENT PROTOCOLS* Example Ovariohysterectomy, castration, cystotomy, exploratory laparotomy or any elective surgical procedure with minimum to moderate tissue trauma Fractures and severe soft tissue trauma†
Arthritis
Drug(s)
Comments
Parenteral opioid and or alpha-2 agonist as part of preanesthetic regimen; NSAID immediately pre- or post-surgery. For cats, oral buprenorphine continued for 1–3 days post-surgery
Any opioid listed in Table 6-4 is acceptable as long as attention is given to dosing interval. For onychectomy, also perform local nerve block of feet. Continue analgesic support for at least 24 hours post-surgery.
Parenteral opioid agonist as part of the premedication plus one or more of the following: epidural opioid for rear limb fractures, abdominal procedures, and perineal surgery; local anesthetic nerve blocks for maxillectomy, mandibulectomy, or thoracotomy; Fentanyl patch applied 12–18 hours preoperatively; CRI‡ of morphine, fentanyl, lidocaine, or ketamine; CRI of a morphine, lidocaine, and ketamine combination. NSAID
Maximum analgesia is needed. Combinations involving several categories (multimodal) are most useful. For example, preoperative opioid pre-med with an epidural opioid, CRI opioid, or opioid combination. Continue postoperative analgesia for at least 48–72 hours.
Use only if normal liver and kidney function are present. Follow manufacturer’s recommendations for pre- and post-administration patient evaluation.
*Refer to drug tables for choice of specific drugs and dosing regimens. For procedures requiring general anesthesia, these recommended drugs are given perioperatively as part of the anesthetic plan (see Chapter 2). Pain treatment protocols depend on drug availability and the availability of qualified personnel to administer controlled drugs. Depending on the pain score, additional analgesic drugs may need to be administered. †Tissue trauma of increasing magnitude requires relatively high doses and multimodal therapy using more than one category of drug. ‡CRI, constant rate infusion.
W0422-Ch006.qxd 11/10/05 4:46 PM Page 105
Chapter 6 / Pain Management in the Surgical Patient
• Dose = 1 to 2 mg/kg. Approximately 1.5 ml per leg
Duration of Action
• Xylazine: Less than 1 hour • Medetomidine: 1 to 2 hours
•
Administration
• IV or intramuscular (IM) (also see Chapter 2) Side Effects
• Cardiovascular effects include hypertension, bradycardia, bradyarrhythmia, output.
105
and
reduced
per 3-kg cat. This volume would be further divided if the procedure is performed on four limbs. Infiltration using a 25-gauge needle is just proximal to carpus and deep to the flexor tendons (palmar) and extensor tendons (dorsal).
Anesthesia of Mandible For mandibular biopsy, mandibulectomy, and dental procedures, see Chapters 99 and 64.
cardiac
Local Anesthesia The local anesthetic techniques described below are intended to augment, not replace, general anesthesia for the surgical procedures.
Local Anesthetic Drugs
• Lidocaine, ropivacaine, bupivacaine
Nerve Blocked
• Inferior alveolar branch of the mandibular nerve Technique
• Insert a needle approximately 1 cm rostral to the •
angular process (caudal edge) of mandible against the medial surface to mandibular foramen. Inject 1 to 2 ml of 0.2% ropivacaine or 0.25% bupivacaine (less in cats).
Duration of Action
Anesthesia of Upper Jaw
• Bupivacaine and ropivacaine have a 4- to 8-hour dura-
For maxillary biopsy, maxillectomy, and dental procedures, see Chapters 99 and 64.
•
tion and lidocaine has a less than 1-hour duration of action after local infiltration or regional nerve blockade. Onset of action is shorter with lidocaine (a few minutes) than with ropivacaine or bupivacaine (30 minutes).
Administration
• Local anesthetic drugs are used for local tissue infil• •
tration, regional nerve blockade, epidural administration, or intravenous infusion. Local infiltration or regional nerve blockade results in sensory and motor blockage. Lidocaine can be administered by intravenous infusion in dogs to treat mild to moderate pain.
Local Anesthesia for Onychectomy See Chapter 114.
Nerve Blocked
• Br. of median, ulnar, radial. Area Blocked
• Digits Technique Use ropivacaine or bupivacaine; note that both of these drugs are commercially available in varying concentrations. It is important to use the least concentrated formulation (0.2% for bupivacaine or 0.25% for ropivacaine) to provide sufficient volume for the block.
Nerve Blocked
• Maxillary nerve deep at vertical portion of palatine bone
Area Blocked
• Maxilla and associated teeth Technique
• Insert a 1- or 1.5-inch needle ventral to the zygomatic process and anterior to the ramus of the mandible.
• The needle is advanced until it contacts the palatine bone.
• Inject 1 to 2 ml of 0.2 % ropivacaine or 0.25% bupivacaine.
Intercostal Nerve Block For thoracotomy, see Chapter 167.
Nerves Blocked
• Intercostal nerves proximally and at the caudal edge of the ribs
Area Blocked
• Chest wall Technique
• Two intercostal spaces cranial to and two caudal to and including the space receiving the surgical incision
W0422-Ch006.qxd 11/10/05 4:46 PM Page 106
106
Section 1 / Patient Management
• Ropivacaine (0.2%) or bupivacaine (0.25%); 1 to 2 mg/kg divided among the five intercostal spaces
• Slowly inject and withdraw the needle. • The appropriate dose (mg/kg) is delivered in a 1 ml/ 4.5 kg volume.
Epidural Anesthesia or Analgesia For surgery of the caudal abdomen, tail, perineum, or anus.
• Opioids, local anesthetics, alpha-2 agonists, and ket• •
amine have all been injected into the epidural space for analgesia (see Tables 6-4, 6-5, and 6-7). Local anesthetics produce a dose related sensory and motor blockade (epidural anesthesia). Opioids, alpha-2 agonists, or ketamine induce doserelated analgesia with minimal motor blockade (epidural analgesia).
Area Blocked
• Caudal abdomen, tail, perineum, and anus Anatomy and Landmarks
• The lumbo-sacral space is located on the midline on • •
a line drawn between the left and the right cranialdorsal iliac spines. Palpate the spinous process of vertebrae L7 and the median sacral crest. The space is located midway between these structures. The spinal cord ends at L7 in the dog and between L7 and S1 in the cat.
Lidocaine Constant Rate (IV) Infusion • Can be used as an adjunct to other analgesic therapy. • Better for soft tissue pain rather than orthopedic. • Dosage = 20 to 60 mg/kg/min, IV • Begin with mid-range dosage for dogs. Cats may develop cardiovascular depression from lidocaine infusion.
Nonsteroidal Anti-inflammatory Drugs These drugs traditionally have been used to treat chronic pain and to reduce inflammation as a result of their inhibition of the cyclooxygenase (Cox) 1 and 2 enzymes. Cox 1 is the normally present constitutive enzyme, and Cox 2 is induced during inflammation. Both enzymes may be involved in normal renal function.
• They potentiate the action of opioid analgesics. • Injectable NSAIDs can be administered immediately
•
Technique
• Position the animal in lateral or sternal recumbency. • Clip hair and do an aseptic preparation. Surgical •
gloves should be worn when performing the procedure. A 22-gauge, 1- to 3-inch spinal needle is inserted on the midline. Advance the needle through the yellow ligament until a sudden loss of resistance is felt as the needle enters the epidural space. Depth of insertion will vary from 0.5 cm in a cat to 7 cm in a large-breed or obese dog.
•
before or after surgery. Oral NSAIDs can be prescribed postoperatively. NSAIDs do not produce sedation. They can cause gastrointestinal ulceration, liver, and kidney damage, and they should be used cautiously if at all in animals with hypotension, gastrointestinal, or renal disease. Do not use NSAIDs with corticosteroids.
SUPPLEMENTAL READING Gaynor JS, Muir WW: Handbook of Veterinary Pain Management. St. Louis: CV Mosby, 2002. Mathews KA (ed): Veterinary Clinics of North America: Management of Pain. Philadelphia: WB Saunders, 2000. Thurmon JC, Tranquilli WJ, Benson GJ: Lumb and Jones’ Veterinary Anesthesia, 3rd ed. Philadelphia: Williams & Wilkins, 1996.
W0422-Ch007.qxd 11/10/05 4:46 PM Page 107
▼
Section
Chapter
▼
2 7
Infectious Disease Robert G. Sherding
Vaccination Guidelines for the Dog and Cat Richard B. Ford
Proposed changes in vaccination protocols for companion animals, the safety of licensed vaccines, and advances in vaccine technology are among the most important issues practicing veterinarians face as we enter the 21st Century. While many would argue that these are already issues, the future promises to be especially challenging as the vaccines we use and the protocols we recommend undergo unprecedented change.
HISTORICAL BACKGROUND Prior to 1998, vaccination recommendations were limited to the Compendium of Animal Rabies Prevention and Control, published annually by the National Association of State Public Health Veterinarians (at www.nasphv.org). In 1998, the American Association of Feline Practitioners (AAFP) published the first report of an Advisory Panel on Feline Vaccines recommending that adult cats be vaccinated every 3 years, rather than annually, against feline parvovirus (panleukopenia). Reaction to this report was profound. Veterinarians throughout North America voiced concerns that anything other than annual vaccination of adult cats against panleukopenia was inappropriate, irrational, and quite possibly detrimental to the health of the cat population. In December of 2000, the same Advisory Panel published a second iteration of the Guidelines for Feline Vaccination. In that report, the Panel expanded the “every 3 year” booster recommendation to include feline herpesvirus-1, feline calicivirus, and panleukopenia.
Then, in March 2003, the American Animal Hospital Association (AAHA) Canine Vaccine Task Force released its Guidelines on canine vaccination. In that document, 3-year booster intervals in adult dogs are recommended for distemper, parvovirus, adenovirus-2, and parainfluenza virus. In 2004, some vaccine manufacturers announced results of challenge studies verifying the ability of their canine distemper, parvovirus, and adenovirus-2 combination vaccines to protect dogs against virulent challenge, thereby validating the recommendations outlined in the canine vaccination guidelines.
FUTURE VACCINATION ISSUES It is important to remember, however, that despite the controversy over 3-year booster intervals for some vaccines, there are several strategic issues justifying the need for veterinarians to reassess recommendations for the selection and use of vaccines. Included among these issues are vaccine safety profiles, profound variation in exposure risk of individual dogs and cats, and changes in vaccine technology (e.g., recombinant vaccines). These issues will take on even more importance in the future as new vaccines continue to be introduced and as more veterinarians question the need for and safety of these products. The introduction of so many vaccines in the past 10 years, and the promise of more to come, justify the need for the veterinary profession to critically address which 107
W0422-Ch007.qxd 11/10/05 4:46 PM Page 108
108
Section 2 / Infectious Disease
vaccines are administered to which patients and at which stage of life. ▼ Key Point To merely accept any and all newly licensed vaccines as part of an annual protocol for all patients is, quite simply, wrong.
Non-Core Vaccines Non-Core vaccines, on the other hand, are those vaccines recommended for administration to a dog or cat that has a reasonable risk of exposure to a known infectious agent. Examples include the feline leukemia virus (FeLV) and canine Lyme borreliosis (Borrelia burgdorferi) vaccines.
THE VACCINE GUIDELINES First, and most importantly, the published Canine and Feline Vaccination Guidelines do not represent vaccination standards. The Guidelines were never intended to be used as a set of enforceable requirements against which all practices would be held accountable. They are merely guidelines. However, the published guidelines are becoming templates for the standard of care appropriate to vaccination practices in the United States. For that reason alone, they are worth reading. ▼ Key Point Current editions of both the Canine and Feline Vaccination Guidelines and updates on new vaccines can be reviewed at www.dvmvac.com.
Secondly, the Canine and Feline Vaccination Guidelines do not represent a vaccination protocol. Attempting to use the Guidelines as a defined protocol in practice would be frustrating. Instead, the Guidelines serve as a tool for clinicians to use in developing a rational vaccination protocol appropriate for the individual patient. Vaccine selection and use in veterinary medicine remain the responsibility of the individual practitioner.
CORE VERSUS NON-CORE VACCINES Canine and Feline Vaccination Guidelines are developed around the concept of Core and Non-Core vaccines. It is important to understand that Vaccination Guidelines merely suggest, they do not mandate, which vaccines should be Core or Non-Core. However, it is in the interest of the individual practice to establish which vaccines meet the definition of Core, then ensure that information is communicated to all professional staff, technicians, and office staff, thereby assuring consistent, clear communication to clients.
Core Vaccines Core vaccines are those vaccines recommended for administration to every dog or cat presented to the practice. Recommendations for designating a particular vaccine as Core are determined by: (1) severity of disease caused by the agent, (2) the risk of transmission of the agent to susceptible animals, and (3) the potential for a particular infection to be zoonotic.
DURATION OF IMMUNITY Perhaps one of the greatest paradigms challenged by the publication of Canine and Feline Vaccination Guidelines is the time-honored “annual booster recommendation.” Recommendations that some vaccines can be administered 3 years (or more) apart without reduction in protective immunity have not been universally accepted. However, the fact remains that over the last decade, the quality of companion animal vaccines has improved. Recent studies have clearly shown that the duration of immunity for many, although not all, canine and feline vaccines is well beyond 1 year. Clearly there is a growing body of data that validates triennial booster vaccination in adult dogs and cats for those vaccines listed in the guidelines as “Core.” However, some vaccines (e.g., Bordetella bronchiseptica, leptospirosis, and Chlamydophila felis vaccines) may not consistently provide a 1-year duration of immunity, despite a product label (package insert) stipulating “annual booster recommended.”
ANNUALIZED VACCINATION PROTOCOLS The fact that the Canine and Feline Vaccination Guidelines recommend triennial vaccination for certain vaccines in no way stipulates that adult dogs and cats should only be vaccinated every 3 years. In fact, annual vaccination does represent a high standard of medical care as long as the vaccination appointment incorporates a thorough health and wellness examination. Considering the large population of pet dogs and cats and the remarkable spectrum of risk factors for exposure to infectious pathogens, it is quite unreasonable to assume that a single vaccination protocol would be applicable in all patients seen in practice. Two of the most important variables to consider when assessing risk are: (1) the age of the patient, and (2) the patient’s “lifestyle.” In implementing a vaccination protocol in clinical practice, it is critical for the clinician to consider these factors for the individual patient when recommending for, or against, Non-Core vaccines. Tables 7-1 through 7-12 show annualized vaccination protocols for dogs and cats at moderate risk (applies to most), high risk, and low risk of exposure to infectious agents, while also taking into consideration the recommendations set forth in the Canine and Feline Vaccination Guidelines.
W0422-Ch007.qxd 11/10/05 4:46 PM Page 109
Chapter 7 / Vaccination Guidelines for the Dog and Cat
109
Table 7-1. ANNUALIZED VACCINATION PROTOCOL FOR DOGS AT MODERATE RISK OF EXPOSURE Age at Vaccination 6–8 weeks
10–12 weeks
14–16 weeks
+1 year
Vaccine Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Optional + Parainfluenza virus Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Rabies (1 dose at 12, 14, or 16 weeks of age) Optional + Parainfluenza virus + B. bronchiseptica (killed-parenteral, 2 doses required, 3–4 wks apart) + Leptospirosis (serovars as indicated at 12 wks or older) Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Rabies (now or at 12 wks) Optional + Parainfluenza virus + B. bronchiseptica (live-intranasal, 1 dose or the 2nd killed-parenteral dose) + Leptospirosis (serovars as indicated) Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Rabies (booster required) Optional + B. bronchiseptica (intranasal or parenteral) + Parainfluenza + Leptospirosis (serovars as indicated)
Age at Vaccination +2 years
+3 years
+4 years
+5 years
+6 years
+7 years
Beyond 7 years
Vaccine Optional + B. bronchiseptica (intranasal or parenteral) + Leptospirosis (serovars as indicated) Optional + B. bronchiseptica (intranasal or parenteral) + Leptospirosis (serovars as indicated) Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Rabies Optional + B. bronchiseptica (parenteral) + Parainfluenza + Leptospirosis (serovars as indicated) Optional + B. bronchiseptica (parenteral) + Leptospirosis (serovars as indicated) Optional + B. bronchiseptica (parenteral) + Leptospirosis (serovars as indicated) Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Rabies Optional + B. bronchiseptica (parenteral) + Parainfluenza + Leptospirosis (serovars as indicated) Cycle repeats as indicated
For any vaccine preceded by “+,” see defining criteria in Table 7-2. NOTE: All intranasal B. bronchiseptica vaccines also contain parainfluenza virus; some also contain canine adenovirus-2. NOTE: In some States or municipalities, annual rabies vaccination may be required.
Table 7-2. DEFINING CRITERIA FOR MODERATE-RISK CANINES (APPLIES TO MOST DOGS) B. Bronchiseptica Vaccination Is Indicated If Dog is ever boarded in a commercial kennel Dog requires occasional grooming Dog regularly has supervised walks/runs outside with likelihood of contact with other dogs Parainfluenza* Vaccination Is Indicated If Dog is ever boarded in a commercial kennel Dog requires occasional grooming Dog regularly has supervised walks/runs outside with likelihood of contact with other dogs Leptospira Vaccination Is Indicated If The dog is 12 wks of age or older Dog has opportunities for unsupervised outdoor activities Cases of leptospirosis are known to have been confirmed in the area† Dog has access (supervised or otherwise) to areas inhabited by “reservoir” hosts (e.g., opossum, skunk, raccoon, vole) or other domestic animals such as cattle, pigs, or horses Lyme Borreliosis Vaccination Is Not Indicated Unless Dog will travel to known endemic areas (Northeast or upper Midwest) and will spend time outside Lyme borreliosis cases have been diagnosed (via IDEXX Snap 3Dx or Western Blot analysis) in the community Dog is not receiving any form of topical tick preventative (e.g., fipronil) *Note: Parainfluenza vaccine is combined with all intranasal B. bronchiseptica vaccines. †Note: Risk of exposure is not limited to rural areas.
W0422-Ch007.qxd 11/10/05 4:46 PM Page 110
110
Section 2 / Infectious Disease
Table 7-3. ANNUALIZED VACCINATION PROTOCOL FOR DOGS AT LOW RISK OF EXPOSURE Age at Vaccination 6–8 weeks
10–12 weeks
14–16 weeks
+1 year
+2 years
Vaccine Distemper (MLV or Recombinant) Parvovirus Adenovirus-2 Optional + Parainfluenza virus Distemper (MLV or Recombinant) Parvovirus Adenovirus-2 + Rabies (1 dose at 12, 14, or 16 wks of age) Optional + Parainfluenza virus Distemper (MLV or Recombinant) Parvovirus Adenovirus-2 + Rabies (now or at 12 wks) Optional + Parainfluenza virus Distemper (MLV or Recombinant) Parvovirus Adenovirus-2 Rabies (required in most states) Optional + Parainfluenza Health Examination Non-Core vaccines considered if risk assessment changes
Age at Vaccination +3 years
+4 years
+5 years
+6 years
+7 years
Beyond 7 years
Vaccine Health Examination Non-Core vaccines considered if risk assessment changes Distemper (MLV or Recombinant) Parvovirus Adenovirus-2 Rabies (required in most States) Optional + Parainfluenza Health Examination Non-Core vaccines considered if risk assessment changes Health Examination Non-Core vaccines considered if risk assessment changes Distemper Parvovirus Adenovirus-2 + Rabies (required in most states) Optional + Parainfluenza Cycle repeats as indicated
For any vaccine preceded by “+,” see defining criteria in Table 7-4. Note: All intranasal B. bronchiseptica vaccines also contain parainfluenza virus; some also contain canine adenovirus-2. Note: In some states or municipalities, annual rabies vaccination may be required.
Table 7-4. DEFINING CRITERIA FOR LOW-RISK CANINES (ONLY CORE VACCINES NEED BE ADMINISTERED) B. Bronchiseptica Is Not Indicated Because Dog is never boarded in a commercial kennel Grooming is not an issue Dog lives exclusively indoors Dog has no exposure to other dogs (or it occurs rarely) Parainfluenza* Vaccination Is Indicated If Dog is ever boarded in a commercial kennel Dog requires occasional grooming Dog regularly has supervised walks/runs outside with likelihood of contact with other dogs Leptospira Canicola, L. Icterohemmorhagiae, L. Pomona, and L. Grippotyphosa Vaccinations Are Not Indicated Because There is no exposure to other dogs There is no opportunity for unsupervised outdoor activity The dog lives exclusively indoors Leptospirosis is not known to occur in the area Lyme Borreliosis Vaccination Is Not Indicated Because Dog does not reside in a known Lyme borreliosis endemic area Dog does not travel to known endemic areas Dog neither lives in or travels into a known tick-vector area Dog is reliably treated with topical flea and tick preparation Dog has never known a tick and never will *Note: Parainfluenza vaccine is combined with all intranasal B. bronchiseptica vaccines.
W0422-Ch007.qxd 11/10/05 4:46 PM Page 111
Chapter 7 / Vaccination Guidelines for the Dog and Cat
111
Table 7-5. ANNUALIZED VACCINATION PROTOCOL FOR DOGS AT HIGH RISK OF EXPOSURE Age at Vaccination 6–8 weeks
10–12 weeks
14–16 weeks
+1 year
+2 years
Vaccine Recombinant Distemper Parvovirus Adenovirus-2 Parainfluenza B. bronchiseptica (intranasal recommended) Recombinant Distemper Parvovirus Adenovirus-2 Parainfluenza Rabies (at 12, 14, or 16 weeks) B. bronchiseptica (intranasal recommended) Optional + Leptospirosis + Lyme borreliosis (recombinant) Recombinant Distemper Parvovirus Adenovirus-2 Parainfluenza B. bronchiseptica (intranasal recommended) Rabies (now or at 12 wks) Optional + Leptospirosis + Lyme borreliosis (recombinant) Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Parainfluenza B. bronchiseptica (intranasal or parenteral) Rabies (required) Optional + Leptospirosis + Lyme borreliosis (recombinant) B. bronchiseptica (intranasal or parenteral) Optional
Age at Vaccination
+3 years
+4 years
+5 years
+6 years
+7 years
Beyond 7 years
Vaccine + Leptospirosis + Lyme borreliosis (recombinant) B. bronchiseptica (intranasal or parenteral) Optional + Leptospirosis + Lyme borreliosis (recombinant) Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Parainfluenza B. bronchiseptica (intranasal or parenteral) Rabies (required) Optional + Leptospirosis + Lyme borreliosis (recombinant) B. bronchiseptica (intranasal or parenteral) Optional: + Leptospirosis + Lyme borreliosis (recombinant) B. bronchiseptica (intranasal or parenteral) Optional: + Leptospirosis + Lyme borreliosis (recombinant) Distemper (MLV or recombinant) Parvovirus Adenovirus-2 Parainfluenza B. bronchiseptica (intranasal or parenteral) Rabies (required) Optional + Leptospirosis + Lyme borreliosis (recombinant) Cycle repeats as indicated
For any vaccine preceded by “+,” see defining criteria in Table 7-6. Note: All intranasal B. bronchiseptica vaccines also contain parainfluenza virus; some also contain canine adenovirus-2. Note: In some states or municipalities, annual rabies vaccination may be required.
Table 7-6. DEFINING CRITERIA FOR HIGH-RISK CANINES B. Bronchiseptica Booster Is Indicated If Dog is regularly boarded in a commercial kennel Dog is routinely groomed at a facility where other dogs are maintained Dog is regularly allowed outdoors and is unsupervised Dog has regular exposure to other, unknown dogs Dog is on a first-name basis with animal control officers Annual Leptospira spp Booster Is Indicated If Dog lives outside and is not constrained to a gated kennel Dog lives on a farm and has ample outdoor activity Dog is regularly allowed to roam freely Dog lives exclusively outdoors. Dog is used for hunting or other extended outdoor activity Cases of leptospirosis are known to have been confirmed in the area Dog has access (supervised or otherwise) to areas inhabited by “reservoir” hosts (e.g., opossum, skunk, raccoon, vole) or other domestic animals such as cattle, pigs, or horses Annual Lyme Borreliosis Booster Is Indicated If Dog resides in a known Lyme borreliosis endemic area (e.g., Northeast or upper Midwest) Dog lives outside most or all of the time and does have tick exposure Dog regularly travels to known endemic areas Cases of Lyme borreliosis have been identified by serologic testing (IDEXX Snap 3Dx or Western Blot analysis) among dogs in the patient population Dog is inconsistently treated with topical flea and tick preparation Dog is only treated with over-the-counter tick preparations Ticks are known to be constant companions for this dog
W0422-Ch007.qxd 11/10/05 4:46 PM Page 112
112
Section 2 / Infectious Disease
Table 7-7. ANNUALIZED VACCINATION PROTOCOL FOR CATS AT MODERATE RISK OF EXPOSURE Age at Vaccination 9–10 weeks
12–14 weeks
+1 year
+2 years +3 years
Vaccine Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) Optional + FeLV (recombinant, transdermal) Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) Optional: + FeLV (recombinant, transdermal) Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + Rabies (recombinant, transdermal) + Rabies (recombinant)
Age at Vaccination +4 years
+5 years +6 years +7 years
+8 years +9 years +10 years
Beyond 10 years
Vaccine Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) + Rabies (recombinant) + Rabies (recombinant) Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) + Rabies (recombinant) + Rabies (recombinant) Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) Cycle repeats as indicated
For any vaccine preceded by “+,” see defining criteria in Table 7-8.
Table 7-8. DEFINING CRITERIA FOR MODERATE-RISK FELINES (APPLIES TO MOST CATS) FeLV Vaccine Is Indicated If Cat lives indoors predominately, but not exclusively, and Cat is less than 6 months of age, and Cat is known to occasionally have contact with other cats of unknown health status, or Other cats in the household are known to be FeLV infected, or Other cats live in the household but are of unknown FeLV status, or Other cats in the household are known to roam at will, or Owner may bring stray cats into the household Bordetella Bronchiseptica and Chlamydophila Felis Vaccines Are Not Indicated If Cat is an adult (current literature suggests that clinical B. bronchiseptica infections are most likely to occur in kittens), and Cat does not have exposure to other cats, and Any other cats in the household are known to be strictly indoor cats, and Owner is unlikely to bring stray cats into the household Rabies Vaccination in Cats Is not required by many states and municipalities; however, in accordance with the Feline Vaccination Guidelines, rabies is a Core vaccine and is highly recommended for all cats.
Table 7-9. ANNUALIZED VACCINATION PROTOCOL FOR CATS AT LOW RISK OF EXPOSURE Age at Vaccination 9–10 weeks 12–14 weeks
+1 year
+2 years +3 years +4 years
Vaccine Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) Panleukopenia (MLV) Herpesvirus and Calicivirus (MLV) + Rabies (recombinant) Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) + Rabies (recombinant) + Rabies (recombinant) Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant)
Age at Vaccination +5 years +6 years +7 years
+8 years +9 years +10 years
Beyond 10 years
Vaccine + Rabies (recombinant) + Rabies (recombinant) Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) + Rabies (recombinant) + Rabies (recombinant) Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) Cycle repeats as indicated
For any vaccine preceded by “+,” see defining criteria in Table 7-10. Note: Although administration of rabies vaccine to cats may not be required by state or local statutes, it is recommended for all cats, regardless of risk.
W0422-Ch007.qxd 11/10/05 4:46 PM Page 113
Chapter 7 / Vaccination Guidelines for the Dog and Cat
113
Table 7-10. DEFINING CRITERIA FOR LOW-RISK FELINES (PROTOCOL CENTERS AROUND CORE VACCINES) FeLV and FIV Vaccines Are Not Indicated If Cat is known to be a strictly indoor cat, and Any other cats in the household are known to be both FeLV and FIV-free and were tested within the last 12 months, and Other cats in the household are known to be strictly indoor cats Owner does not bring stray cats into the household Bordetella Bronchiseptica and Chlamydophila Vaccines Are Not Indicated If The cat is an adult (current literature suggests that clinical B. bronchiseptica infections are most likely to occur in kittens), and The cat does not have exposure to other cats, and Any other cats in the household are known to be strictly indoor cats Owner does not bring stray cats into the household Rabies Vaccination in Cats Is not required by many states and municipalities; however, in accordance with the Feline Vaccination Guidelines, rabies is a Core vaccine and is highly recommended for all cats.
Table 7-11. ANNUALIZED VACCINATION PROTOCOL FOR CATS AT HIGH RISK OF EXPOSURE Age at Vaccination 9–10 weeks
12–14 weeks
+1 year
+2 years
+3 years
+4 years
Vaccine Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) Optional + FeLV (non-adjuvanted) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (Recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV
Age at Vaccination +5 years
+6 years
+7 years
+8 years
+9 years
+10 years
Beyond 10 years
Vaccine + Rabies (Recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV Panleukopenia (MLV) Herpesvirus-1 and Calicivirus (MLV) + Rabies (recombinant) Optional + FeLV (recombinant, transdermal) + B. bronchiseptica + Chlamydophila (non-adjuvanted) + FIV Cycle repeats as indicated
For any vaccine preceded by “+,” see defining criteria in Table 7-12. Note: Chlamydia psittaci has been renamed Chlamydophila felis (the name on vaccine label may not reflect the new classification).
W0422-Ch007.qxd 11/10/05 4:46 PM Page 114
114
Section 2 / Infectious Disease
Table 7-12. DEFINING CRITERIA FOR HIGH-RISK FELINES Both FeLV and FIV Vaccines Are Indicated If Cat is known to roam at will and engage in fighting (risk of FIV in male cats is 4 times greater than in female cats), or There is likely exposure to other cats with unknown health status, or There are other cats in the household that are known to roam at will and engage in fighting, or Owner regularly adopts (or hoards) cats Bordetella Bronchiseptica and Chlamydophila Felis Vaccines Are Indicated If Cat is a kitten and resides within a cluster household (current literature suggests that clinical B. bronchiseptica infections are most likely to occur in kittens), or Cat has regular exposure to other cats of unknown health status, or There are other cats in the household known to roam at will and have contact with other cats, or Owner regularly adopts (or hoards) cats Rabies Vaccination in Cats Is not required by many states and municipalities; however, in accordance with the Feline Vaccination Guidelines, rabies is a Core vaccine and is highly recommended for all cats.
SUPPLEMENTAL READING Ford RB (ed): Veterinary Clinics of North America: Small Animal Practice. Philadelphia: WB Saunders, 2001. Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force: 2003 Canine Vaccine Guidelines and Recom-
mendations. J Am Anim Hosp Assoc 39:119–131, 2003. (the complete report, including supporting literature, is available to AAHA members at www.aahanet.org). Richards J, Rodan I, Elston T, et al: 2000 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Vaccines, Nashville, TN.
Chapter
▼
W0422-Ch008.qxd 11/10/05 4:45 PM Page 115
8
Feline Leukemia Virus Robert G. Sherding
ETIOLOGY Feline leukemia virus (FeLV) is an RNA retrovirus that is a transmitted both vertically (mother to fetus) and horizontally (cat to cat). FeLV infects cats worldwide and causes lymphoma, leukemia, bone marrow suppression, immunodeficiency, and a variety of other clinical syndromes. Fortunately, widespread testing and vaccination since the mid-1980s have resulted in a substantial decrease in the prevalence of FeLV infection.
Structure of the Virus Certain structural components of the FeLV virion have clinical implications.
• Core contains the viral RNA and reverse transcriptase
• •
•
enzyme that allows DNA copies of the virus to be transcribed and inserted into the genome of infected host cells. Core protein (p27) is the group-specific FeLV antigen detected by conventional FeLV diagnostic tests. Envelope glycoprotein (gp70) defines the FeLV antigenic subgroup as A, B, C, or combinations of these; determines infectivity, host range, and pathogenicity; and elicits the protective host neutralizing-antibody response that occurs with natural exposure or vaccination. Only subgroup A is infectious. Envelope protein (p15e) is a mediator of FeLV-related immunodeficiency.
prevalence statistics below, the dates for earlier surveys are shown:
• Purebred catteries—Less 0.1% (if testing and vaccination are used)
• Healthy pet cats—Less than 1% • Free-roaming stray and feral cats—1% to 4% • Cats seen at U.S. teaching hospitals—2% (of 409,417 cats; 1972–1998)
• Cats tested at Tufts Laboratory—Decreased from 8% to 4% from 1989 to 1995 (of 13,000 cats)
• High-risk and clinically sick cats—13% (of 27,976 cats; 1990–1991)
• In highly endemic households with many viremic cats—30% to 70% of unvaccinated kittens compared with only 10% to 20% of unvaccinated adult cats ▼ Key Point Most purebred catteries have completely eliminated FeLV, and infection is rare in household pet cats. FeLV is most frequently found in multi-cat households that take in untested strays, especially kittens.
Transmission ▼ Key Point FeLV is contagious through prolonged close contact with infected cats. Transmission is primarily through saliva.
• Persistently viremic cats continuously shed large
Prevalence The prevalence of FeLV varies with age, health, environment, and lifestyle. Kittens less than 4 months of age are much more susceptible to infection than adults. Resistance develops with age, but even healthy adults can become infected. The prevalence of FeLV infection and related diseases, such as lymphoma, has been steadily declining over the last 2 decades because of client education, FeLV testing, and vaccination. Recent epidemiological surveys are few, and most of the older published surveys overstate the prevalence of FeLV compared with what is seen today. In the
•
• • •
amounts of virus in saliva and, to a lesser extent, in naso-ocular secretions. Infected queens shed large amounts of virus in milk. Feces, urine, and fleas are less likely sources of infection. Transmission most often occurs through direct oronasal contact with infectious saliva during mutual grooming and sharing of food and water bowls or through bite wound inoculation of saliva. Transplacental transmission can occur, but milkborne infection in nursing kittens is more common. Iatrogenic transmission of FeLV can occur through contaminated blood transfusions, needles, surgical and dental instruments, and endotracheal tubes. FeLV usually does not survive more than a few hours outside of the cat, up to a maximum of 48 hours 115
W0422-Ch008.qxd 11/10/05 4:45 PM Page 116
116
Section 2 / Infectious Disease
under optimal temperature and moisture conditions. Heat, drying, detergents, and disinfectants readily destroy FeLV. ▼ Key Point The risk of FeLV transmission is minimal in shelters and veterinary hospitals that house cats in separate cages and routinely use hand washing and disinfection procedures for cages, food and water dishes, and litter pans.
PATHOGENESIS Sequence of FeLV Infection The sequence of FeLV infection includes inoculation followed by replication in local lymphoid, systemic lymphoid, bone marrow, and polyglandular tissues.
• After oronasal or percutaneous inoculation, FeLV
•
•
replicates in local lymphoid tissues and then in systemic lymphoid tissues throughout the body, such as lymph nodes, spleen, and thymus. Viral antigen may first become detectable in the blood (antigenemia) at this stage with enzyme-linked immunosorbent assay (ELISA) tests (see “Diagnosis”). A successful immune response may terminate the infection at this stage or even before antigenemia is detectable. If infection progresses, FeLV infects the bone marrow, leading to circulation of virus-infected leukocytes and platelets (cell-associated viremia) that are detectable in the blood by the immunofluorescent antibody (IFA) test (see “Diagnosis”). This usually indicates that FeLV has overwhelmed the host immune response and that the infection is likely to persist indefinitely. Concurrent with the development of viremia, FeLV infects glandular cells throughout the body (e.g., salivary glands, lacrimal glands, mammary glands, and mucosal epithelial glands). This leads to shedding of virus in most body secretions, with especially high concentrations of virus in saliva and the milk of lactating queens. At this stage, FeLV-infected cats are contagious to other cats in close contact, and queens can infect their nursing kittens.
Host Immune Response Immunity to FeLV is the collective result of humoral antibody, cytotoxic T lymphocytes and other cellmediated immune mechanisms, complement, and interferon. Humoral antibody responses have been characterized as follows:
• Antiviral response is mediated by neutralizing antibody directed against FeLV envelope antigens. Transient infection and recovery occur if the immune response is successful, whereas bone marrow infection and persistent viremia occur if the virus overwhelms the host immune response.
• Antitumor response is mediated by antibody directed against FeLV-associated antigens on the surface of FeLV-induced neoplastic cells.
Categories of Infection The outcome of FeLV exposure depends on many factors, including viral dose and route of exposure, environmental conditions, and host factors such as the cat’s age, innate immunity, vaccination status, and health status. Cats exposed to FeLV can be categorized as noninfected, persistently infected, transiently infected, or latently infected.
Cats That Resist Infection Many cats exposed to FeLV do not get infected, either because of an inherent resistance to infection or because of insufficient exposure. The most important factor is age-related resistance in cats over 4 months of age.
Transient Infection The majority of cats exposed to FeLV develop a transient replicating (“regressive”) infection that is subsequently rejected by a vigorous immune response, resulting in a full clinical recovery.
• Transiently infected cats usually eliminate the virus
•
•
swiftly within 4 to 6 weeks after exposure, with either no detectable antigenemia or a transient antigenemia lasting 1 to 5 weeks. However, FeLV-infected cats can potentially eliminate the virus at any stage, rarely even after many months or years as a persistent carrier. Many cats are vaccinated against FeLV, and upon exposure, most will resist persistent infection and instead go through a brief transient infection (see “Vaccination”). Transiently infected cats frequently develop latent infection as they recover (see the next section).
Latent Infection Non-viremic cats that “recover” from transient infection often become latent carriers of non-replicating FeLV for a variable period of time.
• In latent FeLV infection, non-replicating FeLV provirus remains dormant within the DNA genome of bone marrow and lymphoid cells of the cat. This can only be detected by specialized virus culture techniques or polymerase chain reaction (PCR) assays (see “Diagnosis”); thus, it is difficult to distinguish cats that have truly cleared the virus from cats with latent infection. ▼ Key Point Latent FeLV infection cannot be detected by conventional immunochromatographic (IC), ELISA, and IFA diagnostic tests.
W0422-Ch008.qxd 11/10/05 4:45 PM Page 117
Chapter 8 / Feline Leukemia Virus
• In most transiently infected cats, the latent stage of
•
•
infection eventually is eliminated uneventfully within 6 to 9 months as part of the normal recovery process, but it sometimes can take a year or more. Latent infection persists indefinitely in an estimated 10% of “recovered” cats. The clinical significance of FeLV latency is the rare possibility of reactivation to a replicating infection, either spontaneously or in response to immunosuppression (e.g., corticosteroid-induced). In addition, reactivation of infection in latent-infected queens may rarely transmit FeLV to kittens in utero or during nursing. Latent infected cats have minimal risk of developing FeLV-related disease. They also have minimal risk of being contagious to other cats, except for the rare occurrences of reactivation mentioned above.
Persistent Infection Cats with persistent or “progressive” FeLV infection have generalized lymphoid, bone marrow, and polyglandular infection with persistent cell-associated viremia and continuous shedding of virus. This widespread replicating FeLV infection persists for the remainder of the cat’s life with only rare exceptions.
• Persistent infection eventually leads to fatal FeLV-
•
•
related disease in most cats after a variable diseasefree interval. The mortality rate in persistent FeLV-positive cats is 30% at 6 months, 60% at 2 years, and 90% at 4 years. Persistent infection will develop in approximately 10% to 30% of unvaccinated cats that receive continuous heavy exposure, such as living in an endemically infected household. In this situation, kittens less than 4 months of age are most susceptible, and the persistent infection rate can reach 70% in this group. Vaccination prevents persistent infection in many cats. Reducing the risk of exposure combined with vaccination has greatly decreased the prevalence of persistent FeLV infection.
dysfunction has been associated with immune-mediated and autoimmune diseases.
Nonspecific Clinical Signs Presenting clinical signs that are common in FeLVinfected cats include weight loss, fever, dehydration, oculonasal discharge, anemia, diarrhea, stomatitis, and lymphadenopathy. ▼ Key Point The majority of FeLV-infected cats are asymptomatic at the time they are identified on routine screening tests during wellness exams.
Lymphoma and Leukemia FeLV can be a primary cause of lymphoma, leukemia, and myelodysplasia. For additional information regarding diagnosis and treatment of these neoplastic conditions, see Chapters 26 and 27. In the mid-1970s, 70% of cats with lymphoma and leukemia were FeLV positive. Virus-negative alimentary lymphoma was uncommon. However, with the decline in prevalence of FeLV infection, FeLV-negative lymphomas now comprise 85% to 90% of the lymphomas seen in cats, and alimentary lymphoma is the predominant form. Some of these FeLV-negative lymphomas have molecular evidence of FeLV provirus, but most feline lymphomas are now caused by factors other than FeLV.
Alimentary Lymphoma
• Mesenteric lymph nodes—Palpable enlargement • Stomach—Vomiting, anorexia, and weight loss • Intestine—Diffuse infiltrative thickening of the • •
intestinal wall or palpable obstructing mass (weight loss, vomiting, diarrhea, and inappetence) Liver—Diffuse hepatomegaly or nodular tumor masses within the liver (icterus, weight loss, vomiting, and abnormal liver tests) Spleen—Diffuse splenomegaly
▼ Key Point FeLV-negative
alimentary lymphoma affecting middle-aged and older cats (mean age of 8 years) is now the predominant form of lymphoma in cats.
CLINICAL DISEASE SYNDROMES The clinical manifestations of FeLV are attributable to the oncogenic, cytopathic, and immunosuppressive effects of the virus. FeLV-induced neoplasia can be lymphoid or myeloid. Degenerative and cytopathic effects on various cells include bone marrow cells (anemia, neutropenia, thrombocytopenia), lymphocytes (T lymphocyte depletion, lymphoid atrophy, lymphoid hyperplasia), intestinal cells (enteritis), and the fetus and placenta (abortion, stillbirth). The immunosuppressive effects of FeLV cause profound immunodeficiency, resulting in susceptibility to a wide variety of opportunistic infections. In addition, FeLV-related immune
117
Mediastinal Lymphoma Characterized by a cranial mediastinal mass due to lymphoma of the mediastinal lymph nodes or thymus.
• • • • • •
Pleural effusion (dyspnea) Tracheal compression (dyspnea, cough) Esophageal compression (dysphagia, regurgitation) Sympathetic trunk impingement (Horner’s syndrome) Decreased cranial thoracic compressibility Mass palpable at thoracic inlet
W0422-Ch008.qxd 11/10/05 4:45 PM Page 118
118
Section 2 / Infectious Disease
Multicentric Lymphoma
• Generalized involvement of external and internal lymph nodes.
• Bone marrow, liver, spleen, and other extranodal sites are often affected.
Extranodal Forms of Lymphoma Renal Lymphoma
• Signs—Nonspecific signs (early); renal failure and uremia (late)
•
•
• Kidneys palpably enlarged and nodular (“lumpy”) Ocular Lymphoma
• • • •
Retrobulbar mass—Mimics retrobulbar abscess Third eyelid mass—Mimics “cherry eye” Corneal infiltration—Mimics eosinophilic keratitis Uveal infiltration and hemorrhage—Mimics anterior uveitis or chorioretinitis
•
Myelodysplasia
• Myelodysplasia (preleukemia) is characterized by
Neural Lymphoma
• Brain—Seizures, ataxia, blindness, behavior aberra• •
tions, motor deficits, and cranial nerve signs Spinal (usually extradural)—Paresis or paralysis Peripheral nerve—Variable neuropathies
Cutaneous Lymphoma
• Multiple firm, non-painful cutaneous nodules Other Extranodal Sites for Lymphoma
• Nasal cavity, lung, heart, and urinary bladder. Leukemia and Myelodysplasia FeLV infection of bone marrow hemopoietic cells can result in acute lymphoid leukemia, non-lymphoid leukemia, or myelodysplasia (preleukemia). Clinical signs include pallor (anemia), petechial and ecchymotic hemorrhages (thrombocytopenia), fever, lethargy, weight loss, hepatosplenomegaly, and mild lymphadenopathy. Abnormal blast cells are usually identified in the blood and bone marrow. For additional information, see Chapters 22 and 27.
Acute Lymphoid Leukemia
• Acute lymphoblastic leukemia is characterized by
•
extensive infiltration of the bone marrow with neoplastic lymphoblasts, often accompanied by neoplastic infiltration of the liver, spleen, and lymph nodes. The complete blood count (CBC) shows nonregenerative anemia, other cytopenias, and circulating lymphoblasts. Bone marrow cytology is diagnostic.
Acute Myeloid (Non-lymphoid) Leukemia
• This group of neoplastic diseases is characterized by the proliferation of one or more cell lines in the bone
marrow at the expense and to the eventual exclusion of normal hemopoietic cells. These disorders are classified on the basis of the cellular origin of the abnormal cells as acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and erythroleukemia. Diffuse hepatomegaly, splenomegaly, and lymphadenopathy occur from extramedullary hematopoiesis and/or neoplastic infiltration. Neoplastic infiltration of the liver may cause jaundice. Anemia and thrombocytopenia are common, and the diagnosis is based on identification of neoplastic blast cells in the blood and bone marrow. Non-lymphoid leukemias are poorly responsive to chemotherapy.
• •
anemia and other cytopenias caused by abnormal hemopoietic cell maturation in the bone marrow. The bone marrow is hypercellular and dysplastic, and it may have myelofibrosis. Myelodysplasia may progress to overt acute myeloid leukemia after a few weeks to months. The prognosis is poor, but blood transfusion and supportive care may be palliative.
Anemia and Other Cytopenias FeLV-Related Anemia Anemia is a common primary presenting clinical sign in FeLV-infected cats (see Chapter 22). Nonregenerative anemia is most common and is indicated by an absent or minimal reticulocyte response. Regenerative anemia with reticulocytosis also can occur.
Pathogenesis
• Nonregenerative anemia is associated with primary
• •
FeLV infection of bone marrow hemopoietic stem cells and supporting stromal cells, resulting in destruction, suppression, and abnormal maturation of erythrocyte precursors. Nonregenerative anemia can also be caused by disruption of the bone marrow from leukemia or myelodysplasia (see the previous section). Regenerative anemia associated with FeLV infection can result from immune-mediated hemolysis; from opportunistic hemotropic infections, such as Mycoplasma haemofelis, Mycoplasma haemominutum (formerly hemobartonellosis), Ehrlichia, and Babesia; or from blood loss related to thrombocytopenia.
Diagnosis • Clinical signs of severe anemia are lethargy, weakness, tachypnea, mucous membrane pallor, anemic murmur, splenomegaly, retinal hemorrhages, and pica.
W0422-Ch008.qxd 11/10/05 4:45 PM Page 119
Chapter 8 / Feline Leukemia Virus
• CBC usually shows normochromic-normocytic or •
• •
macrocytic nonregenerative anemia (packed cell volume [PCV] <10%). Reticulocytosis indicates regenerative anemia. Consider hemolytic causes. Evaluate blood smears for hemotropic organisms, and consider Mycoplasma PCR, which is more sensitive, or a therapeutic trial of doxycycline (see Chapter 22). Leukopenia or thrombocytopenia may accompany nonregenerative anemia, especially in myelodysplasia and leukemia. Bone marrow cytology in FeLV-related nonregenerative anemia is usually hypoplastic or aplastic, but it can be hypercellular, dysplastic, or neoplastic.
Treatment
119
FeLV-Related Thrombocytopenia Platelets and megakaryocytes are often infected in FeLV.
• Thrombocytopenia can be associated with FeLV-
•
• •
• For regenerative anemia, treat the associated underlying cause of hemolysis.
induced leukemia, myelodysplasia, or immunemediated disease. This may lead to petechial and ecchymotic hemorrhages and gastrointestinal (GI) blood loss. Macroplatelets with bizarre shapes are a common incidental finding in viremic cats, especially those with severe anemia. These may be miscounted as red blood cells by electronic counters. Platelet dysfunction occurs but is clinically insignificant. Treat life-threatening thrombocytopenia with transfusion of whole blood or platelet-rich plasma. Treat suspected immune-mediated thrombocytopenia with prednisolone (2–3 mg/kg PO q24h).
• For nonregenerative anemia, use blood transfusion •
and palliative supportive care (median survival with treatment in 49 cats was 4 months). Recombinant human erythropoietin (Epogen, Amgen; 35 to 100 IU/kg SC q48h until PCV rises, then weekly) has been beneficial in some cats with FeLV-related nonregenerative anemia, but most do not respond. Endogenous erythropoietin is already elevated in many cases.
FeLV-Related Neutropenia Neutrophils and myeloid precursors are often infected in FeLV (see Chapter 22).
• FeLV-induced neutropenia can be transient (in the
• •
• •
first 3 to 5 weeks of bone marrow infection), persistent, or cyclic (8- to 14-day intervals). Neutropenia also can be associated with FeLV-induced leukemia or myelodysplasia. Signs include chronic or recurrent fever, bacterial infections, or life-threatening sepsis. Myeloblastopenia (panleukopenia-like syndrome) is characterized by profound panleukopenia (white blood cell count is 300–3000/ml) and acute enterocolitis with fever, vomiting, and bloody diarrhea. Intestinal epithelial cells are infected heavily with FeLV. Coinfection with panleukopenia virus is likely. Treat complicating bacterial infections with antibiotics. Some cats with persistent or cyclic neutropenia respond to prednisolone (2–3 mg/kg PO q24h). Recombinant human granulocyte colony-stimulating factor (rhG-CSF) (Neupogen, Amgen; 5 mg/kg SC daily) has been beneficial for stimulating myelopoiesis in some cases of FeLV-associated neutropenia; however, cats form antibodies against this human protein after a few weeks that limit the effectiveness of this treatment.
Secondary Infections from Immune Suppression FeLV causes profound lymphoid depletion and immune suppression (especially T lymphocytes). In addition, neutrophil, complement, and cytokine responses may be impaired. Thus, FeLV-infected cats have increased susceptibility to a wide variety of opportunistic infections. Some examples follow:
• • • • •
Viral—Feline infectious peritonitis, herpesvirus Fungal—Cryptococcus, Aspergillus, dermatophytosis Protozoal—Toxoplasma, Cryptosporidium Mycoplasma—M. haemofelis, M. haemominutum Bacterial • Oral—Gingivitis, periodontitis, stomatitis • Respiratory infections—Rhinitis, sinusitis, pneumonia, pyothorax • Enteritis—Salmonella, Campylobacter, diarrhea of undetermined cause • Cutaneous—Pyoderma, non-healing sores, abscesses, draining fistulas • Septicemia
Peripheral Lymph Node Hyperplasia • FeLV occasionally causes severe, generalized, non-
• •
painful enlargement of peripheral and visceral lymph nodes (especially mandibular nodes) up to 3 times normal size. This lymphadenopathy is not neoplastic. This has been seen mostly in young adult cats (6 months to 2 years of age); 50% are asymptomatic and 50% have fever, anorexia, and depression. Most cases resolve in 2 to 4 weeks either spontaneously or in response to corticosteroids, cyclophosphamide, and vincristine. In some cats the lymphadenopathy recurs or develops into lymphoma months to years later.
W0422-Ch008.qxd 11/10/05 4:45 PM Page 120
120
Section 2 / Infectious Disease
Immune-Mediated Disorders Several immune-mediated disorders have been associated with FeLV infection. The exact role of FeLV in these disorders is not fully understood, but it presumably involves viral antigen-antibody complexes or FeLV-induced disruption of immune regulation.
• • • • • •
Immune-mediated hemolytic anemia Immune-mediated thrombocytopenia Immune-complex glomerulonephritis Chronic progressive polyarthritis Pemphigus-like mucocutaneous disorders Systemic lupus erythematosus-like syndrome
Reproductive Failure FeLV-infected breeding queens frequently have reproductive failure associated with transplacental or milkborne transmission of FeLV. Presenting clinical signs can include infertility, fetal resorption, abortion, stillbirth, “fading kitten syndrome” (viremic kittens), or milk-borne transmission to nursing kittens.
Miscellaneous A role for FeLV in the following disorders has been suggested but unproved: multicentric osteochondromatosis (multiple skeletal tumors in young cats), olfactory neuroblastoma (a rare nasal tumor), chronic enteritis, seborrheic dermatitis, eosinophilic granuloma complex, cutaneous horns, idiopathic anisocoria, neurologic dysfunction, and degenerative myelopathy.
DIAGNOSIS
known. Identification of FeLV-infected cats provides the opportunity to treat these cats and to prevent the spread of infection to other cats. FeLV status should be known before vaccination because it is useless to vaccinate a cat that is already infected. This also prevents preexisting infections being mistaken as vaccination failures. Indications for FeLV testing are listed in Table 8-1. ▼ Key Point To maintain a FeLV-negative household, test all new cats before entry.
ELISA and Immunochromatographic Tests ▼ Key Point ELISA and other IC tests are the preferred screening tests for FeLV, because they are rapid, widely available, slightly more sensitive, and detect infection earlier than the IFA test.
The membrane-based ELISA and other IC test kits detect soluble FeLV p27 antigen, a major viral core protein. These are sensitive screening tests that provide accurate results in less than 10 minutes. They are designed for rapid, point-of-care diagnosis of FeLV infection (Table 8-2). Table 8-1. INDICATIONS FOR FELINE LEUKEMIA VIRUS TESTING Test cats that have never been tested. Test kittens at any age. Kittens can be born infected, or nursing kittens can be infected via milk. Test cats prior to vaccination for FeLV. Test cats that are newly adopted. Test new cats before entering them into a household of healthy cats. Test cats with potential recent exposure. Test all cats in a cattery or household with FeLV, then separate infected and uninfected cats. Test outdoor cats at least annually since they have ongoing risk of exposure. Test cats with signs of illness consistent with FeLV.
Diagnostic testing for FeLV infection is one of the most frequently performed procedures in clinical practice. FeLV tests are used to diagnose FeLV-related illnesses, to routinely screen healthy cats for subclinical infection, and to identify and eliminate FeLV infections in multicat households and catteries. Diagnostic kits are widely available for rapid in-office screening for FeLV infection. These are based on ELISA or other IC technologies. Commercial diagnostic laboratories offer these as well as the IFA test. PCR assay and virus isolation are confirmatory tests that require a specialized laboratory.
Test Kit
▼ Key Point ELISA and other IC screening tests detect soluble FeLV antigen in serum or plasma (antigenemia). The IFA test detects intracellular virus in circulating leukocytes and platelets (cell-associated viremia), indicating bone marrow infection.
Indications for FeLV Testing The American Association of Feline Practitioners recommends that the FeLV status of all cats should be
Modified from the guidelines of the American Association of Feline Practitioners (www.aafponline.org).
Table 8-2. IC AND ELISA TEST KITS FOR FELINE LEUKEMIA VIRUS Manufacturer
Format
Witness FeLV
Synbiotics
ViraCHEK/FeLV ASSURE/FeLV
Synbiotics Synbiotics
SNAP FeLV SNAP FIV/FeLV Combo
IDEXX IDEXX
Membrane rapid immunomigration Microwell ELISA Saliva wand and tube ELISA Membrane ELISA Membrane ELISA (also tests for FIV)
ELISA, enzyme-linked immunosorbent assay; FeLV, feline leukemia virus; FIV, feline immunodeficiency virus; IC, immunochromatographic.
W0422-Ch008.qxd 11/10/05 4:45 PM Page 121
Chapter 8 / Feline Leukemia Virus
▼ Key Point For the most accurate ELISA or IC results, use non-hemolyzed serum or plasma rather than whole blood. Tests that use saliva and tears are unreliable and not recommended.
• For testing clinically ill cats, consider using a combi-
•
nation test kit that simultaneously tests for FeLV and feline immunodeficiency virus (FIV), since the clinical manifestations of these two diseases are often indistinguishable. ELISA and other IC tests detect viral antigen, not antibodies; thus, these tests are not affected by vaccination or maternal antibodies.
•
•
•
•
genemia. Both transient and persistent FeLV infections can be ELISA positive. Confirm positive ELISA or IC results, especially in healthy cats where the prevalence of infection is low, by retesting in 4 to 6 weeks and again at 3 months to distinguish transient from persistent infection and to rule out the occasional false positive caused by laboratory error. For retesting, consider using the IFA test as the confirmatory test, because the IFA correlates better with persistent infection and is slightly less susceptible to false-positive results (the see next section). Interpret weakly positive ELISA or IC reactions as suspicious or inconclusive, and repeat the test, preferably using a different testing method such as the IFA test or an outside laboratory. False-negative ELISA or IC results are highly unlikely because of the inherently high sensitivity of these tests. However, cats tested in the early stages of infection may not yet be antigenemic at the time of the first test. Most cats become antigenemic within 4 weeks of exposure, but it can take up to 3 months and in rare cases longer. Thus, retest all ELISA-negative cats that have a possibility of recent exposure 4 weeks later and again at 3 months.
Immunofluorescent Antibody Test ▼ Key Point The IFA test is the preferred confirmatory test for FeLV, because it is slightly more specific than ELISA and other IC tests, and it correlates highly with persistent infection.
The IFA test is a confirmatory test performed by commercial labs to detect FeLV p27 antigen within the cytoplasm of circulating neutrophils and platelets on blood smears. A positive IFA indicates established FeLV infection involving the bone marrow.
• The IFA test is very specific for FeLV and is highly correlated with persistent infection and the results of
virus isolation; thus, use the IFA test to confirm positive ELISA or IC results. Provide the lab with at least two high-quality, airdried, unfixed blood or bone marrow smears.
Immunofluorescent Antibody Test Interpretation
• Positive IFA results indicate an advanced stage of
•
ELISA Test I